# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/010913

International filing date: 31 March 2005 (31.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/559,042


Filing date: 01 April 2004 (01.04.2004)

Date of receipt at the International Bureau: 12 August 2005 (12.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)





### 

#### '4'(d) Anil (100) Vancous (1000) Series (Course)

#### UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 02, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

**APPLICATION NUMBER: 60/559,042** 

FILING DATE: April 01, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/10913

Certified by

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

PTO/SB/16 (08-03)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

#### PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c). Express Mail Label No. EL 961008104 US

		15.1	VENTORYO	``					<del>-ω</del> €
		IN	VENTOR(S	<del>)</del>			Resid	dence	<u>  그연</u>
Given Name (first and middle [if any] )		Family Name or Sumame			(City and either State or Foreign Count				
Steven		MAH			San Diego, California			85	
Andreas		BRAUN			San Diego, California			22	
Stefan M.	KAMMERER			San Die	go, Cali	fornia	3		
Additional inventors are being named on the1 separately numbered sheets attached hereto									
TITLE OF THE INVENTION (500 characters max)  METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF									
METHODS FOR IDE	NTIFYING	RISK OF OSTE	OARTHRI	TIS A	ND TRE	ATMEN <sup>-</sup>	TS Tł	HEREOF	
Direct all correspondence to	· coi	RRESPONDENCE	ADDRESS			.,,			
OR		<del></del>							
Firm or Individual Name									
Address									
City			State	Ι			Zip	I	<del>.</del>
Country			Telephone	1			Fax		
ENCLOSED APPLICATION PARTS (check all that apply)									
x Specification Number of Pages 162 CD(s), Number									
x Drawing(s) Number of Sheets 1 x Other									
x Application Data Sheet. See 37 CFR 1.76 (4 pages) (specify):									
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT									
x Applicant claims small entity status. See 37 CFR 1.27.									
								FILING FEE	
A check or money order is enclosed to cover the filing fees.								AMOUNT (\$)	ı
The Director is hereby authorized to charge filing					03-19	FO		90.00	
fees or credit any overpayment to Deposit Account Number:						52		80.00	
Payment by credit card. Form PTO-2038 is attached.									
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.									
X No Yes, the name of the U.S. Government agency									
and the	Governmen	t contract number ar							
Respectfully submitted, /	1	/ [P	age 1 of 2	)	Data				
A A A					Date		A	pril 1, 2004	
SIGNATURE	~ <del>`</del>								
TYPED OR						ATION N	Ο.	47,608	
PRINTED NAME Bruce D. Grant			-	f appropria	•	_			
TELEPHONE (858) 720-7962					ocket Nu			52459300890 -	0
USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT									
I hereby certify that this corr			45 45 - 11 C D	-1-1-0			4:-1	"I N - EL 00400040	4.116

in an envelope addressed to: Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. (Deborah Wykes) Signature:



#### PROVISIONAL APPLICATION COVER SHEET Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/06. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number 524593008900								
INVENTOR(S)/APPLICANT(S)								
Given Name (first and middle [if any])  Matthew Roberts Rikard Henry Maria L.	Family or Sumame NELSON RENELAND LANGDOWN	Residence (City and either State or Foreign Country)  San Marcos, California San Diego, California San Diego, California						

[Page 2 of 2]

## METHODS FOR IDENTIFYING RISK OF OSTEOARTHRITIS AND TREATMENTS THEREOF

#### Field of the Invention

[0001] The invention relates to genetic methods for identifying risk of osteoarthritis and treatments that specifically target such diseases.

#### Background

[0002] Osteoarthritis (OA) is a chronic disease usually affecting weight-bearing synovial joints. There are approximately 20 million Americans affected by OA and it is the leading cause of disability in the United States. In addition to extensive human suffering, OA also accounts for nearly all knee replacements and more than half of all hip replacements in the United States. Despite its prevalence, OA is poorly understood and there are few treatments available besides anti-inflammatory drugs and joint replacement.

[0003] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke.

[0004] OA is characterized by the breakdown of cartilage in joints. Cartilage in joints cushions the ends of bones, and cartilage breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rhuem. 32:241-246 (1989)).

#### Summary

[0005] It has been discovered that certain polymorphic variations in human genomic DNA are associated with osteoarthritis. In particular, polymorphic variants in a locus containing a *ADAMTS2* region in human genomic DNA have been associated with risk of osteoarthritis.

[0006] Thus, featured herein are methods for identifying a subject at risk of osteoarthritis and/or a risk of osteoarthritis in a subject, which comprise detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in or around the loci described herein in a human nucleic acid sample. In an embodiment, two or more polymorphic variations are detected in two or more regions of which one is the *ADAMTS2* region. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected.

[0007] Also featured are nucleic acids that include one or more polymorphic variations associated with occurrence of osteoarthritis, as well as polypeptides encoded by these nucleic acids. In addition, provided are methods for identifying candidate therapeutic molecules for treating osteoarthritis, as well as methods for treating osteoarthritis in a subject by identifying a subject at risk of osteoarthritis and treating the subject with a suitable prophylactic, treatment or therapeutic molecule.

[0008] Also provided are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a ADAMTS2 nucleic acid, with a RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid designed from a ADAMTS2 nucleotide sequence. In an embodiment, the RNAi, siRNA, antisense DNA or RNA, or ribozyme nucleic acid is designed from a ADAMTS2 nucleotide sequence that includes one or more polymorphic variations associated with osteoarthritis, and in some instances, specifically interacts with such a nucleotide sequence. Further, provided are arrays of nucleic acids bound to a solid surface, in which one or more nucleic acid molecules of the array have a ADAMTS2 nucleotide sequence, or a fragment or substantially identical nucleic acid thereof, or a complementary nucleic acid of the foregoing. Featured also are compositions comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and/or a ADAMTS2 polypeptide, with an antibody that specifically binds to the polypeptide. Thus, featured is an antibody that specifically binds to an epitope in the polypeptide that includes an amino acid encoded by a polymorphic site associated with osteoarthritis. In certain embodiments, the antibody specifically binds to an epitope comprising a valine or isoleucine encoded by rs398829 (e.g., an antibody that binds to an epitope comprising a valine at position 245 in an ADAMTS2 polypeptide) A valine at position 245 is associated with increased risk of osteoarthitis.

#### Brief Description of the Drawings

[0009] Figure 1 shows proximal SNPs in a *ADAMTS2* region in genomic DNA. The position of each SNP in the chromosome is shown on the x-axis and the y-axis provides the negative logarithm of the p-value comparing the estimated allele to that of the control group. Also shown in the figure are exons and introns of the region in the approximate chromosomal positions.

#### **Detailed Description**

[0010] It has been discovered that a polymorphic variant in a locus containing a *ADAMTS2* region is associated with occurrence of osteoarthritis in subjects. Thus, detecting genetic determinants associated with an increased risk of osteoarthritis occurrence can lead to early identification of a predisposition to osteoarthritis and early prescription of preventative measures. Also, associating a *ADAMTS2* polymorphic variant with osteoarthritis has provided new targets for screening molecules useful in treatments of osteoarthritis.

#### Osteoarthritis and Sample Selection

[0011] Osteoarthritis (OA), or degenerative joint disease, is one of the oldest and most common types of arthritis. It is characterized by the breakdown of the joint's cartilage. Cartilage is the part of the joint that cushions the ends of bones, and its breakdown causes bones to rub against each other, causing pain and loss of movement. Type II collagen is the main component of cartilage, comprising 15-25% of the wet weight, approximately half the dry weight, and representing 90-95% of the total collagen content in the tissue. It forms fibrils that endow cartilage with tensile strength (Mayne, R. Arthritis Rhuem. 32:241-246 (1989)).

[0012] Most commonly affecting middle-aged and older people, OA can range from very mild to very severe. It affects hands and weight-bearing joints such as knees, hips, feet and the back. Knee OA can be as disabling as any cardiovascular disease except stroke. Whereas Ehlers-Danlos syndrome type VIIC is characterized by the retention of the N-terminal propeptide of type I collagen, osteoarthritis has been characterized by increased levels of type II collagen in osteoarthritic cartilage as measured by elevated C-propeptide concentrations (Nelson et al. (1998) J. Clin. Invest. 102(12):2115-2125).

[0013] Osteoarthritis affects an estimated 20.7 million Americans, mostly after age 45, with women more commonly affected than men. Physicians make a diagnosis of OA based on a physical exam and history of symptoms. X-rays are used to confirm diagnosis. Most people over 60 reflect the disease on X-ray, and about one-third have actual symptoms.

[0014] There are many factors that can cause OA. Obesity may lead to osteoarthritis of the knees. In addition, people with joint injuries due to sports, work-related activity or accidents may be at increased risk of developing OA.

[0015] Genetics has a role in the development of OA. Some people may be born with defective cartilage or with slight defects in the way that joints fit together. As a person ages, these defects may cause early cartilage breakdown in the joint or the inability to repair damaged or deteriorated cartilage in the joint.

[0016] Inclusion or exclusion of samples for an osteoarthritis pool may be based upon the following criteria: ethnicity (e.g., samples derived from an individual characterized as Caucasian); parental ethnicity (e.g., samples derived from an individual of British paternal and maternal descent); relevant phenotype information for the individual (e.g., case samples derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic). Control samples may be selected based on relevant phenotype information for the individual (e.g., derived from individuals free of OA at several sites (knee, hand, hip etc)); and no family history of OA and/or rheumatoid arthritis. Additional phenotype information collected for both cases and controls may include age of the individual, gender, family history of OA, diagnosis with osteoarthritis (joint location of OA, date of primary diagnosis, age of individual as of primary diagnosis), knee history (current symptoms,

any major knee injury, menisectomy, knee replacement surgery, age of surgery), HRT history, osteoporosis diagnosis.

[0017] Based in part upon selection criteria set forth above, individuals having osteoarthritis can be selected for genetic studies. Also, individuals having no history of osteoarthritis often are selected for genetic studies, as described hereafter.

#### Polymorphic Variants Associated with Osteoarthritis

[0018] A genetic analysis provided herein linked osteoarthritis with polymorphic variant nucleic acid sequences in the human genome. As used herein, the term "polymorphic site" refers to a region in a nucleic acid at which two or more alternative nucleotide sequences are observed in a significant number of nucleic acid samples from a population of individuals. A polymorphic site may be a nucleotide sequence of two or more nucleotides, an inserted nucleotide or nucleotide sequence, a deleted nucleotide or nucleotide sequence, or a microsatellite, for example. A polymorphic site that is two or more nucleotides in length may be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, 20 or more, 30 or more, 50 or more, 75 or more, 100 or more, 500 or more, or about 1000 nucleotides in length, where all or some of the nucleotide sequences differ within the region. A polymorphic site is often one nucleotide in length, which is referred to herein as a "single nucleotide polymorphism" or a "SNP."

[0019] Where there are two, three, or four alternative nucleotide sequences at a polymorphic site, each nucleotide sequence is referred to as a "polymorphic variant" or "nucleic acid variant." Where two polymorphic variants exist, for example, the polymorphic variant represented in a minority of samples from a population is sometimes referred to as a "minor allele" and the polymorphic variant that is more prevalently represented is sometimes referred to as a "major allele." Many organisms possess a copy of each chromosome (e.g., humans), and those individuals who possess two major alleles or two minor alleles are often referred to as being "homozygous" with respect to the polymorphism, and those individuals who possess one major allele and one minor allele are normally referred to as being "heterozygous" with respect to the polymorphism. Individuals who are homozygous with respect to one allele are sometimes predisposed to a different phenotype as compared to individuals who are heterozygous or homozygous with respect to another allele.

[0020] In genetic analysis that associate polymorphic variants with osteoarthritis, samples from individuals having osteoarthritis and individuals not having osteoarthritis often are allelotyped and/or genotyped. The term "allelotype" as used herein refers to a process for determining the allele frequency for a polymorphic variant in pooled DNA samples from cases and controls. By pooling DNA from each group, an allele frequency for each SNP in each group is calculated. These allele frequencies are then compared to one another. The term "genotyped" as used herein refers to a process for determining a

genotype of one or more individuals, where a "genotype" is a representation of one or more polymorphic variants in a population.

[0021] A genotype or polymorphic variant may be expressed in terms of a "haplotype," which as used herein refers to two or more polymorphic variants occurring within genomic DNA in a group of individuals within a population. For example, two SNPs may exist within a gene where each SNP position includes a cytosine variation and an adenine variation. Certain individuals in a population may carry one allele (heterozygous) or two alleles (homozygous) having the gene with a cytosine at each SNP position. As the two cytosines corresponding to each SNP in the gene travel together on one or both alleles in these individuals, the individuals can be characterized as having a cytosine/cytosine haplotype with respect to the two SNPs in the gene.

[0022] As used herein, the term "phenotype" refers to a trait which can be compared between individuals, such as presence or absence of a condition, a visually observable difference in appearance between individuals, metabolic variations, physiological variations, variations in the function of biological molecules, and the like. An example of a phenotype is occurrence of osteoarthritis.

[0023] Researchers sometimes report a polymorphic variant in a database without determining whether the variant is represented in a significant fraction of a population. Because a subset of these reported polymorphic variants are not represented in a statistically significant portion of the population, some of them are sequencing errors and/or not biologically relevant. Thus, it is often not known whether a reported polymorphic variant is statistically significant or biologically relevant until the presence of the variant is detected in a population of individuals and the frequency of the variant is determined. Methods for detecting a polymorphic variant in a population are described herein, specifically in Example 2. A polymorphic variant is statistically significant and often biologically relevant if it is represented in 5% or more of a population, sometimes 10% or more, 15% or more, or 20% or more of a population, and often 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more of a population.

[0024] A polymorphic variant may be detected on either or both strands of a double-stranded nucleic acid. Also, a polymorphic variant may be located within an intron or exon of a gene or within a portion of a regulatory region such as a promoter, a 5' untranslated region (UTR), a 3' UTR, and in DNA (e.g., genomic DNA (gDNA) and complementary DNA (cDNA)), RNA (e.g., mRNA, tRNA, and rRNA), or a polypeptide. Polymorphic variations may or may not result in detectable differences in gene expression, polypeptide structure, or polypeptide function.

[0025] It was determined that polymorphic variations associated with an increased risk of osteoarthritis existed in a *ADAMTS2* region in SEQ ID NO: 1. In certain embodiments, a polymorphic variant at position rs398829 in the human genome was associated with an increased risk of osteoarthritis, and in a specific embodiment, a guanine at position rs398829 was associated with an increased risk of osteoarthritis.

[0026] Polymorphic variants in and around the ADAMTS2 locus were tested for association with osteoarthritis. These include polymorphic variants at positions in SEQ ID NO: 1 selected from the group consisting of 210, 3608, 3609, 4318, 5593, 5629, 5639, 5640, 8943, 17968, 19887, 21034, 21085, 21596, 23379, 23432, 24007, 26121, 26273, 26755, 27411, 27710, 27842, 28379, 29603, 31232, 31504, 32583, 32794, 32840, 33044, 33150, 33218, 33513, 33959, 34486, 36289, 36570, 38247, 38477, 38518. 38529, 38667, 39781, 39856, 39927, 40506, 41869, 42452, 44788, 46059, 46846, 47712, 48796, 49441, 49602, 49723, 50050, 50171, 50477, 50818, 50833, 50881, 50882, 51386, 51534, 52317, 52368, 52970, 53023, 53356, 53882, 54553, 55475, 55530, 55691, 55848, 55879, 56316, 56911, 57320, 57391, 57437, 57478, 57500, 59111, 59333, 59715, 59804, 59851, 59929, 60052, 60240, 60359, 60381, 60456, 60724, 60875, 60968, 60978, 60998, 61557, 62091, 62645, 62943, 63131, 63145, 63406, 63427, 63554, 63661, 64093, 64153, 64409, 64544, 65257, 65626,65739, 66392, 66720, 69177, 69336, 69636, 69823, 69928, 70547, 70633, 71805, 72181, 72200, 72474, 72567, 72973, 73468, 73889, 75730, 75970, 76114, 76342, 76449, 76465, 76791, 78042, 80758, 80778, 81356, 81576, 81689, 81759, 81950, 82562, 83591, 83700, 83821, 83842, 83923, 83929, 84021, 84175, 84417, 84747, 85746, 86129, 86335, 87315, 87648, 87764, 87770, 88221, 90474, 91148, 91150, 91160, 91733, 91772, 91785, 93140, 93148, 96080, 96157, 96313, 96759, 97026, 97320, 97732, 98713, 99707, 99959, 100009, 100020, 100065, 100086, 101270, 101276, 101371, 101376, 101439, 101820, 102392, 102602, 102604, 102896, 189104, 189134 and 189205. Polymorphic variants at the following positions in SEQ ID NO: 1 in particular were associated with an increased risk of osteoarthritis: 5640, 33150, 38247, 38529, 46846, 49723, 50050, 63427, 73889, 189104 and rs428901, where specific embodiments are directed to positions 46846, 73889, 189104 and/or rs428901. In particular, the following polymorphic variants in SEQ ID NO: 1 were associated with risk of osteoarthritis: a cytosine at position 5640, a cytosine at position 33150, an adenine at position 38247, a thymine at position 38529, an adenine at position 46846, a cytosine at position 49723, a cytosine at position 50050, a cytosine a position 63427, a guanine at position 73889, a thymine at position 189104, and an adenine at position rs428901.

[0027] Based in part upon analyses summarized in Figure 1, a region with significant association has been identified in a locus associated with osteoarthritis. Any polymorphic variants associated with osteoarthritis in a region of significant association can be utilized for embodiments described herein. For example, polymorphic variants in a region spanning chromosome positions 178746000 to 178751000 (approximately 5,000 nucleotides in length) in a *ADAMTS2* locus have significant association (chromosome positions are within NCBI's Genome build 34).

#### Additional Polymorphic Variants Associated with Osteoarthritis

[0028] Also provided is a method for identifying polymorphic variants proximal to an incident, founder polymorphic variant associated with osteoarthritis. Thus, featured herein are methods for

identifying a polymorphic variation associated with osteoarthritis that is proximal to an incident polymorphic variation associated with osteoarthritis, which comprises identifying a polymorphic variant proximal to the incident polymorphic variant associated with osteoarthritis, where the incident polymorphic variant is in a ADAMTS2 nucleotide sequence. The nucleotide sequence often comprises a polynucleotide sequence selected from the group consisting of (a) a polynucleotide sequence of SEQ ID NO: 1-3; (b) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence encoded by a polynucleotide sequence of SEQ ID NO: 1-3; and (c) a polynucleotide sequence that encodes a polypeptide having an amino acid sequence that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3 or a polynucleotide sequence 90% or more identical to the polynucleotide sequence of SEQ ID NO: 1-3. The presence or absence of an association of the proximal polymorphic variant with osteoarthritis then is determined using a known association method, such as a method described in the Examples hereafter. In an embodiment, the incident polymorphic variant is a polymorphic variant associated with osteoarthritis described herein. In another embodiment, the proximal polymorphic variant identified sometimes is a publicly disclosed polymorphic variant, which for example, sometimes is published in a publicly available database. In other embodiments, the polymorphic variant identified is not publicly disclosed and is discovered using a known method, including, but not limited to, sequencing a region surrounding the incident polymorphic variant in a group of nucleic samples. Thus, multiple polymorphic variants proximal to an incident polymorphic variant are associated with osteoarthritis using this method.

[0029] The proximal polymorphic variant often is identified in a region surrounding the incident polymorphic variant. In certain embodiments, this surrounding region is about 50 kb flanking the first polymorphic variant (e.g. about 50 kb 5' of the first polymorphic variant and about 50 kb 3' of the first polymorphic variant), and the region sometimes is composed of shorter flanking sequences, such as flanking sequences of about 40 kb, about 30 kb, about 25 kb, about 20 kb, about 15 kb, about 10 kb, about 7 kb, about 5 kb, or about 2 kb 5' and 3' of the incident polymorphic variant. In other embodiments, the region is composed of longer flanking sequences, such as flanking sequences of about 55 kb, about 60 kb, about 65 kb, about 70 kb, about 75 kb, about 80 kb, about 85 kb, about 90 kb, about 95 kb, or about 100 kb 5' and 3' of the incident polymorphic variant.

[0030] In certain embodiments, polymorphic variants associated with osteoarthritis are identified iteratively. For example, a first proximal polymorphic variant is associated with osteoarthritis using the methods described above and then another polymorphic variant proximal to the first proximal polymorphic variant is identified (e.g., publicly disclosed or discovered) and the presence or absence of an association of one or more other polymorphic variants proximal to the first proximal polymorphic variant with osteoarthritis is determined.

[0031] The methods described herein are useful for identifying or discovering additional polymorphic variants that may be used to further characterize a gene, region or loci associated with a condition, a disease (e.g., osteoarthritis), or a disorder. For example, allelotyping or genotyping data from the additional polymorphic variants may be used to identify a functional mutation or a region of linkage disequilibrium. In certain embodiments, polymorphic variants identified or discovered within a region comprising the first polymorphic variant associated with osteoarthritis are genotyped using the genetic methods and sample selection techniques described herein, and it can be determined whether those polymorphic variants are in linkage disequilibrium with the first polymorphic variant. The size of the region in linkage disequilibrium with the first polymorphic variant also can be assessed using these genotyping methods. Thus, provided herein are methods for determining whether a polymorphic variant is in linkage disequilibrium with a first polymorphic variant associated with osteoarthritis, and such information can be used in prognosis/diagnosis methods described herein.

#### Isolated Nucleic Acids

[0032] Featured herein are isolated *ADAMTS2* nucleic acid variants depicted in SEQ ID NO: 1-3, and substantially identical nucleic acids thereof. A nucleic acid variant may be represented on one or both strands in a double-stranded nucleic acid or on one chromosomal complement (heterozygous) or both chromosomal complements (homozygous). *ADAMTS2* exists in two forms, a "long" form comprising a molecule approximately 130 kDa in length (e.g., SEQ ID NO: 2 for cDNA sequence and SEQ ID NO: 4 for amino acid sequence), and a "short" form comprising a molecule approximately 70 kDa in length (e.g., SEQ ID NO: 3 for cDNA sequence and SEQ ID NO: 5 for amino acid sequence). Provided herein are polynucleotide sequences encoding both the short and long forms of ADAMTS2.

[0033] As used herein, the term "nucleic acid" includes DNA molecules (e.g., a complementary DNA (cDNA) and genomic DNA (gDNA)) and RNA molecules (e.g., mRNA, rRNA, siRNA and tRNA) and analogs of DNA or RNA, for example, by use of nucleotide analogs. The nucleic acid molecule can be single-stranded and it is often double-stranded. The term "isolated or purified nucleic acid" refers to nucleic acids that are separated from other nucleic acids present in the natural source of the nucleic acid. For example, with regard to genomic DNA, the term "isolated" includes nucleic acids which are separated from the chromosome with which the genomic DNA is naturally associated. An "isolated" nucleic acid is often free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular

material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. As used herein, the term "gene" refers to a nucleotide sequence that encodes a polypeptide.

[0034] Also included herein are nucleic acid fragments. These fragments often have a nucleotide sequence identical to a nucleotide sequence of SEQ ID NO: 1-3, a nucleotide sequence substantially identical to a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence that is complementary to the foregoing. The nucleic acid fragment may be identical, substantially identical or homologous to a nucleotide sequence in an exon or an intron in a nucleotide sequence of SEQ ID NO: 1-3, and may encode a domain or part of a domain of a polypeptide. Sometimes, the fragment will comprises one or more of the polymorphic variations described herein as being associated with osteoarthritis. The nucleic acid fragment is often 50, 100, or 200 or fewer base pairs in length, and is sometimes about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 2000, 3000, 4000, 5000, 10000, 15000, or 20000 base pairs in length. A nucleic acid fragment that is complementary to a nucleotide sequence identical or substantially identical to a nucleotide sequence in SEQ ID NO: 1-3 and hybridizes to such a nucleotide sequence under stringent conditions is often referred to as a "probe." Nucleic acid fragments often include one or more polymorphic sites, or sometimes have an end that is adjacent to a polymorphic site as described hereafter.

[0035] An example of a nucleic acid fragment is an oligonucleotide. As used herein, the term "oligonucleotide" refers to a nucleic acid comprising about 8 to about 50 covalently linked nucleotides, often comprising from about 8 to about 35 nucleotides, and more often from about 10 to about 25 nucleotides. The backbone and nucleotides within an oligonucleotide may be the same as those of naturally occurring nucleic acids, or analogs or derivatives of naturally occurring nucleic acids, provided that oligonucleotides having such analogs or derivatives retain the ability to hybridize specifically to a nucleic acid comprising a targeted polymorphism. Oligonucleotides described herein may be used as hybridization probes or as components of prognostic or diagnostic assays, for example, as described herein.

[0036] Oligonucleotides are typically synthesized using standard methods and equipment, such as the ABI™3900 High Throughput DNA Synthesizer and the EXPEDITE™ 8909 Nucleic Acid Synthesizer, both of which are available from Applied Biosystems (Foster City, CA). Analogs and derivatives are exemplified in U.S. Pat. Nos. 4,469,863; 5,536,821; 5,541,306; 5,637,683; 5,637,684; 5,700,922; 5,717,083; 5,719,262; 5,739,308; 5,773,601; 5,886,165; 5,929,226; 5,977,296; 6,140,482; WO 00/56746; WO 01/14398, and related publications. Methods for synthesizing oligonucleotides comprising such analogs or derivatives are disclosed, for example, in the patent publications cited above

and in U.S. Pat. Nos. 5,614,622; 5,739,314; 5,955,599; 5,962,674; 6,117,992; in WO 00/75372; and in related publications.

[0037] Oligonucleotides may also be linked to a second moiety. The second moiety may be an additional nucleotide sequence such as a tail sequence (e.g., a polyadenosine tail), an adapter sequence (e.g., phage M13 universal tail sequence), and others. Alternatively, the second moiety may be a non-nucleotide moiety such as a moiety which facilitates linkage to a solid support or a label to facilitate detection of the oligonucleotide. Such labels include, without limitation, a radioactive label, a fluorescent label, a chemiluminescent label, a paramagnetic label, and the like. The second moiety may be attached to any position of the oligonucleotide, provided the oligonucleotide can hybridize to the nucleic acid comprising the polymorphism.

#### Uses for Nucleic Acid Sequence

[0038] Nucleic acid coding sequences may be used for diagnostic purposes for detection and control of polypeptide expression. Also, included herein are oligonucleotide sequences such as antisense RNA, small-interfering RNA (siRNA) and DNA molecules and ribozymes that function to inhibit translation of a polypeptide. Antisense techniques and RNA interference techniques are known in the art and are described herein.

[0039] Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, hammerhead motif ribozyme molecules may be engineered that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences corresponding to or complementary to *ADAMTS2* nucleotide sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

[0040] Antisense RNA and DNA molecules, siRNA and ribozymes may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated

into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

[0041] DNA encoding a polypeptide also may have a number of uses for the diagnosis of diseases, including osteoarthritis, resulting from aberrant expression of a target gene described herein. For example, the nucleic acid sequence may be used in hybridization assays of biopsies or autopsies to diagnose abnormalities of expression or function (e.g., Southern or Northern blot analysis, in situ hybridization assays).

[0042] In addition, the expression of a polypeptide during embryonic development may also be determined using nucleic acid encoding the polypeptide. As addressed, *infra*, production of functionally impaired polypeptide is the cause of various disease states, such as osteoarthritis. *In situ* hybridizations using polypeptide as a probe may be employed to predict problems related to osteoarthritis. Further, as indicated, *infra*, administration of human active polypeptide, recombinantly produced as described herein, may be used to treat disease states related to functionally impaired polypeptide. Alternatively, gene therapy approaches may be employed to remedy deficiencies of functional polypeptide or to replace or compete with dysfunctional polypeptide.

#### Expression Vectors, Host Cells, and Genetically Engineered Cells

[0043] Provided herein are nucleic acid vectors, often expression vectors, which contain a *ADAMTS2* nucleotide sequence, or a substantially identical sequence thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid, or viral vector. The vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors may include replication defective retroviruses, adenoviruses and adeno-associated viruses for example.

[0044] A vector can include a *ADAMTS2* nucleotide sequence in a form suitable for expression of an encoded target polypeptide or target nucleic acid in a host cell. A "target polypeptide" is a polypeptide encoded by a *ADAMTS2* nucleotide sequence, or a substantially identical nucleotide sequence thereof. The recombinant expression vector typically includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, and the like. Expression vectors can be introduced into host cells to produce target polypeptides, including fusion polypeptides.

[0045] Recombinant expression vectors can be designed for expression of target polypeptides in prokaryotic or eukaryotic cells. For example, target polypeptides can be expressed in *E. coli*, insect cells (e.g., using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

[0046] Expression of polypeptides in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors typically serve three purposes:

1) to increase expression of recombinant polypeptide; 2) to increase the solubility of the recombinant polypeptide; and 3) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety subsequent to purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith & Johnson, *Gene 67:* 31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

[0047] Purified fusion polypeptides can be used in screening assays and to generate antibodies specific for target polypeptides. In a therapeutic embodiment, fusion polypeptide expressed in a retroviral expression vector is used to infect bone marrow cells that are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six (6) weeks).

[0048] Expressing the polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide is often used to maximize recombinant polypeptide expression (Gottesman, S., Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, California 185: 119-128 (1990)). Another strategy is to alter the nucleotide sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al., Nucleic Acids Res. 20: 2111-2118 (1992)). Such alteration of nucleotide sequences can be carried out by standard DNA synthesis techniques.

[0049] When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. Recombinant mammalian expression vectors are

often capable of directing expression of the nucleic acid in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include an albumin promoter (liver-specific; Pinkert et al., Genes Dev. 1: 268-277 (1987)), lymphoid-specific promoters (Calame & Eaton, Adv. Immunol. 43: 235-275 (1988)), promoters of T cell receptors (Winoto & Baltimore, EMBO J. 8: 729-733 (1989)) promoters of immunoglobulins (Banerji et al., Cell 33: 729-740 (1983); Queen & Baltimore, Cell 33: 741-748 (1983)), neuron-specific promoters (e.g., the neurofilament promoter; Byrne & Ruddle, Proc. Natl. Acad. Sci. USA 86: 5473-5477 (1989)), pancreas-specific promoters (Edlund et al., Science 230: 912-916 (1985)), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are sometimes utilized, for example, the murine hox promoters (Kessel & Gruss, Science 249: 374-379 (1990)) and the α-fetopolypeptide promoter (Campes & Tilghman, Genes Dev. 3: 537-546 (1989)).

[0050] A ADAMTS2 nucleic acid also may be cloned into an expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a ADAMTS2 nucleic acid cloned in the antisense orientation can be chosen for directing constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. Antisense expression vectors can be in the form of a recombinant plasmid, phagemid or attenuated virus. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub et al., Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics, Vol. 1(1) (1986).

[0051] Also provided herein are host cells that include a *ADAMTS2* nucleotide sequence within a recombinant expression vector or a fragment of such a nucleotide sequence which facilitate homologous recombination into a specific site of the host cell genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. Such terms refer not only to the particular subject cell but rather also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a target polypeptide can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0052] Vectors can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, transduction/infection, DEAE-dextranmediated transfection, lipofection, or electroporation.

[0053] A host cell provided herein can be used to produce (*i.e.*, express) a target polypeptide or a substantially identical polypeptide thereof. Accordingly, further provided are methods for producing a target polypeptide using host cells described herein. In one embodiment, the method includes culturing host cells into which a recombinant expression vector encoding a target polypeptide has been introduced in a suitable medium such that a target polypeptide is produced. In another embodiment, the method further includes isolating a target polypeptide from the medium or the host cell.

transgene, or which otherwise misexpress target polypeptide. Cell preparations can consist of human or non-human cells, e.g., rodent cells, e.g., mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells include a ADAMTS2 transgene (e.g., a heterologous form of a ADAMTS2 gene, such as a human gene expressed in non-human cells). The transgene can be misexpressed, e.g., overexpressed or underexpressed. In other preferred embodiments, the cell or cells include a gene which misexpress an endogenous target polypeptide (e.g., expression of a gene is disrupted, also known as a knockout). Such cells can serve as a model for studying disorders which are related to mutated or misexpressed alleles or for use in drug screening. Also provided are human cells (e.g., a hematopoietic stem cells) transfected with a ADAMTS2 nucleic acid.

[0055] Also provided are cells or a purified preparation thereof (e.g., human cells) in which an endogenous ADAMTS2 nucleic acid is under the control of a regulatory sequence that does not normally control the expression of the endogenous gene. The expression characteristics of an endogenous gene within a cell (e.g., a cell line or microorganism) can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the corresponding endogenous gene. For example, an endogenous corresponding gene (e.g., a gene which is "transcriptionally silent," not normally expressed, or expressed only at very low levels) may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, e.g., Chappel, US 5,272,071; WO 91/06667, published on May 16, 1991.

#### Transgenic Animals

[0056] Non-human transgenic animals that express a heterologous target polypeptide (e.g., expressed from a ADAMTS2 nucleic acid or substantially identical sequence thereof) can be generated. Such animals are useful for studying the function and/or activity of a target polypeptide and for identifying and/or evaluating modulators of the activity of ADAMTS2 nucleic acids and encoded polypeptides. As used herein, a "transgenic animal" is a non-human animal such as a mammal (e.g., a non-human primate such as chimpanzee, baboon, or macaque; an ungulate such as an equine, bovine, or

caprine; or a rodent such as a rat, a mouse, or an Israeli sand rat), a bird (e.g., a chicken or a turkey), an amphibian (e.g., a frog, salamander, or newt), or an insect (e.g., Drosophila melanogaster), in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA or a rearrangement (e.g., a deletion of endogenous chromosomal DNA) that is often integrated into or occurs in the genome of cells in a transgenic animal. A transgene can direct expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, and other transgenes can reduce expression (e.g., a knockout). Thus, a transgenic animal can be one in which an endogenous nucleic acid homologous to a ADAMTS2 nucleic acid has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal (e.g., an embryonic cell of the animal) prior to development of the animal.

[0057] Intronic sequences and polyadenylation signals can also be included in the transgene to increase expression efficiency of the transgene. One or more tissue-specific regulatory sequences can be operably linked to a *ADAMTS2* nucleotide sequence to direct expression of an encoded polypeptide to particular cells. A transgenic founder animal can be identified based upon the presence of a *ADAMTS2* nucleotide sequence in its genome and/or expression of encoded mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a *ADAMTS2* nucleotide sequence can further be bred to other transgenic animals carrying other transgenes.

[0058] Target polypeptides can be expressed in transgenic animals or plants by introducing, for example, a *ADAMTS2* nucleic acid into the genome of an animal that encodes the target polypeptide. In preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, *e.g.*, a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Also included is a population of cells from a transgenic animal.

#### Target Polypeptides

[0059] Also featured herein are isolated target polypeptides, which are encoded by a *ADAMTS2* nucleotide sequence (e.g., SEQ ID NO: 1-3), or a substantially identical nucleotide sequence thereof. *ADAMTS2* exists in two forms, a "long" form comprising a molecule approximately 130 kDa in length (e.g., SEQ ID NO: 4), and a "short" form comprising a molecule approximately 70 kDa in length (e.g., SEQ ID NO: 5). Thus featured herein are isolated *ADAMTS2* polypeptides, which include long and short isoforms, and substantially identical polypeptides thereof. An *ADAMTS2* polypeptide is a polypeptide encoded by an *ADAMTS2* nucleic acid, where one nucleic acid can encode one or more different polypeptides. The term "polypeptide" as used herein includes proteins and peptides. An "isolated" or "purified" polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical

recursors or other chemicals when chemically synthesized. In one embodiment, the language "substantially free" means preparation of a target polypeptide having less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-target polypeptide (also referred to herein as a "contaminating protein"), or of chemical precursors or non-target chemicals. When the target polypeptide or a biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, specifically, where culture medium represents less than about 20%, sometimes less than about 10%, and often less than about 5% of the volume of the polypeptide preparation. Isolated or purified target polypeptide preparations are sometimes 0.01 milligrams or more or 0.1 milligrams or more, and often 1.0 milligrams or more and 10 milligrams or more in dry weight.

[0060] Further included herein are target polypeptide fragments. The polypeptide fragment may be a domain or part of a domain of a target polypeptide. The polypeptide fragment may have increased, decreased or unexpected biological activity. The polypeptide fragment is often 50 or fewer, 100 or fewer, or 200 or fewer amino acids in length, and is sometimes 300, 400, 500, 600, 700, or 900 or fewer amino acids in length. Thus, featured herein are *ADAMTS2* polypeptides and biologically active or antigenic fragments thereof useful as reagents or targets in assays applicable to treatment and diagnosis of osteoarthritis. In another embodiment, provided herein are *ADAMTS2* polypeptides having a *ADAMTS2* activity (e.g., a zinc binding activity, a metalloprotease activity, a procollagen II processing or synthesis activity, or a collagen II synthesis activity in vitro or in vivo). In certain embodiments, the polypeptides are *ADAMTS2* proteins including at least one propeptide domain, at least one metalloproteinase domain, at least one disintegrin-like domain, at least one, two, three, and often four thrombospondin domains, and sometimes having a *ADAMTS2* activity, e.g., a *ADAMTS2* activity as described herein. *ADAMTS2* polypeptides and fragments thereof often have biological activity, such as excising the N-propeptide of type II procollagens. Methods for monitoring and quantifying this biological activity are known (e.g., Colige et al., J. Biol. Chem. 270: 16724-16730 (1995)).

[0061] Human ADAMTS2 protein (SEQ ID NO: 4-5) includes a signal sequence of about 29 amino acids (from amino acid 1 to about amino acid 29 of SEQ ID NO: 4-5). The ADAMTS2 protein without the signal sequence can be approximately 1182 amino acid residues in length (from about amino acid 30 to amino acid 1211 of SEQ ID NO: 4) or approximately 485 amino acid residues in length (from about amino acid 30 to amino acid 514 of SEQ ID NO: 5). Human ADAMTS2 protein includes a "pro" region homologous to the reprolysin family propeptide, which is typically post-translationally cleaved upon conversion of the inactive (or pro-domain containing) protein to the catalytically active metalloprotease. The prodomain region of human ADAMTS2 protein corresponds to about amino acids 30 to 251, 30 to 252, 30 to 253, 30 to 254, 30 to 255, 30 to 256, 30 to 257, 30 to 258 or 30 to 259 of SEQ ID NO: 4-5, where it is understood that the active form of ADAMTS2 does not contain the propeptide domain.

[0062] Upon cleavage, catalytically active mature protein can be approximately 960, 959, 958, 957, 956, 955, 954, 953 or 952 amino acids in length (from about amino acid 252, 253, 254, 255, 256, 257, 258, 259 or 260 to amino acid 1211 of SEQ ID NO: 4) or approximately 261, 260, 259, 258, 257, 256, 255, 254 or 253 amino acid residues in length (from about amino acid 252, 253, 254, 255, 256, 257, 258, 259 or 260 to amino acid 514 of SEQ ID NO: 5).

[0063] Human *ADAMTS2* contains the following regions or other structural features: a signal sequence at about amino acids 1-29 of SEQ ID NO: 4-5; a reprolysin family propeptide domain located at about amino acid residues 30 to 251, 30 to 252, 30 to 253, 30 to 254, 30 to 255, 30 to 256, 30 to 257, 30 to 258 or 30 to 259 of SEQ ID NO: 4-5; a zinc-metalloprotease catalytic domain at about amino acids 251 to 479, 252 to 479, 253 to 479, 254 to 479, 255 to 479, 256 to 479, 257 to 479, 258 to 479 or 259 to 479 of SEQ ID NO: 4-5; a disintegrin domain at about amino acids 480 to 560 of SEQ ID NO: 4; a cysteine-rich domain at about amino acids 618 to 722 of SEQ ID NO: 4; four thrombospondin motifs-2 motifs at about amino acids 561 to 616, 854 to 912, 914 to 971, and 975 to 1029 of SEQ ID NO: 4; and eight N-glycosylation sites located at about amino acids 112, 251, 949, 993, 1031, 1098, 1145, and 1150 of SEQ ID NO: 4.

[0064] In other embodiments, provided are methods of increasing the synthesis of procollagen II comprising providing or administering to individuals in need of increasing levels of type II collagen the pharmaceutical or physiologically acceptable composition comprising active human *ADAMTS2* protein or fragment thereof, where *ADAMTS2* polypeptide fragments having activity are selected from amino acids 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain.

[0065] Substantially identical target polypeptides may depart from the amino acid sequences of target polypeptides in different manners. For example, conservative amino acid modifications may be introduced at one or more positions in the amino acid sequences of target polypeptides. A "conservative amino acid substitution" is one in which the amino acid is replaced by another amino acid having a similar structure and/or chemical function. Families of amino acid residues having similar structures and functions are well known. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Also, essential and non-essential amino acids may be replaced. A "non-essential" amino acid is one that can be altered without abolishing or substantially altering the biological function of a target polypeptide, whereas altering an "essential" amino acid abolishes or substantially alters the

biological function of a target polypeptide. Amino acids that are conserved among target polypeptides are typically essential amino acids. In certain embodiments, the polypeptide includes one or more non-synonymous polymorphic variants associated with osteoarthritis.

[0066] Also, target polypeptides may exist as chimeric or fusion polypeptides. As used herein, a target "chimeric polypeptide" or target "fusion polypeptide" includes a target polypeptide linked to a non-target polypeptide. A "non-target polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially identical to the target polypeptide, which includes, for example, a polypeptide that is different from the target polypeptide and derived from the same or a different organism. The target polypeptide in the fusion polypeptide can correspond to an entire or nearly entire target polypeptide or a fragment thereof. The non-target polypeptide can be fused to the N-terminus or C-terminus of the target polypeptide.

[0067] Fusion polypeptides can include a moiety having high affinity for a ligand. For example, the fusion polypeptide can be a GST-target fusion polypeptide in which the target sequences are fused to the C-terminus of the GST sequences, or a polyhistidine-target fusion polypeptide in which the target polypeptide is fused at the N- or C-terminus to a string of histidine residues. Such fusion polypeptides can facilitate purification of recombinant target polypeptide. Expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide), and a nucleotide sequence in SEQ ID NO: 1-3, or a substantially identical nucleotide sequence thereof, can be cloned into an expression vector such that the fusion moiety is linked in-frame to the target polypeptide. Further, the fusion polypeptide can be a target polypeptide containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression, secretion, cellular internalization, and cellular localization of a target polypeptide can be increased through use of a heterologous signal sequence. Fusion polypeptides can also include all or a part of a serum polypeptide (e.g., an IgG constant region or human serum albumin).

[0068] Target polypeptides can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. Administration of these target polypeptides can be used to affect the bioavailability of a substrate of the target polypeptide and may effectively increase target polypeptide biological activity in a cell. Target fusion polypeptides may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a target polypeptide; (ii) misregulation of the gene encoding the target polypeptide; and (iii) aberrant post-translational modification of a target polypeptide. Also, target polypeptides can be used as immunogens to produce anti-target antibodies in a subject, to purify target polypeptide ligands or binding partners, and in screening assays to identify molecules which inhibit or enhance the interaction of a target polypeptide with a substrate.

[0069] In addition, polypeptides can be chemically synthesized using techniques known in the art (See, e.g., Creighton, 1983 Proteins. New York, N.Y.: W. H. Freeman and Company; and Hunkapiller et

al., (1984) Nature July 12 -18;310(5973):105-11). For example, a relative short fragment can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the fragment sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoroamino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0070] Polypeptides and polypeptide fragments sometimes are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; and the like. Additional post-translational modifications include, for example, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of prokaryotic host cell expression. The polypeptide fragments may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the polypeptide.

[0071] Also provided are chemically modified derivatives of polypeptides that can provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see e.g., U.S. Pat. No: 4,179,337. The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0072] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if

any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

[0073] The polymers should be attached to the polypeptide with consideration of effects on functional or antigenic domains of the polypeptide. There are a number of attachment methods available to those skilled in the art (e.g., EP 0 401 384 (coupling PEG to G-CSF) and Malik et al. (1992) Exp Hematol. September;20(8):1028-35 (pegylation of GM-CSF using tresyl chloride)). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues, glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. For therapeutic purposes, the attachment sometimes is at an amino group, such as attachment at the N-terminus or lysine group.

[0074] Proteins can be chemically modified at the N-terminus. Using polyethylene glycol as an illustration of such a composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, and the like), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus may be accomplished by reductive alkylation, which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

#### Substantially Identical Nucleic Acids and Polypeptides

[0075] Nucleotide sequences and polypeptide sequences that are substantially identical to a *ADAMTS2* nucleotide sequence and the target polypeptide sequences encoded by those nucleotide sequences, respectively, are included herein. The term "substantially identical" as used herein refers to two or more nucleic acids or polypeptides sharing one or more identical nucleotide sequences or polypeptide sequences, respectively. Included are nucleotide sequences or polypeptide sequences that are 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more (each often within a 1%, 2%, 3% or 4% variability) identical to a *ADAMTS2* nucleotide sequence or the encoded target polypeptide amino acid sequences. One test for determining

whether two nucleic acids are substantially identical is to determine the percent of identical nucleotide sequences or polypeptide sequences shared between the nucleic acids or polypeptides.

[0076] Calculations of sequence identity are often performed as follows. Sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes is sometimes 30% or more, 40% or more, 50% or more, often 60% or more, and more often 70% or more, 80% or more, 90% or more, or 100% of the length of the reference sequence. The nucleotides or amino acids at corresponding nucleotide or polypeptide positions, respectively, are then compared among the two sequences. When a position in the first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, the nucleotides or amino acids are deemed to be identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, introduced for optimal alignment of the two sequences.

[0077] Comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. Percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of Meyers & Miller, *CABIOS 4*: 11-17 (1989), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. Also, percent identity between two amino acid sequences can be determined using the Needleman & Wunsch, *J. Mol. Biol. 48*: 444-453 (1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at the http address www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. Percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http address www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A set of parameters often used is a Blossum 62 scoring matrix with a gap open penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

[0078] Another manner for determining if two nucleic acids are substantially identical is to assess whether a polynucleotide homologous to one nucleic acid will hybridize to the other nucleic acid under stringent conditions. As use herein, the term "stringent conditions" refers to conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y., 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are described in that reference and either can be used. An example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C,

followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Often, stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. More often, stringency conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C.

[0079] An example of a substantially identical nucleotide sequence to a nucleotide sequence in SEQ ID NO: 1-3 is one that has a different nucleotide sequence but still encodes the same polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO: 1-3. Another example is a nucleotide sequence that encodes a polypeptide having a polypeptide sequence that is more than 70% or more identical to, sometimes more than 75% or more, 80% or more, or 85% or more identical to, and often more than 90% or more and 95% or more identical to a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3.

[0080] Nucleotide sequences in SEQ ID NO: 1-3 and amino acid sequences of encoded polypeptides can be used as "query sequences" to perform a search against public databases to identify other family members or related sequences, for example. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.*, *J. Mol. Biol. 215*: 403-10 (1990). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleotide sequences in SEQ ID NO: 1-3. BLAST polypeptide searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to polypeptides encoded by the nucleotide sequences of SEQ ID NO: 1-3. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, *Nucleic Acids Res. 25(17)*: 3389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (*see* the http address www.ncbi.nlm.nih.gov).

[0081] A nucleic acid that is substantially identical to a nucleotide sequence in SEQ ID NO: 1-3 may include polymorphic sites at positions equivalent to those described herein when the sequences are aligned. For example, using the alignment procedures described herein, SNPs in a sequence substantially identical to a sequence in SEQ ID NO: 1-3 can be identified at nucleotide positions that match (*i.e.*, align) with nucleotides at SNP positions in each nucleotide sequence in SEQ ID NO: 1-3. Also, where a polymorphic variation results in an insertion or deletion, insertion or deletion of a nucleotide sequence

from a reference sequence can change the relative positions of other polymorphic sites in the nucleotide sequence.

[0082] Substantially identical nucleotide and polypeptide sequences include those that are naturally occurring, such as allelic variants (same locus), splice variants, homologs (different locus), and orthologs (different organism) or can be non-naturally occurring. Non-naturally occurring variants can be generated by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded product). Orthologs, homologs, allelic variants, and splice variants can be identified using methods known in the art. These variants normally comprise a nucleotide sequence encoding a polypeptide that is 50% or more, about 55% or more, often about 70-75% or more or about 80-85% or more, and sometimes about 90-95% or more identical to the amino acid sequences of target polypeptides or a fragment thereof. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions to a nucleotide sequence in SEQ ID NO: 1-3 or a fragment of this sequence. Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of a nucleotide sequence in SEQ ID NO: 1-3 can further be identified by mapping the sequence to the same chromosome or locus as the nucleotide sequence in SEQ ID NO: 1-3.

[0083] Also, substantially identical nucleotide sequences may include codons that are altered with respect to the naturally occurring sequence for enhancing expression of a target polypeptide in a particular expression system. For example, the nucleic acid can be one in which one or more codons are altered, and often 10% or more or 20% or more of the codons are altered for optimized expression in bacteria (e.g., E. coli.), yeast (e.g., S. cervesiae), human (e.g., 293 cells), insect, or rodent (e.g., hamster) cells.

#### Methods for Identifying Risk of Osteoarthritis

[0084] Methods for prognosing and diagnosing osteoarthritis are included herein. These methods include detecting the presence or absence of one or more polymorphic variations in a nucleotide sequence associated with osteoarthritis, such as variants in or around the loci set forth herein, or a substantially identical sequence thereof, in a sample from a subject, where the presence of a polymorphic variant described herein is indicative of a risk of osteoarthritis. Determining a risk of osteoarthritis sometimes refers to determining whether an individual is at an increased risk of osteoarthritis (e.g., intermediate risk or higher risk).

[0085] Thus, featured herein is a method for identifying a subject who is at risk of osteoarthritis, which comprises detecting an aberration associated with osteoarthritis in a nucleic acid sample from the

subject. An embodiment is a method for detecting a risk of osteoarthritis in a subject, which comprises detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-3; (b) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-3; and (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising the polymorphic site; whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject. In some embodiments, a polymorphic variation at position 733 of SEQ ID NO: 2-3 may be detected (e.g., a guanine in these sequences or a cytosine in a complementary sequence are associated with increased risk of osteoarthritis). In certain embodiments, polymorphic variants at the positions described herein are detected for determining a risk of osteoarthritis, and polymorphic variants at positions in linkage disequilibrium with these positions are detected for determining a risk of osteoarthritis. As used herein, "SEQ ID NO: 1-3" refers to individual sequences in SEQ ID NO: 1, 2 or 3, each sequence being separately applicable to embodiments described herein.

[0086] Risk of osteoarthritis sometimes is expressed as a probability, such as an odds ratio, percentage, or risk factor. Risk often is based upon the presence or absence of one or more polymorphic variants described herein, and also may be based in part upon phenotypic traits of the individual being tested. Methods for calculating risk based upon patient data are well known (see, e.g., Agresti, Categorical Data Analysis, 2nd Ed. 2002. Wiley). Allelotyping and genotyping analyses may be carried out in populations other than those exemplified herein to enhance the predictive power of the prognostic method. These further analyses are executed in view of the exemplified procedures described herein, and may be based upon the same polymorphic variations or additional polymorphic variations.

[0087] In certain embodiments, determining the presence of a combination of two or more polymorphic variants associated with osteoarthritis in one or more genetic loci (e.g., one or more genes) of the sample is determined to identify, quantify and/or estimate, risk of osteoarthritis. The risk often is the probability of having or developing osteoarthritis. The risk sometimes is expressed as a relative risk with respect to a population average risk of osteoarthritis, and sometimes is expressed as a relative risk with respect to the lowest risk group. Such relative risk assessments often are based upon penetrance values determined by statistical methods, and are particularly useful to clinicians and insurance companies for assessing risk of osteoarthritis (e.g., a clinician can target appropriate detection, prevention and therapeutic regimens to a patient after determining the patient's risk of osteoarthritis, and an

insurance company can fine tune actuarial tables based upon population genotype assessments of osteoarthritis risk). Risk of osteoarthritis sometimes is expressed as an odds ratio, which is the odds of a particular person having a genotype has or will develop osteoarthritis with respect to another genotype group (e.g., the most disease protective genotype or population average). In related embodiments, the determination is utilized to identify a subject at risk of osteoarthritis. In an embodiment, two or more polymorphic variations are detected in two or more regions in human genomic DNA associated with increased risk of osteoarthritis, such as a locus containing a *ADAMTS2*, for example. In certain embodiments, 3 or more, or 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more polymorphic variants are detected in the sample. In specific embodiments, polymorphic variants are detected at other genetic loci (e.g., the polymorphic variants can be detected in *ADAMTS2* in addition to other loci or only in other loci), where the other loci include but are not limited to those described in concurrently-filed patent applications having attorney docket number 524593008700, 524593008800, 524593009000 or 524593009200, which is incorporated herein by reference in its entirety.

[0088] Results from prognostic tests may be combined with other test results to diagnose osteoarthritis. For example, prognostic results may be gathered, a patient sample may be ordered based on a determined predisposition to osteoarthritis, the patient sample is analyzed, and the results of the analysis may be utilized to diagnose osteoarthritis. Also osteoarthritis diagnostic method can be developed from studies used to generate prognostic methods in which populations are stratified into subpopulations having different progressions of osteoarthritis. In another embodiment, prognostic results may be gathered, a patient's risk factors for developing osteoarthritis (e.g., age, weight, race, diet) analyzed, and a patient sample may be ordered based on a determined predisposition to osteoarthritis.

[0089] The nucleic acid sample typically is isolated from a biological sample obtained from a subject. For example, nucleic acid can be isolated from blood, saliva, sputum, urine, cell scrapings, and biopsy tissue. The nucleic acid sample can be isolated from a biological sample using standard techniques, such as the technique described in Example 2. As used herein, the term "subject" refers primarily to humans but also refers to other mammals such as dogs, cats, and ungulates (e.g., cattle, sheep, and swine). Subjects also include avians (e.g., chickens and turkeys), reptiles, and fish (e.g., salmon), as embodiments described herein can be adapted to nucleic acid samples isolated from any of these organisms. The nucleic acid sample may be isolated from the subject and then directly utilized in a method for determining the presence of a polymorphic variant, or alternatively, the sample may be isolated and then stored (e.g., frozen) for a period of time before being subjected to analysis.

[0090] The presence or absence of a polymorphic variant is determined using one or both chromosomal complements represented in the nucleic acid sample. Determining the presence or absence of a polymorphic variant in both chromosomal complements represented in a nucleic acid sample from a

subject having a copy of each chromosome is useful for determining the zygosity of an individual for the polymorphic variant (*i.e.*, whether the individual is homozygous or heterozygous for the polymorphic variant). Any oligonucleotide-based diagnostic may be utilized to determine whether a sample includes the presence or absence of a polymorphic variant in a sample. For example, primer extension methods, ligase sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,679,524 and 5,952,174, and WO 01/27326), mismatch sequence determination methods (*e.g.*, U.S. Pat. Nos. 5,851,770; 5,958,692; 6,110,684; and 6,183,958), microarray sequence determination methods, restriction fragment length polymorphism (RFLP), single strand conformation polymorphism detection (SSCP) (*e.g.*, U.S. Pat. Nos. 5,891,625 and 6,013,499), PCR-based assays (*e.g.*, TAQMAN® PCR System (Applied Biosystems)), and nucleotide sequencing methods may be used.

[0091] Oligonucleotide extension methods typically involve providing a pair of oligonucleotide primers in a polymerase chain reaction (PCR) or in other nucleic acid amplification methods for the purpose of amplifying a region from the nucleic acid sample that comprises the polymorphic variation. One oligonucleotide primer is complementary to a region 3' of the polymorphism and the other is complementary to a region 5' of the polymorphism. A PCR primer pair may be used in methods disclosed in U.S. Pat. Nos. 4,683,195; 4,683,202, 4,965,188; 5,656,493; 5,998,143; 6,140,054; WO 01/27327; and WO 01/27329 for example. PCR primer pairs may also be used in any commercially available machines that perform PCR, such as any of the GENEAMP® Systems available from Applied Biosystems. Also, those of ordinary skill in the art will be able to design oligonucleotide primers based upon a *ADAMTS2* nucleotide sequence using knowledge available in the art.

[0092] Also provided is an extension oligonucleotide that hybridizes to the amplified fragment adjacent to the polymorphic variation. As used herein, the term "adjacent" refers to the 3' end of the extension oligonucleotide being often 1 nucleotide from the 5' end of the polymorphic site, and sometimes 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5' end of the polymorphic site, in the nucleic acid when the extension oligonucleotide is hybridized to the nucleic acid. The extension oligonucleotide then is extended by one or more nucleotides, and the number and/or type of nucleotides that are added to the extension oligonucleotide determine whether the polymorphic variant is present. Oligonucleotide extension methods are disclosed, for example, in U.S. Pat. Nos. 4,656,127; 4,851,331; 5,679,524; 5,834,189; 5,876,934; 5,908,755; 5,912,118; 5,976,802; 5,981,186; 6,004,744; 6,013,431; 6,017,702; 6,046,005; 6,087,095; 6,210,891; and WO 01/20039. Oligonucleotide extension methods using mass spectrometry are described, for example, in U.S. Pat. Nos. 5,547,835; 5,605,798; 5,691,141; 5,849,542; 5,869,242; 5,928,906; 6,043,031; and 6,194,144, and a method often utilized is described herein in Example 2.

[0093] A microarray can be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A microarray may include any oligonucleotides described herein, and

methods for making and using oligonucleotide microarrays suitable for diagnostic use are disclosed in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,589,330; 5,695,940; 5,849,483; 6,018,041; 6,045,996; 6,136,541; 6,142,681; 6,156,501; 6,197,506; 6,223,127; 6,225,625; 6,229,911; 6,239,273; WO 00/52625; WO 01/25485; and WO 01/29259. The microarray typically comprises a solid support and the oligonucleotides may be linked to this solid support by covalent bonds or by non-covalent interactions. The oligonucleotides may also be linked to the solid support directly or by a spacer molecule. A microarray may comprise one or more oligonucleotides complementary to a polymorphic site set forth herein.

[0094] A kit also may be utilized for determining whether a polymorphic variant is present or absent in a nucleic acid sample. A kit often comprises one or more pairs of oligonucleotide primers useful for amplifying a fragment of a nucleotide sequence of SEQ ID NO: 1-3 or a substantially identical sequence thereof, where the fragment includes a polymorphic site. The kit sometimes comprises a polymerizing agent, for example, a thermostable nucleic acid polymerase such as one disclosed in U.S. Pat. Nos. 4,889,818 or 6,077,664. Also, the kit often comprises an elongation oligonucleotide that hybridizes to a ADAMTS2 nucleotide sequence in a nucleic acid sample adjacent to the polymorphic site. Where the kit includes an elongation oligonucleotide, it also often comprises chain elongating nucleotides, such as dATP, dTTP, dGTP, dCTP, and dITP, including analogs of dATP, dTTP, dGTP, dCTP and dITP, provided that such analogs are substrates for a thermostable nucleic acid polymerase and can be incorporated into a nucleic acid chain elongated from the extension oligonucleotide. Along with chain elongating nucleotides would be one or more chain terminating nucleotides such as ddATP, ddTTP, ddGTP, ddCTP, and the like. In an embodiment, the kit comprises one or more oligonucleotide primer pairs, a polymerizing agent, chain elongating nucleotides, at least one elongation oligonucleotide, and one or more chain terminating nucleotides. Kits optionally include buffers, vials, microtiter plates, and instructions for use.

[0095] An individual identified as being at risk of osteoarthritis may be heterozygous or homozygous with respect to the allele associated with a higher risk of osteoarthritis. A subject homozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively high risk of osteoarthritis, a subject heterozygous for an allele associated with an increased risk of osteoarthritis is at a comparatively intermediate risk of osteoarthritis, and a subject homozygous for an allele associated with a decreased risk of osteoarthritis is at a comparatively low risk of osteoarthritis. A genotype may be assessed for a complementary strand, such that the complementary nucleotide at a particular position is detected.

[0096] Also featured are methods for determining risk of osteoarthritis and/or identifying a subject at risk of osteoarthritis by contacting a polypeptide or protein encoded by a *ADAMTS2* nucleotide sequence from a subject with an antibody that specifically binds to an epitope associated with increased

risk of osteoarthritis in the polypeptide (e.g., an epitope comprising a valine at position 245 in an *IR1LR1* polypeptide).

#### Applications of Prognostic and Diagnostic Results to Pharmacogenomic Methods

[0097] Pharmacogenomics is a discipline that involves tailoring a treatment for a subject according to the subject's genotype as a particular treatment regimen may exert a differential effect depending upon the subject's genotype. For example, based upon the outcome of a prognostic test described herein, a clinician or physician may target pertinent information and preventative or therapeutic treatments to a subject who would be benefited by the information or treatment and avoid directing such information and treatments to a subject who would not be benefited (e.g., the treatment has no therapeutic effect and/or the subject experiences adverse side effects).

[0098] The following is an example of a pharmacogenomic embodiment. A particular treatment regimen can exert a differential effect depending upon the subject's genotype. Where a candidate therapeutic exhibits a significant interaction with a major allele and a comparatively weak interaction with a minor allele (e.g., an order of magnitude or greater difference in the interaction), such a therapeutic typically would not be administered to a subject genotyped as being homozygous for the minor allele, and sometimes not administered to a subject genotyped as being heterozygous for the minor allele. In another example, where a candidate therapeutic is not significantly toxic when administered to subjects who are homozygous for a major allele but is comparatively toxic when administered to subjects heterozygous or homozygous for a minor allele, the candidate therapeutic is not typically administered to subjects who are genotyped as being heterozygous or homozygous with respect to the minor allele.

[0099] The methods described herein are applicable to pharmacogenomic methods for preventing, alleviating or treating osteoarthritis. For example, a nucleic acid sample from an individual may be subjected to a prognostic test described herein. Where one or more polymorphic variations associated with increased risk of osteoarthritis are identified in a subject, information for preventing or treating osteoarthritis and/or one or more osteoarthritis treatment regimens then may be prescribed to that subject.

[0100] In certain embodiments, a treatment or preventative regimen is specifically prescribed and/or administered to individuals who will most benefit from it based upon their risk of developing osteoarthritis assessed by the methods described herein. Thus, provided are methods for identifying a subject predisposed to osteoarthritis and then prescribing a therapeutic or preventative regimen to individuals identified as having a predisposition. Thus, certain embodiments are directed to a method for reducing osteoarthritis in a subject, which comprises: detecting the presence or absence of a polymorphic variant associated with osteoarthritis in a nucleotide sequence in a nucleic acid sample from a subject, where the nucleotide sequence comprises a polynucleotide sequence selected from the group consisting of: (a) a nucleotide sequence of SEQ ID NO: 1-3; (b) a nucleotide sequence which encodes a polypeptide

consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3; (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-3; and (d) a fragment of a polynucleotide sequence of (a), (b), or (c); and prescribing or administering a treatment regimen to a subject from whom the sample originated where the presence of a polymorphic variation associated with osteoarthritis is detected in the nucleotide sequence. In these methods, predisposition results may be utilized in combination with other test results to diagnose osteoarthritis.

[0101] Certain preventative treatments often are prescribed to subjects having a predisposition to osteoarthritis and where the subject is diagnosed with osteoarthritis or is diagnosed as having symptoms indicative of an early stage of osteoarthritis. The treatment sometimes is preventative (e.g., is prescribed or administered to reduce the probability that osteoarthritis arises or progresses), sometimes is therapeutic, and sometimes delays, alleviates or halts the progression of osteoarthritis. Any known preventative or therapeutic treatment for alleviating or preventing the occurrence of osteoarthritis is prescribed and/or administered. For example, the treatment often is directed to decreasing pain and improving joint movement. Examples of OA treatments include exercises to keep joints flexible and improve muscle strength. Different medications to control pain, including corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., Voltaren); cyclooxygenase-2 (COX-2) inhibitors (e.g., Celebrex, Vioxx, Mobic, and Bextra); monoclonal antibodies (e.g., Remicade); tumor necrosis factor inhibitors (e.g., Enbrel); or injections of glucocorticoids, hyaluronic acid or chondrotin sulfate into joints that are inflamed and not responsive to NSAIDS. Orally administered chondroitin sulfate also may be used as a therapeutic, as it may increase hyaluronic acid levels and viscosity of synovial fluid, and decrease collagenase levels in synovial fluid. Also, glucosamine can serve as an OA therapeutic as delivering it into joints may inhibit enzymes involved in cartilage degradation and enhance the production of hyaluronic acid. For mild pain without inflammation, acetaminophen may be used. Other treatments include: heat/cold therapy for temporary pain relief; joint protection to prevent strain or stress on painful joints; surgery to relieve chronic pain in damaged joints; and weight control to prevent extra stress on weight-bearing joints.

[0102] As therapeutic approaches for treating osteoarthritis continue to evolve and improve, the goal of treatments for osteoarthritis related disorders is to intervene even before clinical signs first manifest. Thus, genetic markers associated with susceptibility to osteoarthritis prove useful for early diagnosis, prevention and treatment of osteoarthritis.

[0103] As osteoarthritis preventative and treatment information can be specifically targeted to subjects in need thereof (e.g., those at risk of developing osteoarthritis or those in an early stage of osteoarthritis), provided herein is a method for preventing or reducing the risk of developing

osteoarthritis in a subject, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying a subject with a predisposition to osteoarthritis, whereby the presence of the polymorphic variation is indicative of a predisposition to osteoarthritis in the subject; and (c) if such a predisposition is identified, providing the subject with information about methods or products to prevent or reduce osteoarthritis or to delay the onset of osteoarthritis. Also provided is a method of targeting information or advertising to a subpopulation of a human population based on the subpopulation being genetically predisposed to a disease or condition, which comprises: (a) detecting the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) identifying the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; and (c) providing information only to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition.

[0104] Pharmacogenomics methods also may be used to analyze and predict a response to osteoarthritis treatment or a drug. For example, if pharmacogenomics analysis indicates a likelihood that an individual will respond positively to osteoarthritis treatment with a particular drug, the drug may be administered to the individual. Conversely, if the analysis indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. The response to a therapeutic treatment can be predicted in a background study in which subjects in any of the following populations are genotyped: a population that responds favorably to a treatment regimen, a population that does not respond significantly to a treatment regimen, and a population that responds adversely to a treatment regimen (e.g., exhibits one or more side effects). These populations are provided as examples and other populations and subpopulations may be analyzed. Based upon the results of these analyses, a subject is genotyped to predict whether he or she will respond favorably to a treatment regimen, not respond significantly to a treatment regimen, or respond adversely to a treatment regimen.

[0105] The tests described herein also are applicable to clinical drug trials. One or more polymorphic variants indicative of response to an agent for treating osteoarthritis or to side effects to an agent for treating osteoarthritis may be identified using the methods described herein. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

[0106] Thus, another embodiment is a method of selecting an individual for inclusion in a clinical trial of a treatment or drug comprising the steps of: (a) obtaining a nucleic acid sample from an individual; (b) determining the identity of a polymorphic variation which is associated with a positive response to the treatment or the drug, or at least one polymorphic variation which is associated with a negative response to the treatment or the drug in the nucleic acid sample, and (c) including the individual in the clinical trial if the nucleic acid sample contains said polymorphic variation associated with a positive response to the treatment or the drug or if the nucleic acid sample lacks said polymorphic variation associated with a negative response to the treatment or the drug. In addition, the methods described herein for selecting an individual for inclusion in a clinical trial of a treatment or drug encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination. The polymorphic variation may be in a sequence selected individually or in any combination from the group consisting of (i) a nucleotide sequence of SEQ ID NO: 1-3; (ii) a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3; (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3, or a nucleotide sequence about 90% or more identical to a nucleotide sequence of SEQ ID NO: 1-3; and (iv) a fragment of a polynucleotide sequence of (i), (ii), or (iii) comprising the polymorphic site. The including step (c) optionally comprises administering the drug or the treatment to the individual if the nucleic acid sample contains the polymorphic variation associated with a positive response to the treatment or the drug and the nucleic acid sample lacks said biallelic marker associated with a negative response to the treatment or the drug.

[0107] Also provided herein is a method of partnering between a diagnostic/prognostic testing provider and a provider of a consumable product, which comprises: (a) the diagnostic/prognostic testing provider detects the presence or absence of a polymorphic variation associated with osteoarthritis at a polymorphic site in a nucleotide sequence in a nucleic acid sample from a subject; (b) the diagnostic/prognostic testing provider identifies the subpopulation of subjects in which the polymorphic variation is associated with osteoarthritis; (c) the diagnostic/prognostic testing provider forwards information to the subpopulation of subjects about a particular product which may be obtained and consumed or applied by the subject to help prevent or delay onset of the disease or condition; and (d) the provider of a consumable product forwards to the diagnostic test provider a fee every time the diagnostic/prognostic test provider forwards information to the subject as set forth in step (c) above.

#### Compositions Comprising Osteoarthritis-Directed Molecules

[0108] Featured herein is a composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and one or more molecules specifically directed and targeted to a nucleic acid

comprising a ADAMTS2 nucleotide sequence or amino acid sequence. Such directed molecules include, but are not limited to, a compound that binds to a ADAMTS2 nucleotide sequence or amino acid sequence referenced herein; a RNAi or siRNA molecule having a strand complementary or substantially complementary to a ADAMTS2 nucleotide sequence (e.g., hybridizes to a ADAMTS2 nucleotide sequence under conditions of high stringency); an antisense nucleic acid complementary or substantially complementary to an RNA encoded by a ADAMTS2 nucleotide sequence (e.g., hybridizes to a ADAMTS2 nucleotide sequence under conditions of high stringency); a ribozyme that hybridizes to a ADAMTS2 nucleotide sequence (e.g., hybridizes to a ADAMTS2 nucleotide sequence under conditions of high stringency); a nucleic acid aptamer that specifically binds a polypeptide encoded by ADAMTS2 nucleotide sequence; and an antibody that specifically binds to a polypeptide encoded by ADAMTS2 nucleotide sequence or binds to a nucleic acid having such a nucleotide sequence. In specific embodiments, the osteoarthritis directed molecule interacts with a nucleic acid or polypeptide variant associated with osteoarthritis, such as variants referenced herein. In other embodiments, the osteoarthritis directed molecule interacts with a polypeptide involved in a signal pathway of a polypeptide encoded by a ADAMTS2 nucleotide sequence, or a nucleic acid comprising such a nucleotide sequence.

[0109] Compositions sometimes include an adjuvant known to stimulate an immune response, and in certain embodiments, an adjuvant that stimulates a T-cell lymphocyte response. Adjuvants are known, including but not limited to an aluminum adjuvant (e.g., aluminum hydroxide); a cytokine adjuvant or adjuvant that stimulates a cytokine response (e.g., interleukin (IL)-12 and/or gamma-interferon cytokines); a Freund-type mineral oil adjuvant emulsion (e.g., Freund's complete or incomplete adjuvant); a synthetic lipoid compound; a copolymer adjuvant (e.g., TitreMax); a saponin; Quil A; a liposome; an oil-in-water emulsion (e.g., an emulsion stabilized by Tween 80 and pluronic polyoxyethlene/polyoxypropylene block copolymer (Syntex Adjuvant Formulation); TitreMax; detoxified endotoxin (MPL) and mycobacterial cell wall components (TDW, CWS) in 2% squalene (Ribi Adjuvant System)); a muramyl dipeptide; an immune-stimulating complex (ISCOM, e.g., an Agmodified saponin/cholesterol micelle that forms stable cage-like structure); an aqueous phase adjuvant that does not have a depot effect (e.g., Gerbu adjuvant); a carbohydrate polymer (e.g., AdjuPrime); Ltyrosine; a manide-oleate compound (e.g., Montanide); an ethylene-vinyl acetate copolymer (e.g., Elvax 40W1,2); or lipid A, for example. Such compositions are useful for generating an immune response against osteoarthritis directed molecule (e.g., an HLA-binding subsequence within a polypeptide encoded by a ADAMTS2 nucleotide sequence). In such methods, a peptide having an amino acid subsequence of a polypeptide encoded by a ADAMTS2 nucleotide sequence is delivered to a subject, where the subsequence binds to an HLA molecule and induces a CTL lymphocyte response. The peptide sometimes is delivered to the subject as an isolated peptide or as a minigene in a plasmid that encodes the

peptide. Methods for identifying HLA-binding subsequences in such polypeptides are known (see e.g., publication WO02/20616 and PCT application US98/01373 for methods of identifying such sequences).

[0110] The cell may be in a group of cells cultured *in vitro* or in a tissue maintained *in vitro* or present in an animal *in vivo* (e.g., a rat, mouse, ape or human). In certain embodiments, a composition comprises a component from a cell such as a nucleic acid molecule (e.g., genomic DNA), a protein mixture or isolated protein, for example. The aforementioned compositions have utility in diagnostic, prognostic and pharmacogenomic methods described previously and in therapeutics described hereafter. Certain osteoarthritis directed molecules are described in greater detail below.

### Compounds

[0111] Compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive (see, e.g., Zuckermann et al., J. Med. Chem.37: 2678-85 (1994)); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; "one-bead one-compound" library methods; and synthetic library methods using affinity chromatography selection. Biological library and peptoid library approaches are typically limited to peptide libraries, while the other approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des. 12: 145, (1997)). Examples of methods for synthesizing molecular libraries are described, for example, in DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90: 6909 (1993); Erb et al., Proc. Natl. Acad. Sci. USA 91: 11422 (1994); Zuckermann et al., J. Med. Chem. 37: 2678 (1994); Cho et al., Science 261: 1303 (1993); Carrell et al., Angew. Chem. Int. Ed. Engl. 33: 2061 (1994); and in Gallop et al., J. Med. Chem. 37: 1233 (1994).

[0112] Libraries of compounds may be presented in solution (e.g., Houghten, Biotechniques 13: 412-421 (1992)), or on beads (Lam, Nature 354: 82-84 (1991)), chips (Fodor, Nature 364: 555-556 (1993)), bacteria or spores (Ladner, United States Patent No. 5,223,409), plasmids (Cull et al., Proc. Natl. Acad. Sci. USA 89: 1865-1869 (1992)) or on phage (Scott and Smith, Science 249: 386-390 (1990); Devlin, Science 249: 404-406 (1990); Cwirla et al., Proc. Natl. Acad. Sci. 87: 6378-6382 (1990); Felici, J. Mol. Biol. 222: 301-310 (1991); Ladner supra.).

[0113] A compound sometimes alters expression and sometimes alters activity of a polypeptide target and may be a small molecule. Small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole,

organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

# Antisense Nucleic Acid Molecules, Ribozymes, RNAi, siRNA and Modified Nucleic Acid Molecules

[0114] An "antisense" nucleic acid refers to a nucleotide sequence complementary to a "sense" nucleic acid encoding a polypeptide, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire coding strand, or to a portion thereof or a substantially identical sequence thereof. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence (e.g., 5' and 3' untranslated regions in SEQ ID NO: 1).

[0115] An antisense nucleic acid can be designed such that it is complementary to the entire coding region of an mRNA encoded by a nucleotide sequence (e.g., SEQ ID NO: 1), and often the antisense nucleic acid is an oligonucleotide antisense to only a portion of a coding or noncoding region of the mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length. The antisense nucleic acids, which include the ribozymes described hereafter, can be designed to target a *ADAMTS2* nucleotide sequence, often a variant associated with osteoarthritis, or a substantially identical sequence thereof. Among the variants, minor alleles and major alleles can be targeted, and those associated with a higher risk of osteoarthritis are often designed, tested, and administered to subjects.

[0116] An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using standard procedures. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0117] When utilized as therapeutics, antisense nucleic acids typically are administered to a subject (e.g., by direct injection at a tissue site) or generated in situ such that they hybridize with or bind to

cellular mRNA and/or genomic DNA encoding a polypeptide and thereby inhibit expression of the polypeptide, for example, by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then are administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, for example, by linking antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. Antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. Sufficient intracellular concentrations of antisense molecules are achieved by incorporating a strong promoter, such as a pol II or pol III promoter, in the vector construct.

[0118] Antisense nucleic acid molecules sometimes are alpha-anomeric nucleic acid molecules. An alpha-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al., Nucleic Acids. Res. 15: 6625-6641 (1987)). Antisense nucleic acid molecules can also comprise a 2'-o-methylribonucleotide (Inoue et al., Nucleic Acids Res. 15: 6131-6148 (1987)) or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215: 327-330 (1987)). Antisense nucleic acids sometimes are composed of DNA or PNA or any other nucleic acid derivatives described previously.

[0119] In another embodiment, an antisense nucleic acid is a ribozyme. A ribozyme having specificity for a *ADAMTS2* nucleotide sequence can include one or more sequences complementary to such a nucleotide sequence, and a sequence having a known catalytic region responsible for mRNA cleavage (see e.g., U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach, Nature 334: 585-591 (1988)). For example, a derivative of a Tetrahymena L-19 IVS RNA is sometimes utilized in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a mRNA (see e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742). Also, target mRNA sequences can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules (see e.g., Bartel & Szostak, Science 261: 1411-1418 (1993)).

[0120] Osteoarthritis directed molecules include in certain embodiments nucleic acids that can form triple helix structures with a *ADAMTS2* nucleotide sequence, or a substantially identical sequence thereof, especially one that includes a regulatory region that controls expression of a polypeptide. Gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of a nucleotide sequence referenced herein or a substantially identical sequence (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of a gene in target cells (see e.g., Helene, Anticancer Drug Des. 6(6): 569-84 (1991); Helene et al., Ann. N.Y. Acad. Sci. 660: 27-36 (1992); and Maher, Bioassays 14(12): 807-15 (1992). Potential sequences that can be targeted for triple helix formation can be increased by creating a so-called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one

strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

[0121] Osteoarthritis directed molecules include RNAi and siRNA nucleic acids. Gene expression may be inhibited by the introduction of double-stranded RNA (dsRNA), which induces potent and specific gene silencing, a phenomenon called RNA interference or RNAi. See, e.g., Fire et al., US Patent Number 6,506,559; Tuschl et al. PCT International Publication No. WO 01/75164; Kay et al. PCT International Publication No. WO 03/010180A1; or Bosher JM, Labouesse, Nat Cell Biol 2000 Feb;2(2):E31-6. This process has been improved by decreasing the size of the double-stranded RNA to 20-24 base pairs (to create small-interfering RNAs or siRNAs) that "switched off" genes in mammalian cells without initiating an acute phase response, i.e., a host defense mechanism that often results in cell death (see, e.g., Caplen et al. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9742-7 and Elbashir et al. Methods 2002 Feb;26(2):199-213). There is increasing evidence of post-transcriptional gene silencing by RNA interference (RNAi) for inhibiting targeted expression in mammalian cells at the mRNA level, in human cells. There is additional evidence of effective methods for inhibiting the proliferation and migration of tumor cells in human patients, and for inhibiting metastatic cancer development (see, e.g., U.S. Patent Application No. US2001000993183; Caplen et al. Proc Natl Acad Sci U S A; and Abderrahmani et al. Mol Cell Biol 2001 Nov21(21):7256-67).

[0122] An "siRNA" or "RNAi" refers to a nucleic acid that forms a double stranded RNA and has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is delivered to or expressed in the same cell as the gene or target gene. "siRNA" refers to short double-stranded RNA formed by the complementary strands. Complementary portions of the siRNA that hybridize to form the double stranded molecule often have substantial or complete identity to the target molecule sequence. In one embodiment, an siRNA refers to a nucleic acid that has substantial or complete identity to a target gene and forms a double stranded siRNA.

[0123] When designing the siRNA molecules, the targeted region often is selected from a given DNA sequence beginning 50 to 100 nucleotides downstream of the start codon. See, e.g., Elbashir et al,. Methods 26:199-213 (2002). Initially, 5' or 3' UTRs and regions nearby the start codon were avoided assuming that UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. Sometimes regions of the target 23 nucleotides in length conforming to the sequence motif AA(N19)TT (N, an nucleotide), and regions with approximately 30% to 70% G/C-content (often about 50% G/C-content) often are selected. If no suitable sequences are found, the search often is extended using the motif NA(N21). The sequence of the sense siRNA sometimes corresponds to (N19) TT or N21 (position 3 to 23 of the 23-nt motif), respectively. In the latter case, the 3' end of the sense siRNA often is converted to TT. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and

antisense 3' overhangs. The antisense siRNA is synthesized as the complement to position 1 to 21 of the 23-nt motif. Because position 1 of the 23-nt motif is not recognized sequence-specifically by the antisense siRNA, the 3'-most nucleotide residue of the antisense siRNA can be chosen deliberately. However, the penultimate nucleotide of the antisense siRNA (complementary to position 2 of the 23-nt motif) often is complementary to the targeted sequence. For simplifying chemical synthesis, TT often is utilized. siRNAs corresponding to the target motif NAR(N17)YNN, where R is purine (A,G) and Y is pyrimidine (C,U), often are selected. Respective 21 nucleotide sense and antisense siRNAs often begin with a purine nucleotide and can also be expressed from pol III expression vectors without a change in targeting site. Expression of RNAs from pol III promoters often is efficient when the first transcribed nucleotide is a purine.

[0124] The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Often, the siRNA is about 15 to about 50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, sometimes about 20-30 nucleotides in length or about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The siRNA sometimes is about 21 nucleotides in length. Methods of using siRNA are well known in the art, and specific siRNA molecules may be purchased from a number of companies including Dharmacon Research, Inc.

[0125] Antisense, ribozyme, RNAi and siRNA nucleic acids can be altered to form modified nucleic acid molecules. The nucleic acids can be altered at base moieties, sugar moieties or phosphate backbone moieties to improve stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup et al., Bioorganic & Medicinal Chemistry 4 (1): 5-23 (1996)). As used herein, the terms "peptide nucleic acid" or "PNA" refers to a nucleic acid mimic such as a DNA mimic, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. Synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described, for example, in Hyrup et al., (1996) supra and Perry-O'Keefe et al., Proc. Natl. Acad. Sci. 93: 14670-675 (1996).

[0126] PNA nucleic acids can be used in prognostic, diagnostic, and therapeutic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNA nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as "artificial restriction enzymes" when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup et al., (1996) supra; Perry-O'Keefe supra).

[0127] In other embodiments, oligonucleotides may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across cell membranes (see e.g., Letsinger et al., Proc. Natl. Acad. Sci. USA 86: 6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci. USA 84: 648-652 (1987); PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al., Bio-Techniques 6: 958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res. 5: 539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

[0128] Also included herein are molecular beacon oligonucleotide primer and probe molecules having one or more regions complementary to a *ADAMTS2* nucleotide sequence, or a substantially identical sequence thereof, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantifying the presence of the nucleic acid in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi et al., U.S. Patent No. 5,854,033; Nazarenko et al., U.S. Patent No. 5,866,336, and Livak et al., U.S. Patent 5,876,930.

### **Antibodies**

[0129] The term "antibody" as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. An antibody sometimes is a polyclonal, monoclonal, recombinant (e.g., a chimeric or humanized), fully human, non-human (e.g., murine), or a single chain antibody. An antibody may have effector function and can fix complement, and is sometimes coupled to a toxin or imaging agent.

[0130] A full-length polypeptide or antigenic peptide fragment encoded by a nucleotide sequence referenced herein can be used as an immunogen or can be used to identify antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. An antigenic peptide often includes at least 8 amino acid residues of the amino acid sequences encoded by a nucleotide sequence referenced herein, or substantially identical sequence thereof, and encompasses an epitope. Antigenic peptides sometimes include 10 or more amino acids, 15 or more amino acids, 20 or more amino acids, or 30 or more amino acids. Hydrophilic and hydrophobic fragments of polypeptides sometimes are used as immunogens.

[0131] Epitopes encompassed by the antigenic peptide are regions located on the surface of the polypeptide (e.g., hydrophilic regions) as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human polypeptide sequence can be used to indicate the regions that

have a particularly high probability of being localized to the surface of the polypeptide and are thus likely to constitute surface residues useful for targeting antibody production. The antibody may bind an epitope on any domain or region on polypeptides described herein.

[0132] Also, chimeric, humanized, and completely human antibodies are useful for applications which include repeated administration to subjects. Chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al International Application No. PCT/US86/02269; Akira, et al European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al European Patent Application 173,494; Neuberger et al PCT International Publication No. WO 86/01533; Cabilly et al U.S. Patent No. 4,816,567; Cabilly et al European Patent Application 125,023; Better et al., Science 240: 1041-1043 (1988); Liu et al., Proc. Natl. Acad. Sci. USA 84: 3439-3443 (1987); Liu et al., J. Immunol. 139: 3521-3526 (1987); Sun et al., Proc. Natl. Acad. Sci. USA 84: 214-218 (1987); Nishimura et al., Canc. Res. 47: 999-1005 (1987); Wood et al., Nature 314: 446-449 (1985); and Shaw et al., J. Natl. Cancer Inst. 80: 1553-1559 (1988); Morrison, S. L., Science 229: 1202-1207 (1985); Oi et al., BioTechniques 4: 214 (1986); Winter U.S. Patent 5,225,539; Jones et al., Nature 321: 552-525 (1986); Verhoeyan et al., Science 239: 1534; and Beidler et al., J. Immunol. 141: 4053-4060 (1988).

[0133] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar, Int. Rev. Immunol. 13: 65-93 (1995); and U.S. Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Fremont, CA) and Medarex, Inc. (Princeton, NJ), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above. Completely human antibodies that recognize a selected epitope also can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody (e.g., a murine antibody) is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described for example by Jespers et al., Bio/Technology 12: 899-903 (1994).

[0134] An antibody can be a single chain antibody. A single chain antibody (scFV) can be engineered (see, e.g., Colcher et al., Ann. N Y Acad. Sci. 880: 263-80 (1999); and Reiter, Clin. Cancer Res. 2: 245-52 (1996)). Single chain antibodies can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target polypeptide.

[0135] Antibodies also may be selected or modified so that they exhibit reduced or no ability to bind an Fc receptor. For example, an antibody may be an isotype or subtype, fragment or other mutant, which

does not support binding to an Fc receptor (e.g., it has a mutagenized or deleted Fc receptor binding region).

[0136] Also, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0137] Antibody conjugates can be used for modifying a given biological response. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, gamma-interferon, alpha-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Also, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, for example.

[0138] An antibody (e.g., monoclonal antibody) can be used to isolate target polypeptides by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an antibody can be used to detect a target polypeptide (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor polypeptide levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials

include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include <sup>125</sup>I, <sup>131</sup>I, <sup>35</sup>S or <sup>3</sup>H. Also, an antibody can be utilized as a test molecule for determining whether it can treat osteoarthritis, and as a therapeutic for administration to a subject for treating osteoarthritis.

[0139] An antibody can be made by immunizing with a purified antigen, or a fragment thereof, e.g., a fragment described herein, a membrane associated antigen, tissues, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions.

[0140] Included herein are antibodies which bind only a native polypeptide, only denatured or otherwise non-native polypeptide, or which bind both, as well as those having linear or conformational epitopes. Conformational epitopes sometimes can be identified by selecting antibodies that bind to native but not denatured polypeptide. Also featured are antibodies that specifically bind to a polypeptide variant associated with osteoarthritis.

### Methods for Identifying Candidate Therapeutics for Treating Osteoarthritis

[0141] Current therapies for the treatment of osteoarthritis have limited efficacy, limited tolerability and significant mechanism-based side effects, and few of the available therapies adequately address underlying defects. Current therapeutic approaches were largely developed in the absence of defined molecular targets or even a solid understanding of disease pathogenesis. Therefore, provided are methods of identifying candidate therapeutics that target biochemical pathways related to the development of osteoarthritis.

[0142] Thus, featured herein are methods for identifying a candidate therapeutic for treating osteoarthritis. The methods comprise contacting a test molecule with a target molecule in a system. A "target molecule" as used herein refers to a *ADAMTS2* nucleic acid, a substantially identical nucleic acid thereof, or a fragment thereof, and an encoded polypeptide of the foregoing. The methods also comprise determining the presence or absence of an interaction between the test molecule and the target molecule, where the presence of an interaction between the test molecule and the nucleic acid or polypeptide identifies the test molecule as a candidate osteoarthritis therapeutic. The interaction between the test molecule and the target molecule may be quantified.

[0143] Test molecules and candidate therapeutics include, but are not limited to, compounds, antisense nucleic acids, siRNA molecules, ribozymes, polypeptides or proteins encoded by a *ADAMTS2* nucleotide sequence, or a substantially identical sequence or fragment thereof, and immunotherapeutics (e.g., antibodies and HLA-presented polypeptide fragments). A test molecule or candidate therapeutic may act as a modulator of target molecule concentration or target molecule function in a system. A

"modulator" may agonize (i.e., up-regulates) or antagonize (i.e., down-regulates) a target molecule concentration partially or completely in a system by affecting such cellular functions as DNA replication and/or DNA processing (e.g., DNA methylation or DNA repair), RNA transcription and/or RNA processing (e.g., removal of intronic sequences and/or translocation of spliced mRNA from the nucleus), polypeptide production (e.g., translation of the polypeptide from mRNA), and/or polypeptide post-translational modification (e.g., glycosylation, phosphorylation, and proteolysis of pro-polypeptides). A modulator may also agonize or antagonize a biological function of a target molecule partially or completely, where the function may include adopting a certain structural conformation, interacting with one or more binding partners, ligand binding, catalysis (e.g., phosphorylation, dephosphorylation, hydrolysis, methylation, and isomerization), and an effect upon a cellular event (e.g., effecting progression of osteoarthritis).

[0144] As used herein, the term "system" refers to a cell free *in vitro* environment and a cell-based environment such as a collection of cells, a tissue, an organ, or an organism. A system is "contacted" with a test molecule in a variety of manners, including adding molecules in solution and allowing them to interact with one another by diffusion, cell injection, and any administration routes in an animal. As used herein, the term "interaction" refers to an effect of a test molecule on test molecule, where the effect sometimes is binding between the test molecule and the target molecule, and sometimes is an observable change in cells, tissue, or organism.

[0145] There are many standard methods for detecting the presence or absence of interaction between a test molecule and a target molecule. For example, titrametric, acidimetric, radiometric, NMR, monolayer, polarographic, spectrophotometric, fluorescent, and ESR assays probative of a target molecule interaction may be utilized.

[0146] ADAMTS2 activity and/or ADAMTS2 interactions can be detected and quantified using assays known in the art. For example, an immunoprecipitation assay or a kinase activity assay that employs a kinase-inactivated MEK can be utilized. Kinase inactivated MEKs are known in the art, such as a MEK that includes the mutation K97M. In these assays, mammalian cells (e.g., COS or NIH-3T3) are transiently transfected with constructs expressing ADAMTS2, and in addition, the cells are cotransfected with oncogenic RAS or SRC or both. Oncogenic RAS or SRC activates ADAMTS2 kinase activity. ADAMTS2 is immunoprecipitated from cell extracts using a monoclonal antibody (e.g., 9E10) or a polyclonal antibody (e.g., from rabbit) specific for a unique peptide from ADAMTS2. ADAMTS2 is then resuspended in assay buffer containing GST-Mek1 or GST-Mek2 and/or GST-ERK2. In addition, [gamma <sup>32</sup>P] ATP can be added to detect and/or quantify phosphorylation activity. Samples are incubated for 5-30 minutes at 30°C, and then the reaction is terminated by addition of EDTA. The samples are centrifuged and the supernatant fractions are collected. Phosphorylation activity is detected using one of two methods: (i) activity of GST-ERK2 kinase can be measured using MBP (myelin basic

protein, a substrate for ERK) as substrate, or (ii) following incubation of immunoprecipitated *ADAMTS2* in reaction buffer containing GST-ERK and [gamma <sup>32</sup>P] ATP, transfer of labeled ATP to kinase-dead ERK can be quantified by a phosphor-imager or densitometer following PAGE separation of polypeptide products (phosphorylated and non-phosphorylated forms). These types of assays are described in Weber et al., Oncogene 19: 169-176 (2000); Mason et al., EMBO J. 18: 2137-2148 (1999); Marais et al., J. Biol. Chem. 272: 4378-4383 (1997); Marais et al., EMBO J. 14: 3136-3145 (1995).

[0147] As noted above, *ADAMTS2* includes a domain having metalloprotease activity, and modulators of such activity are known. Examples of such modulators are set forth in WO03063762A2; WO-09937625; WO-09918076; WO-09838163; WO-09837877; WO9947550A1; WO0177092A1; WO0040577A1; WO9942436A1; WO9838163A1; WO9837877A1; WO04014379A1; WO03106381A2; WO03014098A1; WO03014092A1 and WO02096426A1.

[0148] Test molecule/target molecule interactions can be detected and/or quantified using assays known in the art. For example, an interaction can be determined by labeling the test molecule and/or the target molecule, where the label is covalently or non-covalently attached to the test molecule or target molecule. The label is sometimes a radioactive molecule such as <sup>125</sup>I, <sup>131</sup>I, <sup>35</sup>S or <sup>3</sup>H, which can be detected by direct counting of radioemission or by scintillation counting. Also, enzymatic labels such as horseradish peroxidase, alkaline phosphatase, or luciferase may be utilized where the enzymatic label can be detected by determining conversion of an appropriate substrate to product. In addition, presence or absence of an interaction can be determined without labeling. For example, a microphysiometer (e.g., Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indication of an interaction between a test molecule and target molecule (McConnell, H. M. et al., Science 257: 1906-1912 (1992)).

[0149] In cell-based systems, cells typically include a *ADAMTS2* nucleic acid, an encoded polypeptide, or substantially identical nucleic acid or polypeptide thereof, and are often of mammalian origin, although the cell can be of any origin. Whole cells, cell homogenates, and cell fractions (*e.g.*, cell membrane fractions) can be subjected to analysis. Where interactions between a test molecule with a target polypeptide are monitored, soluble and/or membrane bound forms of the polypeptide may be utilized. Where membrane-bound forms of the polypeptide are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as noctylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-

cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

[0150] An interaction between a test molecule and target molecule also can be detected by monitoring fluorescence energy transfer (FET) (see, e.g., Lakowicz et al., U.S. Patent No. 5,631,169; Stavrianopoulos et al. U.S. Patent No. 4,868,103). A fluorophore label on a first, "donor" molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, "acceptor" molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the "donor" polypeptide molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the "acceptor" molecule label may be differentiated from that of the "donor". Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the "acceptor" molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

[0151] In another embodiment, determining the presence or absence of an interaction between a test molecule and a target molecule can be effected by monitoring surface plasmon resonance (see, e.g., Sjolander & Urbaniczk, Anal. Chem. 63: 2338-2345 (1991) and Szabo et al., Curr. Opin. Struct. Biol. 5: 699-705 (1995)). "Surface plasmon resonance" or "biomolecular interaction analysis (BIA)" can be utilized to detect biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

[0152] In another embodiment, the target molecule or test molecules are anchored to a solid phase, facilitating the detection of target molecule/test molecule complexes and separation of the complexes from free, uncomplexed molecules. The target molecule or test molecule is immobilized to the solid support. In an embodiment, the target molecule is anchored to a solid surface, and the test molecule, which is not anchored, can be labeled, either directly or indirectly, with detectable labels discussed herein.

[0153] It may be desirable to immobilize a target molecule, an anti-target molecule antibody, and/or test molecules to facilitate separation of target molecule/test molecule complexes from uncomplexed forms, as well as to accommodate automation of the assay. The attachment between a test molecule and/or target molecule and the solid support may be covalent or non-covalent (see, e.g., U.S. Patent No. 6,022,688 for non-covalent attachments). The solid support may be one or more surfaces of the system, such as one or more surfaces in each well of a microtiter plate, a surface of a silicon wafer, a surface of a

bead (see, e.g., Lam, Nature 354: 82-84 (1991)) that is optionally linked to another solid support, or a channel in a microfluidic device, for example. Types of solid supports, linker molecules for covalent and non-covalent attachments to solid supports, and methods for immobilizing nucleic acids and other molecules to solid supports are well known (see, e.g., U.S. Patent Nos. 6,261,776; 5,900,481; 6,133,436; and 6,022,688; and WIPO publication WO 01/18234).

[0154] In an embodiment, target molecule may be immobilized to surfaces via biotin and streptavidin. For example, biotinylated target polypeptide can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In another embodiment, a target polypeptide can be prepared as a fusion polypeptide. For example, glutathione-S-transferase/target polypeptide fusion can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivitized microtiter plates, which are then combined with a test molecule under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, or the matrix is immobilized in the case of beads, and complex formation is determined directly or indirectly as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of target molecule binding or activity is determined using standard techniques.

[0155] In an embodiment, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that a significant percentage of complexes formed will remain immobilized to the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of manners. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface, e.g., by adding a labeled antibody specific for the immobilized component, where the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody.

[0156] In another embodiment, an assay is performed utilizing antibodies that specifically bind target molecule or test molecule but do not interfere with binding of the target molecule to the test molecule. Such antibodies can be derivitized to a solid support, and unbound target molecule may be immobilized by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

[0157] Cell free assays also can be conducted in a liquid phase. In such an assay, reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (see, e.g., Rivas, G., and Minton, Trends Biochem Sci Aug; 18(8): 284-7 (1993)); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (see, e.g., Ausubel et al., eds. Current Protocols in Molecular Biology, J. Wiley: New York (1999)); and immunoprecipitation (see, e.g., Ausubel et al., eds., supra). Media and chromatographic techniques are known to one skilled in the art (see, e.g., Heegaard, J Mol. Recognit. Winter; 11(1-6): 141-8 (1998); Hage & Tweed, J. Chromatogr. B Biomed. Sci. Appl. Oct 10; 699 (1-2): 499-525 (1997)). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

[0158] In another embodiment, modulators of target molecule expression are identified. For example, a cell or cell free mixture is contacted with a candidate compound and the expression of target mRNA or target polypeptide is evaluated relative to the level of expression of target mRNA or target polypeptide in the absence of the candidate compound. When expression of target mRNA or target polypeptide is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as an agonist of target mRNA or target polypeptide expression. Alternatively, when expression of target mRNA or target polypeptide is less (e.g., less with statistical significance) in the presence of the candidate compound than in its absence, the candidate compound is identified as an antagonist or inhibitor of target mRNA or target polypeptide expression. The level of target mRNA or target polypeptide expression can be determined by methods described herein.

[0159] In another embodiment, binding partners that interact with a target molecule are detected. The target molecules can interact with one or more cellular or extracellular macromolecules, such as polypeptides *in vivo*, and these interacting molecules are referred to herein as "binding partners." Binding partners can agonize or antagonize target molecule biological activity. Also, test molecules that agonize or antagonize interactions between target molecules and binding partners can be useful as therapeutic molecules as they can up-regulate or down-regulated target molecule activity *in vivo* and thereby treat osteoarthritis.

[0160] Binding partners of target molecules can be identified by methods known in the art. For example, binding partners may be identified by lysing cells and analyzing cell lysates by electrophoretic techniques. Alternatively, a two-hybrid assay or three-hybrid assay can be utilized (see, e.g., U.S. Patent No. 5,283,317; Zervos et al., Cell 72:223-232 (1993); Madura et al., J. Biol. Chem. 268: 12046-12054 (1993); Bartel et al., Biotechniques 14: 920-924 (1993); Iwabuchi et al., Oncogene 8: 1693-1696 (1993); and Brent WO94/10300). A two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. The assay often utilizes two different DNA constructs. In one construct, a ADAMTS2 nucleic acid (sometimes referred to as the

"bait") is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In another construct, a DNA sequence from a library of DNA sequences that encodes a potential binding partner (sometimes referred to as the "prey") is fused to a gene that encodes an activation domain of the known transcription factor. Sometimes, a ADAMTS2 nucleic acid can be fused to the activation domain. If the "bait" and the "prey" molecules interact in vivo, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to identify the potential binding partner.

[0161] In an embodiment for identifying test molecules that antagonize or agonize complex formation between target molecules and binding partners, a reaction mixture containing the target molecule and the binding partner is prepared, under conditions and for a time sufficient to allow complex formation. The reaction mixture often is provided in the presence or absence of the test molecule. The test molecule can be included initially in the reaction mixture, or can be added at a time subsequent to the addition of the target molecule and its binding partner. Control reaction mixtures are incubated without the test molecule or with a placebo. Formation of any complexes between the target molecule and the binding partner then is detected. Decreased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule antagonizes target molecule/binding partner complex formation. Alternatively, increased formation of a complex in the reaction mixture containing test molecule as compared to in a control reaction mixture indicates that the molecule agonizes target molecule/binding partner complex formation. In another embodiment, complex formation of target molecule/binding partner can be compared to complex formation of mutant target molecule/binding partner (e.g., amino acid modifications in a target polypeptide). Such a comparison can be important in those cases where it is desirable to identify test molecules that modulate interactions of mutant but not non-mutated target gene products.

[0162] The assays can be conducted in a heterogeneous or homogeneous format. In heterogeneous assays, target molecule and/or the binding partner are immobilized to a solid phase, and complexes are detected on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the molecules being tested. For example, test compounds that agonize target molecule/binding partner interactions can be identified by conducting the reaction in the presence of the test molecule in a competition format. Alternatively, test molecules that agonize preformed complexes, e.g., molecules with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed.

[0163] In a heterogeneous assay embodiment, the target molecule or the binding partner is anchored onto a solid surface (e.g., a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored molecule can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the molecule to be anchored can be used to anchor the molecule to the solid surface. The partner of the immobilized species is exposed to the coated surface with or without the test molecule. After the reaction is complete, unreacted components are removed (e.g., by washing) such that a significant portion of any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface is indicative of complex. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored to the surface; e.g., by using a labeled antibody specific for the initially non-immobilized species. Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

[0164] In another embodiment, the reaction can be conducted in a liquid phase in the presence or absence of test molecule, where the reaction products are separated from unreacted components, and the complexes are detected (e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes). Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

[0165] In an alternate embodiment, a homogeneous assay can be utilized. For example, a preformed complex of the target gene product and the interactive cellular or extracellular binding partner product is prepared. One or both of the target molecule or binding partner is labeled, and the signal generated by the label(s) is quenched upon complex formation (e.g., U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). Addition of a test molecule that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt target molecule/binding partner complexes can be identified.

[0166] Candidate therapeutics for treating osteoarthritis are identified from a group of test molecules that interact with a target molecule. Test molecules are normally ranked according to the degree with which they modulate (e.g., agonize or antagonize) a function associated with the target molecule (e.g., DNA replication and/or processing, RNA transcription and/or processing, polypeptide production and/or processing, and/or biological function/activity), and then top ranking modulators are selected. Also, pharmacogenomic information described herein can determine the rank of a modulator. The top 10% of ranked test molecules often are selected for further testing as candidate therapeutics, and sometimes the top 15%, 20%, or 25% of ranked test molecules are selected for further testing as candidate therapeutics. Candidate therapeutics typically are formulated for administration to a subject.

### **Therapeutic Formulations**

[0167] Formulations and pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier one or more target molecule modulators. The modulator often is a test molecule identified as having an interaction with a target molecule by a screening method described above. The modulator may be a compound, an antisense nucleic acid, a ribozyme, an antibody, or a binding partner. Also, formulations may comprise a target polypeptide or fragment thereof in combination with a pharmaceutically acceptable carrier.

[0168] Formulations or pharmaceutical compositions typically include in combination with a pharmaceutically acceptable carrier, a compound, an antisense nucleic acid, a ribozyme, an antibody, a binding partner that interacts with an *ADAMTS2* polypeptide, a *ADAMTS2* nucleic acid, or a fragment thereof. The formulated molecule may be one that is identified by a screening method described above. Also, formulations may comprise a *ADAMTS2* polypeptide or fragment thereof, where the *ADAMTS2* polypeptide contains an isoleucine at position 245 of SEQ ID NO: 4, and a pharmaceutically acceptable carrier. Also, formulations may comprise an active *ADAMTS2* polypeptide or fragment thereof, where *ADAMTS2* polypeptide fragments having activity are selected from amino acids 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain. As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.

[0169] As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions. Pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0170] A pharmaceutical composition typically is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with

acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0171] Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, *e.g.*, gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0172] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL<sup>TM</sup> (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0173] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which

yields a powder of the active ingredient plus any additional desired ingredient from a previously sterilefiltered solution thereof.

[0174] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0175] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Molecules can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0176] In one embodiment, active molecules are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

[0177] It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

[0178] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Molecules which exhibit high therapeutic indices are preferred. While molecules that exhibit toxic side effects may be used, care should be taken to design a delivery system

that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0179] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such molecules lies preferably within a range of circulating concentrations that include the  $ED_{50}$  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any molecules used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the  $IC_{50}$  (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0180] As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, sometimes about 0.01 to 25 mg/kg body weight, often about 0.1 to 20 mg/kg body weight, and more often about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, sometimes between 2 to 8 weeks, often between about 3 to 7 weeks, and more often for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

[0181] With regard to polypeptide formulations, featured herein is a method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject with a first polypeptide, where the subject comprises a second polypeptide having one or more polymorphic variations associated with cancer, and where the first polypeptide comprises fewer polymorphic variations associated with cancer than the second polypeptide. The first and second polypeptides are encoded by a nucleic acid which comprises a nucleotide sequence in SEQ ID NO: 1-3; a nucleotide sequence which encodes a polypeptide consisting of an amino acid sequence encoded by a nucleotide sequence referenced in SEQ ID NO: 1-3; a nucleotide sequence which encodes a polypeptide that is 90% or more identical to an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 1-3 and a nucleotide sequence 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-3. The subject often is a human.

[0182] For antibodies, a dosage of 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg) is often utilized. If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is often appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al., J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193 (1997).

[0183] Antibody conjugates can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a polypeptide such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

[0184] For compounds, exemplary doses include milligram or microgram amounts of the compound per kilogram of subject or sample weight, for example, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid described herein, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

[0185] With regard to nucleic acid formulations, gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al., (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). Pharmaceutical preparations of gene therapy vectors can include a gene therapy vector in an acceptable

diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.

Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells (e.g., retroviral vectors) the pharmaceutical preparation can include one or more cells which produce the gene delivery system. Examples of gene delivery vectors are described herein.

### Therapeutic Methods

[0186] A therapeutic formulation described above can be administered to a subject in need of a therapeutic for inducing a desired biological response.. Therapeutic formulations can be administered by any of the paths described herein. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from pharmacogenomic analyses described herein.

[0187] As used herein, the term "treatment" is defined as the application or administration of a therapeutic formulation to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect osteoarthritis, symptoms of osteoarthritis or a predisposition towards osteoarthritis. A therapeutic formulation includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides. Administration of a therapeutic formulation can occur prior to the manifestation of symptoms characteristic of osteoarthritis, such that osteoarthritis is prevented or delayed in its progression. The appropriate therapeutic composition can be determined based on screening assays described herein.

[0188] As discussed, successful treatment of osteoarthritis can be brought about by techniques that serve to agonize target molecule expression or function, or alternatively, antagonize target molecule expression or function. These techniques include administration of modulators that include, but are not limited to, small organic or inorganic molecules; antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')<sub>2</sub> and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof); and peptides, phosphopeptides, or polypeptides.

[0189] Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above. It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode

and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that the target gene encodes an extracellular polypeptide, it can be preferable to co-administer normal target gene polypeptide into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

[0190] Another method by which nucleic acid molecules may be utilized in treating or preventing osteoarthritis is use of aptamer molecules specific for target molecules. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to ligands (see, e.g., Osborne, et al., Curr. Opin. Chem. Biol. 1(1): 5-9 (1997); and Patel, D. J., Curr. Opin. Chem. Biol. Jun; 1(1): 32-46 (1997)).

therapy, which can also be referred to as allele therapy. Provided herein is a gene therapy method for treating osteoarthritis in a subject, which comprises contacting one or more cells in the subject or from the subject with a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1-3). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. Allele therapy methods often are utilized in conjunction with a method of first determining whether a subject has genomic DNA that includes polymorphic variants associated with osteoarthritis.

[0192] In another allele therapy embodiment, provided herein is a method which comprises contacting one or more cells in the subject or from the subject with a polypeptide encoded by a nucleic acid having a first nucleotide sequence (e.g., the first nucleotide sequence is identical to or substantially identical to the nucleotide sequence of SEQ ID NO: 1-3). Genomic DNA in the subject comprises a second nucleotide sequence having one or more polymorphic variations associated with osteoarthritis (e.g., the second nucleotide sequence is identical to or substantially identical to a nucleotide sequence of SEQ ID NO: 1). The first and second nucleotide sequences typically are substantially identical to one another, and the first nucleotide sequence comprises fewer polymorphic variations associated with osteoarthritis than the second nucleotide sequence. The first nucleotide sequence may comprise a gene sequence that encodes a full-length polypeptide or a fragment thereof. The subject is often a human. The method often comprises supplementing arthritis-associated *ADAMTS2* polypeptide with a non-arthritis-associated *ADAMTS2* polypeptide or fragment thereof, where the non-arthritis-associated form of

ADAMTS2 contains an isoleucine at position 245 of SEQ ID NO: 4 having enzymatic activity. The arthritis-associated ADAMTS2 polypeptide sometimes contains a valine at position 245 of SEQ ID NO: 4 having an altered enzymatic activity varying from the non-arthritis-associated polypeptide.

[0193] In an embodiment, provided is a method of increasing the synthesis of procollagen II comprising providing or administering to individuals in need of increasing levels of type II collagen the pharmaceutical or physiologically acceptable composition comprising active human *ADAMTS2* protein or fragment thereof, where *ADAMTS2* polypeptide fragments having activity are selected from amino acids 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4, where it is understood that the active form of *ADAMTS2* does not contain the propeptide domain.

[0194] In another embodiment, provided herein is a method of increasing the synthesis of procollagen II comprising providing or administering to individuals in need of increasing levels of type II collagen the pharmaceutical or physiologically acceptable composition comprising an enzyme or molecule capable of cleaving *ADAMTS2* propeptide, e.g., a furin-type endopeptidase or N-ethylmaleimide described herein

[0195] For antibody-based therapies, antibodies can be generated that are both specific for target molecules and that reduce target molecule activity. Such antibodies may be administered in instances where antagonizing a target molecule function is appropriate for the treatment of osteoarthritis.

[0196] In circumstances where stimulating antibody production in an animal or a human subject by injection with a target molecule is harmful to the subject, it is possible to generate an immune response against the target molecule by use of anti-idiotypic antibodies (see, e.g., Herlyn, Ann. Med.;31(1): 66-78 (1999); and Bhattacharya-Chatterjee & Foon, Cancer Treat. Res.; 94: 51-68 (1998)). Introducing an anti-idiotypic antibody to a mammal or human subject often stimulates production of anti-anti-idiotypic antibodies, which typically are specific to the target molecule. Vaccines directed to osteoarthritis also may be generated in this fashion.

[0197] In instances where the target molecule is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population (see, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA 90: 7889-7893 (1993)).

[0198] Modulators can be administered to a patient at therapeutically effective doses to treat osteoarthritis. A therapeutically effective dose refers to an amount of the modulator sufficient to result in amelioration of symptoms of osteoarthritis. Toxicity and therapeutic efficacy of modulators can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Modulators that exhibit large therapeutic indices are preferred. While modulators that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such molecules to the site of affected tissue in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0199] Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (*i.e.*, the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

[0200] Another example of effective dose determination for an individual is the ability to directly assay levels of "free" and "bound" compound in the serum of the test subject. Such assays may utilize antibody mimics and/or "biosensors" that have been created through molecular imprinting techniques. Molecules that modulate target molecule activity are used as a template, or "imprinting molecule", to spatially organize polymerizable monomers prior to their polymerization with catalytic reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated "negative image" of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell et al., Current Opinion in Biotechnology 7: 89-94 (1996) and in Shea, Trends in Polymer Science 2: 166-173 (1994). Such "imprinted" affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, et al., Nature 361: 645-647 (1993). Through the use of isotope-labeling, the "free" concentration of compound which modulates target molecule expression or activity readily can be monitored and used in calculations of IC<sub>50</sub>. Such "imprinted" affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties

measurably change upon local and selective binding of target compound. These changes readily can be assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly optimized based on its individual IC<sub>50</sub>. An example of such a "biosensor" is discussed in Kriz *et al.*, Analytical Chemistry 67: 2142-2144 (1995).

[0201] The examples set forth below are intended to illustrate but not limit the invention.

## **Examples**

[0202] In the following studies a group of subjects was selected according to specific parameters relating to osteoarthritis. Nucleic acid samples obtained from individuals in the study group were subjected to genetic analysis, which identified associations between osteoarthritis and a polymorphism in the *ADAMTS2* gene on chromosome five. The polymorphism was genotyped again in two replication cohorts consisting of individuals selected for OA. In addition, SNPs proximal to the incident polymorphism were identified and allelotyped in OA case and control pools. Methods are described for producing *ADAMTS2* polypeptide and *ADAMTS2* polypeptide variants *in vitro* or *in vivo*, *ADAMTS2* nucleic acids or polypeptides and variants thereof are utilized for screening test molecules for those that interact with *ADAMTS2* molecules. Test molecules identified as interactors with *ADAMTS2* molecules and *ADAMTS2* variants are further screened *in vivo* to determine whether they treat osteoarthritis.

# Example 1 Samples and Pooling Strategies

### Sample Selection

[0203] Blood samples were collected from individuals diagnosed with knee osteoarthritis, which were referred to as case samples. Also, blood samples were collected from individuals not diagnosed with knee osteoarthritis as gender and age-matched controls. A database was created that listed all phenotypic trait information gathered from individuals for each case and control sample. Genomic DNA was extracted from each of the blood samples for genetic analyses.

## **DNA Extraction from Blood Samples**

[0204] Six to ten milliliters of whole blood was transferred to a 50 ml tube containing 27 ml of red cell lysis solution (RCL). The tube was inverted until the contents were mixed. Each tube was incubated for 10 minutes at room temperature and inverted once during the incubation. The tubes were then centrifuged for 20 minutes at 3000 x g and the supernatant was carefully poured off. 100-200 µl of residual liquid was left in the tube and was pipetted repeatedly to resuspend the pellet in the residual supernatant. White cell lysis solution (WCL) was added to the tube and pipetted repeatedly until

completely mixed. While no incubation was normally required, the solution was incubated at 37°C or room temperature if cell clumps were visible after mixing until the solution was homogeneous. 2 ml of protein precipitation was added to the cell lysate. The mixtures were vortexed vigorously at high speed for 20 sec to mix the protein precipitation solution uniformly with the cell lysate, and then centrifuged for 10 minutes at 3000 x g. The supernatant containing the DNA was then poured into a clean 15 ml tube, which contained 7 ml of 100% isopropanol. The samples were mixed by inverting the tubes gently until white threads of DNA were visible. Samples were centrifuged for 3 minutes at 2000 x g and the DNA was visible as a small white pellet. The supernatant was decanted and 5 ml of 70% ethanol was added to each tube. Each tube was inverted several times to wash the DNA pellet, and then centrifuged for 1 minute at 2000 x g. The ethanol was decanted and each tube was drained on clean absorbent paper. The DNA was dried in the tube by inversion for 10 minutes, and then 1000 µl of 1X TE was added. The size of each sample was estimated, and less TE buffer was added during the following DNA hydration step if the sample was smaller. The DNA was allowed to rehydrate overnight at room temperature, and DNA samples were stored at 2-8°C.

[0205] DNA was quantified by placing samples on a hematology mixer for at least 1 hour. DNA was serially diluted (typically 1:80, 1:160, 1:320, and 1:640 dilutions) so that it would be within the measurable range of standards. 125 µl of diluted DNA was transferred to a clear U-bottom microtitre plate, and 125 µl of 1X TE buffer was transferred into each well using a multichannel pipette. The DNA and 1X TE were mixed by repeated pipetting at least 15 times, and then the plates were sealed. 50 µl of diluted DNA was added to wells A5-H12 of a black flat bottom microtitre plate. Standards were inverted six times to mix them, and then 50 µl of 1X TE buffer was pipetted into well A1, 1000 ng/ml of standard was pipetted into well A2, 500 ng/ml of standard was pipetted into well A3, and 250 ng/ml of standard was pipetted into well A4. PicoGreen (Molecular Probes, Eugene, Oregon) was thawed and freshly diluted 1:200 according to the number of plates that were being measured. PicoGreen was vortexed and then 50µl was pipetted into all wells of the black plate with the diluted DNA. DNA and PicoGreen were mixed by pipetting repeatedly at least 10 times with the multichannel pipette. The plate was placed into a Fluoroskan Ascent Machine (microplate fluorometer produced by Labsystems) and the samples were allowed to incubate for 3 minutes before the machine was run using filter pairs 485 nm excitation and 538 nm emission wavelengths. Samples having measured DNA concentrations of greater than 450 ng/µl were re-measured for conformation. Samples having measured DNA concentrations of 20 ng/µl or less were re-measured for confirmation.

## Pooling Strategies - Discovery Cohort

[0206] Samples were derived from the Nottingham knee OA family study (UK) where index cases were identified through a knee replacement registry. Siblings were approached and assessed with knee x-rays and assigned status as affected or unaffected. In all 1,157 individuals were available. In order to create same-sex pools of appropriate sizes, 335 unrelated female individuals with OA from the Nottingham OA sample were selected for the case pool. The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The female case samples and female control samples are described further in Table 1 below.

[0207] A select set of samples from each group were utilized to generate pools, and one pool was created for each group. Each individual sample in a pool was represented by an equal amount of genomic DNA. For example, where 25 ng of genomic DNA was utilized in each PCR reaction and there were 200 individuals in each pool, each individual would provide 125 pg of genomic DNA. Inclusion or exclusion of samples for a pool was based upon the following criteria: the sample was derived from an individual characterized as Caucasian; the sample was derived from an individual of British paternal and maternal descent; case samples were derived from individuals diagnosed with specific knee osteoarthritis (OA) and were recruited from an OA knee replacement clinic. Control samples were derived from individuals free of OA, family history of OA, and rheumatoid arthritis. Also, sufficient genomic DNA was extracted from each blood sample for all allelotyping and genotyping reactions performed during the study. Phenotype information from each individual was collected and included age of the individual, gender, family history of OA, general medical information (e.g., height, weight, thyroid disease, diabetes, psoriasis, hysterectomy), joint history (previous and current symptoms, joint-related operations, age at onset of symptoms, date of primary diagnosis, age of individual as of primary diagnosis and order of involvement), and knee-related findings (crepitus, restricted passive movement, bony swelling/deformity). Additional knee information included knee history, current symptoms, any major knee injury, menisectomy, knee replacement surgery, age of surgery, and treatment history (including hormone replace therapy (HRT)). Samples that met these criteria were added to appropriate pools based on disease status.

[0208] The selection process yielded the pools set forth in Table 1, which were used in the studies that follow:

TABLE 1

	Female case	Female control
Pool size (Number)	335	335
Pool Criteria (ex: case/control)	control	case
Mean Age (ex: years)	57.21	69.95

## Example 2 Association of Polymorphic Variants with Osteoarthritis

[0209] A whole-genome screen was performed to identify particular SNPs associated with occurrence of osteoarthritis. As described in Example 1, two sets of samples were utilized, which included samples from female individuals having knee osteoarthritis (osteoarthritis cases), and samples from female individuals not having knee osteoarthritis (female controls). The initial screen of each pool was performed in an allelotyping study, in which certain samples in each group were pooled. By pooling DNA from each group, an allele frequency for each SNP in each group was calculated. These allele frequencies were then compared to one another. Particular SNPs were considered as being associated with osteoarthritis when allele frequency differences calculated between case and control pools were statistically significant. SNP disease association results obtained from the allelotyping study were then validated by genotyping each associated SNP across all samples from each pool. The results of the genotyping then were analyzed, allele frequencies for each group were calculated from the individual genotyping results, and a p-value was calculated to determine whether the case and control groups had statistically significant differences in allele frequencies for a particular SNP. When the genotyping results agreed with the original allelotyping results, the SNP disease association was considered validated at the genetic level.

#### SNP Panel Used for Genetic Analyses

[0210] A whole-genome SNP screen began with an initial screen of approximately 25,000 SNPs over each set of disease and control samples using a pooling approach. The pools studied in the screen are described in Example 1. The SNPs analyzed in this study were part of a set of 25,488 SNPs confirmed as being statistically polymorphic as each is characterized as having a minor allele frequency of greater than 10%. The SNPs in the set reside in genes or in close proximity to genes, and many reside

in gene exons. Specifically, SNPs in the set are located in exons, introns, and within 5,000 base-pairs upstream of a transcription start site of a gene. In addition, SNPs were selected according to the following criteria: they are located in ESTs; they are located in Locuslink or Ensembl genes; and they are located in Genomatix promoter predictions. SNPs in the set were also selected on the basis of even spacing across the genome, as depicted in Table 2.

[0211] A case-control study design using a whole genome association strategy involving approximately 28,000 single nucleotide polymorphisms (SNPs) was employed. Approximately 25,000 SNPs were evenly spaced in gene-based regions of the human genome with a median inter-marker distance of about 40,000 base pairs. Additionally, approximately 3,000 SNPs causing amino acid substitutions in genes described in the literature as candidates for various diseases were used. The case-control study samples were of female Caucasian origin (British paternal and maternal descent) 670 individuals were equally distributed in two groups: female controls and female cases. The whole genome association approach was first conducted on 2 DNA pools representing the 2 groups. Significant markers were confirmed by individual genotyping.

TABLE 2

General Statistics		Spacing Statistics		
Total # of SNPs	25,488	Median	37,058 bp	
# of Exonic SNPs	>4,335 (17%)	Minimum*	1,000 bp	
# SNPs with refSNP ID	20,776 (81%)	Maximum*	3,000,000 bp	
Gene Coverage	>10,000	Mean	122,412 bp	
Chromosome Coverage	All	Std Deviation	373,325 bp	
		*Excludes outliers	•	

### Allelotyping and Genotyping Results

[0212] The genetic studies summarized above and described in more detail below identified an allelic variant in the ADAMTS2 gene that is associated with osteoarthritis.

## Assay for Verifying, Allelotyping, and Genotyping SNPs

[0213] A MassARRAY<sup>TM</sup> system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME<sup>TM</sup> or homogeneous MassEXTEND<sup>TM</sup> (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND<sup>TM</sup> primer), which is complementary to the amplified target up to but not

including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0214] For each polymorphism, SpectroDESIGNER<sup>TM</sup> software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND<sup>TM</sup> primer which where used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension primers used for analyzing polymorphisms. The initial PCR amplification reaction was performed in a 5 μl total volume containing 1X PCR buffer with 1.5 mM MgCl<sub>2</sub> (Qiagen), 200 μM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

**TABLE 3: PCR Primers** 

SNP Reference	Forward PCR primer	Reverse PCR primer			
rs398829	ACGTTGGATGTAGTCATCGTCCGCAGCATG	ACGTTGGATGAAGACGGTGTCCTCCTTG			

[0215] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0216] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 4, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

**TABLE 4: Extension Primers** 

SNP Reference	Extend Probe	Termination Mix
rs398829	TGGCGTGCTCCTCTAGGA	ACG

[0217] The MassEXTEND<sup>TM</sup> reaction was performed in a total volume of 9 μl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND<sup>TM</sup> primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0218] Following incubation, samples were desalted by adding 16 μl of water (total reaction volume was 25 μl), 3 mg of SpectroCLEAN<sup>TM</sup> sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET<sup>TM</sup> (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP<sup>TM</sup> (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and SpectroTYPER RT<sup>TM</sup> software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

### Genetic Analysis

[0219] Minor allelic frequencies for the polymorphisms set forth in Table A were verified as being 10% or greater using the extension assay described above in a group of samples isolated from 92 individuals originating from the state of Utah in the United States, Venezuela and France (Coriell cell repositories).

[0220] Genotyping results are shown for female pools in Table 5. In Table 5, "AF" refers to allelic frequency; and "F case" and "F control" refer to female case and female control groups, respectively.

 
 SNP Reference
 AF F case
 AF F control
 p-value

 rs398829
 G = 0.740 A = 0.260
 G = 0.652 A = 0.348
 0.0002

**TABLE 5: Genotyping Results** 

[0221] All of the single marker alleles set forth in Table A were considered validated, since the genotyping data agreed with the allelotyping data and each SNP significantly associated with osteoarthritis. Particularly significant associations with osteoarthritis are indicated by a calculated p-value of less than 0.05 for genotype results.

## Example 3

## Association of Polymorphic Variants with Osteoarthritis in Replication Cohorts

[0222] The single marker polymorphism set forth in Table A was genotyped again in two replication cohorts consisting of individuals selected for OA.

## Sample Selection and Pooling Strategies – Replication Sample 1

[0223] A second case control sample (replication sample #1) was created by using 100 Caucasian female cases from Chingford, UK, and 148 unrelated female cases from the St. Thomas twin study. Cases were defined as having Kellgren-Lawrence (KL) scores of at least 2 in at least one knee x-ray. In addition, 199 male knee replacement cases from Nottingham were included. (For a cohort description, see the Nottingham description provided in Example 1). The control pool was made up of unrelated female individuals from the St. Thomas twin study (England) with normal knee x-rays and without other indications of OA, regardless of anatomical location, as well as lacking family history of OA. The St. Thomas twin study consists of Caucasian, female participants from the St. Thomas' Hospital, London, adult-twin registry, which is a voluntary registry of >4,000 twin pairs ranging from 18 to 76 years of age. The replication sample 1 cohort was used to replicate the initial results. Table 6 below summarizes the selected phenotype data collected from the case and control individuals.

**TABLE 6** 

Phenotype	Female cases (n=248): median (range)/ (n,%)	Male cases (n=199): median (range)/ (n,%)	Female controls (n=313): mean (range)/ (n,%)
Age	59 (39- 73)	66 (45- 73)	55 (50- 72)
Height (cm)	162 (141- 178)	175 (152- 198)	162 (141- 176)
Weight (kg)	68 (51- 123)	86 (62- 127)	64 (40- 111)
Body mass index (kg/m²)	26 (18- 44)	29 (21- 41)	24 (18- 46)
Kellgren- Lawrence* left knee	0 (63, 26%), 1 (20, 8%), 2 (105, 43%), 3 (58, 23%), 4 (1, 0%)	NA	NA
Kellgren- Lawrence* right knee	0 (43, 7%), 1 (18, 7%), 2 (127, 52%), 3 (57, 23%), 4 (1, 0%)	NA	NA
KL* >2 both knees	No (145, 59%), Yes (101, 41%)	NA	NA
KL* >2 either knee	No (0, 0%), Yes (248, 100%)	NA	NA

<sup>\* 0:</sup> normal, 1: doubtful, 2: definite osteophyte (bony protuberance), 3: joint space narrowing (with or without osteophyte), 4: joint deformity

## Sample Selection and Pooling Strategies - Replication Sample 2

[0224] A third case control sample (replication sample #2) was created by using individuals with symptoms of OA from Newfoundland, Canada. These individuals were recruited and examined by rheumatologists. Affected joints were x-rayed and a final diagnosis of definite or probable OA was made according to American College of Rheumatology criteria by a single rheumatologist to avoid any interexaminer diagnosis variability. Controls were recruited from volunteers without any symptoms from the musculoskeletal system based on a normal joint exam performed by a rheumatologist. Only cases with a diagnosis of definite OA were included in the study. Only individuals of Caucasian origin were included. The cases consisted of 228 individuals with definite knee OA, 106 individuals with definite hip OA, and 74 individuals with hip OA.

Phenotype Control Case Age at Visit 62.7 52.5 227/119 Sex (Female/Male) 174/101 Knee OA Xray: No 35% (120) 80% (16) Unknown 0%(0)1% (4) Yes 20% (4) 64% (221) Hip OA Xray: No 80% (16) 63% (215) Unknown 0%(0)2% (7) Yes 20% (4) 35% (121)

TABLE 7

Assay for Verifying, Allelotyping, and Genotyping SNPs

[0225] Genotyping of the replication cohorts described in Tables 6 and 7 was performed using the same methods used for the original genotyping, as described herein. A MassARRAY<sup>TM</sup> system (Sequenom, Inc.) was utilized to perform SNP genotyping in a high-throughput fashion. This genotyping platform was complemented by a homogeneous, single-tube assay method (hME<sup>TM</sup> or homogeneous MassEXTEND<sup>TM</sup> (Sequenom, Inc.)) in which two genotyping primers anneal to and amplify a genomic target surrounding a polymorphic site of interest. A third primer (the MassEXTEND<sup>TM</sup> primer), which is complementary to the amplified target up to but not including the polymorphism, was then enzymatically extended one or a few bases through the polymorphic site and then terminated.

[0226] For each polymorphism, SpectroDESIGNER™ software (Sequenom, Inc.) was used to generate a set of PCR primers and a MassEXTEND™ primer which where used to genotype the polymorphism. Other primer design software could be used or one of ordinary skill in the art could

manually design primers based on his or her knowledge of the relevant factors and considerations in designing such primers. Table 3 shows PCR primers and Table 4 shows extension probes used for analyzing (e.g., genotyping) polymorphisms in the replication cohorts. The initial PCR amplification reaction was performed in a 5 μl total volume containing 1X PCR buffer with 1.5 mM MgCl<sub>2</sub> (Qiagen), 200 μM each of dATP, dGTP, dCTP, dTTP (Gibco-BRL), 2.5 ng of genomic DNA, 0.1 units of HotStar DNA polymerase (Qiagen), and 200 nM each of forward and reverse PCR primers specific for the polymorphic region of interest.

[0227] Samples were incubated at 95°C for 15 minutes, followed by 45 cycles of 95°C for 20 seconds, 56°C for 30 seconds, and 72°C for 1 minute, finishing with a 3 minute final extension at 72°C. Following amplification, shrimp alkaline phosphatase (SAP) (0.3 units in a 2 µl volume) (Amersham Pharmacia) was added to each reaction (total reaction volume was 7 µl) to remove any residual dNTPs that were not consumed in the PCR step. Samples were incubated for 20 minutes at 37°C, followed by 5 minutes at 85°C to denature the SAP.

[0228] Once the SAP reaction was complete, a primer extension reaction was initiated by adding a polymorphism-specific MassEXTEND™ primer cocktail to each sample. Each MassEXTEND™ cocktail included a specific combination of dideoxynucleotides (ddNTPs) and deoxynucleotides (dNTPs) used to distinguish polymorphic alleles from one another. Methods for verifying, allelotyping and genotyping SNPs are disclosed, for example, in U.S. Pat. No. 6,258,538, the content of which is hereby incorporated by reference. In Table 7, ddNTPs are shown and the fourth nucleotide not shown is the dNTP.

[0229] The MassEXTEND<sup>TM</sup> reaction was performed in a total volume of 9 μl, with the addition of 1X ThermoSequenase buffer, 0.576 units of ThermoSequenase (Amersham Pharmacia), 600 nM MassEXTEND<sup>TM</sup> primer, 2 mM of ddATP and/or ddCTP and/or ddGTP and/or ddTTP, and 2 mM of dATP or dCTP or dGTP or dTTP. The deoxy nucleotide (dNTP) used in the assay normally was complementary to the nucleotide at the polymorphic site in the amplicon. Samples were incubated at 94°C for 2 minutes, followed by 55 cycles of 5 seconds at 94°C, 5 seconds at 52°C, and 5 seconds at 72°C.

[0230] Following incubation, samples were desalted by adding 16 μl of water (total reaction volume was 25 μl), 3 mg of SpectroCLEAN<sup>TM</sup> sample cleaning beads (Sequenom, Inc.) and allowed to incubate for 3 minutes with rotation. Samples were then robotically dispensed using a piezoelectric dispensing device (SpectroJET<sup>TM</sup> (Sequenom, Inc.)) onto either 96-spot or 384-spot silicon chips containing a matrix that crystallized each sample (SpectroCHIP<sup>TM</sup> (Sequenom, Inc.)). Subsequently, MALDI-TOF mass spectrometry (Biflex and Autoflex MALDI-TOF mass spectrometers (Bruker Daltonics) can be used) and

SpectroTYPER RT™ software (Sequenom, Inc.) were used to analyze and interpret the SNP genotype for each sample.

### Genetic Analysis

[0231] Genotyping results for replication cohorts #1 and #2 are provided in Tables 8 and 9, respectively.

**TABLE 8** 

rsID	Replication #1 (Mixed Male/Female cases and Female controls)			Meta-analysis Disc. + Rep #1	
	AF OA Con	AF OA Cas	Delta	P-value	P-value
rs398829	0.30	0.28	0.02	0.307	0.0260

TABLE 9

rsID	Replication #2 (Newfoundland) (Male/Female cases and controls)			Meta-analysis Disc. + Rep #2	
	AF OA Con	AF OA Cas	Delta	P-value	Not Done
rs398829	0.27	0.28	-0.013	0.627	

[0232] To combine the evidence for association from multiple sample collections, a meta-analysis procedure was employed. The allele frequencies were compared between cases and controls within the discovery sample, as well as within the replication cohort #1 using the DerSimian-Laird approach (DerSimonian, R. and N. Laird. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.)

[0233] The absence of a statistically significant association in one or more of the replication cohorts should not be interpreted as minimizing the value of the original finding. There are many reasons why a biologically derived association identified in a sample from one population would not replicate in a sample from another population. The most important reason is differences in population history. Due to bottlenecks and founder effects, there may be common disease predisposing alleles present in one population that are relatively rare in another, leading to a lack of association in the candidate region. Also, because common diseases such as arthritis-related disorders are the result of susceptibilities in many genes and many environmental risk factors, differences in population-specific genetic and environmental backgrounds could mask the effects of a biologically relevant allele. For these and other reasons, statistically strong results in the original, discovery sample that did not replicate in one or more of the replication samples may be further evaluated in additional replication cohorts and experimental systems.

# Example 4 ADAMTS2 Region Proximal SNPs

[0234] It has been discovered that SNP rs398829 in *ADAMTS2* is associated with occurrence of osteoarthritis in subjects. This gene encodes a disintegrin and metalloproteinase with thrombospondin motifs-2 (*ADAMTS2*), which is a member of the *ADAMTS* protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. *ADAMTS2* is involved in collagens 1, 2 and 5 N-terminal processing, (type II collagen is the major form in cartilage). Mutations in this gene cause Ehlers-Danlos syndrome type VIIC, a recessively inherited connective-tissue disorder that causes loose joints and fragile skin. Mild loss of function may exacerbate physical joint damage leading to a predisposition to OA and incorrectly processed collagen can act dominantly to inhibit self assembly of fibrils. Alternative splicing of the gene generates 2 transcript variants. The short transcript encodes a protein, which has no significant procollagen N-peptidase activity.

[0235] Two hundred-nine additional allelic variants proximal to rs398829 were identified and subsequently allelotyped in osteoarthritis case and control sample sets as described in Examples 1 and 2. The polymorphic variants are set forth in Table 10. The chromosome positions provided in column four of Table 10 are based on Genome "Build 34" of NCBI's GenBank.

TABLE 10

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs2278221	5	210	178695460	c/t
rs1650358	5	3608	178698858	c/g
rs1643818	5	3609	178698859	c/g
rs3733916	5	4318	178699568	c/t
rs1624933	5	5593	178700843	a/g
rs1624857	5	5629	178700879	c/t
rs1624832	5	5639	178700889	a/g
rs1624829	5	5640	178700890	c/t
rs2161171	5	8943	178704193	a/c
rs1530499	5	17968	178713218	a/g
rs888764	5	19887	178715137	a/g
rs873987	5	21034	178716284	a/g
rs4078699	5	21085	178716335	c/t
rs870311	5	21596	178716846	a/g
rs1643817	5	23379	178718629	a/c
rs1643816	5	23432	178718682	a/c
rs1650355	5	24007	178719257	a/c
rs888763	5	26121	178721371	a/g
rs1862212	5	26273	178721523	a/t

P A T E N T Docket <u>524593008900</u>

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs1110514	5	26755	178722005	a/t
rs3797600	5	27411	178722661	c/t
rs3797602	5	27710	178722960	g/t
rs3797603	5	27842	178723092	c/t
rs3776819	5	28379	178723629	c/t
rs252076	5	29603	178724853	c/t
rs252075	5	31232	178726482	c/g
rs252074	5	31504	178726754	a/g
rs252068	5	32583	178727833	c/g
rs252069	5	32794	178728044	a/g
rs194040	5	32840	178728090	c/t
rs252070	5	33044	178728294	c/t
rs3797606	5	33150	178728400	a/c
rs171667	5	33218	178728468	a/g
rs187539	5	33513	178728763	c/t
rs3836834	5	33959	178729209	- /tatcaaactaccatga aa
rs252071	5	34486	178729736	a/g
rs252072	5	36289	178731539	c/t
rs252073	5	36570	178731820	c/t
rs379589	5	38247	178733497	a/t
rs2052472	5	38477	178733727	a/c
rs2052471	5	38518	178733768	c/t
rs2052470	5	38529	178733779	c/t
rs2052469	5	38667	178733917	a/g
rs3797608	5	39781	178735031	c/t
rs3797609	5	39856	178735106	c/t
rs3822601	5	39927	178735177	c/t
rs153131	5	40506	178735756	a/g
rs751546	5	41869	178737119	c/g
rs2279979	5	42452	178737702	c/t
rs252060	5	44788	178740038	c/t
rs3797610	5	46059	178741309	a/c
rs194039	5	46846	178742096	a/g
rs168773	5	47712	178742962	a/t
rs252061	5	48796	178744046	c/t
rs187537	5	49441	178744691	c/g
rs252062	5	49602	178744852	a/t
rs2431255	5	49723	178744973	a/c
rs3797612_	5	50050	178745300	c/t
rs3797613	5	50171	178745421	c/t
rs614114	5	50477	178745727	c/t
rs252063	5	50818	178746068	c/t
rs252064	5	50833	178746083	c/t
rs252065	5	50881	178746131	a/g
rs450502	5	50882	178746132	a/g
rs439252	5	51386	178746636	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs252066	5	51534	178746784	c/t
rs457957	5	52317	178747567	a/g
rs3797614	5	52368	178747618	c/t
rs423552	5	52970	178748220	a/g
rs398829	5	53023	178748273	a/g
rs416646	5	53356	178748606	a/g
rs187450	5	53882	178749132	g/t
rs337807	5	54553	178749803	c/t
rs337806	5	55475	178750725	a/c
rs1396438	5	55530	178750780	a/g
rs1396437	5	55691	178750941	c/t
rs2411811	5	55848	178751098	a/c
rs2898813	5	55879	178751129	c/g
rs189256	5	56316	178751566	a/g
rs173072	5	56911	178752161	a/c
rs337805	5	57320	178752570	a/g
rs191415	5	57391	178752641	c/t
rs180045	5	57437	178752687	c/t
rs189255	5	57478	178752728	c/g
rs652766	5	57500	178752750	c/t
rs466750	5	59111	178754361	g/t
rs442406	5	59333	178754583	a/g
rs662407	5	59715	178754965	a/g
rs592971	5	59804	178755054	a/g
rs457187	5	59851	178755101	a/g
rs459490	5	59929	178755179	c/t
rs459668	5	60052	178755302	c/t
rs462646	5	60240	178755490	c/t
rs458272	5	60359	178755609	g/t
rs463455	5	60381	178755631	a/g
rs675880	5	60456	178755706	c/t
rs810617	5	60724	178755974	c/g
rs464156	5	60875	178756125	c/t
rs458083	5	60968	178756218	a/g
rs467333	5	60978	178756228	c/g
rs465381	5	60998	178756248	c/t
rs466363	5	61557	178756807	c/t
rs2457099	5	62091	178757341	c/t
rs463901	5	62645	178757895	c/t
rs465621	5	62943	178758193	a/c
rs463724	5	63131	178758381	a/t
rs465242	5	63145	178758395	g/t
rs467419	5	63406	178758656	a/g
rs456135	5	63427	178758677	c/g
rs464536	5	63554	178758804	c/t
rs461898	5	63661	178758911	a/g
rs389558	5	64093	178759343	a/g

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs466752	5	64153	178759403	c/t
rs455655	5	64409	178759659	c/g
rs463435	5	64544	178759794	c/t
rs2174971	5	65257	178760507	c/t
rs1979979	5	65626	178760876	a/g
rs411804	5	65739	178760989	a/g
rs1623885	5	66392	178761642	c/t
rs1643811	5	66720	178761970	c/t
rs434430	5	69177	178764427	a/t
rs187538	5	69336	178764586	g/t
rs252067	5	69636	178764886	a/g
rs459319	5	69823	178765073	a/g
rs467289	5	69928	178765178	c/t
rs462644	5	70547	178765797	c/t
rs458752	5	70633	178765883	c/t
rs708320	5	71805	178767055	a/c
rs457954	5	72181	178767431	c/g
rs2411810	5	72200	178767450	c/t
rs3084687	5	72474	178767724	-/at
rs69638	5	72567	178767817	c/g
rs455452	5	72973	178768223	a/g
rs464850	5	73468	178768718	a/g
rs431472	5	73889	178769139	a/g
rs2411809	5	75730	178770980	c/t
rs2457094	5	75970	178771220	a/g
rs2457095	5	76114	178771364	a/g
rs2261740	5	76342	178771592	c/t
rs1109180	5	76449	178771699	a/g
rs1109179	5	76465	178771715	c/t
rs1109178	5	76791	178772041	a/c
rs456909	5	78042	178773292	a/g
rs469124	5	80758	178776008	a/g
rs468039	5	80778	178776028	c/t
rs467017	5	81356	178776606	a/c
rs469290	5	81576	178776826	a/g
rs469090	5	81689	178776939	c/t
rs469568	5	81759	178777009	g/t
rs468386	5	81950	178777200	c/g
rs469349	5	82562	178777812	a/c
rs469099	5	83591	178778841	c/t
rs456868	5	83700	178778950	a/g
rs465389	5	83821	178779071	c/g
rs463892	5	83842	178779092	c/g
rs468548	5	83923	178779173	g/t
rs654612	5	83929	178779179	a/c
rs468542	5	84021	178779271	c/g
rs469262	5	84175	178779425	c/t

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs708323	5	84417	178779667	a/g
rs469089	5	84747	178779997	c/g
rs469396	5	85746	178780996	c/g
rs468723	5	86129	178781379	c/t
rs467604	5	86335	178781585	a/g
rs338874	5	87315	178782565	c/g
rs338875	5	87648	178782898	a/g
rs1385803	5	87764	178783014	a/c
rs1385804	5	87770	178783020	c/g
rs338876	5	88221	178783471	c/t
rs189803	5	90474	178785724	a/c
rs452215	5	91148	178786398	g/t
rs641170	5	91150	178786400	g/t
rs584398	5	91160	178786410	g/t
rs385330	5	91733	178786983	c/t
rs429538	5	91772	178787022	a/c
rs371229	5	91785	178787035	c/t
rs460874	5	93140	178788390	a/t
rs646121	5	93148	178788398	a/t
rs468262	5	96080	178791330	a/g
rs467863	5	96157	178791407	c/g
rs191434	5	96313	178791563	a/c
rs2054782	5	96759	178792009	c/t
rs468499	5	97026	178792009	a/c
rs180287	5	97320	178792570	
rs338877	5	97732	178792570	c/g a/t
	5	<del> </del>	*	<del></del>
rs650665	5	98713	178793963	c/g
rs193419	5	99707	178794957	a/c
rs180288	5	99959	178795209	c/g
rs186834	1	100009	178795259	a/g
rs189266	5	100020	178795270	c/g
rs189267	5	100065	178795315	a/c
rs170937	5	100086	178795336	c/g
rs463263	5	101270	178796520	c/g
rs463262	5	101276	178796526	g/t
rs460454	5	101371	178796621	c/t
rs460455	5	101376	178796626	c/g
rs460505	5	101439	178796689	c/t
rs931316	5	101820	178797070	c/t
rs463431	5	102392	178797642	c/g
rs461542	5	102602	178797852	a/g
rs463557	5	102604	178797854	a/c
rs191453	5	102896	178798146	c/t
rs2271212	5	189104	178884354	c/t
rs462009	5	189134	178884384	c/t
_rs2271211	5	189205	178884455	a/g
rs396474	5	Not mapped	Not mapped	a/c

dbSNP rs#	Chromosome	Position in SEQ ID NO: 1	Chromosome Position	Allele Variants
rs428901	5	Not mapped	Not mapped	a/t
rs452300	5	Not mapped	Not mapped	g/t
rs670256	5	Not mapped	Not mapped	g/t

# Assay for Verifying and Allelotyping SNPs

[0236] The methods used to verify and allelotype the 209 proximal SNPs of Table 10 are the same methods described in Examples 1 and 2 herein. The primers and probes used in these assays are provided in Table 11 and Table 12, respectively.

TABLE 11

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs2278221	ACGTTGGATGTCTCATGGGCCACCACAAC	ACGTTGGATGTATGCTCCTGTCACCGGCAT
rs1650358	ACGTTGGATGTGGATGGCTCCATGTTCTTG	ACGTTGGATGAAGTGCTGGGATTACAGGTG
rs1643818	ACGTTGGATGCTGGGATTACAGGTGTGAAC	ACGTTGGATGTGGATGGCTCCATGTTCTTG
rs3733916	ACGTTGGATGCCGAGCAGGCTGTAGTGTTG	ACGTTGGATGCTTTGTACCACCTGGAACAG
rs1624933	ACGTTGGATGAGGCTGGTCTCAAACTCCTG	ACGTTGGATGTAACAAAAGTTGGCCGTGC
rs1624857	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGGCCACCAAGCCAGACTAAGT
rs1624832	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGGCCACCAAGCCAGACTAAGT
rs1624829	ACGTTGGATGTGAGGTCAGGAGTTTGAGAC	ACGTTGGATGGCCACCAAGCCAGACTAAGT
rs2161171	ACGTTGGATGCCCGTCACCACTTTATTTCC	ACGTTGGATGAGAGTGGATCCAGTCTGCAG
rs1530499	ACGTTGGATGACTCCAAGATTTCCCATTTC	ACGTTGGATGTTCTGTGTTCCACCCTATGG
rs888764	ACGTTGGATGTAGTTGAATGTTGTATTGGC	ACGTTGGATGACCGTGATAAACACAGAATG
rs873987	ACGTTGGATGGCTGTTAATCATGTGTCGGG	ACGTTGGATGATTTGGCCACATCACCAGAC
rs4078699	ACGTTGGATGGTACCGTGGATTCTTTTAGG	ACGTTGGATGGTATTGGAAAAGAGCAGAGAC
rs870311	ACGTTGGATGTCAGGGCTCCAGTGTTGAAG	ACGTTGGATGAAAAGGAGGAGTGCCCTGTG
rs1643817	ACGTTGGATGATGGGAAACTCCTGGTCCTG	ACGTTGGATGAAAATGCAAGCCGCCACCTG
rs1643816	ACGTTGGATGTTTTCTCCCCTTTCTAGCCC	ACGTTGGATGTTGGCATGAGAGATGGACAG
rs1650355	ACGTTGGATGTCAACAGCAACAAACCAAA	ACGTTGGATGTTAAATAGGTCAGAGGGTTG
rs888763	ACGTTGGATGAAGAGAAGAGACATACCAG	ACGTTGGATGAACAACATGGACTCAGGCTG
rs1862212	ACGTTGGATGGGCCACATTTTAAAACAAGGG	ACGTTGGATGTCCCCTGAGGTTCCTATAAG
rs1110514	ACGTTGGATGTGCCCACGTTCCATGTTCAG	ACGTTGGATGATCACTGTAGCCCCTTCCTG
rs3797600	ACGTTGGATGCCTTCCTGTCACCTCCTTTG	ACGTTGGATGGGAAGTGACTGCTGAGCTG
rs3797602	<u>ACGTTGGATGAGAAACAGGGACTGGCTGTGT</u>	ACGTTGGATGAGCAGGCTCCGGGAAGTATG
rs3797603	ACGTTGGATGCACCCATCCATCATGATGTC	ACGTTGGATGTGCTACCTCAAAACAGTGGG
rs3776819	ACGTTGGATGCAAGCACCATTCCATTGCAC	ACGTTGGATGAAATGAGGATTGCAGTCCCC
rs252076	ACGTTGGATGACTTCTGACTTCAGGTGATC	ACGTTGGATGTATAGGAACGAAAGAAAGCC
rs252075	ACGTTGGATGTGGGAGCATTTGCAGGCATG	ACGTTGGATGAAGCCTCAGATGGTTCGGAG
rs252074	ACGTTGGATGTTGCGATGGCCTCCTGGCT	ACGTTGGATGAAGTTGAGGGCTCCGGAGCA
rs252068	ACGTTGGATGGGGTAGGAAGGGTTTAAGC	ACGTTGGATGGCAGCCCCTCAATTCTTTAG
rs252069	ACGTTGGATGTGCCCATTTCCTGTTATTCC	ACGTTGGATGTTTGGACTTGCCGTGCAACT
rs194040	ACGTTGGATGTGCCCATTTCCTGTTATTCC	ACGTTGGATGTTTGGACTTGCCGTGCAACT
rs252070	ACGTTGGATGCTCAAGGACATTGTCCCTGG	ACGTTGGATGGGAGAAGCAGCTCTCCTTTC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs3797606	ACGTTGGATGGTTTCCCCAAACAAGAGAGC	ACGTTGGATGGGAAATGTTCAAAGCCGCAG
rs171667	ACGTTGGATGGGGAAACACATTGTAATGCG	ACGTTGGATGCCTTCCTCATTGTCTATTCC
rs187539	ACGTTGGATGAGCCACCCCAACCTTCAGGA	ACGTTGGATGTTGCTCCTGGACATGGTTTT
rs3836834	ACGTTGGATGAAGAAACGTGACTCTTGCTC	ACGTTGGATGTAGTAATTCTGATCCTGGCC
rs252071	ACGTTGGATGGCTTCAACCTGAAACAACCC	ACGTTGGATGGGGATATTCCCACTCTGAG
rs252072	ACGTTGGATGTTGTTTCCCCAAAGGCGACG	ACGTTGGATGTGTTTTCCAGAGCTGGAG
rs252073	ACGTTGGATGGGGAAAGGCCGAGAAAAGTC	ACGTTGGATGACAAGCTCAGCAGAGTTCCA
rs379589	ACGTTGGATGAAACACGGGAGTACTGAGCA	ACGTTGGATGTTGTTAGCTGTCTGTCCGTC
rs2052472	ACGTTGGATGAACCAGCTCAAGGATCACCC	ACGTTGGATGAAAGGAGACGGTCAGCTGTC
rs2052471	ACGTTGGATGACAGCTGACCGTCTCCTTTG	ACGTTGGATGCCCGTCCTGGACAAGCTTTT
rs2052470	ACGTTGGATGACAGCTGACCGTCTCCTTTG	ACGTTGGATGCCCGTCCTGGACAAGCTTTT
rs2052469	ACGTTGGATGAGGGAAAGATATCGCACGCG	ACGTTGGATGAGTGAACAACTGCTCGCCTC
rs3797608	ACGTTGGATGTGCTTTGCCTTGGCTTCTGC	ACGTTGGATGTGCACTAAGGGAGTGAGTGG
rs3797609	ACGTTGGATGTGCAGAAGCCAAGGCAAAGC	ACGTTGGATGACAGCATTTGGAGTCCCCTG
rs3822601	ACGTTGGATGAGGTCAGTGAGGCCTGAGAT	ACGTTGGATGTCTGGCCTGAAGATCGAG
rs153131	ACGTTGGATGTAATCACGTGTCCTGATCCC	ACGTTGGATGAGCTGTCCTCAGTCATGTTC
rs751546	ACGTTGGATGTCCTGCTGCCGTTCTACA	ACGTTGGATGATCAGCTCAAAGGACCGGTG
rs2279979	ACGTTGGATGTATTGCTACCAGGAACACGTA	ACGTTGGATGAAAAAGGGGCCACTTCAGGG
rs252060	ACGTTGGATGTGGCCAGAGCCCGTGTTTC	ACGTTGGATGCGGCCAATCCCATCTCTATG
rs3797610	ACGTTGGATGAAAAGCTTCTCCCTTGGGTG	ACGTTGGATGCAAGTAGGGCAGAAACTCAG
rs194039	ACGTTGGATGAAAGTGCTGGGATTACAGGC	ACGTTGGATGTGCTGGGAGAAGACATTCAC
rs168773	ACGTTGGATGTGGTGCACTGGAGATATCAC	ACGTTGGATGGATCCCTATCCTACCTCTTC
rs252061	ACGTTGGATGTGTCACACTCCTCTTGTAAG	ACGTTGGATGCTGTCCTTCCATGCTTTTGC
rs187537	ACGTTGGATGCGAGGATGTCATGCTAAGTG	ACGTTGGATGGTACCTCGCATAAGTGGATC
rs252062	ACGTTGGATGAAGCACATTCATGTGGCTGG	ACGTTGGATGCTGAAACTCAATGGGCACAG
rs2431255	ACGTTGGATGGGTGAAGACGGTGACTTATG	ACGTTGGATGCTGGTGTCCTTGAAGAACTG
rs3797612	ACGTTGGATGAGTGAGGACGCAGGGCATTC	ACGTTGGATGAGCGTGGGCGAGGGAGATAA
rs3797613	ACGTTGGATGATCAGAGGCAGAGACCCCCC	ACGTTGGATGGGGTGTCCTGCAGAGGCGG
rs614114	ACGTTGGATGGTTGGAGGATGTCTAGAAC	ACGTTGGATGGGCTGGATCACTAGGGTTTG
rs252063	ACGTTGGATGTTGGAATTACAGTCCGATGG	ACGTTGGATGCTGAGAGACTGAAAAGCACA
rs252064	ACGTTGGATGCTGAGAGACTGAAAAGCACA	ACGTTGGATGTTGGAATTACAGTCCGATGG
rs252065	ACGTTGGATGAAAACTAAGGCTCAGAGGAC	ACGTTGGATGTGGGCTTGGAATTACAGTCC
rs450502	ACGTTGGATGATGAGAAAACCAAGGCTCAG	ACGTTGGATGCTGGGCTTGGAATTACAGTC
rs439252	ACGTTGGATGATCTCCTGACCTCGTGATCC	ACGTTGGATGTCATAATAACGGCCGGGTGC
rs252066	ACGTTGGATGTTTCCTCTTGACCGGTCTTG	ACGTTGGATGTAAAACGAATTCTGCCGATG
rs457957	ACGTTGGATGTTCACGTGCATTAGAGCGAG	ACGTTGGATGAATTCCCTCCCCAATTCCTC
rs3797614	ACGTTGGATGACTGCGAGCTTTAAGGAGGG	ACGTTGGATGCCAAACAGAAGCCCCTTTTC
rs423552	ACGTTGGATGGCAGGACCTCGATGTTGTAG	ACGTTGGATGATCCTAGAGGAGCACGCCAAC
rs398829	ACGTTGGATGTAGTCATCGTCCGCAGCATG	ACGTTGGATGAAGACGGTGTCCTCCTTG
rs416646	ACGTTGGATGGCTGGGTCTCTCACAGTCTC	ACGTTGGATGAGACAGGCACCTCTGTGACTT
rs187450	ACGTTGGATGAGAAGGCAGGACGATATCC	ACGTTGGATGACCAAGATGAACCCCTCTGT
rs337807	ACGTTGGATGTCACCCAGTGCTGACAGCAG	ACGTTGGATGATGCTGGGATGCCATGGGTC
rs337806	ACGTTGGATGAATTAAGAGATGGGGCCACC	ACGTTGGATGGCCCTGTGTGTTTTGTCTCC
rs1396438	ACGTTGGATGTACCTTCTGGTGCCAGAATG	ACGTTGGATGCCTGGAGACAAAACACACAG
rs1396437	ACGTTGGATGTAAAAACTCTGCCTGCTCGG	ACGTTGGATGTCCAGACATTCCCCGTAGGA
rs2411811	ACGTTGGATGGAGGGATGCTCTAGAACATA	ACGTTGGATGCTGAATTTCACCTGAAATGG
rs2898813	ACGTTGGATGTCCTCACCCACTTTGCCTTT	ACGTTGGATGATCGTGATAATTTTGGGGTG

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs189256	ACGTTGGATGCTCCCTATAGCAAGGCTCTA	ACGTTGGATGTTAACCCAGGCCATGAAGAG
rs173072	ACGTTGGATGAGCTGGAGATCTCTTTGCTC	ACGTTGGATGCTAAAACAGGATGGCTCTGG
rs337805	ACGTTGGATGGAAACAAACCAAGGAGCAGG	ACGTTGGATGATGTGGACACGTTGGACTC
rs191415	ACGTTGGATGAATTACATGACTCGGACAAG	ACGTTGGATGTGCTGGTGAAGTACAGAAGG
rs180045	ACGTTGGATGGTCCCAGGTTTTCTGTTCTC	ACGTTGGATGTGTACTTCACCAGCACTGAG
rs189255	ACGTTGGATGAGGTTGCAGACTCAGTCCCA	ACGTTGGATGGGGTGATTTGCGGGAATGAG
rs652766	ACGTTGGATGGGGTGATTTGCGGGAATGAG	ACGTTGGATGACCATCCCACGATGCTCCC
rs466750	ACGTTGGATGTATCTCCTTAAATGCCTTGG	ACGTTGGATGTGACCAGGAGGAGTTAAAAC
rs442406	ACGTTGGATGTGACAAGGTCACGTGTTCTG	ACGTTGGATGCCAGACAAGTCTGATACAGC
rs662407	ACGTTGGATGCCACAGTCACCATTACTGAG	ACGTTGGATGCTTGAGCCATGAGTGGAATG
rs592971	ACGTTGGATGGGAAGCATTTCTTTGACTGC	ACGTTGGATGATTCCATCTCATGGCTCAAG
rs457187	ACGTTGGATGTGAGATGAGGAGTATCTG	ACGTTGGATGGCAGTCAAAGAAATGCTTCC
rs459490	ACGTTGGATGACAGATACTCCTCATCTCAC	ACGTTGGATGGGGAGTTTTGCTGTTATAGC
rs459668	ACGTTGGATGGCTTCATTTACTGAGGTCTTC	ACGTTGGATGTGAATGTTCAACGACTACAC
rs462646	ACGTTGGATGCAATTATTCGACGGAGATTA	ACGTTGGATGCTCCTCCAAATGAATCAAGAA
rs458272	ACGTTGGATGATGCCTCCTCATTGTCATTC	ACGTTGGATGCCCAACAAGTGATTCCAAC
rs463455	ACGTTGGATGATGCCTCCTCATTGTCATTC	ACGTTGGATGCCCAACAAGTGATTCCAAC
rs675880	ACGTTGGATGCAGCTCCATTGATCTGTTTC	ACGTTGGATGAAGAATGACAATGAGGAGGC
rs810617	ACGTTGGATGTGATCTCAGCTTACCACAGC	ACGTTGGATGATGCCTGTAATCCCAGCTAC
rs464156	ACGTTGGATGCAGATCCAAGAATATGTGGG	ACGTTGGATGTTCTAGAAAGGAGCCAAATC
rs458083	ACGTTGGATGTTGTTTCTTCCCCTCCTG	ACGTTGGATGTGGCTCCTTTCTAGAATCCC
rs467333	ACGTTGGATGCTTGTTATTTCTTCCCCTCC	ACGTTGGATGTTGGCTCCTTTCTAGAATCC
rs465381	ACGTTGGATGACTTGCCCATCTGTTTCCAG	ACGTTGGATGACAAGCCTCTAAGGATAGGG
rs466363	ACGTTGGATGAAGTGACCCTGAGGTGATGG	ACGTTGGATGTGAAGACAGTTCACCCCGTG
rs2457099	ACGTTGGATGTCTCCTTACACTGCCAGCGT	ACGTTGGATGCACTGTATTGCTACTTGAGC
rs463901	ACGTTGGATGAGAGTGCAAAAGG	ACGTTGGATGTGTCTTGCGTCTGTGTATCC
rs465621	ACGTTGGATGGAAGTCATGGAAGTGCTAG	ACGTTGGATGAAAGAGCCCTAGGCTTGGAA
rs463724	ACGTTGGATGAGTGTGCCTGTCTGCCCTCA	ACGTTGGATGAAGGGCAGATGGCACACTTG
rs465242	ACGTTGGATGAGTGTGCCTGTCTGCCCTCA	ACGTTGGATGAAGGGCAGATGGCACACTTG
rs467419	ACGTTGGATGAGTCCCCAAAACGTAAGTCC	ACGTTGGATGAGTCTAATTCCCTGAGCCTC
rs456135	ACGTTGGATGAGTCTAATTCCCTGAGCCTC	ACGTTGGATGACGTAAGTCCTAATGACCGC
rs464536	ACGTTGGATGTGCTCCAGGCTTTGGTCCTC	ACGTTGGATGAATTAGACTAAGGCCATGATG
rs461898	ACGTTGGATGGGGAATACACAGCCACAGAG	ACGTTGGATGAGGTCAACGGGAACAAGGTC
rs389558	ACGTTGGATGGCAGTCCTGACAGTTCTCTA	ACGTTGGATGTTTTTCTCCCTGAAGCATGG
rs466752	ACGTTGGATGGGCCTTCTCTCTCTTAGTGC	ACGTTGGATGAGTCCTGACAGTTCTCTAAA
rs455655	ACGTTGGATGCTATTTGCACCCCATATGGC	ACGTTGGATGAACACACAGCATCAGGTTCC
rs463435	ACGTTGGATGTTCAGCCATAGCTGGATTTG	ACGTTGGATGCTCTGCTGGGAAAATGTGAC
rs2174971	ACGTTGGATGAACACAACTTCCCCTTCGTC	ACGTTGGATGTGAATCCTTGGAGGTGAGTG
rs1979979	ACGTTGGATGTGGCTGTCAGCACCCCACTT	ACGTTGGATGCCCAAAGGAAGGGAGAATTC
rs411804	ACGTTGGATGCAGATGACAGGCGGAAAATC	ACGTTGGATGAGGCTTCCAGATGATGTCCA
rs1623885	ACGTTGGATGAATCAGCTAGGAAGAGCCTG	ACGTTGGATGTTCCTGACCCCTCTAGGTCAG
rs1643811	ACGTTGGATGCAGGGCCCTGGTACTTTCAG	ACGTTGGATGCATGGTGGTGATTGCACCTG
rs434430	ACGTTGGATGTCCAGGAGTTCACTGTAGAG	ACGTTGGATGCACATGCATACATTCATCAC
rs187538	ACGTTGGATGACATGGGGCTTGGCAAAATG	ACGTTGGATGCACCTGCTCAGAAGTAGCAT
rs252067	ACGTTGGATGAGAATTGCTGTGGTGTGAGG	ACGTTGGATGTTTTCTTGGGAGCTGTCGC
rs459319	ACGTTGGATGCCATCTCTCTGACCTAGACA	ACGTTGGATGGCTCCAAGGAAAATTGGGAG
rs467289	ACGTTGGATGGGCCCTCTTGGCTTGTCTTT	ACGTTGGATGAGGCAGTGTGCCCTCTCATC

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs462644	ACGTTGGATGATGTGGGTGAGCCCTTG	ACGTTGGATGTAACACTCAGCACGCACCAG
rs458752	ACGTTGGATGCACCCACATCATGTGCGCTT	ACGTTGGATGCCCTTCTCTACCCAGCACTT
rs708320	ACGTTGGATGAAACCAGCCTGGCTAACATG	ACGTTGGATGACAGGTGCCTGCTATCATAC
rs457954	ACGTTGGATGAACCAGACCTTGACTGATGG	ACGTTGGATGCCTCATACAAGTAGCCAAGG
rs2411810	ACGTTGGATGGCTTAACCAGACCTTGACTG	ACGTTGGATGAGTGTAAGGATATCCACGGC
rs3084687	ACGTTGGATGATCCCTTGAGCCAGAGATTC	ACGTTGGATGATGTCCTGTGCACACACAAG
rs69638	ACGTTGGATGTGCTCATTGCTGTCCTCATC	ACGTTGGATGAGAAGAAGGTGTGCAGTGG
rs455452	ACGTTGGATGAGTGATGAGCCTGCTGG	ACGTTGGATGTCAGGTTCCCTCTCTGTGTC
rs464850	ACGTTGGATGTCTCTCTGTGCTCCAGACCA	ACGTTGGATGTGGGCTGAGATTTCTGTGGG
rs431472	ACGTTGGATGAACCAGTGTGGGTGTGAAGC	ACGTTGGATGAGAGACTGCATCAGGCAGGA
rs2411809	ACGTTGGATGAGCGCATAAGTGACCACCAG	ACGTTGGATGGCACTCACAGGGCATTGATG
rs2457094	ACGTTGGATGTTACTGTCACCTTGGGTCTC	ACGTTGGATGGGAAGTCTGTATAGACGCAG
rs2457095	ACGTTGGATGTTATCAAGGCCTGCGCAGTG	ACGTTGGATGACTCCTGACCTCAGGCAATC
rs2261740	ACGTTGGATGATCGTGCCACTGCACTCCAG	ACGTTGGATGTCATCTTTTGGTAGCCCCCC
rs1109180	ACGTTGGATGCCAGGCCTGTATTGCACATC	ACGTTGGATGAGAATGCGTGTGCATGTGGG
rs1109179	ACGTTGGATGTGTAATGGTATGCAGACCCC	ACGTTGGATGGAGTGCCGTATTTGTCCTTC
rs1109178	ACGTTGGATGGCAAACAACAACAGCAACAG	ACGTTGGATGAAGTGTGGATTTGTGCAGAC
rs456909	ACGTTGGATGTAGCTGCTTCATCTGTAAAG	ACGTTGGATGGGCACTTTACCGATCTACTC
rs469124	ACGTTGGATGACTTGGACACACATAGGCTG	ACGTTGGATGTGAAATGCTCAGGGTGTGTG
rs468039	ACGTTGGATGTGAAATGCTCAGGGTGTGTG	ACGTTGGATGAGGACTTGGACACACATAGG
rs467017	ACGTTGGATGGTCTAGCTGCCACTAAACAG	ACGTTGGATGATGTGCCAAGAGGCTTTGAG
rs469290	ACGTTGGATGTGCCCTTTGTGTGCTCAGAG	ACGTTGGATGTCCCTCTGTGCTGTTTTGG
rs469090	ACGTTGGATGACTTGTCTTCAGGTGCTTGG	ACGTTGGATGGATGGTTAGTCTCCTGGTTC
rs469568	ACGTTGGATGAGCACCTCTGGCTTTCATTG	ACGTTGGATGATTCACCAGGAAATCCCAAC
rs468386	ACGTTGGATGTAATCCCAGCCCTTTGGAAG	ACGTTGGATGTATGGAGACAGGGTTTTACC
rs469349	ACGTTGGATGTTAGAGACAGAGTCTCACTC	ACGTTGGATGTTGATCCCAGGAGTTCAAGG
rs469099	ACGTTGGATGTTGGAGCTGCTCTAGTTCTC	ACGTTGGATGTGAAAACCGGGACTCAGCTC
rs456868	ACGTTGGATGACAGAGCAGGGAGCTGCGGT	ACGTTGGATGATTCACCCCCAGCTACTGTG
rs465389	ACGTTGGATGAGGCTTTGTAGACAGCTCCC	ACGTTGGATGTGCCAGTGCTCTGAGTATGC
rs463892	ACGTTGGATGAGGCTTTGTAGACAGCTCCC	ACGTTGGATGTGCCAGTGCTCTGAGTATGC
rs468548	ACGTTGGATGACTGGAAGGGAACATGCAAG	ACGTTGGATGCCTGGATGCCCTTTATAGAC
rs654612	ACGTTGGATGACTGGAAGGGAACATGCAAG	ACGTTGGATGTGGATGCCCTTTCTAGACAC
rs468542	ACGTTGGATGGCCTCCATTTTCCTTCTCAC	ACGTTGGATGTGTCTAGAAAGGGCATCCAG
rs469262	ACGTTGGATGTTCTGAGCTGAACGAAGCAG	ACGTTGGATGGGTCAGGGATCCTTTGATGC
rs708323	ACGTTGGATGCACATACTATACAGGTCACC	ACGTTGGATGGAGGGAGAAGATGTTGTGAA
rs469089	ACGTTGGATGTTTGGAAGTACCACCTCAGC	ACGTTGGATGAATGGAAGGAAGGATCAGCC
rs469396	ACGTTGGATGAGTGACTCCAATGAGGGAAC	ACGTTGGATGTCTCACACCACTGATCCTTC
rs468723	ACGTTGGATGTGTGGATCTTGCTGTTTGGG	ACGTTGGATGTATTGGCATCGCGTATCAGG
rs467604	ACGTTGGATGACTCCTGCCATTAAACTCTC	ACGTTGGATGCTTGGCTTAACTTACAAGGG
rs338874	ACGTTGGATGCCCCACCACAGCCACTGGG	ACGTTGGATGAAGGGCCTTGCCCCACCCAA
rs338875	ACGTTGGATGTGCTGTCTTGCTCGCGTGTG	ACGTTGGATGACACTGGATATGTCAGGGTC
rs1385803	ACGTTGGATGTCACCACCATTCCAGAAGTG	ACGTTGGATGACCTTCCTTATTGCTGTGGC
rs1385804	ACGTTGGATGTCACCACCATTCCAGAAGTG	ACGTTGGATGACCTTCCTTATTGCTGTGGC
rs338876	ACGTTGGATGTTAGGGCTGGGTGGAGGAAG	ACGTTGGATGTCCAACTCCCAGTGACAGAG
rs189803	ACGTTGGATGCCTCCAGTTTCTCTCTCTG	ACGTTGGATGATCCTGGATTAGCCAGATGG
rs452215	ACGTTGGATGTAGCTCTATTCTTCCACCCC	ACGTTGGATGAGCGAGACTCCGTCTCAAAA
rs641170	ACGTTGGATGATAGCTCTATTCTTCCACCC	ACGTTGGATGAGCGAGACTCCGTCTCAAAA

dbSNP rs#	Forward PCR primer	Reverse PCR primer
rs584398	ACGTTGGATGTTCCTGTGAGCTATAGAAAC	ACGTTGGATGCGAGACTCCGTCTCAAAAAAA
rs385330	ACGTTGGATGTTGCCCCAACTATTGTCCTG	ACGTTGGATGGGTTTCCCAGACAGTGTTTG
rs429538	ACGTTGGATGTATTATCTGCAGACACCTGG	ACGTTGGATGATCTCATTCCCACCCTCTTC
rs371229	ACGTTGGATGTATTATCTGCAGACACCTGG	ACGTTGGATGATCTCATTCCCACCCTCTTC
rs460874	ACGTTGGATGGTCCTGCGGCTAAAAATTCC	ACGTTGGATGGGGCAGGTCAACTAGAAAAC
rs646121	ACGTTGGATGGGCAGGTCAACTAGAAAAC	ACGTTGGATGGTCCTGCGGCTAAAAATTCC
rs468262	ACGTTGGATGGCCAGGTTTCGAAAGTTAGG	ACGTTGGATGTGGGTTGGTCATGCGGTAAC
rs467863	ACGTTGGATGTTTCGAAACCTGGCTGATGG	ACGTTGGATGTGCCACTGTCAGAAGACAAG
rs191434	ACGTTGGATGCCAGCTGAAACACTAGACAG	ACGTTGGATGAGCTGAAGAGGTCTTTCTCC
rs2054782	ACGTTGGATGAAAAAGCAGGCCTCAGACC	ACGTTGGATGTCTGACTCTCATCTGCAGAC
rs468499	ACGTTGGATGCTCCAGGAGGGACACTACGT	ACGTTGGATGTGGCCAGCTTCTCCTCGATG
rs180287	ACGTTGGATGTTGTCTGCAGAATTACCTAT	ACGTTGGATGGAAAAAAAAAAAAAAAAAAAAAAAAAAAA
rs338877	ACGTTGGATGCGTGGATGGAAATTTACATT	ACGTTGGATGTTCTTTGGATCAATGTTGCC
rs650665	ACGTTGGATGCCCATCTTACTCTATGATCTC	ACGTTGGATGAAAGTGCTGGGATTATAGGC
rs193419	ACGTTGGATGGCAAATCCAAAGACACAGGG	ACGTTGGATGATGTTTTCATCACCCCAGTG
rs180288	ACGTTGGATGTGACCTGGTAGCTTAGAG	ACGTTGGATGTTGTAGGAGGTCAGAAGAGG
rs186834	ACGTTGGATGTAAGCTACCAGGTCACACAC	ACGTTGGATGAGTTGATAGGAGAGTCAGGC
rs189266	ACGTTGGATGTAAGCTACCAGGTCACACAC	ACGTTGGATGAGTTGATAGGAGAGTCAGGC
rs189267	ACGTTGGATGCCTCATTGTGCCCTGTTGTG	ACGTTGGATGCTCTGCCTGACTCTCCTATC
rs170937	ACGTTGGATGCCTATCAACTGTTGATGGCG	ACGTTGGATGTTCCTCATTGTGCCCTGTTG
rs463263	ACGTTGGATGTACTGGACCCCTTTGCACAG	ACGTTGGATGTGCCCATGCTCATGTGTTGG
rs463262	ACGTTGGATGTGCCCATGCTCATGTGTTGG	ACGTTGGATGACCCCTTTGCACAGATGCTG
rs460454	ACGTTGGATGAAGAAGGACCGTGTCAGAGA	ACGTTGGATGACATGAGCATGGGCAGGTAC
rs460455	ACGTTGGATGACATGAGCATGGGCAGGTAC	ACGTTGGATGAAGAAGGACCGTGTCAGAGA
rs460505	ACGTTGGATGACCGTGGACAGCGTCTCTGA	ACGTTGGATGTGCTCTGAGGGCAGAACAAG
rs931316	ACGTTGGATGATGCACACACCCATGGTCAG	ACGTTGGATGCGGTTCACTCCAGCATTTCC
rs463431	ACGTTGGATGTCACCACAGCCCATGGGGA	ACGTTGGATGTTTGAAACTCACAATGTGGG
rs461542	ACGTTGGATGTGATGAAGGCCAAGAATGCT	ACGTTGGATGTGTCCAGAACGTCAGGTG
rs463557	ACGTTGGATGTGATGAAGGCCAAGAATGCT	ACGTTGGATGTGTCCAGAACGTCAGGTG
rs191453	ACGTTGGATGCATCCAACAGCTCTGTCTGC	ACGTTGGATGACCCATCTGTAGCGCATCAG
rs2271212	ACGTTGGATGAGCTTCCCCGGAGGCAACGA	ACGTTGGATGTGCAGGTCTCGGCCAAAGAC
rs462009	ACGTTGGATGCAGGCTCCTCCTCGTTGCC	ACGTTGGATGTTGGTGTCCCACGTGGTGT
rs2271211	ACGTTGGATGTCGTACCCCTGCTCTGGACG	ACGTTGGATGACTGACGCCCAGGGCCGCTT
rs396474	ACGTTGGATGTGGGAGTTGAG	ACGTTGGATGTTCCTCAGATCCCAGTCAAG
rs428901	ACGTTGGATGTCAGTGACAGAGCGAGACTC	ACGTTGGATGGGGCTCGATAATGTAGCCAT
rs452300	ACGTTGGATGAGCACAAGCTGAAGAGGTCT	ACGTTGGATGAGGAGAGAGTGCACAGATC
rs670256	ACGTTGGATGTAGCTCTATTCTTCCACCCC	ACGTTGGATGAGCGAGACTCCGTCTCAAAA

**TABLE 12** 

dbSNP rs#	Extend Primer	Term Mix
rs2278221	CAAACGCTGAGGAGAAGCC	ACT
rs1650358	AAGAGACAAAAGGCCGGGC	ACT
rs1643818	TACAGGTGTGAACCACCGC	ACT
rs3733916	AGGCTGTAGTGTTGACAGAC	ACG

dbSNP rs#	Extend Primer	Term Mix
rs1624933	GTCTCAAACTCCTGACCTCA	ACT
rs1624857	AGACCAGCCTGGCCAACAT	ACT
rs1624832	GGCCAACATGGTGAAACCC	ACG
rs1624829	TGGCCAACATGGTGAAACCCT	ACT
rs2161171	TGGAATAAGAGCCCTGCAGTGG	ACT
rs1530499	CCCCTGCCCCAGCCACAGGAA	ACT
rs888764	ATGTTGTATTGGCTATATTTGTCA	ACG
rs873987	AAAACCTAAAAGAATCCACGGTA	ACG
rs4078699	GACACATGATTAACAGCAAACAAT	ACT
rs870311	AAGGCGTGACGGCCCC	ACT
rs1643817	GAAAGGGGAGAAAAGATTATCCC	CGT
rs1643816	AGGACCAGGAGTTTCCCATTTT	ACT
rs1650355	GAATCAATGAAGAAGAGAGCTT	ACT
rs888763	GGTCAGGAGGCAGAGGGA	ACT
rs1862212	GGGGTGAAAGGGAGCAGGG	CGT
rs1110514	CAGGCCCCAGGTGAGGAA	CGT
rs3797600	CTTTGTTGGTTAACCAAACCC	ACG
rs3797602	GCTGACAGCTCCGGACATG	ACT
rs3797603	TGTCATTCTCCTTGTGAACCCTC	ACT
rs3776819	CCATTCCATTGCACCTGCATG	ACT
rs252076	CAAAGTGCTGGGATTGCAGG	ACG
rs252075	GAGCATTTGCAGGCATGCCCTCT	ACT
rs252074	CTGGGTGGCTGCTGGGC	ACG
rs252068	GGAAGGGTTTAAGCAAGGAG	ACT
rs252069	TGAGCACCTACTATGGGCTAG	ACT
rs194040	ATTCCATATCTTCAAAGTGATTCA	ACG
rs252070	CCTGGGCTTCCCCTCCC	ACG
rs3797606	AGCCCTTGGCCTCTCCC	ACT
rs171667	CGCCTTTTGCTTATGCAAAGA	ACG
rs187539	AACCTTCAGGAAAGTTCCCAT	ACT
rs3836834	TCAAAATATCAAACTACCATGAAA	ACG
rs252071	ACCCTGAGACACAGGGACT	ACT
rs252072	GCTGGGTCACACTCGCGGA	ACG
rs252073	GCCGAGAAAAGTCAGGGATTCT	ACT
rs379589	CGGGAGTACTGAGCACCCAGG	CGT
rs2052472	CCCCACTGTGACTATCTCCAC	ACT
rs2052471	GTCTCCTTTGGCTGCCAAG	ACT
rs2052470	TGCCAAGGCCCTGTCCTC	ACT
rs2052469	CGCGGGGAAGTACTCGGC	ACT
rs3797608	GTCCTCCTGTTCTGAGGCCC	ACT
rs3797609	GGCAGAGCGGATGGCCTG	ACG
rs3822601	GTGAGGCCTGAGATGAGAACC	ACG
rs153131	TCCCCATACTCCTGTGCTC	ACG
rs751546	CCGTTCTACAGCGGTTAAGA	ACT

dbSNP rs#	Extend Primer	Term Mix
rs2279979	GGCCACCAGACAGATGTAAG	ACT
rs252060	CGTGTTTCGGCAGAGGTGA	ACT
rs3797610	CTTCTCCCTTGGGTGATGTGTT	ACT
rs194039	CCACCGTGCCGGGACATTTTTTT	ACT
rs168773	ACTGGAGATATCACGGGAGC	CGT
rs252061	CCAGCTGGTCACAGGGCTCCC	ACG
rs187537	TCATGCTAAGTGAAATAAGCCA	ACT
rs252062	GCCACCACCGTCCACAGA	CGT
rs2431255	CTGTATATTTCACCGCAATTAAAA	ACT
rs3797612	GGCATTCATCGTCAGGGCAA	ACG
rs3797613	CCGCCGCCGGTCTCCCA	ACG
rs614114	GAACGTTCTCTCACTTTTGCC	ACT
rs252063	CTCCCGTCCTCTGAGCCTT	ACT
rs252064	GAAAACTAAGGCTCAGAGGAC	ACT
rs252065	TGGAAAAGGCGAGGCCTGGAGT	ACG
rs450502	GGAAAAGGCGAGGCCTGGAGTT	ACT
rs439252	GCCTCCCAAAGTGCTGGGATTA	ACG
rs252066	TAGCCCTCTGGAGCCCAG	ACG
rs457957	GGGCCCCTCCTTAAAGCTC	ACT
rs3797614	TGGCCCTCGCTCTAATGCA	ACG
rs423552	CTCGATGTTGTAGTCATCGTC	ACG
rs398829	TGGCGTGCTCCTCTAGGA	ACG
rs416646	CTCAGCAGGTCTGATCCATC	ACT
rs187450	GGGCAGACTCCCCAGGAT	ACT
rs337807	GCAGGCCACTCGGTGGAC	ACT
rs337806	CCACCCCAGGGGTAGCCC	ACT
rs1396438	GGCAGGCAGGTGGCCTG	ACT
rs1396437	CGGCAGAAGCAGCCTCAAGA	ACG
rs2411811	ACATAATTTCCAAATTTCACCCC	CGT
rs2898813	GGTCCTGGGTGGAGGGAT	ACT
rs189256	AGCAAGGCTCTATTTGGGGA	ACT
rs173072	CTTTGCTCACATCGTGGCCAAA	ACT
rs337805	GGAGCAGGAAAATTACATGACT	ACG
rs191415	GAGTCCAACGTTGTCCACAT	ACT
rs180045	ACTIGITICTACAATTCTCATTC	ACG
rs189255	GACTCAGTCCCAGGTTTTCT	ACT
rs652766	AGAAAACCTGGGACTGAGTCT	ACT
rs466750	TCCTTAAATGCCTTGGTTGGCAAT	ACT
rs442406	TTCTGGCTGTTGGGTTTGAAC	ACT
rs662407	AAACATCTGAAATTAAAAGCACC	ACT
rs592971	AGCATTTCTTTGACTGCTCTTTCA	ACT
rs457187	GGAGTATCTGTTCCTTGTGG	ACT
rs459490	TTGAACATAGGAATAACCCGC	ACT
rs459668	GTCTTCTTTTGTGTTTTTTGGAGA	ACG

dbSNP rs#	Extend Primer	Term Mix
rs462646	ATTATTCGACGGAGATTATTTGAC	ACT
rs458272	ATTATTTTTCTGTCTGGTGTGG	ACT
rs463455	CCTCCTCATTGTCATTCTTTTTC	ACT
rs675880	CTTTCATGACATTGACACAACTAC	ACT
rs810617	CCACAGCCTCCGCCTCCC	ACT
rs464156	GGGTTTCCAGGTTAAAATGGC	ACT
rs458083	CTCCTGCTCTGCCTATCCTT	ACT
rs467333	ATTTCTTCCCCTCCTGCTCT	ACT
rs465381	GCCTCCCACAGTTCCCTTGTT	ACT
rs466363	GTGATGGCTCTGCACCAGA	ACG
rs2457099	AGCGTGTGCCAGCTCTCC	ACT
rs463901	GACACAATTCAGAGCGACTTAC	ACT
rs465621	AAGTGCTAGAAGAAAATGTAGC	ACT
rs463724	CCTTGCGCCATCCCCTAG	CGT
rs465242	TGTGCCCATCCCCCCTT	ACT
rs467419	AACGTAAGTCCTAATGACCGCCC	ACG
rs456135	CCCTCTCCTCTTCTGGGCA	ACT
rs464536	GCTTTGGTCCTCCTGAGCC	ACG
rs461898	CACAGAGCGACTCTCTCTTGGTT	ACT
rs389558	CTGACAGTTCTCTAAACTCCCA	ACG
rs466752	TTCCTTTTTCTCCCTGAAGCA	ACG
rs455655	CACCCCATATGGCTCATGGG	ACT
rs463435	GGGAAGGAGGTACTTAGCAG	ACG
rs2174971	GTGCCACTCTCCAGCGGCC	ACG
rs1979979	TTGCCGGCCCCACCTC	ACG
rs411804	GAAAATCCCTGTCACCAGTC	ACG
rs1623885	CTTGGCTGCAGCACCCCA	ACT
rs1643811	GCCCTGGTACTTTCAGCTCCCT	ACG
rs434430	GTGTGCATGTGTGCCTG	CGT
rs187538	TAAACGGGCCAAAAACGCCTAT	ACT
rs252067	GCGCCTACGGATGTCAGG	ACT
rs459319	CATGTTGAACAGAGAGAAACGGTC	ACG
rs467289	TCACTGAGAAATATTTTGCTCCC	ACT
rs462644	GGTGAGCCCTTGGCTGTG	ACG
rs458752	TAAAGCGCTCTTACAAATCAACA	ACT
rs708320	TGGTGAAATCCTGTCTCTACTAAA	CGT
rs457954	CACCGTTTCTTATAATGCAGCC	ACT
rs2411810	GGGGACGTTACTTCTTTCAC	ACG
rs3084687	ATTTATATATGTGTGTGTACACAT	ACT
rs69638	CCCATTGGCTGTCCTGGAA	ACT
rs455452	CCTCAACCCCAGATGCCCTC	ACG
rs464850	ACTCCTGCCTGAGTGTCTC	ACT
rs431472	GTGAAGCGGAAGGAGACTC	ACG
rs2411809	CTGCACACCCTCTGCACAG	ACG

dbSNP rs#	Extend Primer	Term Mix
rs2457094	TGGCTGGCACCACTGCACTGC	ACT
rs2457095	TGGCTCATGCTTCTAATCCCA	ACT
rs2261740	CTGCACTCCAGCCTGGGC	ACT
rs1109180	ACATCAGTGACAGTGTAATGGTA	ACG
rs1109179	TATGCAGACCCCCTCCCC	ACT
rs1109178	AACAACAGCAACAGAAATGAAG	ACT
rs456909	CGATTCCCACGCGTGTCTG	ACG
rs469124	CCTGGCTCCATTGGTGTGAA	ACT
rs468039	CCTTCACACCAATGGAGCCAG	ACT
rs467017	CTGCCACTAAACAGATGAGAA	ACT
rs469290	ATTTCTGGGCCCAAAGTCCA	ACT
rs469090	CCAATTGTTCCAGCCACTCCC	ACT
rs469568	TGATATTGCTTGCTTGGGTCTTAG	ACT
rs468386	GGTCAAGAATTCAAGAGCAGC	ACT
rs469349	GTGCAGTGGCACGATCCTA	ACT
rs469099	GCAGGTGGAACCGCAGAC	ACT
rs456868	GGAGCTGCGGTGACTCCC	ACT
rs465389	CCCTGGCACTCGCAGACC	ACT
rs463892	AGCTCCCCCGCACCAC	ACT
rs468548	AAGGGAACATGCAAGCAAAGACTC	ACT
rs654612	TGCAAGCAAAGACTCGAATGA	ACT
rs468542	TCACTCACTTGATTCCTGCCATC	ACT
rs469262	CACTGTGGGATTTCCAGCAGA	ACT
rs708323	TATACAGGTCACCCATTTAAAGT	ACT
rs469089	CCTCGGCCTTCCCCAGCT	ACT
rs469396	AATGAGGGAACCTGCAGTTTAAGA	ACT
rs468723	CAGACCCCATGCCTTGCC	ACT
rs467604	GAGTTTCCTCCTCTTTCACAA	ACT
rs338874	CACAGCCACTGGGGAGTAG	ACT
rs338875	TTGCTCGCGTGTGCCAGCAAAT	ACG
rs1385803	AAGTGGAATTCTCATGGCAGAT	ACT
rs1385804	CATTCCAGAAGTGGAATTCTCATG	ACT
rs338876	AGGAAGGTGCTCCGGCCT	ACG
rs189803	тдсттсссссттссссст	CGT
rs452215	TCTATTCTTCCACCCCCATCTTT	ACT
rs641170	CTATTCTTCCACCCCCATCT	ACT
rs584398	CTCTTATATAGCTCTATTCTTCC	CGT
rs385330	AGGTGTCTGCAGATAATACATT	ACG
rs429538	CCTGGGGCACAGGACAATA	ACT
rs371229	GACAATAGTTGGGGCAAGAC	ACT
rs460874	ACAAAACTATCCTTCAAAAATACA	CGT
rs646121	GTTTTGTTTCTCTGAAAGTGTCT	CGT
rs468262	CACCCAACTACTTGCTCCC	ACG
rs467863	GCTGATGGGAGGCCAATGT	ACT

dbSNP rs#	Extend Primer	Term Mix
rs191434	GTCCAGAGATCCTGCTCACT	CGT
rs2054782	CCCCTCCATCACCTCCC	ACG
rs468499	GTGAGCCAGCAATTCTCCTA	ACT
rs180287	CAATGATCAGAACTCAGAGGTTTT	ACT
rs338877	AGAGATAAATTTCCAGTGTGAG	CGT
rs650665	AGACATCCCGGCCGGGC	ACT
rs193419	CCAAAGACACAGGGAGTAGATTA	ACT
rs180288	GAGAATATTCTTGTGGGCTTAAT	ACT
rs186834	CCAGGTCACACACACACTC	ACG
rs189266	CACACACTCCCTCTCACTGT	ACT
rs189267	TTCTGTGCATCTTTGACGCCATC	CGT
rs170937	GATGGCGTCAAAGATGCACA	ACT
rs463263	CCCCTTTGCACAGATGCTG	ACT
rs463262	GGGAGCAGCCAGTTCCTA	ACT
rs460454	AGAGGCTGGGGACAGAGAA	ACT
rs460455	GGTACCCACCAGTCTCCTTCT	ACT
rs460505	CAGCGTCTCTGACACGGTC	ACG
rs931316	GGTCAGAGCAGACACATCCACAT	ACG
rs463431	CCCATGGGGAGCACCAAG	ACT
rs461542	TGGGAGCTCCCGGGATATTGCC	ACG
rs463557	GCTCCCGGGATATTGCCCA	ACT
rs191453	CTGGGCTGGGGCCCTGC	ACT
rs2271212	CGAGGAGGAGCCTGGCAG	ACG
rs462009	CTCCTCGTTGCCTCCGGG	ACT
rs2271211	GACGTAGCTGCCGACACCA	ACG
rs396474	CTGGTGGCCCATCTATCCTGG	ACT
rs428901	GAGCGAGACTCCGTCTCAA	CGT
rs452300	CTGAAGAGGTCTTTCTCCTTCC	CGT
rs670256	TTCTTCCACCCCCATCTTTG	ACT

## Genetic Analysis

[0237] Allelotyping results from the discovery cohort are shown for cases and controls in Table 13. The allele frequency for the A2 allele is noted in the fifth and sixth columns for osteoarthritis case pools and control pools, respectively, where "AF" is allele frequency. The allele frequency for the A1 allele can be easily calculated by subtracting the A2 allele frequency from 1 (A1 AF = 1-A2 AF). For example, the SNP rs2278221 has the following case and control allele frequencies: case A1 (C) = 0.36; case A2 (T) = 0.64; control A1 (C) = 0.37; and control A2 (T) = 0.63, where the nucleotide is provided in paranthesis. Some SNPs are labeled "untyped" because of failed assays.

**TABLE 13** 

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs2278221	210	178695460	С/Т	0.64	0.63	0.770
rs1650358	3608	178698858	C/G			-
rs1643818	3609	178698859	C/G			
rs3733916	4318	178699568	С/Т			
rs1624933	5593	178700843	A/G	0.69	0.71	0.255
rs1624857	5629	178700879	С/Т	0.79	0.81	0.574
rs1624832	5639	178700889	A/G	0.41	0.44	0.203
rs1624829	5640	178700890	С/Т	0.89	0.93	0.044
rs2161171	8943	178704193	A/C			
rs1530499	17968	178713218	A/G	0.39	0.39	0.861
rs888764	19887	178715137	A/G			
rs873987	21034	178716284	A/G			
rs4078699	21085	178716335	С/Т	0.56	0.54	0.374
rs870311	21596	178716846	A/G	0.51	0.50	0.590
rs1643817	23379	178718629	A/C	0.27	NA	NA
rs1643816	23432	178718682	A/C			
rs1650355	24007	178719257	A/C			
rs888763	26121	178721371	A/G	0.40	0.42	0.390
rs1862212	26273	178721523	A/T	0.55	0.54	0.753
rs1110514	26755	178722005	A/T	0.29	0.28	0.572
rs3797600	27411	178722661	C/T	0.56	0.57	0.738
rs3797602	27710	178722960	G/T	0.65	0.64	0.564
rs3797603	27842	178723092	C/T			
rs3776819	28379	178723629	С/Т	0.46	0.46	0.850
rs252076	29603	178724853	C/T	0.46	0.48	0.519
rs252075	31232	178726482	C/G	0.35	0.36	0.859
rs252074	31504	178726754	A/G	0.35	0.34	0.816
rs252068	32583	178727833	C/G	0.47	0.48	0.656
rs252069	32794	178728044	A/G	0.28	0.27	0.626
rs194040	32840	178728090	C/T	0.31	0.32	0.665
rs252070	33044	178728294	С/Т	0.58	0.57	0.573
rs3797606	33150	178728400	A/C	0.88	0.88	0.684
rs171667	33218	178728468	A/G	0.48	0.51	0.166
rs187539	33513	178728763	С/Т	0.33	0.34	0.652
rs3836834	33959	178729209	/TATCA AACTAC CATGAA A			
rs252071	34486	178729736	A/G	0.30	0.31	0.666
rs252072	36289	178731539	C/T	0.49	0.50	0.677
rs252073	36570	178731820	С/Т			
rs379589	38247	178733497	A/T	0.59	0.63	0.096
rs2052472	38477	178733727	A/C	0.05	0.06	0.508
rs2052471	38518	178733768	С/Т	0.89	0.88	0.459
rs2052470	38529	178733779	С/Т	0.83	0.80	0.125
rs2052469	38667	178733917	A/G	0.83	0.80	0.172
rs3797608	39781	178735031	С/Т	0.06	0.07	0.578
rs3797609	39856	178735106	С/Т	0.05	0.05	0.812
rs3822601	39927	178735177	С/Т	0.08	0.08	0.802
rs153131	40506	178735756	A/G	0.76	0.77	0.944
rs751546	41869	178737119	C/G	0.93	0.92	0.585
rs2279979	42452	178737702	С/Т	0.93	0.92	0.436
rs252060	44788	178740038	C/T	0.81	0.82	0.760
rs3797610	46059	178741309	A/C	0.17	0.17	0.858

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs194039	46846	178742096	A/G	0.41	0.47	0.035
rs168773	47712	178742962	A/T	0.35	0.38	0.266
rs252061	48796	178744046	C/T	0.21	0.19	0.508
rs187537	49441	178744691	C/G	- 0.21	0.10	0.000
rs252062	49602	178744852	A/T	0.95	0.95	0.960
rs2431255	49723	178744973	A/C	0.24	0.19	0.034
rs3797612	50050	178745300	C/T	0.38	0.43	0.036
rs3797613	50171	178745421	C/T	0.21	0.21	0.941
rs614114	50477	178745727	C/T	0.50	0.53	0.387
rs252063	50818	178746068	C/T	0.57	0.55	0.313
rs252064	50833	178746083	C/T	0.52	0.52	0.806
rs252065	50881	178746131	A/G	0.22	0.22	0.857
rs450502	50882	178746132	A/G	5.22	<u> </u>	0.00.
rs439252	51386	178746636	C/T			
rs252066	51534	178746784	C/T	0.19	0.18	0.618
rs457957	52317	178747567	A/G	0.67	0.70	0.172
rs3797614	52368	178747618	C/T	- 5.51	J., J	02
rs423552	52970	178748220	A/G	0.90	0.92	0.215
rs398829	53023	178748273	A/G		3102	0.2.0
rs416646	53356	178748606	A/G	0.56	0.57	0.650
rs187450	53882	178749132	G/T		0.0.	3.333
rs337807	54553	178749803	C/T	0.55	0.59	0.208
rs337806	55475	178750725	A/C	0.11	0.10	0.925
rs1396438	55530	178750780	A/G	0.56	0.54	0.494
rs1396437	55691	178750941	С/Т	0.00	3.5.	
rs2411811	55848	178751098	A/C			
rs2898813	55879	178751129	C/G			
rs189256	56316	178751566	A/G	0.19	0.19	0.988
rs173072	56911	178752161	A/C	1		
rs337805	57320	178752570	A/G	0.25	0.24	0.657
rs191415	57391	178752641	С/Т			
rs180045	57437	178752687	С/Т	0.51	0.47	0.211
rs189255	57478	178752728	C/G	0.15	0.12	0.273
rs652766	57500	178752750	C/T	0.57	0.61	0.213
rs466750	59111	178754361	G/T	0.35	0.33	0.493
rs442406	59333	178754583	A/G	0.57	0.59	0.420
rs662407	59715	178754965	A/G	0.31	0.27	0.102
rs592971	59804	178755054	A/G			
rs457187	59851	178755101	A/G	0.23	0.24	0.842
rs459490	59929	178755179	C/T	0.21	0.20	0.604
rs459668	60052	178755302	C/T_	0.20	0.19	0.648
rs462646	60240	178755490	С/Т	0.43	0.43	0.905
rs458272	60359	178755609	G/T	0.22	0.20	0.523
rs463455	60381	178755631	A/G	0.25	0.24	0.644
rs675880	60456	178755706	С/Т	0.63	0.65	0.591
rs810617	60724	178755974	C/G	-	1	
rs464156	60875	178756125	C/T	0.34	0.34	0.892
rs458083	60968	178756218	A/G	0.80	0.82	0.499
rs467333	60978	178756228	C/G	0.11	0.12	0.369
rs465381	60998	178756248	C/T			
rs466363	61557	178756807	C/T	0.31	0.34	0.358
rs2457099	62091	178757341	С/Т	0.44	0.44	0.956
rs463901	62645	178757895	C/T	0.43	0.45	0.395
rs465621	62943	178758193	A/C	0.62	0.63	0.534
rs463724	63131	178758381	A/T	0.09	0.08	0.523
rs465242	63145	178758395	G/T	<del> </del>		
rs467419	63406	178758656	A/G	0.65	0.66	0.647

P A T E N T Docket <u>524593008900</u>

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs456135	63427	178758677	C/G	0.79	0.80	0.686
rs464536	63554	178758804	C/T	0.36	0.34	0.296
rs461898	63661	178758911	A/G	0.30	0.32	0.411
rs389558	64093	178759343	A/G	0.24	0.26	0.325
rs466752	64153	178759403	C/T	0.35	0.37	0.446
rs455655	64409	178759659	C/G	0.87	0.89	0.536
rs463435	64544	178759794	C/T	0.68	0.66	0.428
rs2174971	65257	178760507	C/T	0.52	0.51	0.695
rs1979979	65626	178760876	A/G	0.07	0.06	0.692
rs411804	65739	178760989	A/G	0.78	0.78	0.976
rs1623885	66392	178761642	C/T	0.82	0.80	0.492
rs1643811	66720	178761970	C/T	0.24	0.24	0.924
rs434430	69177	178764427	A/T	<del></del>		
rs187538	69336	178764586	G/T			
rs252067	69636	178764886	A/G	0.21	0.23	0.606
rs459319	69823	178765073	A/G	0.19	0.20	0.640
rs467289	69928	178765178	C/T	0.26	0.26	0.988
rs462644	70547	178765797	C/T	0.59	0.58	0.914
rs458752	70633	178765883	C/T	0.18	0.20	0.513
rs708320	71805	178767055	A/C	0.10	0.20	0.010
rs457954	72181	178767431	C/G	0.71	0.73	0.327
rs2411810	72200	178767450	C/T	0.28	0.26	0.252
rs3084687	72474	178767724	-/AT	0.13	0.12	0.884
rs69638	72567	178767817	C/G	0.54	0.52	0.449
rs455452	72973	178768223	A/G	0.59	0.60	0.733
rs464850	73468	178768718	A/G	0.11	0.09	0.249
rs431472	73889	178769139	A/G	0.33	0.34	0.713
rs2411809	75730	178770980	С/Т	0.55	0.54	0.713
rs2457094	75970	178771220	A/G	0.71	0.73	0.383
rs2457095	76114	178771364	A/G	0.74	0.76	0.551
rs2261740	76342	178771592	С/Т	0.75	0.36	0.702
rs1109180	76449	178771699	A/G	0.55	0.50	0.702
rs1109179	76465	178771715	C/T			
rs1109178	76791	178772041	A/C	0.46	0.45	0.820
rs456909	78042	178773292	A/G	0.55	0.53	0.020
rs469124	80758	178776008	A/G	0.55	0.55	0.444
rs468039	80738	178776028	C/T	+-		
rs467017	81356	178776606	A/C	0.33	0.32	0.665
rs469290	81576	178776826	A/G	0.57	0.57	0.871
rs469090	81689	178776939	C/T	0.82	0.83	0.387
rs469568	81759	178777009		0.38		
rs468386	81950	178777200	C/G	0.38	0.38	0.888
rs469349	82562	178777812	A/C			
rs469099	83591	178778841	С/Т	0.66	0.63	0.264
rs456868	83700	178778950	A/G	0.00	0.03	0.204
rs465389	83821	178779071	C/G		_	
rs463892	83842	178779092	C/G	+		
rs468548	83923	178779173	G/T	<del>                                     </del>		
rs654612	83929	178779179	A/C	+		
rs468542	84021	178779271	C/G	<del> </del>		
				0.45	0.47	0.405
rs469262	84175	178779425	C/T	0.45	0.47	0.405
rs708323	84417	178779667	A/G	0.73	0.69	0.138
rs469089	84747	178779997	C/G	0.20	0.07	0.047
rs469396	85746	178780996	C/G	0.38	0.37	0.817
rs468723 rs467604	86129	178781379	C/T	0.37	0.38	0.754
rean/hll/l	86335	178781585	l A/G	0.34	0.32	0.504

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs338875	87648	178782898	A/G	0.48	0.50	0.289
rs1385803	87764	178783014	A/C			
rs1385804	87770	178783020	C/G			
rs338876	88221	178783471	C/T	0.39	0.39	0.889
rs189803	90474	178785724	A/C			
rs452215	91148	178786398	G/T			
rs641170	91150	178786400	G/T			•
rs584398	91160	178786410	G/T			
rs385330	91733	178786983	C/T			
rs429538	91772	178787022	A/C			
rs371229	91785	178787035	C/T			
rs460874	93140	178788390	A/T	0.74	0.71	0.351
rs646121	93148	178788398	A/T	0.93	0.94	0.687
rs468262	96080	178791330	A/G			
rs467863	96157	178791407	C/G			_
rs191434	96313	178791563	A/C			
rs2054782	96759	178792009	C/T	0.44	0.42	0.353
rs468499	97026	178792276	A/C			
rs180287	97320	178792570	C/G			
rs338877	97732	178792982	A/T	0.04	0.04	0.863
rs650665	98713	178793963	C/G			
rs193419	99707	178794957	A/C			
rs180288	99959	178795209	C/G			
rs186834	100009	178795259	A/G		,	
rs189266	100020	178795270	C/G			
rs189267	100065	178795315	A/C			
rs170937	100086	178795336	C/G			
rs463263	101270	178796520	C/G			
rs463262	101276	178796526	G/T			
rs460454	101371	178796621	С/Т			
rs460455	101376	178796626	C/G			
rs460505	101439	178796689	С/Т			
rs931316	101820	178797070	С/Т	_		
rs463431	102392	178797642	C/G			
rs461542	102602	178797852	A/G			
rs463557	102604	178797854	A/C			
rs191453	102896	178798146	C/T	0.11	0.14	0.123
rs2271212	189104	178884354	C/T	0.65	0.57	0.003
rs462009	189134	178884384	C/T			
rs2271211	189205	178884455	A/G			ļ
rs396474	Not mapped	Not mapped	A/C			
rs428901	Not mapped	Not mapped	A/T	0.64	0.72	0.015
rs452300	Not mapped	Not mapped	G/T			
rs670256	Not mapped	Not mapped	G/T	.]	1	ļ

[0238] The ADAMTS2 proximal SNPs were also allelotyped in the replication cohorts using the methods described herein and the primers provided in Tables 11 and 12. The replication allelotyping results for replication cohort #1 and replication cohort #2 are provided in Tables 14 and 15, respectively.

**TABLE 14** 

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs2278221	210	178695460	С/Т	0.64	0.62	0.624
rs1650358	3608	178698858	C/G			
rs1643818	3609	178698859	C/G			
rs3733916	4318	178699568	C/T			
rs1624933	5593	178700843	A/G	0.65	0.69	0.322
rs1624857	5629	178700879	C/T	0.81	untyped	NA
rs1624832	5639	178700889	A/G	0.38	0.42	0.265
rs1624829	5640	178700890	С/Т	0.87	untyped	NA
rs2161171	8943	178704193	A/C			
rs1530499	17968	178713218	A/G	0.39	0.40	0.765
rs888764	19887	178715137	A/G			
rs873987	21034	178716284	A/G			
rs4078699	21085	178716335	С/Т	0.55	0.54	0.733
rs870311	21596	178716846	A/G	0.50	0.50	0.828
rs1643817	23379	178718629	A/C	0.27	untyped	
rs1643816	23432	178718682	A/C			
rs1650355	24007	178719257	A/C			
rs888763	26121	178721371	A/G	0.40	0.40	0.816
rs1862212	26273	178721523	Α/T	0.55	0.55	0.936
rs1110514	26755	178722005	A/T	0.29	0.29	0.997
rs3797600	27411	178722661	C/T	0.57	0.58	0.604
rs3797602	27710	178722960	G/T	0.64	0.63	0.879
rs3797603	27842	178723092	С/Т			·
rs3776819	28379	178723629	С/Т	0.47	0.46	0.889
rs252076	29603	178724853	C/T	0.46	0.49	0.410
rs252075	31232	178726482	C/G	0.35	0.37	0.572
rs252074	31504	178726754	A/G	0.35	0.35	0.914
rs252068	32583	178727833	C/G	0.48	0.48	0.853
rs252069	32794	178728044	A/G	0.29	0.28	0.765
rs194040	32840	178728090	C/T	0.31	0.33	0.450
rs252070	33044	178728294	С/Т	0.57	0.58	0.609
rs3797606	33150	178728400	A/C	0.87	0.91	0.119
rs171667	33218	178728468	A/G	0.45	0.50	0.125
rs187539	33513	178728763	C/T	0.33	0.34	0.709
rs3836834	33959	178729209	/TATCA AACTAC CATGAA A			
rs252071	34486	178729736	A/G	0.30	0.32	0.566
rs252072	36289	178731539	C/T	0.48	0.51	0.400
rs252073	36570	178731820	С/Т			
rs379589	38247	178733497	A/T	0.59	0.65	0.035
rs2052472	38477	178733727	A/C	0.04	0.06	0.493
rs2052471	38518	178733768	С/Т	0.87	0.88	0.697
rs2052470_	38529	178733779	С/Т	0.84	0.78	0.036
rs2052469	38667	178733917	A/G	0.84	0.79	0.086
rs3797608	39781	178735031	C/T	0.06	0.07	0.530
rs3797609	39856	178735106	С/Т	0.04	0.05	0.841
rs3822601	39927	178735177	С/Т	0.08	0.08	0.904
rs153131	40506	178735756	A/G	0.77	0.77	0.964
rs751546	41869	178737119	C/G	0.94	0.92	0.265
rs2279979	42452	178737702	C/T	0.94	0.92	0.238
rs252060	44788	178740038	С/Т	0.82	0.80	0.553
rs3797610	46059	178741309	A/C	0.16	0.18	0.459

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs194039	46846	178742096	A/G	0.43	0.45	0.589
rs168773	47712	178742962	A/T	0.34	0.35	0.845
rs252061	48796	178744046	C/T	0.23	0.22	0.884
rs187537	49441	178744691	C/G			
rs252062	49602	178744852	A/T	0.98	0.96	0.310
rs2431255	49723	178744973	A/C	0.24	0.19	0.108
rs3797612	50050	178745300	C/T	0.42	0.46	0.254
rs3797613	50171	178745421	C/T	0.19	0.21	0.576
rs614114	50477	178745727	C/T	0.52	0.54	0.717
rs252063	50818	178746068	С/Т	0.55	0.57	0.537
rs252064	50833	178746083	C/T	0.52	0.50	0.609
rs252065	50881	178746131	A/G	0.21	0.25	0.234
rs450502	50882	178746132	A/G			
rs439252	51386	178746636	C/T			
rs252066	51534	178746784	С/Т	0.20	0.20	0.883
rs457957	52317	178747567	A/G	0.66	0.71	0.162
rs3797614	52368	178747618	С/Т			
rs423552	52970	178748220	A/G	0.90	0.92	0.380
rs398829	53023	178748273	A/G			
rs416646	53356	178748606	A/G	0.58	0.59	0.915
rs187450	53882	178749132	G/T			
rs337807	54553	178749803	C/T	0.60	NA	NA
rs337806	55475	178750725	A/C	0.10	0.10	0.997
rs1396438	55530	178750780	A/G	0.52	0.57	0.188
rs1396437	55691	178750941	C/T	0.02	0.07	0.100
rs2411811	55848	178751098	A/C	-		
rs2898813	55879	178751129	C/G			
rs189256	56316	178751566	A/G	0.21	0.20	0.852
rs173072	56911	178752161	A/C	0.21	0.20	0.002
rs337805	57320	178752570	A/G	0.24	0.24	0.950
rs191415	57391	178752641	C/T	0.24	0.24	0.330
rs180045	57437	178752687	C/T	0.47	0.46	0.918
rs189255	57478	178752728	C/G	0.14	0.13	0.764
rs652766	57500	178752750	C/T	0.59	0.61	0.570
rs466750	59111	178754361	G/T	0.38	0.37	0.606
rs442406	59333	178754583	A/G	0.56	0.57	0.882
rs662407	59715	178754965	A/G	0.32	0.27	0.002
rs592971	59804	178755054	A/G	0.52	0.27	0.134
rs457187	59851	178755101	A/G	0.23	0.25	0.451
rs459490	59929	178755101	C/T	0.22	0.23	0.431
rs459668	60052	178755302	C/T	0.22	0.19	0.712
rs462646	60240	178755490	С/Т	0.42	0.13	0.439
rs458272	60359	178755609	G/T	0.42	0.21	0.755
rs463455	60381	178755631	A/G	0.25	0.25	0.783
rs675880	60456	178755706	C/T	0.62	0.63	0.741
rs810617	60724	178755700	C/G	0.02	0.00	0.171
rs464156	60875	178756125	С/Т	0.32	0.34	0.541
rs458083	60968	178756218	A/G	0.80	0.82	0.499
rs467333	60978	178756228	C/G	0.10	0.13	0.433
rs465381	60998	178756248	С/Т	1 3.10	0.10	0.270
rs466363	61557	178756807	C/T	0.31	0.34	0.494
rs2457099	62091	178757341	C/T	0.45	0.45	0.494
rs463901	62645	178757895	C/T	0.45	0.45	0.852
rs465621	62943	178758193	A/C	0.46	0.48	0.853
rs463724	63131	178758381	A/C A/T	0.09	0.08	0.833
rs465242	63145	178758395	G/T	0.08	0.00	0.731
1 13703646	00140	1 110100000	1 3/1	1	1	i

dbSNP	Position in SEQ ID NO:	Chromosome	A1/A2	F A2	F A2	F p-
rs#	SEQIDINO:	Position	Allele	Case AF	Control AF	Value
rs456135	63427	178758677	C/G	0.79	0.76	0.339
rs464536	63554	178758804	C/T	0.36	0.34	0.553
rs461898	63661	178758911	A/G	0.31	0.33	0.727
rs389558	64093	178759343	A/G	0.27	0.28	0.762
rs466752	64153	178759403	C/T	0.34	0.38	0.223
rs455655	64409	178759659	C/G	0.87	untyped	NA
rs463435	64544	178759794	C/T	0.65	0.65	0.973
rs2174971	65257	178760507	С/Т	0.49	0.51	0.476
rs1979979	65626	178760876	A/G	0.08	0.07	0.579
rs411804	65739	178760989	A/G	0.77	0.79	0.420
rs1623885	66392	178761642	C/T	0.81	0.78	0.451
rs1643811	66720	178761970	C/T	0.26	0.25	0.715
rs434430	69177	178764427	A/T			
rs187538	69336	178764586	G/T			
rs252067	69636	178764886	A/G	0.22	0.22	0.978
rs459319	69823	178765073	A/G	0.19	0.22	0.245
rs467289	69928	178765178	C/T	0.26	0.29	0.377
rs462644	70547	178765797	C/T	0.58	0.56	0.637
rs458752	70633	178765883	C/T	0.18	0.23	0.129
rs708320	71805	178767055	A/C			
rs457954	72181	178767431	C/G	0.69	0.73	0.143
rs2411810	72200	178767450	C/T	0.28	0.23	0.083
rs3084687	72474	178767724	-/AT	0.12	0.13	0.767
rs69638	72567	178767817	C/G	0.53	0.49	0.157
rs455452	72973	178768223	A/G	0.58	0.61	0.313
rs464850	73468	178768718	A/G	0.13	0.10	0.171
rs431472	73889	178769139	A/G	0.32	0.39	0.048
rs2411809	75730	178770980	C/T			
rs2457094	75970	178771220	A/G	0.70	0.75	0.157
rs2457095	76114	178771364	A/G	0.74	0.75	0.707
rs2261740	76342	178771592	C/T	0.34	untyped	NA
rs1109180	76449	178771699	A/G			
rs1109179	76465	178771715	C/T			
rs1109178	76791	178772041	A/C	0.47	0.48	0.715
rs456909	78042	178773292	A/G	0.56	0.54	0.537
rs469124	80758	178776008	A/G			-
rs468039	80778	178776028	C/T			
rs467017	81356	178776606	A/C	0.33	0.31	0.480
rs469290	81576	178776826	A/G	0.63	0.66	0.427
rs469090	81689	178776939	C/T	0.80	0.83	0.300
rs469568	81759	178777009	G/T	0.39	0.43	0.234
rs468386	81950	178777200	C/G			
rs469349	82562	178777812	A/C			
rs469099	83591	178778841	С/Т	0.66	0.60	0.066
rs456868_	83700	178778950	A/G_			
rs465389	83821	178779071	C/G		ļ	
rs463892	83842	178779092	C/G			
rs468548	83923	178779173	G/T			
rs654612	83929	178779179	A/C			
rs468542	84021	178779271	C/G	<u> </u>		
rs469262	84175	178779425	C/T	0.46	0.50	0.232
rs708323	84417	178779667	A/G	0.72	0.66	0.071
rs469089	84747	178779997	C/G	1		
rs469396	85746	178780996	C/G	0.37	0.35	0.522
rs468723	86129	178781379	C/T	0.39	0.41	0.495
rs467604	86335	178781585	A/G	0.33	0.30	0.303
rs338874	87315	178782565	C/G	0.44	0.46	0.628

dbSNP rs#	Position in SEQ ID NO:	EQ ID NO: Chromosome Position		F A2 Case AF	F A2 Control AF	F p- Value
rs338875	87648	178782898	A/G	0.49	0.54	0.106
rs1385803	87764	178783014	A/C			
rs1385804	87770	178783020	C/G			
rs338876	88221	178783471	C/T	0.38	0.36	0.609
rs189803	90474	178785724	A/C			
rs452215	91148	178786398	G/T			
rs641170	91150	178786400	G/T			
rs584398	91160	178786410	G/T			
rs385330	91733	178786983	C/T			
rs429538	91772	178787022	A/C			
rs371229	91785	178787035	C/T	L		
rs460874	93140	178788390	A/T	0.74	0.69	0.118
rs646121	93148	178788398	A/T	0.93	0.95	0.477
rs468262	96080	178791330	A/G			
rs467863	96157	178791407	C/G			
rs191434	96313	178791563	A/C			
rs2054782	96759	178792009 178792276	C/T	0.45	0.42	0.514
rs468499			A/C_			
rs180287	97320	178792570	C/G			
rs338877	97732	178792982	A/T	0.04	0.04	0.781
rs650665	98713	178793963	C/G			
rs193419	99707	178794957	A/C			
rs180288	99959	178795209	C/G			<u> </u>
rs186834	100009	178795259	A/G			
rs189266	100020	178795270	C/G			
rs189267	100065	178795315	A/C			·
rs170937	100086	178795336	C/G			
rs463263	101270	178796520	C/G	<u> </u>		
rs463262	101276	178796526	G/T			
rs460454	101371	178796621	C/T			
rs460455	101376	178796626	C/G		ļ	
rs460505	101439	178796689	C/T			
rs931316	101820	178797070	C/T			
rs463431	102392	178797642	C/G	<u> </u>		
rs461542	102602	178797852	A/G	ļ		
rs463557	102604	178797854	A/C	- 2.5		0.400
rs191453	102896	178798146	C/T	0.15	0.19	0.139
rs2271212	189104	178884354	С/Т	0.64	0.58	0.072
rs462009	189134	178884384	C/T	-	<del></del>	
rs2271211	189205	178884455	A/G	1	-	
rs396474	Not mapped	Not mapped	A/C	1 0.00		NIA.
rs428901	Not mapped	Not mapped	A/T	0.66	untyped	NA
rs452300 rs670256	Not mapped Not mapped	Not mapped Not mapped	G/T G/T	+		

**TABLE 15** 

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs2278221	210	178695460	C/T	0.64	0.64	0.837
rs1650358	3608	178698858	C/G			
rs1643818	3609	178698859	C/G			
rs3733916	4318	178699568	С/Т			
rs1624933	5593	178700843	A/G	0.73	0.75	0.447
rs1624857	5629	178700879	C/T	0.78	0.81	0.289

dbSNP rs#	Position in SEQ ID NO: 1	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs1624832	5639	178700889	A/G	0.44	0.47	0.423
rs1624829	5640	178700890	С/Т	0.90	0.93	0.294
rs2161171	8943	178704193	A/C			
rs1530499	17968	178713218	A/G	0.39	0.36	0.499
rs888764	19887	178715137	A/G			
rs873987	21034	178716284	A/G	_		
rs4078699	21085	178716335	С/Т	0.57	0.54	0.316
rs870311	21596	178716846	A/G	0.52	0.50	0.579
rs1643817	23379	178718629	A/C			
rs1643816	23432	178718682	A/C			
rs1650355	24007	178719257	A/C			
rs888763	26121	178721371	A/G	0.40	0.44	0.264
rs1862212	26273	178721523	A/T _	0.56	0.53	0.529
rs1110514	26755	178722005	A/T	0.30	0.27	0.381
rs3797600	27411	178722661	С/Т	0.55	0.54	0.840
rs3797602	27710	178722960	G/T	0.68	0.65	0.534
rs3797603	27842	178723092	C/T			
rs3776819	28379	178723629	С/Т	0.45	0.47	0.662
rs252076	29603	178724853	С/Т	0.46	0.46	0.986
rs252075	31232	178726482	C/G	0.36	0.34	0.666
rs252074	31504	178726754	A/G	0.35	0.33	0.604
rs252068	32583	178727833	C/G	0.47	0.48	0.648
rs252069	32794	178728044	A/G	0.27	0.26	0.640
rs194040	32840	178728090	С/Т	0.31	0.30	0.734
rs252070	33044	178728294	C/T	0.61	0.55	0.157
rs3797606	33150	178728400	A/C	0.91	0.83	0.005
rs171667	33218	178728468	A/G	0.51	0.52	0.674
rs187539	33513	178728763	С/Т	0.32	0.33	0.836
rs3836834	33959	178729209	/TATCA AACTAC CATGAA A			
rs252071	34486	178729736	A/G	0.30	0.30	0.942
rs252072	36289	178731539	С/Т	0.50	0.49	0.684
rs252073	36570	178731820	С/Т			
rs379589	38247	178733497	A/T	0.60	0.61	0.981
rs2052472	38477	178733727	A/C	0.06	0.06	0.856
rs2052471	38518	178733768	C/T	0.91	0.86	0.079
rs2052470	38529	178733779	C/T	0.82	0.83	0.828
rs2052469	38667	178733917	A/G_	0.82	0.82	0.983
rs3797608	39781	178735031	С/Т	0.06	0.06	0.969
rs3797609	39856	178735106	С/Т	0.05	0.05	0.879
rs3822601	39927	178735177	С/Т	0.07	0.08	0.838
rs153131	40506	178735756	A/G	0.76	0.76	0.981
rs751546	41869	178737119	C/G	0.91	0.92	0.526
rs2279979	42452	178737702	C/T	0.92	0.92	0.906
rs252060	44788	178740038	C/T	0.81	0.85	0.157
rs3797610	46059	178741309	A/C	0.18	0.16	0.593
rs194039	46846	178742096	A/G	0.39	0.49	0.005
rs168773	47712	178742962	A/T	0.37	0.43	0.098
rs252061	48796	178744046	С/Т	0.19	0.15	0.164
rs187537	49441	178744691	C/G		ļ	
rs252062	49602	178744852	A/T	0.93	0.95	0.290
rs2431255	49723	178744973	A/C	0.23	0.19	0.201
rs3797612	50050	178745300	С/Т	0.32	0.38	0.102
rs3797613	50171	178745421	C/T	0.23	NA	

P A T E N T Docket <u>524593008900</u>

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value	
rs614114	50477	178745727	C/T	0.48	0.51	0.423	
rs252063	50818	178746068	C/T	0.60	0.51	0.011	
rs252064	50833	178746083	C/T	0.51	0.56	0.265	
rs252065	50881	178746131	A/G	0.22	0.18	0.175	
rs450502	50882	178746132	A/G		-		
rs439252	51386	178746636	C/T				
rs252066	51534	178746784	C/T	0.18	0.16	0.451	
rs457957	52317	178747567	A/G	0.67	0.68	0.728	
rs3797614	52368	178747618	C/T	0.07	0.00	0.,20	
rs423552	52970	178748220	A/G	0.89	0.91	0.398	
rs398829	53023	178748273	A/G	3.50	0.01	0.000	
rs416646	53356	178748606	A/G	0.54	0.55	0.643	
rs187450	53882	178749132	G/T	0.01	0.00	0.0.0	
rs337807	54553	178749803	C/T	0.49	0.59	0.009	
rs337806	55475	178750725	A/C	0.11	0.10	0.889	
rs1396438	55530	178750780	A/G	0.61	0.50	0.007	
rs1396437	55691	178750941	C/T	0.01	0.50	0.007	
rs2411811	55848	178751098	A/C			· · · · · · · · · · · · · · · · · · ·	
rs2898813	55879	178751129	C/G			~~~	
rs189256	56316	178751566	A/G	0.17	0.17	0.923	
rs173072	56911	178752161	A/C	0.17	0.17	0.525	
rs337805	57320	178752570	A/G	0.27	0.25	0.582	
rs191415	57391	178752641	С/Т	0.21	0.23	0.302	
rs180045	57437	178752687	С/Т	0.56	0.48	0.115	
rs189255	57478	178752728	C/G	0.16	0.12	0.113	
rs652766	57500	178752720	C/T	0.55	0.61	0.100	
rs466750	59111	178754361	G/T	0.33	0.28	0.473	
rs442406	59333	178754583	A/G	0.58	0.63	0.209	
rs662407	59715	178754965	A/G	0.30	0.03	0.449	
rs592971	59804	178755054	A/G	0.30	0.20	0.449	
rs457187	59851	178755101	A/G	0.23	0.21	0.402	
rs459490	59929	178755101	СЛ	0.20	0.19	0.708	
rs459668	60052	178755302	С/Т	0.20	0.19	0.700	
rs462646	60240	178755490	C/T	0.21	0.20	0.460	
rs458272	60359	178755609	G/T	0.22	0.20	0.524	
rs463455	60381	178755631	A/G	0.23	0.22	0.629	
rs675880	60456	178755706	С/Т	0.65	0.22	0.564	
rs810617	60724	178755700	C/I C/G	0.05	0.07	0.304	
rs464156	60875	178756125	СЛ	0.37	0.34	0.439	
rs458083	60968	178756218	A/G	0.37	0.34	0.438	
rs467333	60978	178756228		0.11	0.11	0.003	
rs465381	60998	178756248	C/G C/T	0.11	0.11	0.902	
rs466363	61557	178756807	C/T	0.32	0.34	0.547	
rs2457099	62091	178757341	C/T	0.32	0.43	0.974	
rs463901	62645	178757895	СЛ	0.43	0.43	0.974	
rs465621	62943	178758193	A/C	0.59	0.43	0.342	
rs463724	63131	178758381	A/T	0.09	0.07	0.195	
rs465242	63145	178758395	G/T	0.09	0.07	0.338	
rs467419	63406	178758656		0.66	0.67	0.750	
	<del></del>		A/G C/G	0.66 0.79	0.67	0.752	
rs456135	63427	178758677			0.85	0.029	
rs464536	63554	178758804	C/T	0.36	0.32	0.332	
rs461898	63661	178758911	A/G	0.28	0.31	0.423	
rs389558	64093	178759343	A/G	0.20	0.23	0.311	
rs466752	64153	178759403	С/Т	0.36	0.35	0.781	
rs455655	64409 64544	178759659 178759794	C/G C/T	0.72	0.72 0.68	NA 0.230	
rs463435							

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs1979979	65626	178760876	A/G	0.05	0.05	0.993
rs411804	65739	178760989	A/G	0.80	0.77	0.343
rs1623885	66392	178761642	С/Т	0.84	0.84	0.819
rs1643811	66720	178761970	C/T	0.22	0.23	0.847
rs434430	69177	178764427	A/T			
rs187538	69336	178764586	G/T			
rs252067	69636	178764886	A/G	0.21	0.24	0.369
rs459319	69823	178765073	A/G	0.18	0.15	0.353
rs467289	69928	178765178	C/T	0.27	0.22	0.179
rs462644	70547	178765797	C/T	0.60	0.61	0.609
rs458752	70633	178765883	C/T	0.18	0.15	0.271
rs708320	71805	178767055	A/C			
rs457954	72181	178767431	C/G	0.72	0.72	0.882
rs2411810	72200	178767450	С/Т	0.29	0.30	0.630
rs3084687	72474	178767724	-/AT	0.13	0.11	0.509
rs69638	72567	178767817	C/G	0.54	0.57	0.440
rs455452	72973	178768223	A/G	0.60	0.58	0.499
rs464850	73468	178768718	A/G	0.10	0.09	0.839
rs431472	73889	178769139	A/G	0.35	0.27	0.025
rs2411809	75730	178770980	C/T			
rs2457094	75970	178771220	A/G	0.71	0.70	0.792
rs2457095	76114	178771364	A/G	0.75	0.76	0.602
rs2261740	76342	178771592	C/T	0.36	0.36	0.924
rs1109180	76449	178771699	A/G			
rs1109179	76465	178771715	C/T	<u> </u>		
rs1109178	76791	178772041	A/C	0.45	0.42	0.420
rs456909	78042	178773292	A/G	0.53	0.51	0.598
rs469124	80758	178776008	A/G			
rs468039	80778	178776028	C/T	0.04	0.05	0.700
rs467017	81356	178776606	A/C	0.34	0.35	0.762
rs469290	81576	178776826	A/G	0.49	0.44	0.223
rs469090	81689	178776939	C/T	0.83	0.84	0.883
rs469568	81759	178777009	G/T	0.36	0.30	0.115
rs468386	81950	178777200	C/G A/C	-	1	
rs469349	82562	178777812		0.65	0.67	0.560
rs469099 rs456868	83591 83700	178778841 178778950	C/T A/G	0.65	0.67	0.560
rs465389	83821	178779071	C/G			
rs463892	83842	178779071	C/G	<del> </del>		
rs468548	83923	178779173	G/T		-	
rs654612				+	<del> </del>	
rs468542	83929 84021	178779179 178779271	C/G	+		
rs469262	84175	178779425	C/T	0.45	0.43	0.762
rs708323	84417	178779667	A/G	0.74	0.74	0.702
rs469089	84747	178779997	C/G	0.74	0.17	0.000
rs469396	85746	178780996	C/G	0.39	0.42	0.569
rs468723	86129	178781379	С/Т	0.36	0.34	0.573
rs467604	86335	178781585	A/G	0.35	0.36	0.763
rs338874	87315	178782565	C/G	0.42	0.40	0.564
rs338875	87648	178782898	A/G	0.46	0.45	0.701
rs1385803	87764	178783014	A/C	1 - 0.70	55	
rs1385804	87770	178783020	C/G	<del> </del>	† · · · · · · · · · · · · · · · · · · ·	
rs338876	88221	178783471	<u>С/Т</u>	0.41	0.44	0.580
rs189803	90474	178785724	A/C	3.41	1 3.17	0.555
rs452215	91148	178786398	G/T	1-	1	-
rs641170	91150	178786400	G/T			
rs584398	91160	178786410	G/T	<del> </del>	<del>                                     </del>	

dbSNP rs#	Position in SEQ ID NO:	Chromosome Position	A1/A2 Allele	F A2 Case AF	F A2 Control AF	F p- Value
rs385330	91733	178786983	C/T			
rs429538	91772	178787022	A/C			
rs371229	91785	178787035	C/T			
rs460874	93140	178788390	A/T	0.73	0.75	0.550
rs646121	93148	178788398	A/T	0.93	0.92	0.697
rs468262	96080	178791330	A/G			
rs467863	96157	178791407	C/G			
rs191434	96313	178791563	A/C			
rs2054782	96759	178792009	C/T	0.43	0.40	0.473
rs468499	97026	178792276	A/C			
rs180287	97320	178792570	C/G			
rs338877	97732	178792982	A/T	0.04	0.04	0.928
rs650665	98713	178793963	C/G			
rs193419	99707	178794957	A/C			-
rs180288	99959	178795209	C/G			
rs186834	100009	178795259	A/G			
rs189266	100020	178795270	C/G			
rs189267	100065	178795315	A/C			_
rs170937	100086	178795336	C/G			
rs463263	101270	178796520	C/G			
rs463262	101276	178796526	G/T			
rs460454	101371	178796621	C/T			
rs460455	101376	178796626	C/G			
rs460505	101439	178796689	C/T			
rs931316	101820	178797070	C/T			
rs463431	102392	178797642	C/G			
rs461542	102602	178797852	A/G			
rs463557	102604	178797854	A/C			
rs191453	102896	178798146	C/T	0.06	0.06	0.929
rs2271212	189104	178884354	C/T	0.66	0.56	0.012
rs462009	189134	178884384	С/Т			
rs2271211	rs2271211 189205 178884		A/G			
rs396474	rs396474 Not mapped Not mapped		A/C			
rs428901			A/T	0.61	0.72	0.002
rs452300	Not mapped	Not mapped	G/T			·
rs670256	Not mapped	Not mapped	G/T			

[0239] Allelotyping results were considered particularly significant with a calculated p-value of less than or equal to 0.05 for allelotype results. These values are indicated in bold. The allelotyping p-values were plotted in Figure 1 for the discovery cohort. The position of each SNP on the chromosome is presented on the x-axis. The y-axis gives the negative logarithm (base 10) of the p-value comparing the estimated allele in the case group to that of the control group. The minor allele frequency of the control group for each SNP designated by an X or other symbol on the graphs in Figure 1 can be determined by consulting Table 13. For example, the left-most X on the left graph is at position 178695460. By proceeding down the Table from top to bottom and across the graphs from left to right the allele frequency associated with each symbol shown can be determined.

[0240] To aid the interpretation, multiple lines have been added to the graph. The broken horizontal lines are drawn at two common significance levels, 0.05 and 0.01. The vertical broken lines are drawn

every 20kb to assist in the interpretation of distances between SNPs. Two other lines are drawn to expose linear trends in the association of SNPs to the disease. The light gray line (or generally bottom-most curve) is a nonlinear smoother through the data points on the graph using a local polynomial regression method (W.S. Cleveland, E. Grosse and W.M. Shyu (1992) Local regression models. Chapter 8 of Statistical Models in S eds J.M. Chambers and T.J. Hastie, Wadsworth & Brooks/Cole.). The black line provides a local test for excess statistical significance to identify regions of association. This was created by use of a 10kb sliding window with 1kb step sizes. Within each window, a chi-square goodness of fit test was applied to compare the proportion of SNPs that were significant at a test wise level of 0.01, to the proportion that would be expected by chance alone (0.05 for the methods used here). Resulting p-values that were less than 10<sup>-8</sup> were truncated at that value.

[0241] Finally, the exons and introns of the genes in the covered region are plotted below each graph at the appropriate chromosomal positions. The gene boundary is indicated by the broken horizontal line. The exon positions are shown as thick, unbroken bars. An arrow is place at the 3' end of each gene to show the direction of transcription.

## Example 5

## Effect of ADAMTS2 Polypeptides on

## Biosynthesis of Type II Collagen in Patients with OA

[0242] To investigate the effect of *ADAMTS2* polypeptides on Type II collagen biosynthesis and processing, human articular cartilage from OA patients undergoing joint replacement is harvested, dissected and maintained as described by Nelson *et al.* (1998) *supra*. Type II procollagen levels in osteoarthritic patients and autopsy controls is determined by radioimmunoassay (RIA) as previously described. Allelic variations (*e.g.*, rs398829) are determined for the OA patients and controls by genotyping (See Examples 1 and 2). As type II procollagen is processed by *ADAMTS2*, increased levels of Type II procollagen in individuals with the allelic variation associated with OA demonstrates that this variation leads to reduced procollagen processing activity and ultimately to OA.

## Example 6

# Effect of ADAMTS2 Polypeptides on Type II Collagen Processing Activity

[0243] To investigate the effect of ADAMTS2 polypeptide variants on ADAMTS2 collagen processing activity, recombinant polypeptides encompassing the ADAMTS2 variation of SEQ ID NO: 2 at position 733 and a wild-type ADAMTS2 polypeptide are expressed in cell lines such as chondrocytes. Since the allelic variation of ADAMTS2 at position 733 of SEQ ID: NO: 2 will prevent the conversion of the ADAMTS2 pro-enzyme to the catalytically active enzyme, processing of ADAMTS2 pro-enzyme is monitored by SDS-PAGE analysis followed by Western Blotting using antibodies to ADAMTS2 and

methods common to someone skilled in the art. Reduced levels of pro-enzyme cleavage are apparent by the increased levels of immunopositive protein of higher molecular weight than of the cleaved active protein.

#### Example 7

# In Vitro Production of Target Polypeptides

[0244] cDNA is cloned into a pIVEX 2.3-MCS vector (Roche Biochem) using a directional cloning method. A cDNA insert is prepared using PCR with forward and reverse primers having 5' restriction site tags (in frame) and 5-6 additional nucleotides in addition to 3' gene-specific portions, the latter of which is typically about twenty to about twenty-five base pairs in length. A Sal I restriction site is introduced by the forward primer and a Sma I restriction site is introduced by the reverse primer. The ends of PCR products are cut with the corresponding restriction enzymes (*i.e.*, Sal I and Sma I) and the products are gel-purified. The pIVEX 2.3-MCS vector is linearized using the same restriction enzymes, and the fragment with the correct sized fragment is isolated by gel-purification. Purified PCR product is ligated into the linearized pIVEX 2.3-MCS vector and *E. coli* cells transformed for plasmid amplification. The newly constructed expression vector is verified by restriction mapping and used for protein production.

[0245] E. coli lysate is reconstituted with 0.25 ml of Reconstitution Buffer, the Reaction Mix is reconstituted with 0.8 ml of Reconstitution Buffer; the Feeding Mix is reconstituted with 10.5 ml of Reconstitution Buffer; and the Energy Mix is reconstituted with 0.6 ml of Reconstitution Buffer. 0.5 ml of the Energy Mix was added to the Feeding Mix to obtain the Feeding Solution. 0.75 ml of Reaction Mix, 50  $\mu$ l of Energy Mix, and 10  $\mu$ g of the template DNA is added to the E. coli lysate.

[0246] Using the reaction device (Roche Biochem), 1 ml of the Reaction Solution is loaded into the reaction compartment. The reaction device is turned upside-down and 10 ml of the Feeding Solution is loaded into the feeding compartment. All lids are closed and the reaction device is loaded into the RTS500 instrument. The instrument is run at 30°C for 24 hours with a stir bar speed of 150 rpm. The pIVEX 2.3 MCS vector includes a nucleotide sequence that encodes six consecutive histidine amino acids on the C-terminal end of the target polypeptide for the purpose of protein purification. Target polypeptide is purified by contacting the contents of reaction device with resin modified with Ni<sup>2+</sup> ions. Target polypeptide is eluted from the resin with a solution containing free Ni<sup>2+</sup> ions.

## Example 8

## Cellular Production of Target Polypeptides

[0247] Nucleic acids are cloned into DNA plasmids having phage recombination cites and target polypeptides are expressed therefrom in a variety of host cells. Alpha phage genomic DNA contains short sequences known as attP sites, and *E. coli* genomic DNA contains unique, short sequences known as attB sites. These regions share homology, allowing for integration of phage DNA into *E. coli* via directional, site-specific recombination using the phage protein Int and the *E. coli* protein IHF. Integration produces two new att sites, L and R, which flank the inserted prophage DNA. Phage excision from *E. coli* genomic DNA can also be accomplished using these two proteins with the addition of a second phage protein, Xis. DNA vectors have been produced where the integration/excision process is modified to allow for the directional integration or excision of a target DNA fragment into a backbone vector in a rapid *in vitro* reaction (Gateway<sup>TM</sup> Technology (Invitrogen, Inc.)).

[0248] A first step is to transfer the nucleic acid insert into a shuttle vector that contains attL sites surrounding the negative selection gene, ccdB (e.g. pENTER vector, Invitrogen, Inc.). This transfer process is accomplished by digesting the nucleic acid from a DNA vector used for sequencing, and to ligate it into the multicloning site of the shuttle vector, which will place it between the two attL sites while removing the negative selection gene ccdB. A second method is to amplify the nucleic acid by the polymerase chain reaction (PCR) with primers containing attB sites. The amplified fragment then is integrated into the shuttle vector using Int and IHF. A third method is to utilize a topoisomerase-mediated process, in which the nucleic acid is amplified via PCR using gene-specific primers with the 5' upstream primer containing an additional CACC sequence (e.g., TOPO® expression kit (Invitrogen, Inc.)). In conjunction with Topoisomerase I, the PCR amplified fragment can be cloned into the shuttle vector via the attL sites in the correct orientation.

[0249] Once the nucleic acid is transferred into the shuttle vector, it can be cloned into an expression vector having attR sites. Several vectors containing attR sites for expression of target polypeptide as a native polypeptide, N-fusion polypeptide, and C-fusion polypeptides are commercially available (e.g., pDEST (Invitrogen, Inc.)), and any vector can be converted into an expression vector for receiving a nucleic acid from the shuttle vector by introducing an insert having an attR site flanked by an antibiotic resistant gene for selection using the standard methods described above. Transfer of the nucleic acid from the shuttle vector is accomplished by directional recombination using Int, IHF, and Xis (LR clonase). Then the desired sequence can be transferred to an expression vector by carrying out a one hour incubation at room temperature with Int, IHF, and Xis, a ten minute incubation at 37°C with proteinase K, transforming bacteria and allowing expression for one hour, and then plating on selective media. Generally, 90% cloning efficiency is achieved by this method. Examples of expression vectors

are pDEST 14 bacterial expression vector with att7 promoter, pDEST 15 bacterial expression vector with a T7 promoter and a N-terminal GST tag, pDEST 17 bacterial vector with a T7 promoter and a N-terminal polyhistidine affinity tag, and pDEST 12.2 mammalian expression vector with a CMV promoter and neo resistance gene. These expression vectors or others like them are transformed or transfected into cells for expression of the target polypeptide or polypeptide variants. These expression vectors are often transfected, for example, into murine-transformed a adipocyte cell line 3T3-L1, (ATCC), human embryonic kidney cell line 293, and rat cardiomyocyte cell line H9C2.

[0250] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention, as set forth in the claims which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0251] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

## Nucleotide and Amino Acid Sequence Embodiments

[0252] Table A includes information pertaining to the incident polymorphic variant associated with osteoarthritis identified herein. Public information pertaining to the polymorphism and the genomic sequence that includes the polymorphism are indicated. The genomic sequences identified in Table A may be accessed at the http address www.ncbi.nih.gov/entrez/query.fcgi, for example, by using the publicly available SNP reference number (e.g., rs398829). The chromosome position refers to the position of the SNP within NCBI's Genome Build 34, which may be accessed at the following http address: www.ncbi.nlm.nih.gov/mapview/map\_search.cgi?chr=hum\_chr.inf&query=. The "Contig Position" provided in Table A corresponds to a nucleotide position set forth in the contig sequence (see "Contig Accession No."), and designates the polymorphic site corresponding to the SNP reference number. The sequence containing the polymorphisms also may be referenced by the "Nucleotide Accession No." set forth in Table A. The "Sequence Identification" corresponds to cDNA sequence that encodes associated target polypeptides (e.g., ADAMTS2). The position of the SNP within the cDNA sequence is provided in the "Sequence Position" column of Table A. If the SNP falls within an exon, the corresponding amino acid position (and amino acid change, if applicable) is provided as well. Also, the

allelic variation at the polymorphic site and the allelic variant identified as associated with osteoarthritis is specified in Table A. All nucleotide and polypeptide sequences referenced and accessed by the parameters set forth in Table A are incorporated herein by reference.

Table A

RS_ID	Chrom- -osome	Chrom Position	Contig Accession No. [1]	Contig Position	Nucleotide Accession No. [2]	Sequence Position	Amino Acid Position	Locus	Locus ID	A [3]	Allelic Vari- ability	OA Assoc. Allele
rs398829						coding-						
	5	178748273	Hs5_77500_34:3	1729878	NM_014244	nonsynon	V245I	ADAMTS2	9509	R	[G/A]	G J

[1] Contig Accession Number which can be found in the NCBI Database: http address: www.ncbi.nih.gov/entrez/query.fcgi

[2] Sequence Identification or Nucleotide Accession Number which can be found in the NCBI Database:

http address: www.ncbi.nih.gov/entrez/query.fcgi

[3] "A" column is the sequence orientation ("F" is forward, "R" is reverse).

[0253] The following is a genomic nucleotide sequence for an *ADAMTS2* region. The following nucleotide representations are used throughout: "A" or "a" is adenosine, adenine, or adenylic acid; "C" or "c" is cytidine, cytosine, or cytidylic acid; "G" or "g" is guanosine, guanine, or guanylic acid; "T" or "t" is thymidine, thymine, or thymidylic acid; and "I" or "i" is inosine, hypoxanthine, or inosinic acid. Exons are indicated in italicized lower case type, introns are depicted in normal text lower case type, and polymorphic sites are depicted in bold upper case type. SNPs are designated by the following convention: "R" represents A or G, "M" represents A or C; "W" represents A or T; "Y" represents C or T; "S" represents C or G; "K" represents G or T; "V" represents A, C or G; "H" represents A, C, or T; "D" represents A, G, or T; "B" represents C, G, or T; and "N" represents A, G, C, or T.

## ADAMTS2 Genomic Sequence (SEQ ID NO. 1)

```
>5:178695251-178884700
       gggcctcggg ccagcactgc ccagcgctgg gaagacagga gaccacaccc caagtggctt
1
61
       tgacacaggg cgtgtccctc ttaaggcaca gaggagaagt gggcagccag ggctggggat
121
       cctagggtgg cccctctgtg ccccaccctt ccccaqqcca cttacacqtg gccaqtctca
181
       tgggccacca caaacgctga ggagaagccR tcctcatggt tcagggtgca gctgcggacc
241
       ggatggcaca tgccggtgac aggagcatag cctgggagga gacaagaggc ggctccagat
301
       gctgccatag cctggccggg aaggtgaggc ctggcctaac tcccaggcgc tgcttctcct
361
       caaggcccca atgccctctc taccacaggc aactgccccc ggctggcaca gctcagaaga
421
       caccacagca gacageteat ageetgtgae atetggetga cagcaggeee ceageeegte
481
       accacacaag ccccgtggcc gttctgcctg taacagccac actgcagctg gggccctctg
541
       cttagtcaga tgtcacctgc tatggcttgt ctgacacctg actttcctgc ctgccgttct
601
       ctttcacgcc acctgcctct gccccctgcc tgcctcactg agtggcccct gagcagcacc
661
       tgcttccaca cctctctctg ctagaggcat cctgcccctc gtctgcctgg tatcacaccc
721
       tccaagccca cctcctctgg ggggcgtttc ttgggtctcc ccgtgtttct ctggggtcct
       tgagacccta gctagacctg tttccataat gccgcagaag gctgcaaagc tgttcagccg
781
```

```
841
       atgggccaca ctaccetgca gaatateeca geaggggget ggetggtgeg gaetgggagg
901
       tcagagccgc cgtagaagat gaggccagtg gcctacgaca gcccagggcc agggggaggg
961
       tggcagaagt tcatgacgca gagaccccac gtcaaactga ggaagatgga taatgagacc
1021
       tattcacttc cccagctcct gtctcagcag agggaggcgg cttggaaaga tagggaagtg
1081
       cctacagggc tatgggtgcc acacgaggtc tctgcttgta cccctgggag tcttcctaga
1141
       ggcctgccaa gcatggagcc ctgactttca gaaccccaac ctgccctcac tcctgccatg
1201
       ccccactgag agaccctgag gccacgcgtt ccacagagaa gggaaggagg gccactggga
1261
       eccegggtga getggeggtg tacgegeeta aaaatagaag categtgate taaccettgt
1321
       cttttcccgt tgtaataaac aggaaaatct gcattttttg ctctgcagat tttgagacga
1381
       gcgtggagtc tgtgtgcctg agtggaacgt tgccatctcc tctttgccct ttqtatqcca
1441
       ggcttgcaga tgcatctgcc tccgtgggag gctttccatt catcctactc agcattacag
1501
       gagectgega gatetgaaag egeatettta tgtttttett tgttttette eetettattt
1561
       tactttgtgg ctgttttctc tctccggaat cttattagat agagtgtgcc tcctcgatgg
1621
       agggtetgte tectaaettt teteteatgt taatettttt gtettttget eccattggga
1681
       gatggccttg actititatt tcagctitcg attititit tittititg agatggagtc
1741
       teactetgee gtecaggetg gagtgeagtg gtgtgatete ggeteactge aaceteegee
1801
       teetgggtte agtecattet actgeeteag ceteetgagt agetgggaet acaggeacee
       gccaccatgc tcagctaatt tttgtatttt tactagagac gggatttcac catgttagcc
1861
1921
       aggatggtet ceateteetg acctegtgae etgeeegeet eggeeteeea eagtgetggg
1981
       attacaggcg tgagccaccg cgccccgtct acctttcgaa ttttttactt cccccatcct
2041
       atccataatt ttatacaaat ggtttgttgt tctctaattt ttcatagaaa actcttaqqq
2101
       tttatggatg tattttctca aacattctgg gaatactact tttaaaaaaca tgcttttctt
2161
       gtctctaaat tatctctatt ttctcttaga gccagttttc aaactttttg ttttgtttta
2221
       catcttggtc catcttttc atgctgtaag gatttcttgt gttttggttt ttttaaaata
2281
       totggtaacc cttggctgtc ctttcatttt ttctttttt tttttttt tttgagacag
2341
       agtettgete tgttgeecag getggagtge agtggeacaa teteggetea etgeaacete
2401
       tgcctccggg gttctagtga ttttcctgcc tcagcctcct gagtagctgg gattacaggc
2461
       acctgccact acactggcta atttttgtgt ttttagtaga gatgttggcc aggctggtca
2521
       cgaactcctg acctcaagtg atccgcccgc cttggcctcc caaagtgctg ggattacagg
2581
       agtgagccac cacacccagc caatttcaca tttttaaatg agggatcagg tcacttaata
2641
       taaaagctgt gtcggtttcc cctcctaggg gatagctctg ctccccatta gtgccctccc
2701
       caagacaaaa cagccaacag cacteteate acatggtcag ggcaacacet ggctgcgctg
2761
       tgtttgaggg gagctatcca ctcctcaccc agacatggta gtttcagtct ttttaaccta
       gctatgctat taggtgcgtc ttgatatttc attgtgtttt taaattttcc ttttttttt
2821
2881
       ttettgtaag acaaggeete getetgteac eeaggetgga gtgeagtggt gtgateatag
2941
       ctcacttcct gggctcaaac aatcctccca cctcaggttc ccgagtggct gggactacag
       gcatccacca ccatgcccag cctcattgtt ttaattgcat ttttccaatg tctagtgagg
3001
3061
       ttgagtgcct tttcatatgt ttattgctca ttcatatttt gtcaagagcc tgataagagt
3121
       ctcctgccca ttatctgact ggattgtctt tattatcctt attatgattt gtaggcgttc
3181
       ttcacatact tcagatataa atccttttt ataaatattt cccccagtgg attagcgtgc
3241
       ctttaatgca caaacttttg aaatgtgcta ctatttatca gttttttcca ttgagttcat
3301
       ggtttgtttg gttttttttg tctctttttt ttttgagaca gagtctcgca ctgtctccca
       ggctggagca aagtggtgcg atctcgactc attgcaaact ccgcctcccg ggttcacacc
3361
3421
       attotoctgo ctcagoctco ogggtagotg ggactacagg ogcocgocac catgocotgo
3481
       taattttttt gtatttttat tagagacggg gtttcaccat gttagccaag atggtctcga
3541
       teteetgace tegtgateta eetgeeteeg aeteecaaag tgetgggatt aeaggtgtga
3601
       accaccgSSc ccggcctttt gtctcttttt aaagaaaaca tctcttactc caagaacatg
3661
       gagccatcca cctacgttat cttctttcat tattttgcgt ttcttattta gacctaaaat
3721
       ccatgtgaga tgctctctgt ctatagagtg agtggaggtg acaggcctcc tttctttcca
3781
       aattggcccc acaccatttg ttaggctgtt ttcctcctct tctctgaaat gtcacttttg
3841
       tgacacatta gcgtccctat acacataggt ccaattcagg acactggatt ctcttctaat
3901
       gatgtatttg tccatcagtg cactgcccca caccetcace cagetaaggt ggccacggcc
3961
       ttecctgecc tgacactett ecctgggetg ggecaagget eccggggece ettgeatgge
4021
       caggggctca tttccagctt cacgcctctg tqqccctqca tqqqtqaqqc tcaccttqca
4081
       tgccggaagg cccaaagtcc tgccgtgtga ggaagatggc gtgatcgtgg tattcatcgt
4141
       ggcccgtgtc tggcttctgc tggaggtagg cccagcggca gacattctcc aggctctgag
4201
       aggggttccc gatctcgatg aggctcatgg actgcagggg gatggagaga aatggaagag
4261
       agaggttggc gcctggtggc ccagtggggg gccgagcagg ctgtagtgtt gacagacYcc
       atccactggg aatctgttcc aggtggtaca aaggccctgc ccggtcactc tcaggacctg
4321
4381
       ctcccactgg gctccagtct ttgacaggga agaaaagttt ccccagtcac actcacctgc
       gtgagtttcc acacaaagtc accgcagttt tcaggtgaga tgcagaagcc aagctctacg
4441
4501
       teatetaagg cetegeatag teceacegte taccecattt ecaqaagtee etgtgtttgt
4561
       tetatgagge acctgtteeg tgeaaggeet ceacagaagg caaatgteat gtggacetea
       ccccaaagag ctcacagttt tgggagggtc cgtggcaggg gaggcggaaa ttccagtgtg
4621
```

```
gtgtgcaagg ccagaggaag cagatcacct tatacgttcc ccccgtgtga aggtacttgc
4741
       agaaaccaac acaatggagg aaaagaaaca gcaactgaca tatttggtgg gtgcaaaagt
4801
       aatcgcagta ttgccatgaa aagtaatggc aaagactttg gcatcaacct aatagaaaaa
4861
       cagccatatc aagaacaagg gcatacacag atgattccca caggaactat gcatgggaag
4921
       ccccgggaa ccatcccatt ccattttgta tcatgacgca cacctgacag ctagggtggc
4981
       ctegggaceg etegtettge acactetete tgeaceatga cateageagg caeteceatt
5041
       tagaetteag gaetaagaag eetgtettgg acaggaaact gagaeteaga gaagttaaga
5101
       agettgeeca ggteatgaaa etaggaagta ggagaattga gateggatee caagaagget
5161
       gaaaccaaaa tctagattca actcactgcc ctaaacttcc tccttaaata agacatacac
5221
       aatatcattt caaaagcaag gcttctgtga gcggcaccct tccttttttc ctccacaatc
5281
       ctcacagcag gcattttggt ttctgttctc accatagact ccaaacaccg aagtagttcc
5341
       ctccaagaga accgagagcc cctctgagtc ctgggcatgt tcttttcccc tttaaggatt
5401
       tatctggcca taaaatagag atgtgcattc cttggaagct acgtatgcag gtgttttttc
5461
       tcttgcataa atgtatccac aaagtagagc cacgtatttc tctttgtgtc tataaataac
5521
       aaaaagttgg ccgtgcgcgg tggctcacac ctgtaatccc agcactttgg gaggctgagg
5581
       caggtggatc acYtgaggtc aggagtttga gaccagcctg gccaacatRg tgaaacccYR
5641
       tetetactaa aaatgeaaaa ettagtetgg ettggtggeg taateecage aacetgggag
5701
       gctgaggaag gagaatcgct tgaacccggg aggtggaggt tgcagtgagc tgagatcacg
5761
       5821
       caacaaaggg tattgttagc aagccagtta gttccagaag aagggagcac aattcaaggc
       taggtaagac aagtcgttcc caggggtccc agtcaatgac tgacaagatg gcagaccaat
5881
5941
       tcccaagtcc caagcacaga gttaattgta aagactttat ttcctgctcc tgggagataa
6001
       gataactcat tctaacaagg tttccatgag tcccgatgaa ataagtcata aatcagagtg
6061
       tgatgtcctg tgactaagac ttgtgggaca ttggcataga agtggacaga ccagaggaag
6121
       ctggaggagg gcaaggggag gtgcacttcc tgttcccatc atgaccagga agagcatgtg
6181
       actagetetg gecaatgage tgtgageaaa agtggggeat gtetetttte ggttggagea
6241
        totaatttoo cattgagaco ottoagagag ototoottto tggcacgaga totggcaaca
6301
       taaagacagt ggctgctctg tcacctagga cctgagtgac gatgagaccc gaatcctccg
6361
        ccaacccaca ttgaacatac agcgtgagca ggaaatcttg gtcgttttaa gccactggga
6421
       tgcaaagtgt gtttgtttct gtagcataac ctcacctact ataattgata caggaggaag
6481
       ggagtgggta tctgcatcac atccaagcct gacccctgca gctcatctcg agtccctgcc
6541
        aggtagtate egeetetggg tageettgag aggteaeagt tetgaaggag gaategggeg
6601
       aaagaatgte cetteteact gtetecaget agggggtgag ettgggatgg cacaagaagg
       aagggaaact cggggtggat gtgattcggt gctagagcgt gggccttgtg gttggttgta
6661
6721
        ctcgctgaac ttaagattgg cagcccagat atggatgagc ctgggggacc ttatgctaaa
6781
        tgaaataagc caggctcaga aagacaaata ctgcacgctc tcactcatac gtggaagcta
6841
       aaacagttga tgtcacagaa atagagagta gttcctggag agtggggggc agcgggctgg
6901
       ggattgccaa ggctggttaa catatccaaa agtgcggcaa gatgggggaa taagcgttag
6961
        tgccctatag tgccggaaag cgcctggaat ccgtaagaat gtattgtgca ttttcaaata
7021
       gctagaagag tggactttga atgttcccaa cacaaagaaa tgataatgtt tgaggtgaca
7081
       gatatgctaa ttaccctgat gtaatcatta cacattgcat acacgtgtct aaatatcaca
7141
       ccctacccca gaaatatgta caattattac atgccaatta aaaataacag taagagcaaa
7201
        atcaaaaacc aaacaagaat gactttttaa catacatttt ttaaaaaattg ccagtccaaa
7261
       tecaaatcag agggtcagea caaaggtcae taataagege ttttgetagg gtggtggeag
7321
       ggcccctgct gcagtgtgag tgtctccatc caggacaccc agcacagctc ggtagccttg
7381
        ctgggctcca gggaaagggg ccttgcttcc tccagggcac gtctcccagc atcagtgtca
7441
        agggagtcct gtccaagatg aactcacctg ccctcagggt cctaagcccc atgtagtggg
7501
        acggtccctt ccgatgccct ggtgggttgc ggtgacttct gcctgccctt gtttcccttt
7561
        cgtgaaactt cccctcttt aatctgagtc agaccccagg cttcaggggc aggcaggcct
7621
        ggccaatccc agcaccacgc cttcctggcc accatgaagg atcagggtga acatacaacc
7681
        aaagcgggcc aaggagtagg caaggtgtga ggtggggggc ctgcagcggc tggagccccc
7741
       ctgcactaca ggagaccccc caccaaggat taaaggagga tgagaccact gtcgagctaa
7801
        gactggggct gcagtctcat ctgaaggctg taccggaggc gggtcagctc ccaggctcat
7861
        teaggtggte acggeggee ecagetgage tgttgcacae catacegtat gggeceetee
7921
        tggggccgtc acccatgtca gctttacccc acacggtcgc ccctgctcga gggacccaag
7981
        agacaacaag agaaggcacc tcccctacag aagccacagt ctgcttttga tagaatctca
8041
        gtcccgccta ccgcagggca tggacattaa gagactgggt cactggcggc catcacgaag
8101
        gctgcctgcc actgacgggt gtcatttatg cctgaagaag ttcctctcct tgtgaaagcc
8161
        aattetgagt tgtgetettg teaettgeag egaagagaat etgageeacg tgetteetee
8221
        tttgggggac cacagggacc ccagtcagga cactcgctgg cccatgaaag atggcgtctg
        atctgggggc agctgatatg ttctgggggc agtttatatg cttctcagtg ggagaagggc
8281
8341
        cctggccaag tctttgagga ggagtcaaga gtccagccag aaagacatgc cccaatatca
8401
       ggaccagagg caggaatgag gctagtgtgt aggacagagc tgcgggagga gccaggctga
8461
       ggcaggctgg gggtgtgcag ggaggtccgc tatcctagtg tgtgggcttg tggggagtac
```

```
8521
       cgggaggatg ctagaaaccc aagcgcctac aggagcaagg caggtgacaa gtcaatgagg
8581
       caggctggtt gcacgaaaag taagtccatc ttgtgttttc ccagttttga aggagaaagg
8641
       gtacagagga atatttccct attagaatag agtgggggtc ggtgataagg agtggcgagg
8701
       actgtggcaa acccaggtgc ccaggcacag ctgaagggag caacatccgc ccagtgctgg
8761
       caqqaacaqa qqcccaqaqc tqctgqatca qatttctcag gtcaatcgtg aaatctqqat
8821
       tetacagaca ectacetaat agtaaacaet ggeteaaatt gaaateagtt atgeagacaa
8881
       aacaacgcat ceteceegte accaetttat tecagaacee tggaataaga geeetgeagt
8941
       ggKcagecce ttetecaegt cetgeagaet ggatecaete tggeegatea ceteteteet
9001
       eccagatget ggettetgtg gtteageetg ggtteecage cegtettage agecaaagtg
9061
       atcttgctgc tgcggcaaga caatttattg aaatattgat ttgtgttttt gttcttgcct
9121
       cgctttgttc tcggcccagt ccaagaaggc agcctgccac tttcgttctc caaccccaag
9181
       gaggttgtgc tgcagggtcc agagctaaag gggtctatga cccccttctg gctttggggt
9241
       tetgaggaga etecetgagg agggggcaga ggggaggget ggggtgcatg ggcacaggga
9301
       ggggaagetg caetggggee aggggageee tgggaggeag gaetteagga gacatgagag
9361
       9421
       gttacctcag tgtccgggca ccccaggact caacctgcca ctgggagctt aactgacaag
9481
       ccacagaget gettgtgett cetetetete tetgecaaeg teccaacate tecaaggtee
9541
       cagectatet etgaegggea cagaggagee caggggeaga gatettgtee ttgetgggte
9601
       tggagcattc aagggctatg gggtacccat gaggcccaga cattgacctt gtgcccagag
9661
       gccagggcaa ggtctgtgtg cattcttaaa acagcccttt gggtcagtga ggaaggagtg
9721
       gggatagaag gggacagtgt ggcactgaga tgcatgcagg tgtggctggt gccacgtcag
9781
       gagggtcagg acctggtggc aggagctgag aggcatcagg gctgcagggc gggagcaatg
9841
       aggcagagac ggcaccagtg tctggctttg gggattggta gcaaggcaga agaggcggcg
9901
       cgggaagggg acggcaagtg ccagaggaag agcgtggggt ccgcagtgca ggaaacatgg
9961
       teaeggeaat gtettteetg geeagettge tegttgggaa gagetggget gttttgettt
10021
       gggagetete ceaettetgg gggtgeagee ettgtgggtg ateagteeca ageegtaget
10081
       gggacccatg ttaggcccat ggagcacagg ttcgaaagga ctgaaaactg gctgaagtgg
10141
       gtttgcctgg tggcagcacc caaaacaacc atccgcaaac tcaggctcat gcaccccaga
10201
       gcccctttc ctccacccac tcctcccact ccatgagagc tacaggcagc cttgggttct
10261
       gcatgcctct aaggactcct cacagaaaga aactgatgtc caggcagaga catcggggca
10321
       gctggacagg tctgcggccc aggagggaag tctgggctgg ccgtggacag ggcaaggccc
10381
       tegetactgg aggeagtegg aacceaaggg aagageeaag eteaggtete teegetgaga
10441
       cctccagcca aggatactgt cctgacatgc agtgaactcc cctgtgggtc acttgggetc
10501
       cagogggacc acctgctggg atgcgacctc ctttgctcct ctgccacctg gcctgcatgc
       aggaggccag atgggtccct gctgcctggg gcaccccagc ccccaccatc ctgtgccctt
10561
10621
       getatgtate aageetggga aetgtgette eeetgagega gaagaagaea eattteteat
10681
       atatggatet eeteeagaag tgagggagge tgeactgett gttteeactg aggagtettt
10741
       caccageteg ceetggteat etacgteect eccagteetg aatgeacetg aettecaget
10801
       geotgetegg ctctgcacgg ctcctctagg aaagtctgtc tgtgtgactc cacctgttcc
10861
       tagctgtgct gagggggga ccaggagtga gccgtagcac cctgggctct gcaaaggggg
10921
       tggctgcagg accagccagg gactttacag ggcagccagt ccctcccagg ggcagccgcg
10981
       ggcacccagc ctccagagca gggggcggta gatggtgctg tatgaccggg gatggacatt
11041
       tcgaggccct ggggctgcat ggtagctgca gggtccacct cctgagtgag gcagggcctc
11101
       tgagggcaga ctcttcacag cggcagcagc tcccagaact cccaggtcca gcctagggcc
11161
       ccagaagagc caggcgggag aagcctgcag tagggctgtg gatgaagtcc aggggcccat
11221
       ccagcccagg atgcaggagg agtcctgagt gggctgaccc tagctcagag cacgggaaca
11281
       gatgagette caagaggetg ateggateet etacagggge eecaggacag tegteaceee
11341
       tcatggaggg ctctgccacc cctgtttgga ggtgacatcg accactgcag acatgggctc
11401
       ccaactgggc tccactgccc gagtgctctg gggccctgga ccaggctggc tcttccagag
11461
       tgcagggtcc tccttggcca tcatgagtgc ccacctatgt ccacatggag accetecttg
11521
       ctatgctggt tcacagagct gcccagatgc aggaggcaga cactcgtcca ggcccctggg
11581
       gccctcccac agcagcaccg ggagcctggt cccaagaagg atggtgtttc ctccgggttc
11641
       agcctgtttg gctcccctgg cccgggctgg aaagggtctg aggacatgcc tgaaagaccc
11701
       agggatecea ccatgaggtg gagagggcag atetgaggge ettagggagg caagagettg
11761
       atggecetea cettgggtea gaaggteact ttgetgaatg etececaggg etgteaggag
11821
       gcttggccag ggcaagggtg aggaaacact gcgggcccct gaacctcagg cccagcctgc
11881
        aggggtctgg gtaaccccac gggcctcagg gaacagccag gagcttaggg ggcccgtggg
11941
       cettgggtgg acgagtagge tgcgtccage tccaagtece agececatee tggccgcggg
12001
       accetggete tgagetgeee geegggteee teeteetgeg tgegateggt cacetgeeag
12061
        atggggcacc tactggggat gtgcctgttg ctgtcgctgg cctctgagtc actaaagcct
12121
        aagctccttg agggccgggt ggttgctggg cccgagtctg tgccccagcc ctggcccacg
12181
       cctgccctca gtagccccac tcctcccttc acggagcaat cccggcttct gctctccatg
12241
        ccaggatgag gcagcgaacg cggccagagg accccggctg ctgggcgctc agtgatgaag
12301
       gaatgaacac gagcaccete aggagccagg etgggcaggg agggaggcgc eggetgeggg
```

12361		ggaggcctgg				
12421		tcaccgtccg				
12481		cttcattttc				
12541	ggactcgcct	gagtcccaca	gccggaaaga	ggtcggggtg	ctgccccccg	cgcggggcgg
12601		ggccgggccc				
12661	cccgggccgg	ggacgcaccc	ggcgcccaga	ctccgcggcc	gcacccgggc	tcccggggcc
12721		caagacagcc				
12781	aaaagttctg	ttccaatcgt	tgctctccga	catttccatt	gtttgctctg	gaaggagctg
12841	aattatctat	gctcttccct	ccttcagtca	aggagacgtg	ggaggaaacc	gggatgggga
12901		ggaggccgcc				
12961	gctgggcaag	gcgcactcag	ccagccccgc	aggccgccac	gcgaccgagg	ctcaccaagt
13021		tggcaggtga				
13081		cttgggcaag				
13141		ttggagctgg				
13201		tgtcccttgt				
13261		ggggactggc				
13321		gcttctcaac				
13381		gtgcaggata				
13441		agcactccag				
13501	ccctattcat	ggcaggatgt	tgagcacacc	cctgggcact	ccttaccaga	acccagtoga
13561		tagtcgtgac				
13621		ggtggcaaag				
13681		tgaagctggt				
13741		gtggctccac				
13801		ctgtcaaatg				
13861						
13921		aaagtcacat				
13981	tanananan	ttgcacgaac	geetttatga	cogcogcoat	tettasatta	tgetggggtt
14041	atagasasa	cctcttatgg	gggaaactaa	ggeeeeatga	tgitadatig	ctcaccaaag
	tatatasaas	tatggacaaa	gecagaacga	acggcaggga	caaggreeca	ccatccctgc
14101	tergregagea	catgttctac	egrgeeeeee	agetgagtge	aaagtgggct	cccccaaggc
14161	cagaggtete	ttgttccagg	tagggettae	agatcaaatc	ccaccacgac	agagaaccac
14221		gcaggaggcg				
14281	taccecaca	ccagccatct	tccccaaagc	ctgggaagct	attcccagag	agagccaagc
14341		ggattctcaa				
14401		aggggcctcc				
14461	tgaaagetga	gaaccaatgt	tatggtatta	ggaagtgtgg	tetttgagag	gtcattaggt
14521	catgagggtg	gagtctccat	aaatgagatt	agcaccctta	caaaagaagc	ctgagggagc
14581	ctgttcaccc	ttccatcatg	cgagggcaca	gctagaaggt	gccctctagg	aggaatgggt
14641		catcagttct				
14701		aattccattg				
14761		ctaaggcacc				
14821	tggacccagg	taggtctggg	tgaggaggtg	gatggaggat	gatgtgggtg	ggccatcatg
14881		ctatcaggtt				
14941		aggcatgggg				
15001		tcctccccag				
15061		ctaccctata				
15121		tgctttccac				
15181		aaattccagc				
15241		tgtccttctc				
15301		aggaaatatt				
15361		aaaagccagt				
15421		tattgtataa				
15481	ggagaaaaat	gttgttttag	gaaaaacttg	agataactca	gaggcttctc	ataagctaga
15541	agacaaacat	gtcactcaaa	caagtgctac	caattttatc	cccactggag	cctggtgagg
15601		aggcaatggg				
15661	tgggatgaat	aacaggaacc	gagtatctgg	gccactttct	gcccaagtct	gggtcatggt
15721	ctcacatccc	ccagagtctg	tccccaccgt	ggggggaca	gctcagcccc	ctcctgactg
15781	ccatcgcctt	ggttttgcca	tgctaaaatt	cttctagaga	cgggggcctc	attccttgac
15841	gggaagcctg	tggttccttg	aagagcagct	catcagaatt	catccccacc	atgtgccaaa
15901		agagccccat				
15961	ctgttccctt	ggacacagga	gctaggcctt	ttgcccccag	atcttggctg	ggaagtcccc
16021	atcctggctg	ctccatccat	ggtcccctat	tgcctgccac	cctgctgtat	tccttgccgg
16081	tgctcaccac	tctgtcgctg	tcttgtctgc	tgctactgcc	tggacacagg	gctcctctcc
16141	cctcctcgtt	catgcacctc	cctgggatta	aacagcagct	gctcgggaag	ccagaggctc

```
16201
       tgggctggcc ggatgctttg ggggcacaag gatacatctc ctcccacgtt catcagacac
16261
       ctcaqaqacc tgaaaacagg gcctccccca gtgctatgca aagtqaaqtc tgtqcctqqt
16321
       ggacacaaac tgttccagtc cacagtgaga taagtacaga aactagaaac ttttatagca
16381
       attggacggg ttgagtttat gtccacagaa tttaataata aaaatccaga cctagagttt
16441
       ttggatacct cggtttttgt cacatttgct tttcccagta attcatttat aacqtatqqt
16501
       acggaagtat tggtctgtga tgggtttgaa ataggaaaaa gaaaacagcc aggtctttgq
       cattqaqqtq cactqtgtac tgctgctccc aggatggcct ctcccctggc cacctgggqa
16561
16621
       tggcagatgg ctcctccggt cccacagacg ctgctcccaa gccctgtggc ccacagcaca
16681
       ttegetaagt cagecaggge ceatgaceag aacceatttt cetageeget gtgeeeteta
16741
       ccccaagcet tcagcccagc ccctagcagt gccacctcct ctgctctact atttcctgca
16801
       cttttgcagt aggtccaacc taaagcaacg aggactcata gcctcgqctc acttcccctc
16861
       teacageeca gaaceecca gagaagggea cageageggg caggeecgge tettetqqea
16921
       gtctacactc agctgatcaa ctcaggagat ccccgggatg gagcggaccc catgggcact
16981
       ggcgtcccct acccccatca ctgcctcctg tgcttgatct gggaggcttc taggaggaaq
17041
       gcggggtagg gccaggcaga aaaaggtggg cagagtatgg ggtgagcttt gctgagccc
17101
       actotgggca ggcatgagtt aggagcagaa aaaaaggccc agaatgctgg aatgttccag
17161
       aacattccag gaggccaatc atccctgaat tcccggggtc tgacagaggg accggctgtg
17221
       tgttgtcctc caagctaggc tgaggggcct gggaacaggc actggggtgt cctgggtccc
17281
       acacccctca caacccagca ctgcctctcc cctgcctcct cagctgcggg tccactgagc
17341
       cctcggggcc gggggtaagc tggttccatc tggagttagc tctggaagcg tgcgtccagc
17401
       ttccggttct gtcttccaat ccctcaccac catcagttct caagcccctt cccagcagga
17461
       ggcggaagca aggccagcct cagttcacct atgtcctctc tgttctcttt gtacctgggt
17521
       cgcagaagtt gcccggtgcc caccacaggc atgagctgcc ctggtttgct ggctatggat
17581
       ctcagcaccc ccagggcctg cacatgtccc catgttgtcc ctgggaagag caggctgcac
17641
       ctgacaaccg gtcccctgcc cactgcccca ttcccaactc tgccaaaagt ggaagtgggg
17701
       ccccagcatg gccccagtga agcagagctt ctgcaggtgc atgaggggtg ggggtcccag
17761
       caaagcagaa cttctgcagg caaggcgcat gaggggcagg ggccaaggag gccctggcca
17821
       ggagggtggt gcctgctaac ccaggggcgt gggcttctca tgcaggggag accacgtacc
17881
       tatggcagcc tgcgtcctca ctccaagatt tcccatttcc ttcaggtgga cccgctgcag
       gtggaccccc tgccccagcc acaggaaRcg tgagctagcg cccatagggt ggaacacaga
17941
18001
       aacctcatta ctcctcccca gcccactgca gagatgacgt gccaagggaa agcatgaatt
18061
       ctctttgatg tcttcattga aatcagaaat aaaggactga gcgtgacaga gccctgtggc
18121
       atgccaccgg agacctttct ccagagtgct gaattcagtc aaacggcatc atttggatcc
       taccattttt aaatgatttt ttaaaaaaatc atttaaaaaa tttaaatttc acaaatttaa
18181
18241
       aatgcagtgt tttgtttata aaagaaacat gctggtccag gctcagctgc tcacacctgt
18301
       aatcccagtg ctatgggagg cagaggcagg agaatcattt gagcctggga gttcaagacc
18361
       agcctgggca acagagtgag accctgtctc tacaaaaaaa aaaagaaaaa aaaattagtc
       gagtgtggtg gtgcgtgcct gtagtccaag ctacttggga ggccgagatg agaggatccc
18421
18481
       ttgagcccaa gagatggagg ctgcagtgag ttatgatcac accactccac tctaqtctqq
       18541
18601
       aaaccatgct catcatattg aatttaaaaa attcagtaaa gtacaaagaa gaaaatgaaa
18661
       attaattagc ctactgccca cagagaaatc ctgttcacat ttgatgtgtt ccttccagtc
18721
       tttttggtaa atatatttgt acaccaaatt gagatcatac ggaaaactga gatcctgctt
18781
       ttcaaacaac aaacagcttt agactgtaac catttcccaa tgccattaaa catgtttcga
       aaatgcaatt ttgtggcagc ctaatactct accacatagg tttatcatta cttaactaga
18841
18901
       ccactattat tggacaatat aggttgtttg ctgttgttca catqaqaqat aatqccatqa
18961
       cccttgtctt gttcctaaaa cttggcccac agctgggatc actgctttgg aacagagttg
       tagaaatgaa tgtctggggt cacagaaatg aatgtctggg ggcaaacatc aagaacattt
19021
19081
       taaaggccaa atgcggtggc tcgcgccca taaccccagc actttgggag gccgaggcgg
19141
       atcacctgag gtcaggagtt caagaccagc ctggccaacc tggtgaaacc ccatctctac
       taaaaataca aaaaattagc tgggtgtggt ggcaggtgcc tgtaatccca gctacttggg
19201
19261
       aggctgaggc aggagaatca cttgaaccca ggtggcagag gttgcagtga gctgaggtcg
19321
       19381
       agaaagaaaa aaagaacatt tttaagggca gtgataaata ttgctacatt tccttagaat
19441
       atotgtactc atactcaaag tgtgcctgct tcattcaccc agccataaat ccctcttcat
19501
       cttaacaggg ttgatgcttt ataaatggtg tattatttat ttctttaaca gtagagttag
19561
       atatttttcc atatgggctt tctcttagcc acttggattt ttttctttgt ttccttccat
19621
       tgacaatttt gtttccttat gatttagagg aggttttata tattaagata tatttatcac
19681
       attgcaaatg tttttcctgc ttgtcatttg ccttttcatt gtgttttttg acagaagttt
19741
       ggtattatac ttatccaaat atatccatat tcccctttac aattccttca attggattta
19801
       tgcttagaaa gctcttgaca accaatattt tcttcttgat ttgtgtgatt taaatagttg
19861
       aatgttgtat tggcttatat ttqtcaYatq ataatttaat ttcctattta ttaaatttat
19921
       gttatatatt tatttataac acaataagca ttctgtgttt atcacggtag gttatttgta
19981
       agaggggtat tttcaactat tttattcaac tgaactgtct atgaaagttt atgcacatat
```

```
20041
       ggcactattt taattatett caetttacaa gatgtttgga ggaagtetet taettgettg
20101
       ggtcccacag ctgtctcggc cattcttgac cgttcatgtt cctttggagg aagtctcttc
20161
       cttgcttggg ttccgcagct gtctcagcca ttcttgacca ttcatgttcc tttggaggaa
       gtctcttcct tgcttgggtt ccgcagctgt ctcagccatt cttgaccatt catgttcctt
20221
20281
       tggaggaagt ctcttccttg cttgggctcc gcagctgtct cagccattct tgaccgttca
20341
       tgttcctttg gaggaagtct cttccttgct tgggttccgc agctgtctca gccattcttg
       accepticate treetitigga ggaagtetet teetigetig ggtteegeag etgteteage
20401
20461
       cattettgac tgttcatgtt cctttggagg aagtetette ettgettggg tteegcaget
20521
       gtotcagoca ttottgacog tocatgttgo tttggaggaa gtotottoot tgottgggtt
20581
       ccgcagctgt ctcagccatg cttgaccgtt catgttcctt tggaggatgt ctcttccttg
20641
       cttgggttcc gcagctgtct cagccattct tgaccgttcg tgttcctaga tggtgcttag
20701
       aatcacttca taacatttcc aactatgaat ctgggaaagg ccaacctctc gattataccc
20761
       agetteceat gaggacagea tttgtgtett catttgtgat caetttette etateattaa
20821
       tcaggtacaa tttccttcca atgggtccat tgtcttgtca ggactattcc aggtattcta
20881
       catttttggt tactaccata atggaaattt tctctccctg ttttccccac taccaaggct
20941
       gttgtttttg gttcacacag aagctactga ttttttaaac aatggtctga tatttggcca
21001
       catcaccaga ctcctctct aactctacaa gttRtaccgt ggattctttt aggttttccc
21061
       gacacatgat taacagcaaa caatRagaat ttgtctctgc tcttttccaa tactagtttc
21121
       atgtcacata caagtatcta ggattttcag aaccacagta actagtttat gggtcttttt
21181
       tgtttgtttg tttccaagac tatctccagg gcagtgctcc ccagagcagg ttcagcaggc
21241
       tgcggatctg ctgaqcaaga agcttccgtg gagaaagttt tcagagacca cctgtactgc
21301
       teggaetete ggaggtacae catgeacage tecacaggaa agteteeggg aaattteace
21361
       cccaggaatg cccattttcc tttgtttgac cagcattttc cagacttctt tgaccttggg
21421
       acccetetat agtectetgt aacatetaet catateetaa gaattegetg tgcagaacae
21481
       ttttagggaa atgtgcttct ttttccgcct ttaaatacaa tcttggttgt cctgttgccc
21541
       tctgttacta gttttctggg gatctggaaa aggaggagtg ccctgtgagg ggctaYgggg
21601
       cogteacgee cttgecetge cagaggette aacactggag ccetgaggee teteteccag
21661
       getececeta ggeageaage teeteatgee tgeagttget tetgetaeee ceageteeag
21721
       accccgcagg gctccagacc cacatccaca tcttcttggc ctcctccgct gggatggcac
21781
       caggtacete taaetgeaca teteagetga cetetteage tteeeteetg tgeteeceaa
21841
       tctcaggggt tgataccatc atctacccag ctgagagtct ctccgccttc acccacctag
21901
       tgccacatcc tetegaagtg gccteetetg teeteetgte tgtatecetg gacccaggee
21961
       tggtcccagt ccagctgcca gcatccccca tttgatggca gtgactgtct cctaagccac
22021
       tgctcccacc tgccccttct gcacacagga gccagtgatc ttcttagaaa tgcacatggg
22081
       atcgtgtcac tgcttaaagc tgccctcatg ggcaagccaa accccttggc gggagacgca
22141
       ggtctgctct gctccttgcg atcggctcct tccgacgtct ttggcattgg gtctgctgtt
       22201
22261
       ctcagagcat ctctatgctg gtgacttcac tggaccatct tcaggtgtgg gtggaacggt
22321
       cactteetee egitgetitt cetgacettg taaggaaaga etgeetgace egegteteet
22381
       ccatccagcc ctgagccctg gtacaattgt ttccttgtct agatctgcct tctggaagcg
22441
       gteecetgag gacagagaet atgecagtga atatteecag cacagcaett cecacacaga
22501
       agcccttcaa acagtatttg ttagaggatg agttttgtca tttggaaact gatgtgatga
22561
       actgtatgaa tagatttcct gatattaaac aatctccaca ttcctaggat aagccctaga
22621
       tgatcacggt agaagtttct ctttatacat tattcaatta aactcttaat gccttgggat
22681
       ttttacttct atttttagaa gtgagacagg tctgtacttt gtcctgacgg gctacctttg
22741
       gcatctttgg gtataagggt cccattgact acgaaagaca cattgggtag atttcagaat
22801
       acatgagttt acagggtatt gtattagtct tgcctgataa atgcttgcaa atgagtatga
22861
       atgeactggc aaaactttgg aaaaggtgaa gaacttgagt teeeteeatg gttatgggae
22921
       ttatggcata ttctccattt tttggagtca gctttgaaat attcacatcc caggaaatcc
22981
       tcaatttccc caggatctcc gtgtccctgg catagagatc ctcaaattct caccttcagg
23041
       gtttgactct cttctgcaaa tgttctgact gtgatcacat actccttcta cctacctgag
23101
       gcagttaagg aaaaaaaag aaaaagaaaa agaaaaggct tagggtcggg ataatttagc
23161
       atagageetg ctaaggagta attaataaag gaggetttat teeatcaagt acteaagaet
23221
       gggaaagagc agacactttt caggccaaat aagatccaaa gctttgccag cactggtaag
23281
       caattaaccc tagtcaatta caaaattctt ctttttaaac aatgtaggag caacctgggg
       gaaaatgcaa gccgccacct ggcacccaga ccaatcaaKg ggataatctt ttctcccctt
23341
23401
       tctagcccca ggaccaggag tttcccattt tKggaaactt ccaaaagagg atataactct
       gtccatctct catgccaaag gcttgagaat tcctaaaaca ccagaggatc ctggccagga
23461
23521
       agggacaggc tggaaagacc cggcttgggg aaggccggaa cagggaactc cactggaggc
23581
       aggcagccag ccacatggga tagtccaaag atccccccg cacctccccg cctgtgaatg
23641
       gagagetgga accggattge tgggetgggg cccaccccca ggetetgcat etgtgtggte
23701
       caaageeeee tgecacaaae etgggataga gggeteageg ageetetete tgeceteeta
23761
       gccagcattc actggcagag gatgccctgc acatccctcc tccactgatc atccctggac
       ctccgaagtg gccggctgca gagagcctcc caacagcttc ctagtgggca gatggccctg
23821
```

```
23881
       catgetttee tttetgecag gagaagtate tttttgtagt cacattacat atactettte
23941
       tgatetttta gtttgtgeet tetetetttt tttetagatt aaataggtea gagggttget
24001
       ttttccMaag ctctcttctt cattgattct atgtgtttct tccattttct aatttattga
24061
       tttctgcttt ttctgaacta tttccttatt tttgctttcc ttaagttttt ggttttgttg
24121
       ctgttgaaat tcattcaaat gtactgagtt gaaggcaggg ctaatgtgtg tcgaacatat
24181
       cacccaagga agaagctttt ggaaaacatc tgtgaatttg cctctgaata cagctttaac
24241
       cacattecaa aagatttgac aqtaqtgete ttgtttttat taqtgtteca aataqtetqt
24301
       actgcagtcc taatattctc tttccttgct ctgttaccca ggctggagcg cagtggtgtg
24361
       atctcagete actgcaacet etgeeteeeg ggttcaagea attegeeeae eteageetee
24421
       caaatagttg ggactacagg cacatgccac cacacccggc taatttttgt attttttgq
24481
       tagagacagg gtttcaccac gttagctagg ctggtctcaa actcctgacc tcaagtgatc
24541
       tacccacctt ggcctcccaa agtgctagga ttacaggtgt gagcgaccat gcctggccc
24601
       tagtaggttt ttttttttt taatgttttc aaatgaattg gattttttta ggtttataaa
24661
       ttctgctgcc cccaccccta cttttaggca tttcatcagc gaagatggac aaaatcgttt
24721
       tagctgtata aaattcacaa tattttcttt atgacccaaa acacttctgt aatttttaaq
24781
       tgttctatga ttcctcgaaa agaaggttca tctttcttt tttctgtagg gcaagggaaa
24841
       cagtgatata actactaatt tagctttact cattgtgtca ttcaaaaatt ctatgcctta
24901
       ttagcatcta atctgtgaaa qqcttttaaa aqtqtattaq aqactctcat aqttaqqttt
24961
       ttgccaattt cccctttgtt ccaaggattt gttttgggat gttttgtgtt ctcttggggt
25021
       acacgaaggc ctgcaactgg catccgccct gtgggtgcct tcggtcactg tggaatgagg
25081
       tgcttggtgg gtgtagggaa gtggccccaa atctacttag tattcctggg atcccttctq
25141
       ccaccggagt ccttcgtcat catttttaca tcgtgtgcct tataagttgt atgcagtttg
25201
       attitattit tigagaciga gattetetti gaacagagit caacittitat ataattatet
25261
       gatgtatttg atcctattat gatttgattt tctatgcaca gccagaccac aggctcgaat
25321
       tctgctgtct gggtaagaag cctgactcct cgggtgctgg atggccctgg ctgcttacct
25381
       gggcatgtca ctaagtcaca ttaagcctcg gtgttcttat ctgtgaaatg ggcagagtca
25441
       cagtgtgcac ccctccatct gccctgtaga ttaagggcat tcatccatac aaagtgcttc
25501
       ccacacggct ggtacaggca ctttgcagtc tacacgggcc gtaccgtggg gctcctctct
25561
       tectetgtet geacageate eegtgttgee ateceaggte aetgteeetg geggetacae
25621
       acccatgcac accgccagga aaggacgtcc caggtttggc tgcaagagga agtgggacgg
25681
       gcaagagagc ccagctggga cagcagccga ggccagagga gaggaggcca cagatttaat
25741
       acgggggcag aagtccaagg gagggtcgtg ttaaccacgt gtttctgatg ctttgacatc
25801
       cgagcettge tgactetgga gggactgeee egetaagtgg taaccaatet ttagagacag
25861
       gaaacaactc atccatgagc acatttttca gatacaaacc aaccaatcca gcgcccatgt
25921
       ccccagccac ctcctttatc agacttcaca ctctqagcca ctatccccct qccctcatta
25981
       cccagaaaac taactcagga ccgctccact ccccagagcc cactggaatt attcaaactg
26041
       gecaacetta agecagetea ecetgteeee ateggteett eetgeagaaa caacatggae
26101
       tcaggctgct gtttacccaa Ytccctctgc ctcctgacca cccctggtgc ctccctgtgt
26161
       ggccccgtg gcctggtatg tctcttcctc ttgggatctg ggagtaacag actcttttca
26221
       gtgaacaata gtaatggcca cattttaaaa caaggggtga aagggagcag ggWtcttgtt
26281
       tettatagga aceteagggg ageeagggag aggeagggtg gttetggeaa acgeacaca
26341
       tetecaagga ggcccatgce teacteceag geceeteact ecgaggggt ggaggeagge
       ccggctggcc acagtgcact cacctttcca tagctcagga ggatgatccg caccaggacc
26401
26461
       acgttgatgt gggcacccaa ggactcgtca tggtagattt cattgacctg aaagaaacag
       ggaggcatca gcgggaacca caggccctag gactggctct ggctctgcca atgggatgac
26521
26581
       ecceacetge teettettet teecatgett teeacecagg egteaceate aactaggage
26641
       caccttgtga cccctccctc attgccccct gccctctgcc tctccaggct gccaccacca
26701
       cctgctggga tcactgtagc cccttcctga gcaaccccac ccaccagccc agggWttcct
26761
       cacctggggc ctgaacatgg aacgtgggca gggaaagcag ccctacgctt gctgtagcct
26821
       ccagctgaaa cacaacette cetteaacag tgaacgtggg tgatggacce ccgcggcaca
26881
       ggcagggctg ggaccggccc tggcagaagt cactccaagc tatagctggt gggtgtgggg
26941
       attacctacc tgcatcgcta cttggaaatg ggggcggttc taggcccacc accaggtata
27001
       atgttttaac gtgttaataa aaagctcata ttactgcatc cccaatgtgc tctccctgtt
27061
       ctgttttgat ggctggagct cctgcagtcg ccgtctctgt atttatcaca atcatattct
27121
       tacacgtgtt tcattcttca catttaaaac cattattctg agcaggtgcc aatgggcttc
27181
       agcagatatc aaagggaccc gtggcacaaa aacagggggg tgaactcccc ttctacagaa
27241
       cacagccagc aagaccctcc agaaacatag gtcaggttat cccgggctcg aggctgtcag
27301
       gggcttcctt cgcactgagc ccccaccctc cagcttccca ccgcacacac ccagggccct
27361
       ccctagegca geoccettee tgteacetee tttgttggtt aaccaaacee Yacteeteet
27421
       cgaggccage teageagtea etteceeetg gaaggeeeee egeaggeetg ageegeeeet
27481
       catcaagcac aaggtgtgtt atttctggag ccctctgtgt gcccctgtgg gctgggcagc
27541
       cacctgcatc ctccctgctt gcatgcccag agccaggcta agcagcacct ggcaggcact
27601
       cagggatacc cgctgaaagg ctgaagccat tggcaccatc aagaagtgga gaaacaggga
27661
       ctggctgtgt gcagaccgag cccaggggct gctgacagct ccggacatgK ccaagacata
```

```
cttcccggag cctgctgcca cgtcaggcca gcacacactc cctgcactcc aatctgtaga
27781
       gcctgcatct gagcaacagt gattgctacc tcaaaacagt gggaaggcac ctcaggaaac
27841
       cYgagggttc acaaggagaa tgacatcatg atggatgggt ggacaggcat acagggcgtg
27901
       caagacaagg atcccgaggc ccgctggcat cggtgctggg aacaaagatg gcaccgatcg
27961
       tggggcagag ttcatgacat gtggaccctg ctgagggtac catccagccc aaacgcagct
28021
       cetettggca actgetgece ageaaateta catetgattg taaatggget eeccacaact
28081
       cccacctctc tttcctatag gcaagggaca actcatcaga cccacgggag cgtggctggt
28141
       caccgtggct ccgggctgta ggcgtctggg gagggtgggt cagcaacccc tgtaggcgct
28201
       gagggttatc ctctagaccc ccagtgaccc atctcgcccc tgtggctgac aagatggagc
28261
       tecgaggagg geacceaggt eeceaggaag cettgeeatt tggteatege eeteegttte
28321
       ctctgtaaaa tgaggattgc agtcccccca tcacaaagct gttgtgggga tgaaaccgYc
28381
       atgcaggtgc aatggaatgg tgcttgtgca aacaatgaaa cggtttttca ttgctggtaa
28441
       accatagtgc cctgcagctc cctgtgaggt cctgggggta gggtatgcac ccctaaacca
28501
       cagaagtcct tgcccagctt tgagggtcag actagattgt ttagtccacg ctggcacagt
28561
       agccttaaaa gccagttttt cttaagagag aaggggtttc tgtaattgtc cacagtattg
28621
       ctttctctat cacgacaaag cttggccagc ttggctcatg gagtctgacc gagggaaggt
28681
       cccactgcag ctgaagggag cagaatagga gagaggagaa aggccaggga tgaggggcca
       ggetteteet cateeteaac eccaacetea caggteatac agaacagtee tgacatetga
28741
28801
       gaaggaagga aatgcaaaag agcttgatcc tggctgctgc ctgggacctg agaggggaca
28861
       ggtteetage agtaggagtg getteeaggg eccaactggt ggeecageet geteaggeet
28921
       gagagggtgg cccagctccc agctgtgtgt agcagatgcc agggtcccct gcaccccaga
28981
       gacacatggg caagatagtt ggggactggc ttgcaggttt acctggctct agggggcacc
       accaggette agggeaagee caggggggea etggeetaea ggagaggagg geaggeetge
29041
29101
       ttgcaagget actgcagagg ggactcatec ctactgcccc ccaccaggec tetgcetgca
29161
       aatggggctt ttgggaggta attaggggta gatgagttca tgggggtggg accctcatga
29221
       tagggttagt gtcctatagg aacagacacc agagagcctg catcctctct ctctgccgtg
29281
       ggaggaccca gcaagaaggc ggctgtctgc aaaccaggaa gagaatcctc actggggaat
29341
       gacccagctg gcaacatgat cttgaaattc ccagtcttca gaactgtggg aaatgaattc
29401
       ctgtgattta aacccctggg tctatggcat tttgttatac cagcccaagc ggaatgagac
29461
       aaaggettta tggggaagag actgageeac eteceacagg ecagactgea geetteette
29521
       tateetgggg etgagtgeee gagatgaggg eageaceaga tataggaaeg aaagaaagee
29581
       ctggccaggc gcagtggctc acRcctgcaa tcccagcact ttgggaggcc aaggcggtgg
29641
       atcacctgaa gtcagaagtt caagaccagc ctggccaaca cggtgaaacc ctctctctac
29701
       taaaaataca aaattagcca ggcatggtgg cgagcgcttg taatcccagc tgctcaggag
       gctgaggcag gagaatcact tgaacccagg aggcggaggt tgcagtgagc cgagatcgcg
29761
29821
       29881
       aaagaatgaa agaaagttgc atttttcccc acgtttgagc ctaagcgtgt aaatgttgac
29941
       ctcaccgtcc acacagaccc tcagcacagc cacgggcccc tcacaggctc tcaatgggac
30001
       ttctcaaact aaactgaccc tggcctcttg tgcagcccac cacaccctgg gacccagaat
       ggcctgggcg agcctgacct ggtctctcct tccccactgg gctgaggctg gcacccagca
30061
30121
       gacccagcag aaccactgcc tcaccatgaa ttgtggctct gagtagatca gagccagccc
30181
       tectgecagg aggeggagag ggacacteag atgetacgag accageteca ggateacegg
       cctcgaggga aaggcaggga accagaggat atattagtgg gaatctgccc actggggcct
30241
30301
       ggaaggacgt ggcatgtcat gagacctgag aaacagaaca gggtagctca gcaaagcagg
30361
       gatggcgctc ctggcagagg aggcagccca tgcaaacctc ccagggttgg aagcagcgag
30421
       gcaccttcca agcacagagg ggatgtggaa gggatgcccc agcagaggag gtgggagggg
30481
       agcactgagg ccagaccacg aagtcaggag aaggattcca aatcctctct aagagcagtg
30541
       ggaggacatg gaggaaggat gatggcgggg catttaagaa gcttactcca ggtgccttac
30601
       ggaaagtaga tggaaggggt caagatgtgg gaatgtgggg ttcagctttg gggatgagtg
30661
       cagagaaggg acggatgtga gggatgatgt ggattggaat aggggtcatc tgccccgcct
30721
       gagcagggag aggctggggc tctggaaggg cattccggca gctcccacag ggcggaggga
30781
       ggagatgcgg ggctggccct ctcctggctc ctggccaggc cctgcccctc aggacgcaag
30841
       atcttcccac tctcctagcc ctacccctgg ggccgaaggt ggcagctctc atctcaagaa
30901
       ggaatettgt gteettetga acattgagea gatetaatee tgeteeetga tttqqqaeaq
30961
       gaggtgacca accactccaa aagccccgtc gctgggcatg gaactccctg ggatagaccg
31021
       tcagcctcac attctgcttg gaggtggggt cgaggcagct gagccctggg gtgtcaggct
31081
       gctaggegtg ggcccctggc tggggagctc cactgtgggc tgtccgccag cagccagctc
31141
       ccacctcctg cgctgggtgc cctgaccctg gcctctggaa gcctcagatg gttcggagat
31201
       taactggggc tccctggctg ctgaggagct aSagagggca tgcctgcaaa tgctcccagc
31261
       aggtagccag ggagaaggag gccaggccgc agccaaggcc ccctcagccc tccctccctg
31321
       gtagcettca actgtggtge getetecetg atcetetece caggaaacet etgtecette
31381
       ctcccttcca caccagcaca gcacatagtt ccccaggcat gcccactctc tgggaggcag
31441
       gcctgagcaa ggccgtggtg gggcttgcga tggcctcctg gctcctctgg gtggctgctg
31501
       ggcYtgggat cctgctccgg agccctcaac ttggccccct cccaggccag gtctcagcag
```

```
31561
       cccctcccag cagtcaggaa ccccatgggg cactgtggcc cagagaccac tgaccactgg
31621
       cctgggtggt tctcctgccc ctgcgtgtgc tatggcaaag tccaacccac agtccggggc
31681
       cgggctcctt ctgctgtcca gcctctcagt ccccgtaggt taatatgata catcaggaac
31741
       agacatgggg ggcaggcagg gtttgtgggg catgtgagag gcaggggtgc tccacagtgt
31801
       cettgteete egtgggeetg aggagtgage eeegteetge eeeetetaee ateeeaggge
31861
       tctacctgct tttcaggagg ctgcaaaatt gccaaaattt cctgcccagc cctggccaga
31921
       ggcctgcagg gcccacctgg gcatgggaac cactgggagt aatcagtgta attcccgaca
31981
       aaacactggc gtcctcagta aggacacagc ggcaacattt ctgcagagca gagagtcgac
32041
       tgatgtggca aaaagagcaa ctgaagacag aaggcgacct ccacatgcct gcctcctgca
32101
       catececete etececegge eccaeceaet ttetetgeca gacaggagae aggeggtagg
32161
       getecceaac ggtecceete gtgteeteec caececeeca eccacacaca ceattettea
32221
       ctacgatcac caageggaat agateteace tteceettee actgtetaaa acceteaacg
32281
       getetecagt geetteggaa geagggeeca geeettegee tggeattegg ageeetetee
32341
       acgctggccc tggctggctt ctccatgcgt cacttcagat acctccccac atggcaccct
32401
       tgctcctgac agcccagcca gccttcccca gagccggctg ccctctcctg ctgcctgtgc
32461
       tttggttcag gcctggaatc ctcactctcc ctgtgcagcc cctcaattct ttagatatct
32521
       caggagcatt tgaaaaaaa gactcatcct aaaaaatata tctcaaagga aagaggcagt
       gaSctccttg cttaaaccct tcctacccca aggcatgaga ccgcagttcc tggcgtgacc
32581
32641
       tccaggccag gagggtctgg ccctgctgag tcttctcggg ctgccctggc cctgctccct
32701
       gtgctccagc ggctagcccg gctgctcctt gcacaggcag cctgtctcca cctcaggaac
32761
       tttggacttg ccgtgcaact gctcccagca gtgYctagcc catagtaggt gctcagtaaa
32821
       catttgctga atgaatggaR tgaatcactt tgaagatatg gaataacagg aaatgggcaa
32881
       aatgtatgac ccagcgtagg cctgtgaccc ctctcatggg gaggccccca gctaagggcc
32941
       tecectece tecececage agecetgggg geeteeteeg catecaceet acceaaggee
33001
       tgcgtgtgct ggggagaagc agctctcctt tcccaggttg cagRgggagg ggaagcccag
33061
       ggacaatgtc cttgagtact gtctgagaaa ttgatcctgg aatctttaaa ccttgggggg
       aaatgttcaa agccgcagcc atctctgtgM ggagagaggc caagggctct cttgtttggg
33121
33181
       gaaacacatt gtaatgcgcc ttttgcttat gcaaagaYgc agccaagttt ctgttctgga
33241
       atagacaatg aggaaggagc ggctctgcat ggcaatgtaa agtttgcctc actggtggca
33301
       gagttccacc caggggatgg tgagccctgg gaggtggcct gcggctgctg ggcagaggtg
33361
       actttgtcct ctgccaaggt gggggagggg tgcagaaagg ggggaaccgg tgcaggctcc
       ctactgggga ggcctactgg cctgccagcc acagaggaga caggcagggg ccctggaaca
33421
33481
       gcagccaccc caaccttcag gaaagttccc atRtccttcg ctcagctgag ctttgggcca
33541
       ccagaggcag cctgtggccc acctggcaaa accatgtcca ggagcaagcc aggcctgaaa
33601
       agtotgtcag aggcctgggg gaggggggcc tgctgctctg tggcttctct gggaccccct
33661
       gaaataagtg aggagaaggc tgttctctct gtgccccttc ggaggccagg cttggaccac
33721
       caggatggag gcagagaaga gagtgcagcc aggagcaggg gacagaggtc tgctggcctc
33781
       cgtggaggaa gagtttaggc attgcatggt gcctaaacgg ggctgccaga gcctgggctt
33841
       atcatgagaa tcaacgttcc cattgcagat cttcttcacc ctcggctcct cagcagatgc
33901
       ttcagaggga atgctagaag aaacgtgact cttgctcaaa atatcaaact accatgaaNc
33961
       ggaaatggcc aggatcagaa ttactaggct cagttcatac atcaaaaagt gaggtggtca
34021
       gagteeete etteaatace eagegeagga acaetetgee eaaggeeace eeeteactee
34081
       teaggegaeg teteetgtge etgteeacae tetgetgata cetetgeaga tgeeteaggg
34141
       tggggacggg gctcctccac ttccaggcca gctcatcaat gcacagagcc cagcagggtc
34201
       tcaagagatg tgctgcaccc ctcagtgtgg cactccagca ggcacgttga gaagacaggt
34261
       cgcattacaa accttcccgg gtttgtacta acgacggcaa gaggctgccc ctcccctct
34321
       cctgaatttg gggggttagc agagtgtggg ggggatattc ccactctgag gtcagatttc
34381
       atgggtgcca gcatgggctc tgccacaatc ctgctgcgtg acttggggcc agttacttaa
34441
       cctgtctggg cctcagtttc tttatctata aaatggagat aataaYagtc cctgtgtctc
34501
       agggttgttt caggttgaag caacaatgaa aattatcacg tgcgtccatg tgaagagatc
34561
       accaaacagg ctttgtgtga gcaataaagc tttttaatca cctgggtgca ggtgggctga
34621
       gtccaaaaag agagtcagca aagggtggtg ggactaccat tcgttggtat aggtttggga
34681
       tagacggtgg agttaggagc aattttttt ttttttgag acggagtctc tctctgttgc
34741
       ccaggttgga gtgcagtggc atgatctcag ctcactgcca gctccacctc ccaggttcat
34801
       gccattctct tgcctcagcc tcccgagtag ctggggctac aggcgcccgc cagtgcgcct
       ggttttttt tttttttt tttttttt agtagaggca gggtttcaca atgttagcca
34861
34921
       ggatggtctt gatctcctga cttcatgatc tgcccgcctc ggcctcccaa agtgctggga
34981
       ttacaggcgt gagccaccgc gcccggccag gagcaatttt ttgtgggctg gggacggatt
       ttacaaagta cattctcaag ggcggaagaa tattacaaaa tatcttctta aggtaggggg
35041
35101
       ggacaatatt acaaagtatc ttcttaagga tgggggtggg gaagaatatt actaagtatc
35161
       ttcttaagtt ggggggagag aatattacaa agtatcttct caagggtggg gagggtgtat
35221
       catacaaagt agattcacaa gggcgggtcc ggcgggggcg ggtggcaata tcacaaagta
35281
       cattacccca agggcggaga gggtgtattg ttcacaaatt caattgattg atcagctagg
35341
       gtggggcagg aacagatcac aatggtggaa tgccatcagt taaggcagga actatctatt
```

```
35401
       ttcacttctt ttgtggatct tcagttgttt caggccatct ggatgtatat gtgcaqqtca
35461
       caggggatat gatggcttag cttgggctca gaggcctgac attcctgtct tcttatatta
35521
       ataagaaaaa caaaatgaaa tagtggtgaa gtgttggggt ggtgaaaatt tttgggggtg
35581
       atatggagag ataatgggtg atgcttctca gggctgcttc gagcaggatt aggggcagca
35641
       tggaaaccta gagtgggaga gattaagctg aaggaagatt ttggggtaac aggtgatatt
35701
       atggggttgt tagaaggagc atttgtcgta tagaatgatt ggtgatggcc tggatgcagt
35761
       ttggtatgaa ttgagaaact aaacggaaga cacagcgtcc gaataaaaqq aqaaaaacaq
35821
       gtattaaagg actaagaatt gggaggaccc aggacatcca attagagagt gcccaagggg
35881
       gttcagcata attatttgct tggttggcga gtttttgggc tctatccttg agtttatgtt
35941
       gtcatacacc aggccagact gatttaggta aaaacaacac ctaggtgatt caaaagcttt
36001
       attgctcaca caaagcctgg tggtggtctc ttcacacgga catgcgtgac aaaagtgaaa
36061
       tececageae etagtacagg etgaatgaaa etgteateaa attacaggag ggtecaacag
36121
       cccaagetgt ttccctggga ccccatgcac agaatggtcc acctgggctt cgcccttaca
36181
       eccaecetgg eteteeteet ggeeateace ategggagag gtetgagtga acagettgea
36241
       catgecectg tgttttccag agetggaggg getgetgtge ccaggeacRt ccgcgagtgt
36301
       gacccagece tggagetete eccgetgget gegtegeett tggggaaaea acagecatge
36361
       caccacttag ggactgacct tcccacccgc tgaccggatg cctcatcaga aagggaaatg
36421
       ctgcagaacg gggaaggacc agtgctgctg aggctgcagg acgcagaagg acacggccga
36481
       ggcctcaggc cagagcccag tgtcccccag gggcctctcg gccactgcga gccactgaca
36541
       gggaaaggcc gagaaaagtc agggattctR attcttgcta gcagtggctg caggacggcc
36601
       etgeeteect ggaactetge tgagettgte ggetgteect ggecacagag ceetggggg
36661
       ctcagtgagg agtttccttt caaagagggg ccctaagtgg ccagggctcg tgccaccccc
36721
       ggccctggca tcccccaca cgcccgtctc agaggctgtg tggcccggcc catcccgtga
36781
       ctgagctcgg tcacctgggt ccgtttgagc accaccatgt aatttgagaa caatgcattt
36841
       ttattccccc acacatcata ttctgccgct gctctgtcac cagtgtgacc taaggaaaga
36901
       gggaaggaaa atgccgctat gggaggagag agctgtggca tcaggggaca ggaacggtgt
36961
       gggggaggg gcagcaagca gctgccgggg tgggggggg gctgctgagc ccacaccagg
       cttggagccg gagccctatc cctaccgctg cccccgcctt agggtgagat gcagatagtc
37021
37081
       cccggggttc tgggctccac ttcccactga gatgagaccc tctgctgagg gtggaggcca
37141
       acceacatgg tggccaagca ggtggttaga atggagaggg atctcatgtt aatgaatggg
37201
       cctcaggcag cacatggatg cccctcgctc cagaaggggg tgtgtgtgggat gcagcagctc
37261
       ctgctggcga gggccagggc gtgggtagct ggcactggct ggcagaggct gtagagtgga
37321
       cacccatcaa ggcatagggc ttggactggg caggggtcca gcatgcctaa gtggcccagg
37381
       cgtcagaccc gaccacctca gagcaaagct gaggaggact caggccagcc teectactce
37441
       ccaggcatcc atgcatgatg aggaagaagg gagaggccct ggcagagcag gtatgaaccc
37501
       ctcagagact gagaaggcat gacagaggc tgcaggccat caccttgcac tgtgcccctc
       gacctgggca ggggccccca aggcactcag agcgcagggc aagagtaagg tgaaggctgc
37561
37621
       aagaagggtc ctgcattaca agctcacggc aagggtcgtc tgctgccagc gtatccctcc
37681
       ctgaaagege agteatgeag ggtgetttee aacacceaga geagatgtte eagegeetet
37741
       tgggcttggc gggaaacggc tttgcccttc tgtgcagcag gtcacaatcc ccctgcacca
37801
       ccagagtctg tttatgtggc ttagctccct tgccagactc tggcagatgg aaagatagat
37861
       gaaatcctgc ccaccgctac acaggaaacc cagaaccaaa ggaagagggg ccgaattatt
       ggaagcacaa gggtccgtga tcacttctgc tcaggatcag aagggccagc atgggcagcc
37921
37981
       cccaggccag gctccctgcc aggcgcggt gggaggtctt gcaggctgca gccaggtttc
38041
       cttcctcctg tctggctgca gggaagtttc ccttgctctg aagtttcctc actctgtgaa
38101
       catteccacg gggcacceta tgetgeeteg ggtgetgtee cateetggta aetteetgge
38161
       accatcgtga tetecagteg cettegtttg ttagetgtet gteegtetee actaggeagg
38221
       gactgttctg cattcttgct gatgcaWcct gggtgctcag tactcccgtg tttccccagg
38281
       cttcaggacc aaggccaagc tcagccgcac gcgccttctc ccaccccagc gggctcccag
       ggtggccgag ggctggcacc tcttttgcac aaggggctcc tctgtgtgga atgatgccct
38341
38401
       cccactttcc acttgggaga caccaactct gtgaccaaaa ccagctcaag gatcacccca
38461
       ctgtgactat ctccacKacc aggtggagac agctgaccgt ctcctttggc tgccaagRcc
       ctgtcctcRc tgtgccaagg caagcaggtg gcccccatga gaaaaaagct tgtccaggac
38521
38581
       38641
       tggtcggctc tgatcttctc cgcctaYgcc gagtacttcc ccgcgtgcga tatctttccc
38701
       ttcccacacc ctgcgagtga gtgttatccc cgctgtgcca gtgaggaagc cgaggcacag
38761
       agagattgag aggctcacat aagtgggcat gggagtcagt acagaggctc tgaggagcaa
38821
       tttggcaaac ctgctgcaac tagaaactgt atcccgggac ctggccattc agacgtcagc
38881
       atggacgatg gagacacagc ctctgtcata gaagcgaagg cataaggaca cccagccacg
38941
       aggagttcca cacccacaga tagagttcat ttttatggga gtctctgaga tcacagtcgc
39001
       tttatgggaa ttcatttagt cacttattca ttcaaaagag atttactgag cacctactac
39061
       gtgccaggcc ttttccaggt actcagtgaa aaatcaggtg ggcagaccct ctctgggtcc
39121
       gatacaaagt cacctttgtg ggagtcccta accctgctga gacacaccac caaggagacc
39181
       cctggactgg ggaggaagac ccaggattgc ttgactgcaa ctcagctcca ggggcagcct
```

```
gggaggggcc tcagggagtg agagcccacg ccaggtcagc ccgacagccc ggcgtggcac
39301
       atcategeet etgttettgt ggtteagetg teaceteett getggageet geacaagaea
39361
       agctccgagg ctgcctcaag ctgtcatccg ggtgtgtgga tggctggccc tcctcgtcca
39421
       cagggactet aacteceatt etgacaacea teagtteece gegggaggee aaggacagga
39481
       tgctgggagg cttccacatc agctatcagg aggtctgcgg aggagggagg agggaggagg
39541
       tggggagatg tccactggtg gggagggtgc tgcacatttc aggaggaagc agaggtgaga
39601
       tecacecaca agacecetgt tegagtgtte eccacetget caccateact ggtetgtegg
39661
       cetececage cetgetggaa catgtgetee etgeggtetg gatecegtge teaccaegae
39721
       atccccagca cctagggctg ctctatccgg gtgcactaag ggagtgagtg ggcaggcggg
39781
       Ygggcctcag aacaggagga cacagtagat ctatgcagaa gccaaggcaa agcaagaggc
39841
       agageggatg geetgYgggg agaggegggt gtggeeaggg gaeteeaaat getgtgggga
39901
       ggtcagtgag gcctgagatg agaaccYgcg gagcatgcta ggggatttgg gagctctcga
39961
       tetteaggee agacagtagg ggaggaceag cacaggggee acetteecae aggtatgtga
40021
       ctccatctgc cgtgctctgg ccatgtctct ctcagtctca gtgacctgat gcaggcaagg
40081
       gaacctcaca gggccactgg ggcaaggtag tgaggtcaca ggtgtgcctc cttgcacagg
40141
       gccagcacgt gcaaaaccag caaatgtgag ttcccctcct caggtgggga ggggtgtttc
40201
       caaggataga aagcataagc cccaaacctc ctaagagaga ggagtctatc tttgtagacc
       acaaatcaac ctcgctcccg ctctccaagc cccacaagct ccagcagggc ccaatctgcg
40261
40321
       cactgcgatt cacgatgcgg ccaggccttt gcgcgcgctg tgccaccacc aggagtcctc
40381
       attagaggca actgcggtgg cccttgtccg aggagccttc cctgaccagc cgccccaggc
40441
       accettecet gatgaaccaa ggtgtaatca cgtgteetga teeegeteee catacteetg
40501
       tgctcYgagc tcccccagtg cagggatgcg gaggccagga gtccagggag tgccgaacat
40561
       gactgaggac ageteceaat eccageatge teeteceaca eccgtgetet actgageact
40621
       ttcctggtgt tcaactcgag tggtgctccc aacagccccg ggagttggca ctgaccagca
40681
       cagggcgcag caggacaggc agtcgcctcc ttccttctag gctggaaaga acactcaggc
40741
       cacccacaca ccagacttgt cctgcagccg tgttctgctt cacctgtgca gtgtggcttc
40801
       ttaatttcaa tctgtggccc acattgaaaa ataattagat ttcccaaaaa aagtagattt
40861
       ccagcttctc atggaagagc gagctggcag cagtggtctg cttattccta cagaaacaca
40921
       agcgagtgga accacgagga gctctgcagg ggggcgtggc ctctccggtc gcccgagtcc
40981
       ccaccactcc caacageett cagecacetg ggeceetegg geetggetac tgtgageacg
41041
       tgagggcact gccctcttct gagccttgcg tgcagcctcg cacacaccac tggccctcat
41101
       ggctgtgtct cctggtggca cacagggcca ggctgtaagg ccagcgggac aagcgtgagg
41161
       aacagaaaca gtgccagcaa cacccccagg gccacagcac cactagcaga ccctgaaccc
41221
       cgcttgcctc cccccactta agggacccgt gtttcgtgtc cagtttcaga gatgttcttc
41281
       tettteecag gaaccagage cagegacteg tgaactatga ettggggega egeetteege
41341
       ctggctggtt tgcatctctg cggccagttt acgagatttc caccacgacc agctgaaaac
       actoctytcc gaccactycc ttccccaccy ccaccatycy ytctcaycac tcytyaaayt
41401
41461
       tggtgagaaa ttgagcccat atgccttcgg attgtttgca aaccctggca aggctctggt
41521
       aagtccaggc caatttctgg attaaattag aaatgaaaag aggaaaaata tctgaatcct
41581
       ggcatagaga gaaatcattc attcaaaaaa aacggtcgta gaacatactg tacagagaat
41641
       gttctcgtgc tgggaggggt caaaggttat agccgcgact gaaggcgcag aagatccttg
41701
       gattccacgt tctccatagg cctaggagcg tgtctgccct cagcagaaga gatgctttgg
41761
       gggeteagge atteteceag aacataagea gttaacacag etgggagaga etattetgea
41821
       tgcccggaaa cctgctcctc ctgctctgcc gttctacagc ggttaagaSc agttcattct
41881
       atcctttaaa aagaatcccc gaagtagcct caccggtcct ttgagctgat aaggctagtg
41941
       tgggggtggg ctggggtctg agcagcccac tgtgctcagt acttccctaa tacgtacacc
42001
       cacgtgcact gatgtagtga aaggcacatg ctcactttgg aggcctgggg ccatcacagc
42061
        tcaaggcagg cactaagcaa gtacatttet gcacagcetg gtagcaaaaa tteetttage
42121
       acctcatagt gaatgttctc agctttgtgg gccatatggt ttctgttgca actacccaac
42181
       ccactgttgt agcacaaaaa tggccacagg caattcataa atcaataggc gtggctgtgt
42241
        tecaataaaa etttatttae aaaaacaggt gaagggeeag gtggeeetgg ggeeagagtt
42301
       tgccaacaca gctttagaat ctccagttta ccttgacaaa ttcacgtgaa ttttgctttc
42361
       atgcaagtaa tacgtccaaa tttactttaa tgtaaaactg atgttttaaa atgcttacca
42421
       tccaaaaaag gggccacttc agggggagat gYcttacatc tgtctggtgg cctctggcag
42481
       gcctgagagt acgtgttcct ggtagcaata ggttgagcgc tggccttgct gcaggctggg
42541
        tatcacccac tgcaatggtc tgcctcctgt ctacaaggag tgcggtggga ccaggggctc
42601
       acaaagacag ttcaaggtct ttgtagatcc tgatatttaa gcaacacatt gaggccttag
42661
       gcttctcggg aagagtagga ttgaaattag cgctttagtg aaatgcttga agccacaaag
42721
       gaagetteag cettgggeee aagetttata tittettgaag tettggeaea gatagattit
42781
       acttttaaaa atgtatctgt agccaggcgt ggtggctcgt gcctgtgatc ccagctactc
       aggaagctga gacagcagga tcacttaagc ccaggtgatt gagtccacca tgcagcatag
42841
42901
       catgaacctg tetetaaaac aaatetttaa aaaatgagte aggeatgqtg qtqtqtgcet
42961
       gtagtcccag ctgcttggga ggctgaagtt tgaggctgca gtgagctatg attgcagcac
43021
        tacgetecag cetgggtgae tgagtgagae cetgteteaa aaaagaaaaa aatgeatata
```

43081			cggctctgat			
43141			tccctgtctg			
43201	acatctgagc	tgcctcctag	catggcagcc	tcgcctgtca	ggcccaagcc	cactctttag
43261	gggtgcccag	gcccacacac	atggccacag	catctggttt	gtgagcagag	actagcccag
43321	gcgctggcag	agcaagtttt	tgaaaatgtg	agaaatacca	aagccccagg	gtcagtatca
43381	ggcatgttca	gcaatgtcac	ctgtgtccca	gcctggcagc	acccagtact	tcagggagta
43441	tgtttcccaa	gcaggaaagg	tcaaacatga	cagtggtctc	ccaatgccct	cgggggcggg
43501	gggcgggcct	gggcagagga	gagcccctta	tcctcccggc	tgggcccagg	ggaggcagca
43561			gctgagccag			
43621			gtcactctgc			
43681			cacggctctc			
43741		_	tagacggggg		_	
43801		-	gctgagcctc			_
43861			gcgtgtgctc			
43921			tttgggaggc			
43981			catggtgaaa			
44041			cagtagtccc			
44101			ggttgcagtg			
44161	-		atctcaagga			
44221			ccgcccctg			
44281			cgcctgggcc			
44341			aacgggagtc			
44401			tatggggtct			
44461			tagatgacca			
44521						
44581			tgtcttgaag gggcaatgca			
					-	
44641			aggatcaggc			
44701 44761			cacggctggc			
			gaggtgaRcc		-	
44821			ctgggctgga			
44881			cctggccagg			
44941			tgggtgtgcc			
45001			ctcccctcgg			
45061			tctggctgtg			
45121			aaaatacaca			
45181			catttaaaat			
45241			ggttccaatt			
45301			gagagacaga			
45361			gcaccttcct			
45421			gagttactac			
45481			ttgcagcagc			
45541			ttgaattctc			
45601			gagagaatct			
45661			acctccgcct			
45721			caggcacgtg			
45781			atgttggcca			
45841			aaagtcctag			
45901			gagaaattca			
45961			aactggagct			
46021			gggagggcag			
46081			aagactgcag			
46141			cccaggcgga			
46201			tgacagacaa			
46261			caaatcccag			
46321			ttacaaatac			
46381			caacaaaaaa			
46441			gtgaggaggt			
46501			gagaacattc			
46561			tttcagcaac			
46621	atagattcaa	ctctatgaac	gtgatacagt	tagtggcatg	tctgacctct	aatggagaaa
46681	taagttttgc	tatgtgaata	tgtcatataa	ataataagtt	aggtaaaaag	tgtgtgacag
46741	tcatatggtg	cgatgttatg	caatcattaa	aacaacgtag	tagacaatta	actgctggga
46801						aaaatgtccc
46861	ggcacggtgg	ctcacgcctg	taatcccagc	actttggaag	gccaaggtgg	gtggtcacct

```
46921
       gaggtcagga gttcaagacc agcctggcca acatggtgaa accactgtct ttactaaaaa
46981
       tacaaaaaaa aaaaaaaaa aaaattagac ggccgtggtg gtgcatgcct gtaatcccag
47041
       ctactcagga ggctgaggca ggagaatcgt ttgaactcgg gaggaagagg ttgcagtgag
47101
       ccaagatcac accactgtac tccagcctgg gcgacagagt gagactctgt ctcacaataa
47161
       ataaataaat aaaataaatc atctgtgtta aatatggact atttcaataa accaaaaaac
47221
       atgettttet agatgtaagg aggaagataa gaaaactgga cecagcaggg getgetggag
47281
       tgggcaggtg ggtggttgcc taaaccaaaq agcccctttc tgtgcccagg tgqcctcatq
47341
       aagtgctcca tttccaagcc gcttcccttc tggcaagtct gagatgaaaa gggcagcttc
       atctttccca tagaaaaggg aatatcacgt cttgtcttta acatagacag gaagcagccc
47401
47461
       ctccagtgat ttccactgct cccggagcca caggcggctc ccctccacct ctggaaqact
47521
       geggeggeeg geettgeegg eecegactte eectacetgt geeecetget tgacaggeea
47581
       ggetgeetee attetteeag eeggeeeeat teetgeetea gggeettgge geegeetgee
47641
       coctoccca aacctggaac aggcgatocc tatoctacct officeacat cofficegttg
47701
       tegtgageet cWgeteeegt gatateteea gtgcaceage eeetgagetg tagaaagtgg
47761
       cotgectice ectaccette ticettetee atetectaae tattitatit etticatiqe
47821
       atttgtcatt atttgaaatg atcctgtttg tttttcactt cagtatcgtc tgtgcctccc
47881
       ttcccagaat gcaaggtagc agggttacgt cctgtcatgc tcacagctgc accccttgcc
47941
       tgacatataa tagacgcccc ataaacaccg gcccccgtat gaacggcagc caggggcacc
48001
       agacagagga ggatggctat gccgagaatc caccccatct cagcagctga acacaataca
48061
       ccgcacaccg tgtttcctta ctcacaccat ggcgcggggt gggtcgggag ggcccgagcc
48121
       tatgttgcag ctgtacctac tgggacacat ggcttccaag gtttccgtgg caggggagac
48181
       agagatggag gggactccaa gctcttacca gccttggtcc acaggtgacc caggtcactt
48241
       cettteacac aggecactag geaaaactgg ceatgeaget ceacaceage tacaagggag
48301
       actggggagg ggagcacagg ggtgatcgat gaggctgaac tgcctgtgcc acccctggac
48361
       cccatatccc agcccaggct ctgccacaaa gagatcccaa agggagctct gcaggcagaa
       gtcaccccaa atgatgaggg aaactgaggc agtgcagggc tgccagggtg gagctgtgcc
48421
48481
       tgcactcagc ctgccaccac ctcacctcct cctcagagec tgcattccct gggtccccac
48541
       catcagggcc cccaccagct cctcctccca gggctcgacg gcctttccca gggcacaggc
48601
       tgtgccacca ttctctgcat ccagttcagt gggcagctca ttgcccaggg ctggcccca
48661
       gaccccgggc tetggatgtg ccgttgccca gccccacctg etctacaget ccagacaaac
48721
       accteactgg gageceagte ecageegget getgecaegt etgteettee atgettttge
48781
       tttcgctcca gccacRggga gccctgtgac cagctgggac ttacaagagg agtgtgacaa
48841
       gccactggcc aggccttaga gggccacttg gggttgtggt tcgaggcccc catagcaccc
48901
       aagttcagag acagggcacg gtaggcagat cctctgtgca caggcccaac cctgccctgt
48961
       teageacage agetgeeage caeaetgegg ettecateca ggtgaaaatt aatecaaaca
49021
       aagtactctt cggggtggct accgtaaaaa agaaaaaaaa gacaagagtt ggtgacaatt
49081
       tggagagact agaatccctg tacactgttg gtggggggca aaatggcaca gccactgtgg
49141
       gaaacagcgt ggaaactcct caaaaaatta aagaaagaat taccctgtgt cccgcaattc
49201
       tacttatggg catatagtca agagaacgga aaacagagtc tggaacaccc acgttcacgg
49261
       cagcactatt cacagtagcc catgaggggg ccaccggagt gcccatggat ggctggataa
49321
       acaaaatgtg gccgatccac ccacacacgg gatactggtc ctccctgaaa aggaaggaca
       ttcttacaca tgctgcaatg tggatggccc cgaggatgtc atgctaagtg aaataagcca
49381
49441
       Sacacaaaag gacaattatt gtttgatcca cttatgcgag gtacccagag tagtcaaatt
49501
       49561
       gaaactcaat gggcacagtt tcaattttac aagatgaaga gWtctgtgga cggtggtggc
49621
       gatggtggcc cagccacatg aatgtgctta cgccaccgaa tcgcacgctt aaaaatggtg
49681
       aagacggtga cttatgttct gtatatttca ccgcaattaa aaKtttttaa attaaaattc
49741
       tettggaaca aataagaagt taaattaaaa atteagttet teaaggacae cageeacaet
49801
       tcaagtgctc cagagccccg gtggctactg ccccagaaag ggcgagacga gcatctcccc
49861
       agcacegegg gaagetetgt egcacageag ggetetggaa ggteaceett teteagaage
49921
       teccaettge teaatgeece teeteeceaa gaecaecaaa gggteegaea tagettagat
49981
       ctgtcctcag gactctccgg gcatgcagag gctctcagtg aggacgcagg gcattcatcg
50041
       tcagggcaaY gccatgctcc aggcacggcc gcgccttatc tccctcgccc acgctqcgct
50101
       ettgeagtgg gagetgggge teagateaga ggeagagaee eeeegetgae eeteegeege
50161
       cggtctccca Ygccccggga ctctctgcca cgccccgccg cctctgcagg acacccccac
50221
       tgtgcccatg acaagcacac tgtcaacacg tttgctgaat gaatcagtgc tcacttctgt
50281
       gcaacagggg acaacagaca cggcccaaat actttctcaa cttctgagac ttgtctccta
50341
       aaacggtttc tctgttgtga taaaactcat ctcaatttaa gaatttttaa atttctcatg
50401
       cttttctaga aacgaacctt cccattattc aaaatagggg gtacggctgg atcactaggg
50461
       tttgaataaa gttggaYggc aaaagtgaga gaacgttcta gacatcctcc aaccagctgt
50521
       tgtgacagag agaccetggg caccaggaga aaggttgate tgcetetgce agceteatga
50581
       aggacteacc acgggcccca catttggtca gcgcccttgg tgggctatca gaagtgaccc
50641
       ctcctggact gtcactaaac agtgccactg tcatgataac aaaaccacat tttatgtgga
50701
       aactgaaaac gtgttcaccc tactgagaga ctgaaaagca cattcactga cattatctca
```

```
50761
       tgtaatcaca tcaaccccca cgatgaaaac actggcccat tttacagatg agaaaacYaa
50821
       ggctcagagg acRggagcag cgttcccaac gacgcgcctg gaaaaggcga ggcctggagt
50881
       YRccategga etgtaattee aageecagte ettteecege tgggttggaa ggegacataa
50941
       tgctagggga agaactcata ttgtgaaggc agccaagatt ttatacctgc cagtctcaca
51001
       gacctagcat gaggacttcc caagataatt tagcatggca agtgcccagc atgggcccgg
51061
       cacagtcaca tagtaggggc tcgataatgt agccattatg gttttattgt tattattatt
51121
       attattatta ttattatttt tqaqacqqaq tctcqctctg tcactqaqqc taqaqtqcaq
51181
       tggtgcgate teageteact geaageteeg ecteecaggt teacgecatt eteetgeete
51241
       agcetectga gtagetggga etacaggege eegecaccae geeeggetaa ttttttgtat
51301
       ttttagtaga gacggggttt caccgtggtc tcgatctcct gacctcgtga tccgccacc
51361
       teggeeteee aaagtgetgg gattaYagge gtgageeace geaceeggee gttattatga
       ttattgcatt aaaggtacgt ttcaaaaata agatgagggt aagtgtgaca acgctctccc
51421
51481
       aaataaaacg aattetgeeg atgeagegga etteggeeee etgtaeggat aagRetggge
51541
       tccagaggc tagctgactc acccaagacc ggtcaagagg aaagtgagca tgaaggtggt
       gtctctgtcc agtgttcagc tcactcacat cccctcctgc ccctgaggta tcttttcacc
51601
51661
       agggccctgg ggactctgac ccatgtgtca gcttggctcc tggaggggct cacccctggt
51721
       ccgaaaagca gagctgggca gcagatcctg agcagacctg cacaccctgc tgcctgcctc
       tagcccggcc ccagaggacc tcattcatcc acaggtgtgg acacgcagca cggggttcta
51781
51841
       gaacttecca cetgecegge ttecacacca cetecagece tecetaagee ceggetteet
51901
       cccacaaata ccccctgcc cctagggccc cactggcagc atctcacatt ccaggccgtg
51961
       ccctggtcct ccttctcacc cccttctttt ccctgcagga ctcagccaag ccagtctgct
52021
       cccctgggag cctgcatttt gaagactgga cgcccctcat ccccacagtg gctctgacca
       catgaggcag agagaggaaa ggtctgcaca gcctccaccc acacacggtt cagcatcctg
52081
52141
       gcacctcctg cttaggttgt tgggggtatg gaatgagggg gaggtggttc tttaatctct
52201
       tagtgttagg cagaccatgg gcaggtgccc agaagacgaa ggtggcacat agacacccct
52261
       ttcaatagcc cagactcaca gggagaaagg aattccctcc ccaattcctc ccactgYgag
52321
       ctttaaggag gggccctggg ttggtgtctg gccctcgctc taatgcaYgt gaatctctac
52381
       tttaaacaga aaaggggctt ctgtttggag cgagaagaag gcagggctat ccagctgggg
52441
       ctgaataacg tcactttatg tcttactatt atattagctt ttcaggtaaa ataaggttgc
52501
       ctttttaaat gattttagtt ttaaaagtgg caaacatcaa gaaaacatat ttttcaaatg
52561
       acgggacatt gaatgacatt gtcattcaaa cgactggagt ttgcacaaac ccgccttagc
52621
       ctgtgaagag cctcaccaag ttaccatcac ccacgatgtg cagacgagag aactgaggtc
52681
       agggatggtc aacttgtctc acctggggac ccagcaagcc tccctgagac tgtgtcactc
52741
       acctccggct aacaaggaaa tcggcagagc ctcaggggac ctggcccagc tgggcctctc
52801
       tggcctgccc agcccctggt tgaccctccc cgccccaccc tgccccctca gccaccccac
52861
       teacaatgtt catgagtgte ageaggtaet tetgtaegtg eteetteeeg tggaaetgea
52921
       ccacagagtc atccacgccc agcaggacct cgatgttgta gtcatcgtcY gcagcatgcc
52981
       tgegtgeeet eegeetegag etgttggegt geteetetag gaYgeeeagg gegeggetga
53041
       ggctgtccag gctgtccagg gaggcccctg caaggagagg acaccgtctt cagcggcagg
53101
       gcaaacccac ccggacacaa acctaccagg cgccagcttg gccatcctct catttaaaac
53161
       tcatagcacc ctgaaccgag ggtattattc cattttacag aggaaagcga ggtgcagagg
53221
       aagatggcag agacttgcca agctgtctca gacacagcag ggcccagaca ggcacctctg
53281
       tgacttccag gaccgctcgt tccccagccc ctggtggcaa ccccagccac agcagggcc
53341
       acagtggcct ccacaYgatg gatcagacct gctgagactg tgagagaccc agcccagcat
       caccgtctgc cttatggagc ccagggctgg cattcagcca tggagaggtc gggaacctca
53401
53461
       gcccgcactg cctgacgctg gagtgggcag agccacccct tgcccacact gcccgatgct
53521
       ggagtgggta gagccacctc ttctcccccg aagggctgcc aggtgccaaa ggactggtgt
53581
       cccaggtgtc atcgccagct gttatgactg gggaaaccga ggcccatcct gggctgtgca
53641
       tgttccccag tgtctccttg ggccctccc agaactttct gctaagtcct ccactgaagc
       gaggececae atetetggge caggteeegg geceeeteee caggtgaacg gtacegeete
53701
53761
       tggcctgatt gaattgtgca gagaccaaga tgaacccctc tgtggcagct ccgctgcagt
53821
       eggeeetggg caggeactga cetectgeee ecagggtgtg eceetggeea ettggggetg
       cMatcctggg gagtctgccc cggatatcgt ccctgccttc tgtgcagtgc tgtctctgct
53881
53941
       gtgttctgtg tcctgcgggc ctggagacca ccctggacca ggcttcagtt cccagccctc
54001
       cactgcccgt ctgaaggcca cagcaaggct ggccaggctg acctgcagca tcgatggcag
54061
       ccccagacca cactgcccac cgcccccaa gccccagtgt cctggaagcc ccctttccct
54121
       tgcactggtc tctgtgtcta agccaggtcc cagccccagg gtctccatgg cattccccag
54181
       geaggteete agagaeteet ggeeegggae agaeeeaggg etgeaggtea tegtgaeate
54241
       actgacccac agggcggtgg ccaggccccg aggcccctgc agctgaggga gaccagcgtc
54301
       cctgctgcac cacctctcta caaagagtct tccagaacaa cacttttcac ccccaacgcc
54361
       teteteetge tgeetettee aggeagggae aggeaeteee teeetgtgag ggtggeecag
54421
       gacaggeeet ggaggeagaa caaggeeeet geaggeggea eggeeaeteg gacagtgagg
54481
       cagectggta ccaggeete ateceggeae acgetteete acceagtget gacageagge
54541
       cacteggtgg acRtggccat ttccgtttta cagatgggga gacccatggc atcccagcat
```

```
ggccgactct cggccagaag ctctctcctt gcaccctgca gcctggctca gacaagacag
54601
54661
       actgaacatg aaqtttcaqq cacaaacctg cagcccggct gtqqqcaaga ccaaqacaqa
54721
       cagtggaggt gcgaggcgga gggtgagggc tgggaaagag aagaggagta agtggggcca
54781
       gggctgagca gctgctgggg ttccagtacc ttcgggggtc cttgtgccac ccccagctcc
54841
       acagttetgt gteceetegg egeacacaca catgeacaca cacacacatg cacacacatg
54901
       tacacacaca caagcacaca catgcacaca catgtacaca cacaggcaca cacacatgca
54961
       tgtacacagc aaggactttc cagggccact ccagggacag gggtggggcc ggcaggcctg
55021
       egggeaggge tgtggggage egageagtee acttagetge etggatgaet eagggeeate
55081
       catgccgttc ccagaggaag cgccagcaac tcaagcctga caggggggtt gaggaatcgc
       cactetattt ttgtacattt atttetttge atttecaaeg aacagagaca geteacette
55141
55201
       agaatcacct tgggaaggag agtgatggca atttccatag gaaaactctt cctccctqqq
55261
       gaacaggccg ggcgttaccc tctgcccttg tcaaactagg ggtcacacac gggcggtgcc
55321
       ctcggcaaaa ccagaccaca gaggcactcg ttgaggtcac gtggtgccat ctggttgata
55381
       gtatttgaaa actgggagat ttcatgtttt aaaaatctag aacatccagc ttctcttgag
55441
       gaattaagag atggggccac cccaggggta gcccKggtct gtgaattgag gggccacacc
55501
       tggagacaaa acacacaggg cttggctcaY caggccacct gcctgccact gtcaatgtca
55561
       ttctggcacc agaaggtatc acagtatgtc ctcctggccc taaccccaga gtccccatgc
55621
       agggacccct ccagacattc cccgtaggag ggcatgggtg ccgcatcggg acagagctgg
       gctggggcac Rtcttgaggc tgcttctgcc gagcaggcag agtttttaac taaactgtgt
55681
55741
       gttgcaagcc cattaaaaac agcaaaggtt tctaaagatt tagaatctga atttcacctg
55801
       aaatggaatt attattgttg ccatcattat tttaatcgtg ataatttKgg ggtgaaattt
       ggaaattatg ttctagagSa tccctccacc caggaccagt gcctagagag acggcccaag
55861
55921
       gcccaaaggc aaagtgggtg aggagaggaa gacaggggcc tgggccacct ggcaggtgac
55981
       agecacgece tgegtetgge ceetggaage etcagtggtg etcaggetgg acaggacaag
56041
       gggagaagcc ctaagagcag ggggatctgc aatgccctca gacctggggc aacaggagct
56101
       ctggcccagc cccctcctg tcctcctctg tcccaacaag acccggcagt caggctgaag
56161
       ccccagcttg tcaatcacga gtgccacctc agttttcccc acaataagat tgaccctgac
56221
       cctgtcaatc acgagtgcca cctcagtttt tcccacattg ggcttaaccc aggccatgaa
56281
       gagactetga ceacatgetg gecettgeag acetgYtece caaatagage ettgetatag
       ggagctctgg ccagtgggcc tggcgtggtc ctgagtcgtc ttcctagtga tccctttgaa
56341
56401
       gtcaaccttg gccttgggcc tgcccacctg cactggttgc ctacctggtc taacagcccc
56461
       tgttccactt ggtccctcca aggcagaaga gggctatttg ctgctctccc ctcctccct
56521
       gggagetece tgtgtagece ageeetgetg agetgtggtg aetgggaget cacacageet
56581
       ctgctgtatc cctcggcact caccccgcct ggatgagtga tcagcgcacc catctcctgc
56641
       56701
       aagaaggcac tgggccccct gggggtgctg attgaccaag ccccagaagt catacccagg
56761
       tgggctgcag ctaccctgaa gggaggtgtc tgtggcagga tcccatcttt taaataggta
       acacagaget ttcgagttcc tggcattccc tgtgctcagg gccccttttg gatggcaget
56821
56881
       ggagatetet ttgeteacat egtggeeaaa Kaatgaeact gtgggaagea etecagagee
56941
       atcctgtttt agagtctcta gaatggaaca aaaagactct atcgaagagt caatcaataa
57001
       acagggagag gatggaatga ggggaggcag cagttctgtc cagggaattc catcagggga
57061
       acgggtgggt cacagtagcc acgggctcat ccacagtgcc acagtgcaca gggcacgtgg
57121
       gcaagggctg caactgccag catcctaggc acaccccgag tctccaggca ggggtgtgtg
57181
       cacagecett cacagtggca getecatace eccageagee atecaatece etegecaagg
57241
       tggaggcgtg tcaccatcag catatcgtcc tatttcagca tcagggaaac aaaccaagga
57301
       gcaggaaaat tacatgactY ggacaagcca caccaccaga gaggaggagt gggcacgcgc
57361
       ccaggcctct gagtccaacg ttgtccacat Rcccggagcc cttctgtact tcaccagcac
57421
       tgaggggtga tttgcgRgaa tgagaattgt agaaacaagt atgattagac tagagaaSag
57481
       aaaacctggg actgagtctR caacctcggg agcatcgtgg gatggtgcgg gctctgaggg
57541
       tgggtacagt gggcaggtgt gggatctgtg ggcaggtgca gtgggcaggc acgggctctg
57601
       tgggcaggtg tgggctctga aggcaggtgc agtgagcagg cgtgggccct gaaggcaggt
57661
       gcagtgagca ggtgtgggcc ctgagggtgg gttcagtggg cacgtgtggg ccctgagggc
57721
       gggtgcagtg ggcaggcatg ggctctgtgg gcaggtgtgg gctctgaagg caggtgcagt
57781
       gggcaggcgt gggccctgag ggtgggttca gtgggcacgt gtgggccctg agggcgggtg
57841
       cagtgggcag gcacgggctt tgtgggcagg tgtgggctcc gaaggcaggt gcagtgagca
57901
       ggcgtgggtc ctgagggcag gtgcagtggg caggcgtggg ccctgagggt gggttcagtg
57961
       ggcaggtgtg ggccctgagg gcgggtgcag tgggcaggtg tgggccctga gggcgggtgc
58021
       agtgggcagg tgtgggccct gagggcgggt gcagtgggca ggtgtgggcc ctgagggcgg
58081
       gtgcagtggg caggtgtggg cctgagggcg ggtgcagtgg gcaggtgtgg gctgagggca
58141
       agtgcagtgg gcaggtgtgg gctctgaggt caggcagggg ctttgcagtg ctaagggtgg
58201
       ctgggtgttc gctgtcccct gtgcgaagct cagtcctatg ccttttctgg gctggcctct
58261
       tcacctgcga tgcccttttt gctgctgccq ctgtgctggc caaatttagg ccccctgaaa
58321
       gacccagaag gaagggagcc cgctgcctcc catgggactc agagctcttg aaagacagga
58381
       gcatgttctg cccccatctg cctcctgcac agccacactg cgtgccacta ggggacgaca
```

```
58441
       gggacagggg ccggggcagg gatgcttaaa acctgaggac cacactgttc agtgacacqq
58501
       ecgactgetg teceetetee atgggatgge egeeceetea ttgetetett eetteaggtg
58561
       tctgctgaaa tgtcagctcc taagggagaa ctttccttat ttcatcccaa attgaaatca
58621
       geceteeest gattteteee gacageacee egtgetette etteetgtga cactecactg
58681
       caggcaggtc ttgtctcatt tgtgaatttg cctgggcatt aactgacttt ccctctcaga
58741
       tagagaaccc tgggggatgg agaccatggg gtctggtgtg cctcagtgtc cccagtgccc
58801
       cacaggtaac cgcagggctq tqaqqqqcct qqaqccatqq caqaqaqqtq ctctqqqaac
58861
       agagggccca gcagaggcga gctgggggcc tctggggagt tgggaactgg gatagaagga
58921
       gaggcaggtg cagcagggcc ggaggggcca cactgggggt ggggagccga gaacaggagc
58981
       aaaagtgtgg tggcagttgg agaagcatga gatggaacaa aatccagcta caaattactt
59041
       gcatatggca taaccaagtc caaatgacca ggaggagtta aaacaagtgg ggcaaaqaaa
59101
       cgtaccatgt Mattgccaac caaggcattt aaggagataa actgataaaa caaacaactc
59161
       atggaaaaaa atacaaaaga tacgaaactt tatgctccta aagcttcaac ctggtgcaag
59221
       gaaggagaga caaggccaca gtgataggag cactgtaata catttattcc agacaagtct
59281
       gatacagcat taggtaggga tagaaactat ttgaattaat aggaaaacct aaYqttcaaa
59341
       cccaacagcc agaacacgtg accttgtcaa gcacacagg gagaagttcc acattttacc
59401
       acattaggac acaactcaaa aactcaaaag ccgtgcccac agtcaccatt actgagacac
59461
       attaggacac aactcaaaag ccqtqcccac aqtcaccatt actqaqacac attaqqacac
59521
       aactcaaaaa tcgtgctcac agtcaccatt actgagacac attaggacac aactcaaaaa
59581
       tcgtgcccac agtcaccatt actgagacac attaggacac aactcaaaag ccgtgcccac
59641
       aatcaccatt actgagacaa aatcagagat aacaataaaa ccctaaaccc taaacatctq
59701
       aaattaaaag caccRttcta ataggcctag actaaataga aaatatacat tccactcatg
59761
       gctcaagtag aaaacctgaa gaaaccaata acctcagaag aaaYtgaaag agcagtcaaa
59821
       gaaatgette catagaagag tttaaccaaa Yecacaagga acagataete etcateteac
59881
       ataaaataat gcaaagatca agacttcttg aacataggaa taacccgcRa gaaagcagag
59941
       tggaaaaaag agcttatcag ctataacagc aaaactccca agtatctaag aacaaacaaa
60001
       aactaatgaa tgttcaacga ctacacaaaa agtagtataa tatagtctaa gRtctccaaa
60061
       aacacaaaag aagacetcag taaatgaage tacatggaca taateetgga etggaagttg
60121
       gtcctcctcc aaatgaatca agaaatttgg cataatctcc atcaaataat tgttaaaata
60181
       attgttaaaa ttattctccg tcaaataatc tccgtcgaat aattgttaaa attattctcY
60241
       gtcaaataat ctccgtcgaa taattgttaa aataattgtt aaaattattc tccgccaaat
60301
       aatctccatc aaataattgt taaaacccaa caaagtgatt ccaacattca tccggaagMc
60361
       cacaccagac agaaaaataa Ygaaaaagaa tgacaatgag gaggcatatt tttttcaaat
60421
       taatgcagtg tattataaaa taatattaat gaaaaYgtag ttgtgtcaat gtcatgaaag
60481
       aaacagatca atggagctga ataaaacttc caaaaacagg ctgggtgcag tggctcacgc
60541
       ctgtaattcc agtactttgg gaggccgagg cgggtggatc acctgaggtt gggagtttga
60601
       gaccagcctg accaatatgg agaaacccta tctctactaa aaatacaaaa ttagctgggc
60661
       atggtggtgc atgcctgtaa tcccagctac tcgggaggct gaggcaggag aatcgcttga
60721
       accSgggagg cggaggctgt ggtaagctga gatcacgcca ttgcactcca gcctgagcaa
60781
       60841
       ccaagaatat gtggggtttc caggttaaaa tggcRgattg aacacagata tctgatttgg
60901
       ctcctttcta gaatcccatt aaaagttcag taaagaaatt taaaaaaaat ttaaagtcac
60961
       aagcctcYaa ggataggSag agcaggaggg gaagaaaYaa caagggaact gtgggaggct
61021
       ggaaacagat gggcaagtgg taacagactt ggtacatcaa gaaagctgaa tcccaggctg
       gccatgaaga cagccacatt ctacaaagtc tcccggagaa taagaagggg gaaaatcagg
61081
61141
       ttacaggaga ggtcatagac aaagaattgg aatcagaatg actcagagtt ctcaaaagca
61201
       gcattcgatg caggaaaaca gtggaggaaa gccttcagaa ttctgaagga aaatgattgt
61261
       ccaactggaa ttctgcatcc agacacattc cccatcaagt atgaaagtgg aataaggaca
61321
       tttctagaca tgtcagttct caaaagattt atgtgacaag cactcctctc aagaagctac
61381
       tgaaaggtgt gcaccatcaa aaacaaaaaa ggcaacaaag aaagagtaag acacagatat
61441
       agaaaacgga agcccaacac agatagagaa aacgggagcc caacacagaa gacatggcct
61501
       gggaggccca tggagggtgg cgagaagtga ccctgaggtg atggctctgc accagaYgtg
       gagagcgact gagccatact gagcagcgtg acccacgggg tgaactgtct tcaccaagac
61561
61621
       cccacctcca tcaggccatc tgtagcccgg ggacaaaatg cccaggagag cctggcctag
61681
       gttcttggca gtacttggct tggccatgtg ccgatgaggg gcgctcccct cctctgctga
61741
       ggacgcacaa cattcacaga agtttccagc tttcccccca ccgagagctg gaggcaggcc
61801
       gtggcgagct tagaagcagg acgtacaggt cagcccctc cctctgaccg tatttccgct
61861
       gcaggtccag cgcgtggtcc ccacctgggc cctaccaggt gcctgactgt gctgagccca
       agacttcctc gagaccttgc tcacgacttc cccaggaggg gccttgtcag ttcccggaga
61921
61981
       agcagaagtc agaccacgac ctggagactg atctgctcac ctccgggagc ctccatccag
       cgggggcagt gccgccctct ccttacactg ccagcgtgtg ccagctctcc Rctttaatat
62041
62101
       taatcgtctt tgatattcat ttgcatgtaa ttataaatag ttgctcaagt agcaatacag
62161
       tgaataaaat tagtaaatga tacaggtagc aaacggtgct aggaaacggc ggaggtggag
       caggagggga caacctggca gtctggcact actgagggga tcatgaggaa gagcaccatg
62221
```

```
eggeteatat eetaaagata eaggatgtet ateggatage eeagtgeeet eettggaetg
62341
       accettggce catgggecat tgtteggece catggaetgg ettgeagatg ggeaaaettg
62401
       cacaggtctg taaggaggca atggggagct gccccttgca gcattgcttg ggtggagtga
62461
       ggggagctgg aaacaacacg ggggtcatca gtgggtgaga ggagaagcaa atgtggtggg
62521
       ggcatcccac aaagtgctac caaggttaga agtttgatat ctacatagat ggatggatct
62581
       taaaaacaga gtgccaagtg caaaaggtaa gaaacagaat gagacacaat tcagagcgac
62641
       ttacRtaaat tatggataca cagacgcaag acagcaacac tcatgttgca aaaatgtaca
62701
       ctaaggaaag gatacggttt gatcacctga aatggttgct cactgcagga gaaaatcaga
62761
       aggaagagag caggctgggg agataaatgg cttttgtttc tttctttgtt ttaatgatgt
62821
       taggacaact ggttagaggg aggaaaaggt caaattttga cctcatgcct taagcaaaaa
62881
       cagattccaa gtggatgaga tgatcaaaag gaagtcatgg aagtgctaga agaaaatgta
62941
       gcKaggcacc tttttatcat cttgctgttg ggcgggcttt gggttccaag cctagggctc
63001
       tttcccagcc ctctccttag ctgccccatc ccctgtgagc agtttcccac tctgctggac
63061
       tctgctggct gaatgcaagg gcagatggca cacttgctag gggatggtgt gagggggat
63121
       gggcacactc Wctaggggat ggcgMaaggg ggggatgggc acactcacta ggggatggcc
       tgagggcaga caggcacact cactaggtag gggatggcct gagggcagac ggcacactca
63181
63241
       ctaggtaggg gatggcctga gggcagacgg cacactcact gaggcacctg cacacagaca
63301
       gaggtgctgt gctactgcct caacctgcca accatgtgga tgggaacaag tcatcctttt
63361
       tccagtgctt aggagtcccc aaaacgtaag tcctaatgac cgcccYgcag agccagaact
63421
       gccacaStgc ccagaagagg agagggaggc tcagggaatt agactaaggc catgatgttg
63481
       gcaaatggcc aggccagaat gccagcccag ttcctgcaca caagcactgc cagggcctgc
63541
       aggggccacc accRggctca ggaggaccaa agcctggagc accagcagcc tctcctccaa
63601
       catgaggagc cccacccagg ggaggtcaac gggaacaagg tcatcccctc catttcttac
63661
       Yaaccaagag agagtcgctc tgtggctgtg tattccccta aagataatca ttaagatgaa
63721
       atatgtttat gtggaagtgt aatcaggaca cagcagaaag ccctgcttgg aagcaggcag
63781
       getetttgga ggetetggga ageagaagge aggeteagee eeaeggggge cateageaca
63841
       gagccccact ggtgtacttt attaaaagat gctcattagg attattacat cccaqccctt
63901
       tataacttta ttactgactt tgaattaatt tttgcaactt caacagacac agctcatcca
63961
       atgccatttt tatgacctga ggtggatcgg agggtgggga ggggctcctg gggccggcct
64021
       ggccatcagg agcgcatcag gaaccgctgt gccgaatctc aggggcagtc ctgacagttc
64081
       tctaaactcc caYgggatgg gctgccccgc ggacagatgg acgctccagc ccaggcctgc
64141
       teageeteag ceRtgettea gggagaaaaa ggaageaeta aaggagagaa ggeeteteeg
64201
       ggccagtcct cagaacatac ccccgcacag cagaggacaa aggacacccc tcagtggtgg
       acacagaagg teetggeetg eccageacet geacaceete acagageeac etggggttge
64261
64321
       acagcacggt ggcctgccct gtctggccat tacacctttt ctgctagtaa accaccctcc
64381
       cctatttgca ccccatatgg ctcatgggSa gccaatccca ctgcacccca gctccaggag
64441
       tgcccaaggg gtcctgttag gccactggaa cctgatgctg tgtgttggtg tgcacaggaa
64501
       gactecegtg ettteetete tgetgggaaa atgtgaetet gggRetgeta agtaeeteet
64561
       tcccccagga gcagcagagg cgagagatga gggcagcccc gtgtgctgct gacactgttc
64621
       aggtccccaa atccagctat ggctgaaggt gatgcacccc tggacatcct aattcttcag
64681
       gtcaattcat ttagctctct gtctcttgca accacgagag tcctgtgtgc ccttacaaac
64741
       acagacacag ccaaatgtgc tggcctgaga gagacaccat ggtttggctt tgcagccaca
64801
       getetettga acgattgagg catcagacca ggccactete ttetgecetg tgeetgeace
64861
       teccagtgtg gggegaggag aaggtetgea gtatttaagg tetatgacea gaaaagggge
       caggetetgg teeggeteec agatacgtgt cettgggaaa tggtgeecag cagaggtgtg
64921
64981
       aggetgetga ggttgageee aageeageag ggeeatgetg agtgaeeage agetgtgega
65041
       gcccctctga ggtgtcctgc agcagggctg gggcttcctg tctacagccc tcacagaggt
65101
       teceaaacac aactteceee tetteaceee agggetgggg ceteetgtet acageeecea
65161
       cagaggttcc caaacacaac ttccccttcg tccccccagc acccgccgaa ctaccgaggc
       tectetgeae etgeceegtg ceacteteca geggeeYetg eageceacte aceteeaagg
65221
       attcacgggg gtctcggggc cttcagaggc tggggcgggt gacaagagcc agcaagccct
65281
65341
       gcccctgcct agcatctgct taagccaggg agggtcccca ggactcacca cagcccccag
65401
       ggctccaagc cttccctctg ctgggcagtt ggcccaggga aggggagctg gcctgggtaa
65461
       tgtcacgggg gcaccgcagc acgcggcagc caagtggtgg gggccgatgg agaggccggc
65521
       aggtetttta ttgaaaatat teaetgtgaa etteagaaca aaacgaagat eeccaegggt
65581
       cccaaaggaa gggagaattc ccaggggttg tgttctgaac gcagaRgagg tgggggccgg
65641
       caagtggggt gctgacagcc agtgccacgg gacccatgtg gccggaggct tggccagtgg
65701
       ctcagcagat gacaggegga aaatccctgt caccagtcYg gtacatgctc cagagcccct
65761
       gatttggaca tcatctggaa gcctggcatt gctccccgga aggcctcagg tacctcacac
65821
       tcagaaggtc cagggcctgc tgcctcctct gcccgcacgt gcacctccgg ctgcactgcc
       agetgeateg tecacetagg gagtggggee egeatgeage eaggteeatg ceaggageag
65881
65941
       aacctgcctc tcccctccc tcaaaggcag ctccctcctc actcctcaqq qtctctqqaa
66001
       cctacccctc cacgetetat gccetetgta etgeccaege teetgactee ageageatet
66061
       gegeeteece catetetgea etetteaaat ceaagtteea aggeatttet ttacetgeea
```

66121	acctcagttt	cccttgttgt	ggccttcacg	tcctttgatg	ttgagccctg	cgttcatgca
66181	gggtgggcgt	gggccctgca	ggggtgaggt	cctggtcccc	tgggaagagc	ttgcagccaa
66241	cacaagcggg	aggtctcaga	tgctgcccga	ccctgtgcaa	atgaggccct	ctcctacccg
66301	gccatgagcc	acgtgcaggg	actcagcacc	tgcctctgct	ccctcctcct	tcctgacccc
66361	tctaggtcag	gagtccaggc	acacagcagt	gYtggggtgc	tgcagccaag	cacaggctct
66421	tcctagctga	ttgtgggacc	tggggcagcc	ctgcacggtg	ggccacactg	tgccaccaag
66481	ctgccttcct	aggaggaaga	gttcctcaga	tgcccaggca	ccagggactt	cacacacctc
66541			ccggtggagt			
66601			caacaggcac			
66661			atggcccatg			
66721			gccctggccc			
66781			ccccacttt			
66841			gcaggagtga			
66901			aagggtggtg			
66961			acgctcccat			
67021			gccaggctcc			
67081			acgccccct			
67141			gtgtcaggga			-
67201			cctctgctcc			
67261			tctcctgtcc			
67321			aatcccaagg			
67381			agcccagagg			
67441			gtgtgaactc			
67501			accccacaca			
67561			gagggaaggg			
67621	_		aatttgatca	_		-
67681			ctgaaaattt			
67741			gcagggatgc	-		
67801			ggccaccctg			
67861			aacactgcaa			
67921			atcctaattc			
67981			cttccaggta			
68041			ctctggcctg			
68101			tggctgccat			
68161			caagtctggc			
68221			cagggcagga			
68281			cctcccctg			
68341			ctgccctggg			
68401			accttcattt			
68461			catttgccag			
68521			ggctggcctg			
68581			catacacaca			
68641			tacacacatg			
68701			caaacacgca			
68761			cacacgaacg			
68821			cacactcaca			
68881			tgcactcaca			
68941			catactcaca			
69001			cacatgaatg			
69061	-	-	ttcatcacat			_
69121			gcatgtcaca			
69181			aaacgtgcac			-
69241			gacccctctc			
69301			gccaaaaacg			
69361			gtggagacag			
69421			ccttggtggg			
69481			agggagagca			
69541			agccatgcgg			
69601			atggctcccg			
69661			aggcctcaca			
69721			gctaggctgg			
69781			tgttgaacag			
69841			tggagcatgc			
69901	ctcttcactc	agaaatattt	tgctcccRtg	agaaaagggg	tatagacea	gggatgagag
32201	ccccaccy	Lyanacact	- socceeding	-gadaageea	-araaacaaa	22200200

```
ggcacactgc ctccagccca aggtggccag tggtgactag gagggtgcag gtccatgttg
70021
       ctgggtctta tttttgtaag gaagtgagaa atctggattt gcatgtgaag tctctgatct
70081
       ctaaatactg gcaaaaagca atttaagaat aatgtaggtg ctgtgctgct tgtgaaatga
70141
       accaaagctg ggtccccagg tctgtctgcc acctcagctc cacgcccaga ccaaagctgt
70201
       gteeteaggt etgtetgeea ceteggetee aegeeetgag caacegttte eetgtateet
70261
       cctccgtctg gcctggagag gttttgagca cagtaggttc tggccaacca gagtgagtcc
70321
       acctgcctct gcctcacagt ggctgaagct tcccgggccg cagttcacgc cccacttgtt
70381
       tetecacate cettteecac ettgaaggae ageteetgat ggatgtgttt tatggtggaa
70441
       tecteaegea ggggeetgag gaacaeteee tggttateea caeggeaact aacaeteage
70501
       acqcaccagg ctcctcctcc ctctcatqga ctctcaattc agccccRcac agccaaqqqc
70561
       teacceacat catgtgeget teagacaaag gactaattte ettaatacat aaagegetet
       tacaaatcaa caRgaaacaa tccagcaatc caaaagggaa atggacaaac ggtattgata
70621
70681
       caaaagtgct gggtagagaa gggcatgctc cctttaaatg atatggaagc agggaagtgc
70741
       atggtccctg gctaagggct ccaccctcac ggacctatgt gaggacaggc actcttgcct
70801
       ttgtgcccaa atgtcacatt teccaagaee accetggtee accatgteee cateetgtge
70861
       ctataaaaac ccgagaccct aacaggcaga cacaggcggc tggacgtcga gaggagcgca
70921
       tgaggggagg aacacagg cggctggacg tcgagaggaa cgcaccaacg agcaccagca
70981
       cgctgcaggc caccgaccgg cagaagcaga acgacacgga gtttggccgg ggcagtcaga
71041
       ggagagecca ggetgettag eggeeegaet eeagggaaag eeetttgeae eeeateetee
71101
       ttctggcttc ccccatctgc tgagagctac ttccactcaa taaaacctcg cactcattct
71161
       ccaagcccac gtgtgatctg attcttccag gacatcaagg aagaacccga gatacagaaa
71221
       gccctctgtc cttgcgacaa ggtagagggt ctaactgagc tggttaacac aagccgccta
71281
       cagacageta aagtaaaaga gcacatgcag cacacgccca ctggggcttc aggggctgca
71341
       aacattcacc cctagacact gctgtggggt cggagcccca cagcctgccc gtctgtattc
71401
       tececeagag gtttgageag agggaeactg aagaaggaag ceaeaceee atageaegee
71461
       ctgcgaggag gacaagagaa cttctctcat ttcaatatga ggggacaatt gtcagaaaag
71521
       aaaagacagc agcttttctt ttcttcttta tctctttctt tctttccctt ccttctttcc
71581
       71641
       gagacagagt ctctgtcacc caggctggag tacagtggcg tgatctcagc tcactgcaac
71701
       caccycctcc cygattcaag cagttttcct gcctcagcct tccaagcagc tgggattaca
71761
       ggtgcctgct atcatacctg gttaattttt ttttttttt gtatKtttag tagagacagg
71821
       atttcaccat gttagccagg ctggtttcaa actcctgacc tcaggtgatc catccaccct
71881
       ggcctcccac agtgttggta ttacgggtat gagccaccga gcagcttttc agtgtatgag
71941
       aagacgctcg acctcaccct taattaaaga aacaacctgc atcagattgt ccaaataaaa
72001
       atgtacggat caggggtaca tgctgagaga aacggatcca gccaaccatc ctagggttgt
72061
       ggtcatcctt atcaaagttg aaaatgcaca aaccttttga atccacaatt ctagttatca
72121
       aatttaatcc tacaaatgtc ctcatacaag tagccaagga aataagtgta aggatatcca
72181
       Sggctgcatt ataagaaacR gtgaaaagaa gtaacgtccc catcagtcaa ggtctggtta
72241
       agcaagtgat tcacaggatg gaatgcctga gcaggaggaa tgggcaggtc tggaggggct
72301
       gctgtggacg acgtccaaga catgttccct gataatcgca aatgcagggt agcacacggt
72361
       gtagtetaca gtgtgcagga aaaagtcaga aaaacgaaaa cacagtatet acaggacaca
72421
       aaatcccttg agccagagat tctaatccta ggatttatat atgtgtgtgt acaNatgtgt
72481
       atatatatat acttgtgtgt gcacaggaca tcctgaaagg acacagaaga aaggtgtgca
72541
       gtggctgccc tgcagaaagg agctgaSttc caggacagcc aatgggaggg ggatgaggac
72601
       agcaatgagc atttcatatg gctgcaatcc ttagtccagc caaaaagcaa gccacgcaca
72661
       tgcaggagag gccaggactc tcccagcagc tcccccaggg gtcaggggca gagggagccc
72721
       ccagcctggc ctgctccctg acgactctac acttggcagc tgaagggggc caccctgaca
72781
       gtcaaggccc agctgtgatc tggggtggaa ctggtctggc accgatctgc ttggcctggc
72841
       tctgggtgct ggcacggcag tatctggtgg gctgcagggc ccccagctgg ggccctttga
72901
       gtgatgatga gcctgctggg ctgggaccac agagtgagca ggaccagcat cccctcaacc
72961
       ccagatgccc tcYaggactg cagggcccag acacagagag ggaacctgac gctcatgggg
73021
       agggctgaga ggcaggcaga gggggaaggg tgttcctgac cacggcccac aggaccagca
73081
       gtgcagaggg cctgggagtg agggaagccc ctgctgtgcc aaggagggag ggccaggaga
73141
       ggagagatgg ccgaggccgg gaggaggca gaagtgcaga gagactagag ggggcagggc
73201
       agccctggct tggggctgga gagggagcca ggaaggagg tggaaggcag gggaggcagc
73261
       gtgtggacaa agactgagag ggggagtcac agcttgggtg cagaaagtgg ggccagggag
73321
       gattccgggt ttctgacctg ggcaaccggt caccctggga agccttccct gcaagggacc
73381
       ctcgggagga gccgcgtggg aggaggagaa ggccgtgtgg ggcgtgttgg gctgagattt
73441
       ctgtggggac acaaggacag acacccaYga gacactcagg caggagtggt ctggagcaca
73501
       gagagaggt gggccggagg ccccaggtgt gggcggcctc caggatgaat cagctgcaga
73561
       gcaccgcagt ggcgcacaca gatcagtgtc ctgatctgaa aagtaggcat aacgatgctg
73621
       gccacagccc acaagtaaga cacatagaaa acctgaggcc cacagaggtg acaggaacgg
73681
       gccaggtgca cggacagggc tgttcctgac tcagctcact ccaccagaac ccagtctggg
73741
       caccageetg ttttettgte etetecagee ageagggeag aattgggggt ggaettgeee
```

```
73801
       cagcctgaag acctcegggg ccctggctcc tccctgctcc acctgccata gcccaaaacc
73861
       agtgtgggtg tgaaqcqqaa qqagactcYg cagcaaggcc cagctcttat gccggccact
73921
       gccttgcctc ctgcctgatg cagtctctcg gcagcaaggc aggtgccctg agacctggag
73981
       gtgcccccag ccccagaacc caccatgcgc ggctgggccg actgtgcctg cccttaaggc
74041
       aggcagaaca ctaaccaaag ccagcggaca tccactgcct gcggagcatc tggggaaggc
74101
       tectgtgggg etecagaece ggggeggtge etteaceaeg geeteeteat ecageateea
74161
       caactetgga getaggaage ceggtgetee tteecagagg agggageega agetetgeea
74221
       gtctgcactg aagtctgtgg tgtgcggtca cctgagaaca gctcagtcag tctggctgga
74281
       tectgagete etececegge etgtgettga gaggtgacag ecageaegtg ageaagtgee
       ctgggttctg gtcccagcaa agctacctcc agctgtgcac ctcggtcagg cacctccage
74341
74401
       tgtgcacctc ggtcaggcca ccctetctcc gtcagaccct cagtgtcctg atcagtgtcc
74461
       acaagtaaga cacatagaaa acctgaggcc cagagaagcc aaggaagtcc ttacaggctt
74521
       ctgtcagaga atcggaggaa aggagggac gccagagaat ctgggcttaa gtgacttggc
74581
       cgtgatcaaa acacaggcag agtcacaaac acgagacccc gctgcccact cccgacggag
74641
       aggtaattcc acaaacacga gaccccgctg cccactccac aaacatgaga ccccgctgcc
74701
       cacteeegae ggagaggtaa tteeacaaae aegagaeeee getgeeeaet eeacaaaeae
74761
       gagaccccgc tgcccactcc cgacggagag gtaattccac aaacacgaga ccctgctgcc
74821
       cactccacaa acatgagacc ccgctgccca ttcccgacgg agaggtaatt ccaggtcagt
74881
       ggcatccagc cttccccggc ccccaggccc ccagctgcca ccaagaaaca ctctttqtaq
74941
       gggteetgee ceactggggt geagaggtae atececeaag geeeageeee geaggaagee
75001
       cttcctctgc agccattctt gaaatcacct ccaagaaaaa agaaatgctt cagcttccaa
75061
       agatatecee aggeaggaaa tgggeegeag geageatgaa tgtttaatta egttaattgt
75121
       ccaagtccag cgcacatcat ccctcctaag taccttatgg gaaatcgtaa ttaggcgtga
75181
       aatggctcat tttcacaact cocctttctc ggggttctcc agggcgcatg cccctgtcag
75241
       ctggccggac aggcctctct tgccaaggct taccctcctt ggttctaatt taattttgtg
75301
       accttttctc tcgacatcct gaccccgtac atccctgcgc cttggcacac tgcaccaaag
75361
       caccatagaa ttactgagct ataagcctct catggaaatc tgtttttgac tttgttagaa
75421
       aacactataa tcaaatccct gagagtcagg agggatgggc ttggcctgcc agaggaaaca
75481
       tatcaccgga ttaagtgatt tagcagaggt ggtcccggcg ggaggagggc agggcaggct
75541
       gggcaggget gggcgtgagg tgggcaggca gggtgccctc gggqgcaagg gqqqaqggqa
75601
       tgcgcagagg cagaggatgg gcaatgtggg attaccagaa agtgcggtct ggacatccca
75661
       gggcctgcag gcttcctgag tgcctacctg gccctgggca ctcacagggc attgatgccg
75721
       agatgctcaR ctgtgcagag ggtgtgcagg tctggtggtc acttatgcgc tccagggcct
75781
       gcttctgctg atgccagggc aagacccagc ctcaaacaca catcaaatac atacgcttga
75841
       cgttatgccc gggagggctg tgcacacagg cacacagaga cggtgagact tggggatact
75901
       tgggtccagt tactgtcacc ttgggtctca cttctgggag cgtggatttg gctggcacca
75961
       ctgcactgcR gtgtgtctgc gtctatacag acttcctcca tttcacgcat gtacctaaaa
76021
       cataccacca ttcatgtact gtcaggcact ctttcatttt gtaaaacaat agggttatca
76081
       aggeetgege agtggeteat gettetaate ecaReaettt gggaggeega ggeaggegga
76141
       ttgcctgagg tcaggagttc gagaccaggc tggccaacat ggtgaaaccc catttctact
76201
       aaaaaatacaa aaattagccg ggcatggtgg tgggcgcctg taattgcagc tactcaggag
76261
       gctgaggcag gagaatggct tgaacccggg aggcggaggt tgcagtgagc cgagatcgtg
76321
       ccactgcact ccagcctggg cRacagagcg aaactcagtc tcaaaaaaaa aaagccgggg
76381
       gggctaccaa aagatgagag ggacccaggc ctgtattgca catccacatc agtgacagtg
76441
       taatggtaYg cagacccct ccccRcatgc acacgcattc tgaaataagc caggcccaga
       aggacaaata cggcactcgt ccactcacat gaggatctgt aatcaaacgc atgaaagcag
76501
76561
       atgacaccat agaggctgcc agagctgggg gagcgggaaa tggggagttg ctgttcaatg
76621
       ggtgtaaagt tttagtgatg ctggacgagt aagtactaga ggtctgctgt acaacgttgt
76681
       gcctgtagct gaccatgtgg cactgtgcac ttcgaaattc tctgagaggt ctgagctcac
76741
       gttaagtgtt ctttccacaa aagcaaacaa caacagcaac agaaatgaag Kgacagaagg
76801
       aaaccgtggg agaagacgag tgtctaccgc ctcgatgtgc tgatggcgtc ccggtgtctg
76861
       cacaaatcca cacttgctga actgtaaggg gccggtgacc tctacagtcg cctaccatgg
76921
       cgagcataaa cttgcagaga agaggatgag aattctgata ataggacaaa tcaaagctta
76981
       acaagtaatt aaaggacaaa ttggtgcata taacaagtcq ttccctgtct cgcaqctqac
77041
       atggatcaat gtccaaaatt tttatccaaa ttgttataaa tacacatgag agtcttctcg
77101
       gtgcagtgaa tagtgaagtc agcagaggca gtggctcacc cctgcagtct cagcacttta
77161
       ggaggccgag ggggtaggat cacttgagta ccagagttag aggctgcagt gagccatgat
77221
        tgtgccactg cactccagct ggggccacag agcgagaccc tgtctctagg aaaaaaaaa
77281
       agaaaaaaga aaaagaaaaa aaaaaagagg aaattagcca atatcccaga gagtgaaggc
77341
        agaacccgta tcagcttttg ccaaaaatga gaactccaca gttgcctccg cattctgtct
77401
        tttaaaaagt gtcaatttta cattatgaaa tagagtgcat ctttttaaag taaaatcgat
77461
       gctccaggaa gatattccac gtttatcctg gactttggtg ccctctcgac acttggtttt
77521
       gattaaatta atccaaactc cagtttgcta agccagtgca cctgtgtgcg gctgttacat
77581
       tgcaccaatg ttttatcaaa tctccgacta tgcccaagtg cggcgccatg gaagccacac
```

```
77641
       gggatccctg acagacagaa acatccatac tgctcttaag gtggctcagg cactgttcca
77701
       agcacctcgt ctatagttgc ccactgattc ttcgcagcag ctgtgtgagt tagctgtgat
77761
       gettatette attetgeaga tggggaaact gagaaagget atcccaattt cacactqcte
77821
       ggaagtgtca gaaccaggat atgaaccctg gcatggctac caagagtctg tgctcttgaa
77881
       cgctgtgcta ggccactcct tctggggctg ttacatttta actctgacat gtcaagcaaa
77941
       tcactataag tttattgagt catttcttag ctgcttcatc tgtaaagtcg ggtgacaatg
78001
       gctgcaggtc ctgccactca gacgattccc acgcgtgtct gYatcaggat gaggatgagt
78061
       agateggtaa agtgeettgt agaetgtgat gateatattt ttgtetttga tteeactgee
78121
       agcacaatac ctttttttt ttaataaagg gctgttgaac tgcaattccc atgtttgtat
78181
       acattettet tetgtttett tggttaaagt tteaagatte tettagggtt caaatgttta
78241
       aatttcaaat cctttqqctc atctqactaa ttacaaqcat aaaatatqqc atttccaaca
78301
       agtetggaga atggaageae atgaaattat geacgaeeat gageatetgt gtegggagge
78361
       gggaaggcgt tcacccttca aactcaagtg aaaaaggttt gccgtagtta aaggctgctg
78421
       acaaataact actgttctga gaaatcacca ctgtttactg ggagaatcgt ttttcagcaa
78481
       atatatcaag aaaagtaaat atcaagtata atttgcagag ttgcagataa ctccacattt
78541
       tggaataaaa aacttctgtg tctgtgtaca agtgtgcaaa acacagcaga gacatttttc
78601
       tttccaatcc tgcctaaata ctgactgaac atcatcagtg ccatctccca tgactgtgac
78661
       agtgtatctt gtgtgtatgt gttgtatcat attatctgct ttgttaaatg ctatgcttgt
78721
       taaaatgtgt cacattaaaa aacaaaaaca gcccgggcat ggtggctcac gcctgtaatc
78781
       ccagcacttt gaaaggctga gggtggggga gggtggatca cgaggtcaqq aqttcaaqac
78841
       cagcctggcc aacatggcaa aaccctgtct cctctaaaaa atacaaaaat tagccaggcg
78901
       tgttggcagg cacctgtaat cccagctact cgggaggctg gaggcaggag aatcgcttga
78961
       acceggaggg agaggttgeg gtgagaggag attgtaceat tgeacteeag cetgagtgat
79021
       agagtgagac tccgtttcaa aacaaaacaa aatgaacaaa caaacaaaac aaacaaaaac
79081
       aaaaaaacag aaacacacac tacactgact acactgaagc cctcaagccg ctgaqcaqcc
79141
       atctccaggt ccccaaggac caggcaccaa ggtctggggg tggcccagca tccattctcc
79201
       cetttetcag ageageagee cagtgttatt teetggaatt cetggaacee tgeatgeaca
79261
       cagccetece caagccaaac atcetetece teacagagtg tgggatttga geegeaggag
79321
       ccagaagagg aaaaggtagt ggtgtcacta aacacctggt cacaatggtt aagaccctcc
       tgtgtccagg accccgactg ccaggccctt ccacagcccg actccccgtg gactctgcag
79381
79441
       gtttcctaat gtcctcccag taactcttcc tggctcaggg cagctggact tcatgcaaqc
79501
       tetetgecag aagagaeeet eteetgecae aggegeeete eecateagat geeagagata
79561
       teaceagece tegaggetta acceetgete tgtgggggat teetgetget etgeetgaat
79621
       teacceaggt gggcagteet caggtgaett etecagetet geatggagaa ggeeteacea
       tgcatctcag agagaagtgg aggctgcacc cccacaggaa gtggggccca gtccaccgtg
79681
79741
       cootggacgo tgotoatoca ctaggactgg gottocgtgt goagggotto accotogeto
79801
       tectetetge etgetecaca cetgetgett tgacetecat gaceatggae etgetgacag
       gtgccccccg acccacctcc agcctgcacc tccccaggct ccagaccccg cccctgctg
79861
79921
       cctgcaactg cccctggggt gtcacaaggc accttcatgc caacaaqtcc caacaaacc
79981
       tgtcaccttt ccctacccca acccatcage cattgctgct gtgcccatct catctccaca
80041
       tccaaggagt caccgcatcc tggcaccttc cccatctccc cgtccatgat gagctcagcc
80101
       ceteceteta cetggatgea geageeteet eccagacetg geeceateeg etgetgetee
80161
       ctgcccttca ctccctgtag ctcgagtcct cacctgagct tgcccccatt aaaatcctct
80221
       gtacetecet etteceaage etageagace egtgegggag tgegageaea etggetaggg
80281
       cctcctgatg ggcctgacct gcctgccaac cctcccaggg acctgctcat gttcccgcaa
80341
       egecettaca gecatgggte egagaaaaca etgeteaete tgeecagaat geetgeeetg
80401
       ccctttctgg cagactccta ttcagtcttc aaaacccagc tcccagctcg ttaggcccgc
80461
       aaagagagca agttactctc tctcctagac tcaagcaccc tgtgcttcct tcttttaaac
80521
       cactgatcat gcagaagtat aagctcacca gtttccaagt cccctaacca gaccatgagc
80581
       tccaggggta aaatcatgca tcagattcat ctctgggtca cctgccttgg ctgagaggag
80641
       gctcatgaag gtttggcaca atgggatgaa ggaatagaca aggagcaaga atacgagctc
80701
       atcctcatgc ctcagaatag catgaaatgc tcagggtgtg tgggacagaa ctgacgcYtt
80761
       cacaccaatg gagccagRtg ccagcctatg tgtgtccaag tcctaccaag tcccaggctg
80821
       catggaaatc agagggaccc caaatcgaat gagcgagggg cccttaaaga aactcacctg
80881
       geceettigt eteaggiest aggggtiggt getgecagga acteteatag gagaggeet
80941
       81001
       ttgccctgga gaggaaggc agagaggaag gagagggaa gcggggtgga ccacctctgc
81061
       tcagaccaaa ggcagaatcc agtgctgatg gttgccaata gggtcctctc tgttgctggg
81121
       cccccatgaa ccatgtgagc cctgcacaga gctcctgcta gatcctgggg gtctccctgc
81181
       actgggattg ctccaacagt gccccaccc tcagggcatg ggttgccctc tgcatctggc
81241
       caagtgeett eccagacace etgeageete ageeteetgt gaccacteat gtecacetaq
       cctqgtcctg gtcccaggtg ccctcctggt ctagctgcca ctaaacagat gagaaKctcc
81301
81361
       ctcccatccc agccctgaaa tatgctcagc ctcaaagcct cttggcacat ctcagcttcc
81421
       agatgtcctg tgccttgtga gatattaacc acactctgcc tagccctctg ccatgaggtc
```

```
81481
       ageteegete ceaggeaggg ggaagagetg cettgggage aatgatggge ategteeete
81541
       tgtgctgtgt ttggggtctt ccctccctcc aagtcYtgga ctttgggccc agaaatcact
81601
       ttccctccct cctctctgag cacacaaagg gcaggacttg tcttcaggtg cttggggaag
81661
       agggacgcca attgttccag ccactcccRt aagggtgaac caggagacta accatcaaat
81721
       tcaccaggaa atcccaacct ccaggccctg actgaggcMc taagacccaa gcaagcaata
81781
       tcaatgaaag ccagaggtgc ttaaggtggg gaacaagaat gagctgtcag aggcctctga
81841
       taaagaateg tttaaaaaga etttetttge tgeggeteat geetgtaate ceagecettt
81901
       ggaagtetga ggeggtagga teaettgagg teaagaatte aagageageS tgggeaatat
       ggtaaaaccc tgtctccata cacataaaaa aaattagcca aacgtaatgg ggtgcacctg
81961
       cagtcccagc tactcgggag gctgaggtgg gaggactgac tgaccctgag aggttgaggc tgcagtaagc cgagtccatg ctgctgcact tcagcctggg tgacaaagca agacctggtt
82021
82081
82141
       tcagaaaaaa gaatttcccc cttcgatgta tgctatggac tgaatatttg tacccccaaa
82201
       attcatatgt tgaaacctaa tccccagagg gatgatttta ggaggtgggg cctttggggg
82261
       gtaattaggt catgagggtg gggcctcatg aatgggatta gtgcccttat caaagaagcc
82321
       ccatggccag gtgcagtggc ttacaccagt aatctcagca ctttgggggg ttgagacggg
82381
       aggatagett gageacagaa gtacaagace agettggtta acacageaag ceetcateae
       tacaaaaact aaaaataaaa aaaaatatgt tgcatgtggt ggctcacatc tctagcccca
82441
82501
       gctacgtgag aggctgaggc aggaggatcg cttgatccca ggagttcaag gacacagtga
82561
       gMtaggatcg tgccactgca ctccagccta ggtgatgagt gagactctgt ctctaaacat
82621
       ttttttaaat taaaaatgta gaaataacat aaaagaggcc ccagagagct ctcttgcccc
82681
       ttgcaatgca tgaagacaaa gtgcaagaag gtgccatgtg tgaaccagaa ggtaggccct
82741
       cagcagacac aaaatctgcc agcactttga tcttggactt cccagcctcc agaaccatga
82801
       gaaagaaata aacactatgt aagccacctg gtgttggggg tgctttttgt ggtagcagcc
82861
       totactgact aagacagtgt cacttcaget actetcaaga aaggettegt cacetggate
82921
       cagtcgcgtc agttaagcgg tgctgcccag ctctgggagg ctgggggaga tgaggcgatg
       tgtgattctc aaggtcagca tgttggaaag tctagcaggg tttaatgagg acggaattaa
82981
83041
       aggagacggg gcctgatgag gggctctggg cctctctgtg tccctgtctg ctttgtctgg
83101
       aaaatggtga aaggaaggag gcatcttgga gcatctgtgt cctctggttt tccttgatcc
83161
       ctggattcac caggacacaa aaacccagtg cttcttgtac tgcaaggtgc ttgagaaagg
83221
       aagagcaaac ccacaagctg aagagtccca ggcagccatc gctcccgaca cgcacgccgc
83281
       agtgtagctg tggctcctga gaacggcggt gttaaaggac agttacttaa ccagaacttg
83341
       gggtccccct gccccgccc acggaggcct tgaacatcct acaataaaca cacaccgaag
83401
       ccatgttctt ggagagactt tggggaggct gtgcactctg gaaacagcca agctgttctg
83461
       tggcttggaa gaaacaagca gttccatcca ctctgggctc acagatattc ctcctgagct
83521
       tgaaggaagc cacagcggaa cttggagctg ctctagttct ctggaacatg cagcaggtgg
83581
       aaccgcagac Rtctctccag ggagctgagt cccggttttc acctgctggg tgtccacgga
       ttcaccccca gctactgtgt aggggccagc tcccctcagg gactgctcct gggagaccgY
83641
83701
       gggagtcacc gcagctccct gctctgtgga gcggccacgc tagcagaagg aacagagggt
83761
       gccagtgctc tgagtatgcc ggagggcagt gagtgctgcg ggaaggggct ggagggcaca
83821
       Sggtctgcga gtgccagggc aSgtggtgcg gggggagctg tctacaaagc cttagagcgc
83881
       cagggtaggt cccactggaa gggaacatgc aagcaaagac tcKaatgaKg tgggagggtg
83941
       agctgagggt gtctagaaag ggcatccagg cggaaggagg accccatgtg gggttttgaa
       aagaaggca aggaggccca Sgatggcagg aatcaagtga gtgagaagga aaatggaggc
84001
84061
       cacggggtcc cagggcgagg cgctgggtcg tgtggggtct ggtaggtggc ccgggtgctg
84121
       ggtgctgact tctgagctga acgaagcagg agccactgtg ggatttccag cagaRgacag
84181
       acatgateca geagaaggea teaaaggate cetgaceaeg gacegeecea ggaceettee
84241
       accatagtgc aggattcctc ttacaggaaa tgccccagta ggcagatcta gagaggcagg
84301
       aagtggatga atggttgcct ggaaggtggt gggggaggaa ggacgacagc taaggggtgt
84361
       ggggtctttg gggagggaga agatgttgtg aatataataa aaaccattga atcgtaYact
84421
       ttaaatgggt gacctgtata gtatgtgaat tatatctcaa taaagctgtt agagaaaaga
84481
       atccctgctg ctgtgttgag gacacatggg ggtggggagg cagggaggtc tgctgggggc
84541
       tcccaaagtc atcagaagag gacaaaggct tgacgcaagt gacaaccgtg gagatggtga
84601
       gaagtgatca gggtcggggt ggattttgaa agaaaaccta aaaagatttc tcaacaggtt
84661
        teteateagt gtgagaggaa gagagggte aaccetaaet geagagettt ggetgtgeaa
84721
       atggaaggaa ggatcagccg tgcacaSagc tggggaaggc cgagggtgga gtgcggagag
84781
       ggtgagcgcg agttcagtga ggggcgtgct gaggtggtac ttccaaattg aggttggcaa
84841
       gtagagaaat gccttggaac ttggatttga agagtgcaga gacagatgag gtgcagattc
84901
        tgctggagtc aggagcgtgg gcaatacaga gagcatggaa ggtggagggg cagttggaat
84961
       atgagtcttg ggtgcaggag agagatctgg gctggagacg caaatctggg agccatttca
85021
        tggtacataa agcaacaaga ggaatgagat cgcccacaga ggggtgcaga gggagaccaa
85081
       ggagcgtcca ggacagagcc ctgggcgcat caaccccaga gggtgcggga agaggaagga
85141
        tcagcaaagg aaacggggat gaactgtgag tgctgtgatt agaccaagaa agtgggtgtc
85201
       cggtaagcca caccaaggga gcaggaggga ctagcctgcc acgtgctagg gatggcgact
85261
       gaggattggc agggagatgc agcagcatga tgacctcggg gagggtgcct ctggcagagt
```

```
85321
       ggcacacaca gaggcctggt ccaagtgggg ttaagacaca gtgagaggag aggaatcgaa
85381
       gatggcgtct ccacctaggg ggtgctgctg agagagcaaa aagctgggag agtaggtgac
85441
       aqacqaqgga agccqtcaqq tgtgaatgcg gatagggagc agatgttgga ggtgttcaga
85501
       qqacqqaaqa tatqaaaaqt catctggaag gaggcaaaca gactgagggg agcagtctgg
85561
       ctgctagcgg caccttgctg gtgaacatca tcgtaagcaa gagcagaagc agggctgagc
85621
       tttgttcagg ggtacccgtg ccagcatgaa gtaggtagaa agtttcattt taccaggact
85681
       agggcattgt tcagtagatg ttacaaagca agagtgactc caatgaggga acctgcagtt
85741
       taagaSaagg aggctgggta aggggtggag ggaaggatca gtggtgtgag agaccgtgac
85801
       aaggeggeag cateaatgge etgeaggttt getggageac aggteggage aaaagggaac
85861
       cgggaaaata gaaggtcatc agaatgcaac actgcaacgg attatgcagg tataggggcc
85921
       gctggcaaaa gaaggtttaa ggtatgacca aggccaaatc cagtggggag tcctttttgg
85981
       aaaccttgac agctgtggtc atggtcgacc tcatgggaaa ttttgcaaac ttgatcctgt
86041
       gtcaaatgag ttcccgtgac gcgtgtcagt gcgtgtggat cttgctgttt gggggagggc
86101
       agaaactctg cagaccccat gccttgccRc cctcgaccct gatacgcgat gccaatagac
86161
       acactgetge ggaaaccata aacgteacca gatteagage ttgageecae eteteceaga
86221
       ggttttgtcc ggtaaaggga agaggaacag ggttcaactc tcctggcaga actctatgga
86281
       tgccgcagaa gacaacgtta atgagcttgg cttaacttac aagggatttc cggtYttgtg
86341
       aaagaggagg aaactcaaat ctcaggagag tttaatggca ggagtgagct tgagtgttgg
86401
       tttccctaat agatgggttt agctgcatgg gtgaggtaga ccaaggccct ctgtagaata
86461
       tqctqqaqaa caatqattca agactacaaa gaaactgaag tgtgagcgga agataggagt
86521
       gaacettega gaaceggagg ccatgecact geettgttte gggtggagga acaaageett
86581
       gtcactgtgt tgccagggac agagtgcaag gtgcctggaa gctcctcggg aacgttagct
86641
       gtgtccctca tcgcaggcaa tgggaccctg caccagtggc cagtacctgc tgccccagcc
86701
       agcetetgtg aggeacacae tgecagagat gaceteacge tggtggaaaa egaggagaea
86761
       gcagatcaac ccagccgggc ttccacgtcc agcaaaacga ggcgagttcg ggttgttatt
86821
       ctgctctttc atgagtcagg gctttgggcc tcactgcctt ccaaacagag tcaaaatcaa
86881
       tttgacgttc aaaacgacat gaaaattgcc atgtcaaagg ccattctgta atttcagtgt
86941
       attaaaatca aaagagcaca gccttcttga agaagtttcc tttgggcaga attcaagttt
87001
       cctctttctt ttacttgtgc aatttgaatt tatttcactt tttcaggaag tgaccatttt
87061
       tgcaggaaaa gtgtagtcaa aagagataat gcacatgaag tttcttttta agttctgagt
       atgtcgaaga gatttacagt gcattaaaat aaactatagg caaaatagtg tgtgtaccta
87121
87181
       tetetaegea ttttttaaaa ggggeaagtg ggggaceate ttgttgattt tteaeaceag
       tageccettt cegecagegg gaagggeett geeccaceca atgtgtetet ggtggatggg
87241
87301
       taattcatgc ccatSctact ccccagtggc tgtggtgggg gggcacatag cccacacctg
87361
       gtactcaatg ccctcagcac agtgattggt ccagggggtg aacacatgac tggagtgaga
87421
       ctaatcatgg gtcttccatg agatctgaac attgggagaa aaaaatattc ccttcctggc
87481
       tcagtaagct cacagcgtag gcctggggct gcgtatgtga agagccaatc tgagaaggaa
87541
       gtctctgcag aagagagcca agtcctagga ggaggagaga cgctgagcct tggcagcctc
87601
       gtgtgggcca gcggtgcctg ctgtcttgct cgcgtgtgcc agcaaatYtc cttttcttgg
87661
       cttaattgga tttggatctc taattatacc ttgaatgacc ctgacatatc cagtgtcttc
87721
       taccttcctt attgctgtgg ccctttaaaa aaagattagg aatMatctgS catgagaatt
87781
       ccacttctgg aatggtggtg agaggagecc catggacaca ttcccctcag aacaaccata
87841
       actggtgaaa agtattgaaa agtcaccatc aacaacaatt taaagtctct agaaattatc
87901
       ctaagagcac acaacaaact aagcaacatc atctattcaa gaaaatcaac caaatcttgg
87961
       gaagaaaaat cccagtaaga acagcaagaa tcggtggcac ctgagccatc acttgctctc
88021
       tetteccege ttetagteet teeagtteag ettatgggga gtteeactet gggggtgtgt
88081
       qqccaaqaac acaqqqctcc ctcttccctc aqatcccaqt caaqqaatac agtatttcac
88141
       caggatagat gggccaccag cgtttctcat catctccaac tcccagtgac agagggtaac
88201
       tecetgetga gtgtgacega Raggeeggag caeetteete caeecageee taaeteaggg
       caggagetee gteteaggtg cageagggeg agagtgetgg geteetaate accetaagte
88261
       cagcctgctt gctagaaaaa tattccatgc tagggggagg caaaccaaga agatcagagg
88321
88381
       ctacctcctg cccaatacct ggagtggtgg cttcagtgaa gattctggcg gcaagaattt
88441
        aagaggaggc tgacagctct atgagaacaa caacctgaac cacagaccag cttatttact
88501
       ggaaaaaaa aaaaaatca ggagaacaga tcgttatgag gatctcttcc agggggagaa
88561
        tgaatttcaa agactggcct caaaatcatc cctacccaaa tttaattgga tcaaactatg
88621
        tgacaattta tgtctcagga cattgttgaa aataatagag caatcatccc tcaattagtg
88681
        aagcctagta gctgggtgtg ataccaaatg aagcagagag tgtaacagac agatcagaga
88741
        aaqqqacagt catagggagc cctgctgaaa tcactqtcat cccgggatga ccctgcacac
88801
       gctcaaggct gtgccctcca acagctgagg cttcccactg tgaagaatac agactttgtg
88861
       aaaacagtct aaccaaatca ggaaacaaat aaatacacaa acaactgcaa acagcctcag
88921
        agatggggga ggggaatcag tatgcagagc tgccacatga cccaaaatgt ccagtttcac
       acaacagaaa cacaaatgac tcattcacag aaaaaaaaggc ggcaacagac actgctggta
88981
89041
       agaaagccca gatgtcagat gtaacagctg tcagattttg cagcaaagat ttcaaagcag
89101
       ccattggaaa tatgtctttg aaaaaaggaa accatgctta tgtaaaggag tgatgatgac
```

```
89161
       aatatctcat caaataaaga ctatcaataa agagaaatta taaacaagaa ccaaatggaa
89221
       attctggagt tgaaaagcac cataactgag aggcttaaca gtagattgga actggcagaa
       gaaagaatct tgaaaacaga tcaatagaca ttatgcaatt tgaaggacac agggaaaaaa
89281
89341
       gaatgaagaa aagtaaacgg aacttaagaa aaatgtggaa accataaagg gcatgaacat
89401
       atgcacaatg ggagtcccag aaagaggcaa gtgagtataa aggagcagaa aagatggaag
89461
       aaacagtggc aaaaagctcc ctaaatttgg tgaaaacatt aacctacqtq tccqaqaaac
89521
       tcagcaaact tcaaacggga taaatgccaa gagatccaca cccagagaca tcatagtaaa
89581
       aatgccgaaa gccaaagaca aagagaaaat tctgaaagca gcaaaagaaa aatgacttgc
89641
       cacatatgtg ggaatcccag tgggatttcc agccgacttc taataatgga agccagaagg
89701
       cagcagaatg gcatatccaa tgtaaaaaag ctgtcaacca agaatctttc tccagcagaa
89761
       ctatttttca aaattaaggt gcaatataga cagtcccaga taagtaaaaa cagagaatta
89821
       tgagtagacc cattttatca gacatactaa aggaagttct tcaagctgaa agcaagtgac
89881
       ctcagttggt aacttgaatt cacacccaca cacatacagt accagtaaag gtaatcacgc
89941
       aactttaaaa gacaatataa atgggtattt cttctctttt cttcccttaa ctggcttaaa
90001
       aagcaataat atagaagaag atgtatataa ttgtattatt gggcccatat aatatataaa
90061
       tgtaatatat ttgactaaca gcacaaagca ggtgaacaga aacacagcta ctggagtaaa
       aaaatgacac cagatgggaa cttgaatcca ccgcaacaaa tgaagagagc cagaaatggt
90121
90181
       caacaggaag gcaaactgtt gatatatatg tacteteete tettttttea gettetttaa
90241
       gcatgaaatt atataaagca ataattacaa caattgttag gtttgtagca tatatagctg
90301
       tgtggtaggc agaactgtgg ccctccaaag atgttcacat tctaatcccc agaacctatc
90361
       tatctgtaag gttatatgta aaggaaaatt aacattgtaa atcagatgac tttaaaatat
90421
       tgaaattatc ctggattagc cagatgggcc cagtgtaatc acaagggtcc ataKaggggg
90481
       aagggggaag cagaagagag aaactggagg gatggctgca cgggaaggac ttggcctgat
90541
       gttgctggca taaaagacga aggacagaag tcatgagcca aggaatgcag gtggcctcca
90601
       gaaactggaa agggcaagga aacagatcct ccccggagga ggacccagaa ggaacaaaac
90661
       cctgccaaaa ccctgattta aactcagtga gactcatttc agactctgac ttccaaaact
90721
       gcaaaataat accattgcat tatttaagcc actaaatttg tggtaatttg ttaccgcagc
       aatcaaaaac caacacaagt tgcacagcaa gaacagtaca aagatggggg tgggccgggc
90781
90841
       geggtggete acgeetgtaa teecageaet ttgggaggee gaggeaggeg gateacgaqq
90901
       tcaggagatc gagaccatcc tggctaacac ggtgaaaccc cgtctctact aaaaatacaa
90961
       aaaattagcc gggcgtggta gcgggcgcct gtagtcccag ctactcggga ggctgaggca
91021
       ggagaatggc gtgaacccgg gaggcggagc ttgcagtgag ccgagatcgc gccactgcac
91081
       91141
       aaaaaaaMaM agatgggggK ggaagaatag agctatataa gagtaatgtt tctataqctc
91201
       acaggaatta agttaatata aatctaaaga ttctgataag atgcatacga caagggagag
91261
       gacatcacca aagtgacaga atagaggact ccaaaattct gcccctccac aaaaacagga
91321
       aataagctag taaatctcag aatcgacttt tttggaactc cagaatttaa ccagaaacct
91381
       acaacaacca gggaatgctt aatgaagaaa gcagctactg aattttggtg acagtgggtt
       atggtgtttt aatttacttg cttaccatta tcttattctc caactcagca gtggccatga
91441
91501
       agatggcaga ccacattcct ggtgtaggtt gctgatacca acctacacat ccaaggagct
91561
       caatgactcc cagtttgaaa actcaaaaga aagaaatatg gaccttatat ccagagaatt
91621
       gtggttgtgg gttttaaccc atctgctggc ttgcctttgt ttcaactgtc tcggagcttc
91681
       cccaggactg aagtggtttc ccagacagtg tttgtcaaaa gtatttaaag gtRaatgtat
91741
       tagctgcaga cacctggggc acaggacaat aKttggggca agacRcacaa taaacatatc
91801
       taaaggcttg gggaggaaga gggtagggaa ggagatattt gaggaaataa ggtttttgga
91861
       aagetettgt geataceaga gaatetagga ttetaceaet gacatgteta gggtgagatg
91921
       catgctcaga aaaggtctaa gaagactcaa aagttttcac ctctggctga catttagggt
91981
       ctgtacaagt aggaagtgaa ggctaagaca gagttgtaaa cagtctggct aagcatcaaa
92041
       ggtgtgctca aacacagaac caatctacaa agacgaggag agtatttctt cctaccctgg
92101
       cttttaagaa agtctctgtc aaatcactaq ctqaccacta aqctaacaaa acaqaqactt
92161
       tggtggccat atataatgaa caatgcagac tttacaaaaa tagtttagaa aaatcactaa
92221
       acaaacaagc aacaacacat aaaaaacaac aagccccggg aagtgggggg catctgattt
92281
       ccagagtete cacatteaaa atgteeagtt tecaacaaaa aatacaaage atgeaaaata
92341
       acaagaaagg atggtccact cacaggaaat aaaaaagacc ttccctgagg aagcctagac
92401
       acctcatgtg ccagacaaag attttaaata aattgtctta aatgtgttca aagaactaaa
92461
       agaaaccatg ggcaaataac gtaaqtaaaq caaqaacata atqtatcaca aaataqaqaa
92521
       tatcaataaa gaaatagaaa ttataaaaaag gaaccacaaa caattttgga gctgaaaagc
92581
       ataataactg aaataaaaat ttcaatagat cagttcaata gcagatttga gcaggcaaac
92641
       aaagaatcag caaacttaca ttatcagcaa tcatccaatc tgagaagtag aaggaaaaag
92701
       aatgaggaaa aaggaacaga acctaagaga tcaagtacac caaaatacaa aaaaatgaga
92761
       gttcaagaaa gagaatagag aaacaaaggg gcataaagaa tgtttgaaaa aacaatggct
92821
       ccaaattccc caaatttgat aaaaagaaca tgattctaca catccaagga gctcaatgac
92881
       tccaagtttg aaaactcaaa gagttacatc aagatacatt gtaatcaaat tgtcaaaaga
92941
       caaagacaaa aagagagtct tgaaatccac gagagaggag cagcttgcca catatacaag
```

```
93001
       ggctctcaat gagcttaaca actgatttgt catcagaaac aataaaggcc agaaaccaac
93061
       gggatqacat atttaaqqtq ctgaaaaaaa tactgtcctg cggctaaaaa ttccaacaaa
       actatectte aaaaatacaW gaaaaatWag acaettteag agaaacaaaa actgagagag
93121
93181
       tttgttttct agttgacctg ccctccaata agtgttaaag aaagtccttc aggttgaaat
93241
       aaaaggacag aagacagtaa ctcaaagcca tatgatgaaa tgaagaatac taataaaggg
93301
       aaccccaaaa tottogtttg taactottot ottttttoot atatgattta gtotatagat
93361
       gcqtaaaqca ataattataa atctacatta atagacacac atgtatgaaa tgtaacaata
93421
       ttataataaa gggtggggaa gacagagctg tataggagca aagcattttg tatactattg
93481
       acactaagtt gatatcaatt caaacaaaat tgttatgtgt ttaagataat agctgtaatt
93541
       cccaggataa ccaataagac catagctttt aaatatacag caaaataaat gaaaacatga
93601
       atcaaaacag tacactaaaa aacaatgtgt taaacacaaa agaaggaaat atttgaggaa
93661
       ttgaggaata aagaatatga catatacaaa acaaatagca gatagcagaa ttcagtccct
93721
       ccttatcagt aattatttaa atacagatgg actaaatgct gcaattaaaa ttcagagaat
93781
       gggagaatgg attaaaaaat cccaagatat aatccaacta tatgcttatc cacaggggac
93841
       caaatttaga ttcaaaatac acaaatagtt tgaaaatgaa aagatggata aagaaatgct
93901
       atgcaaatag aaaccagaag agacctggga tggccatact aatatcagac aagatagact
93961
       tcaagtccaa aaattttaca acaaagaaca gcattatata ttgatgaaag agtcaatcca
94021
       ccaagaagat ataacaatta taaacataaa cacacctaac aacagaatcc caaaatctat
94081
       gaagcaaaaa ctgacagaat tgaagatgga aatagaccat tttacaataa taqctgaaga
94141
       cttcaatatt ccactttcaa aaatggataa aacaaccggc acatgatcag taagaaaata
94201
       gaggacatga acaacactgt aaatcaacta gacctgacag acatacatag agcacccac
94261
       tcaacagcgg cagaatgtgt attcttctca tgtatgatga tcattctcca ggataggtca
94321
       tatgttaggt cacaaaacaa gtctcaataa ccttaaagag actgaaacca tacaaagcat
94381
       cttctccaac cacagtggaa taaaactaga aatcaatgac agaagaaacc ctttaaaaat
94441
       tcacaaatat gtagaaattt aacaatattc tcttaaagaa ccattaggtc aggtaatatg
       ttacaagata aattagaata tataataaat aataaatctt gagacaaatg aaaataaaaa
94501
94561
       cacaacatac ccaaaactta aaqqacatac aaaaqcaqtq cccaqaaqaa tatttataqc
94621
       ttcaaattcc tacattaaaa ataataaaga tctcaaatca ataacctaac tttacacatg
94681
       aaggaaccag aagaaaagca acagaaactc aaagctaqca qaaaaaaagga aataatcaag
94741
       attatagtga aggtagacaa aatagagaat tgaaaaacaa taagaagact caatgaaacc
94801
       aaaagctggt tctttgaaag atcaacaaaa ctgacaaaca tttagccaaa ctgaccaaga
94861
       taaaaagaga gaaggctcca attactaaaa tcacaaacaa aagtggggac attactaccg
94921
       accttataga aataaaaatg attataagag aatattatgt acaattgtat acgaacaaat
94981
       taaataacct agaagaaatg gacaaattcc tagcaacaca gaaactacca aaattgactc
95041
       aaqqaqaaat qqaaaatttq tacaqatcta taacaaqtaa aqaqcttqaa tcaqtcatca
95101
       aaaactccca ataaagaaaa acctaggacc agatggcttt actgggaatt ctacctatca
95161
       cttaaagaat taatatccat ctttctatga ggccagcatt accctgatac cgaaaccaga
95221
       caaaaacatc ataagaaaac tacagactaa tgtctcttat aaatataggt gcaaaaatcc
95281
       tcaatgatat tctagcaaac caaattcagc agcatattaa aaggcttata tacaatcacc
95341
       aagtgggatt tatccgtgga atgcaagagt ggttcaacac acaaaaatca atccatataa
95401
       tacactacat tcataaaatg gaggaaaata aaccacacag tcatcttggt tgatgcagag
95461
       aaagcattag acagaaccca acaccctttg tgatcaaaaa atactcaaga aacaaggact
95521
       agaagggaaa ttcctcagca tgataaaggg tatttacgaa aagccaaaag tactcatcat
95581
       ggtcaactgt aagactggaa gcctgctctc accacctgta ttcaacatag taccggacat
95641
       tctagtcaga gcaattcagc aagaaaaaaa taaataaata aaaggcatcc acattgcaaa
95701
       ggaaqaagta acacttcttq aqqqaaaatq qqqaatqatq qctcqtqqqt acaqqqtttc
95761
        ttttgggagc aatgaaaatg atctaaagtt gactgtggtg atggttgcac agctgagtga
95821
       atatagtaaa aattatggaa ttatgcgccc gaaacgctga actacagcat atgtgaatta
95881
       cageteaata aacecaccat aaaggaaaga ttaaacaatg atetacteet tacetetgtt
95941
       ctcagagcca tttccagccc agcccaggcc ccaggcaacc ctctgtgggt gacgcagcat
96001
       tacctgcttt ctggctgtcc agtgttgtgt agcgcaaggc cctgggaggc cactgggttg
96061
       gtcatgcggt aaccaagaaR gggagcaagt agttgggtga caaaccctgt acatctgctc
96121
       ctaactttcg aaacctggct gatgggaggc caatgtSacc ctctaacgcc ctcccatagc
96181
       agectegget tgtettetga cagtggeact gtecacceae aggeateacg catectgece
96241
       gcacattgct tccgccagtg gagccccagc tgaaacacta gacaggagag aagtccagag
96301
       atcctgctca ctMtagggaa ggagaaagac ctcttcagct tqtcctgcct cqccaaaqqc
96361
       aaagcetcat geatttgete acteeteeet eeeagggete ageeggeace tgaagetagt
96421
       gtagcagaaa gagcccaatt ctgcatcagg cgggcctggg ttcaaatccc agatcctcca
96481
        ctttctaatt gtgccatctc tgagccttcc atcccttacc tagaaacaga gttctttcca
96541
       cccatgccct tgtgagacag cgtaagtgaa aatgacatcc acacggtact ggaagcagag
       ctgctagaaa cccagccagg cagggtttga acttgttatc tccaaaaagt ctcaggaatc
96601
96661
       qtatttctqc ctqatqqtqa cctacttcaq caaqqaccca atqtaqaaat tactctqcca
96721
        ccaaaaaagc aggcctcaga cccctccat cacctcccYa atttatgaat taaacaacga
96781
       ggccagtgcc tgaggggtct gcagatgaga gtcagaaacc agcagcccc caccccacag
```

```
96841
       agacaggtcc ctgctaacta gacacaagaa ttggccttct ggggtgtctc tgcgtgttct
96901
       gtgtatggtg acctagcccc ggccctccag gagggacact acgtgcagga cattttggaa
96961
       aacagtcttg gtgtttcctc aaaaagtgaa acactgtgtt atcatgtgag ccagcaattc
97021
       tcctaKgcat atacctaaga gtaatgaaca tatatgtaca cacaaagact tgtccacaaa
97081
       tggccatcga ggagaagctg gccacagaga agatggccca gagaggaggt gctgtgtgca
97141
       gaagcagctc tgggaggaaa gacgtgcaca ggccaaattc agattactga cacttttttt
97201
       ttaatgcaga gattgtctgc agaattacct atttttgact tatcttgaaa aactgaggat
97261
       ctggcaacac tgaccccgaa tcttcctaac agcaacaatg atcagaactc agaggttttS
97321
       tgtctcactg atttttttt ctttttcttt tcttttttt tttttttqa gataqqqtct
97381
       gactttgtca cccaggctgg agtgcagtgg tgcactctca gctcactgca acctctacct
97441
       cccaggctca agcaattctc ctgcctcagc ctcccaagta gctggttcca caggtgcatg
97501
       ccaccacgtg tagctaattt ttagattttt ttggtagaga tggggtttca ccattttgcc
97561
       egggetggte tegaacceet gageteaggt gatecateeg ceteagacte ceaaaatget
97621
       gggattatag gcactttgct gcacctggcc ttgtctcact gatttctgat cttattttgt
97681
       attatettt teettetatt ttetttggat caatgttgee tttttetaac tWetcacact
97741
       97801
       ttttgatatt tagtgctttt attatcattg agttgtattt ttgaagttcc actattattt
97861
       cttctttgac ccatgaatta tttaaaagta ttttttttta atttccaaat aatggggatt
97921
       tttgctttgg gggctattaa tttctctctc acaggcatga tggtcaggga acaagacctg
97981
       ctgacactat tcttttagtt tctgtgagat ttgcacttaa ttgaccagtt gttacaagtg
98041
       tttcctatgt gcttgagaaa aagaaataac ctctacttgt cagatgcaaa attcatcaat
98101
       gtcaagctta ttatttgtgt tatttagaac ttccttatct gtgctgggtt ttttgtctac
98161
       ttgatccaac accaattgga aaaaaatggt tggattctct caaaaatgat gataaatttg
98221
       tcaatttctc tatttctaac aaagttcacg tcaaatatgt tgaggttatt ttattaagtg
98281
       acticacctt tagaactgct ttatcatctt ggggaaatga accttttctc attaaacggt
98341
       gacctgtctt tccccagcag cgtctcctgt cttgaggtct gttgagtctg agattgatac
98401
       agcaatgtcg gcttgccttt ggcggcctga taggtctgtt tccatacttt actttccact
98461
       ttttcttgcc tttacacttt actctggtga tagcgtccag ccagattttg aatttggggt
98521
       ttgtctcgtt tgtcagatat gacagcctct gtctttgaat ttgtgagttt aatccattta
98581
       catttacctg gattattgat aaatctgggc ttgtttctcc catcttactc tatgatctca
98641
       atttgtcttg gtttttctgt ccttttttct cctttataat ttgtcttata aaaaaagaca
98701
       tcccggccgg gcScagtggc tcaggcctat aatcccagca ctttgggagg ccaaggtggg
98761
       cggatccctt gaggccagga gttcgagacc agcctgacca acagggtgac accccatctc
98821
       tacaaaaaat acaaaaaaat tcggggggtg tggtggcaca tgcctgtaat cccagctgct
98881
       agggaggctg aggcaggaga atcactggaa cccgagaggc agaggctgca gtgagccgag
98941
       atcgagccac tgcactccag cctgggtaac aaagtgagac tccatctcaa aaaaaaaaa
99001
       ggcatccctt tttctctaat ttgtcctgtc accactgtgc tggctgcccc agccaggctg
99061
       caaccetggg gacacacatg cccetccage agtgagttea gaccettete accetttgge
99121
       ctcaggctcc tcacttcctg ccccctctcc tgagaggtga cacgccatgt ccacaccaac
99181
       tocaaatotg atcatoggot coagtocagt cootgoacca gotgotcatg ggootttoto
99241
       tctggggtgg ggctgggagc tgtggttcct gctgctgtgt cctgcactac tccacatttc
99301
       ccagttcaga ggtgatcgga gccccctcta atatatgcca tcccagggcg gggcagcagg
99361
       gcacaaggcc acttcagtgt caacacggat ctcactgcag gaactaggag gggcctccct
99421
       taggaagagg cactotggac tgttttaacc acagtococa ottotocoto otgtotoaca
99481
       gtcccgagct tcatacacac acgctgctgc ctattctgga attatgcagt attattattt
99541
       tatatteatg tegetgggca tatgatgete ceatgacaag gggeeetgga gettttagat
99601
       caatccttag aaggactcca gccagacccc aaaggccaca tattatcaat tgggtttcta
99661
       tgaagtatac agaataggca aatccaaaga cacagggagt agattaKtgg tcactatgag
99721
       ctgggaaggg gaatggggag tgactgctct gggtgcaggg ttcccactgg ggtgatgaaa
99781
       acattttgga actagatggt gatgatggct gcacaacact gccaaaaacc actggattac
99841
       acactttcat actcatatgt attatagtcc attgattttt aaaaggtcag aggaagcaac
99901
       tcaaatgctt gtaggaggtc agaagaggcc cagatgggtg aagtcggggg ggcgtgcaSa
99961
       ttaagcccac aagaatattc tctaagctac caggtcacac acacactcYc tctcactgtS
100021
      cctgaagece atagececet etgeetgaet etectateaa etgtKgatgg egteaaagat
100081
       gcacaSaaat atattttggc tgaaagaaac acaacagggc acaatgagga agggctgcca
100141
       agcagcctat tagcagcatt tgtcatggtt catctgggag tctgcctttt cccccagcca
100201
       gactetteag ggacagagae cagattgtte atacteagtg cecageaggg egetggeetg
100261
       gggtgcttgc agacactgac tggatgaatg gatggatgga ttgggtggat gaatgagtgt
100321
       100381
       aataattgga tggatggatg ggtagatggg ggatgggtag atggatgagt aagtagatga
100441
       atggagatca atgatggatg gatagatgga tggatgaatg agtgggtaga cgaatgaata
100501
       tggataaatg gatgaatgat tggatagatg gatgaatggg tagacagaaa gactctgata
100561
100621 ctggaaagtg aatccttcac atccatggca agtgaaccgg gtaacaaagt cagaggcaag
```

```
100681
        accatagcag cgtcatttgt cactgttgcc atttatacac atttttgggg cagaatcggt
100741
        catgettgac cacaggtcat ctctagaggg tgaggattgg gggtcaggaa ctgtggggtg
100801
        ggctcagggc tagggctgcc gatgtggcct ttgtgcctgt gagcagactg catttccatc
100861 agenteated coatetteed tetetgeete caccagtgag tteagatect tectacaatt
100921 caatcttggg gtcccctcac tttctgtccc atctcccaag acctggctgg ggcctgactc
100981
       agaatggggt cagcaaagcc ctgaggtaga gccgtctccc aagattatgg cctggctggg
101041
        gcccgcctca cctccattca aaggacacca tgtggaaaac caatgtgccc ccaagcaggg
101101
       gtggcacggc acagacactg atggcacagg ggccacttct tgctccttcc tggtgtcttc
101161 atcctcgggg atcaggggct ctgcagcagc aggcagggct gggcagccct ggagtgtgtg
101221 acacaattcg ggcactgtga ccctactgga cccctttgca cagatgctgS tgggcMtagg
101281 aactggctgc tccccactgg ctgctctggt aggccctggg gtctgcctac acccccaaca
101341
       catgagcatg ggcaggtacc caccagtete YttetStgte eccageetet eccgeagett
101401
       ggccttggtc caccgtggac agcgtctctg acacggtcYt tcttcccaca gggaqaccqg
101461 gagggtcttg ttctgccctc agagcagagg ccccaggctc cttcaggtgg gagcacaggt
101521 gcctttcgca cagggcccag cagccagctc agcccacaga acagtaagcc gccaggtccc
101581 aagttgtcat cttgtgaccc gcccctgggg acacgggtgc ccaacaggaa agaggacggg
101641 ggcttattat aaggaaaata gtgtcaggcc tgccatggag ctttgggcct gaggcctcag
101701
        101761 agctcaggga agctcctggg tgcggctcgg ttcactccag catttcctac atggatgaaR
101821 atgtggatgt gtctgctctg accatgggtg tgtgcatgcc tgcgtgtgtg tgagagagag
101881 agaggagaga gagacggaga gagtttatgt acgtgtaact accaaccaga gtccaggagt
101941 ctcacactcc actgcaaacc aggcaggcgg ggccagcatg agtggggggg ccaggcacga
       atcggcaggg agggagggt tgtgttcgcc catccagagg aggcacagag cctcccaccc
102001
102061 agtgctgctg gcaggaacac gcccagggtg gccaggcctt ctgaaggaac tgaaaattga
102121 gattttcatg tgaaacctcc tgatttttaa gtgtacactc aacatttctg aagccgttgt
102181 acgagtcaaa taaaacattg cggggtgggg cggcgaggcc gcccaagagc tgcagggctg
102241 aggcctggct ttagtccagc accccgatgt acatacagac gagaagactg aggtcaggcc
102301 agagcaagga ctccgcaggc caggcccaca ctggcggccc cggctgcctg gcccatcact
102361 ggggtcacca cagcccatgg ggagcaccaa gSacaccaag aaagggaggc ccaggcctgg 102421 tccccggggt ctctgtcacc aagggcccac attgtgagtt tcaaaggtgg ccgaggtggt
102481 tcctacaggc ctgtqagtcc ccacactcct tcccagttca aggcctcggg acaaatccaa
102541 gcccagcttt gtcctcgtgg tgatgaaggc caagaatgct gggagctccc gggatattgc
102601
       cYaKaacaaa ggagcacagg cacctgacgt tctggacaca agggcagaac cctcttgaga
102661 ccatcatcgg ccgtttgctc tccaggctgc gggggcctgg aggacatcca ggcacgggta
102721 taggtgccgg gagcccgggg aacagaacct cagacccgga actgggcacc agatgcacca
102781 gccgggggtc tgtccgccca gcccggggag tccaggggct gctccgaacc cggcgccacg
102841 cctgctccct cagtgccgca tccaacagct ctgtctgcct gggctggggc cctgcRccct
102901 ccccgctgct ggctcccgct gatgcgctac agatgggctt catcgctgcc tccaagaaca
102961 acaggacgac cgcaggtttc gcctcacaga aacggaaccg ctggaaaggc ctctcttgac
103021 attcccgaaa ggaaaataaa aattcctctg aagtacattt caactccgag gcagccctgg
103081 ccacatccaa gaagctcggt cctgagcgcc gtgggctcca gtgaaggtcc ccagcactga
103141 ggccgcctcc tgacccccat cccggccact gccccgggct gctcaaccct tacacggctt
103201 tcacaaattt tgaattagct gccaacagtt taaaatgaag agattgtaag taaaatcaat
103261
       ttccagcttc tcttataaaaa ttggaggccc tcctgctgct ggccgacccc gtgtctacct
103321 gggcccagtg atctctgctg gcgtcacctg ccaggccccc atcagtgtgc ccatacgaga
103381 ccactgtcct cagcgaacgc ctgaccccca ggctccaggc aaggttgaga ggacagatgc
103441 teteatectg ggggetetgg cetteetggg gecagtgtta tecagetetg ceetecagag
103501 ccctctgcac acgctggggc tgggactgcc catggctgtg ggctctgatt tgggtgggca
103561 gacctgagca ggccatcatg cttcttattc ccagcctgac acccccagac cgcccccgc 103621 caacccagac aatgtgtact gaactcctcg tcaacttgac ccctgagctc ctccccgcag
103681 cccaccaggt gctcctgctg tggtttgggc agcacctagt ccttttcgcc ctgctggacg
103741 tcgcctggcc agacttgcag agccatctca gccctttgtt ctcctgactc catccctcca
103801 agcctggcca ccccagcctc ggccccagct cctgccacgt gaattgtcaa aggcagagca
103861 tgaggagget gaaggeagee eccatggeae acceeacgga gteeetgeag tegteeaaaa
103921 aaggeteaag eetgggeage attgetegea getaggaate tgeagetgga eteaaatatg
103981 tgtccagaat gatctgggaa aggtccttga gaaaagggcc agacacaggg accttcccag
104041 gcccggatcc cacagaggaa atgattctag cgagcgccac ctcgacaggt ctgaggtcca
104101 gacaggggtg gagctgtcac aggcagccgg gtggggctgt gatctgggtc ctcccagcct
104161 cacggtgatt tggaatggga atacggttct gccaggcaag gagtatcccc ctctgaccaa
104221 cctgtggact gcctaccagg actcccaaca cccttcctgc acgatggcgc tgaggggctg
104281 atccggccgc tgctctcatt cccatggcca cctgatccag gccgcagtct ctccctgcac
104341 acaggacage agenteetge eggeteeetg cetetteegt geteacecte eteggaaace
104401 agaccatgcc acctgctgca tggcacagcc cctcctccac gacggagccc acagaagcca
104461 tegtgatetg acctecagte eccteaggee etcaceetge ecctectgee acaceeccaa
```

```
104521 acaageceeg teeteaceee teaggtaett egeatetget geeetggeee etttteetee
        tggggaactg caacccacac tccaggcctc agcccaacgt ccagtgactg cgggctcact
        ctgtggcact tcccaagtct ttcattgtgc aggtatttgt ggactgacta gtgcactgtg
104641
104701 ggctgtatga ggtcagggct gtgcctgtct ggtcccagag cctggcccag tgcccggtcc
104761 tgctgtgcgt qccqqqtaaa qatctgttgq atgaatcaag ggagagaga aqqqqaqcaq
104821 ccctgggatt ccacaggtgc tttatgtcca gagacaaccg cgcagggaac agtggccaag
104881 gcacgctggg agcagtgctc cagcccgacg gcatccccag ggcagaggct gggattcacg
104941 cattgctgcc ctcaggcacc aaacgggcct gtggcagtca caggggcaca ttcctgatac 105001 cgggtctgtc gttccagcat ggacagggcc atcttcctcg ccatctgcag tctggcatca
105061 gacattccca aataaaggac agacagttaa ctgtcagaaa gtgctggtgc ttgggcctgg
105121 aaggaaggga gecegtgtet aetgggeace eccaattttg gecaetgtge agtgeeetgt
105181 gtcctcaacc tcggggcctg gaccacagct ccatgagacc acagggagga agcagagtca
105241 cagaagaaag agtgatgaac agcactggcc acttgatttg cagggcacag tgcaaaatgg
105301 aaacgcacag tcccttgttc aaaaagtgat tacgacttct aaggcaggaa tgacagagtg
105361 ttaaagtggg catagggccc tgccggatgg gtcacaagcc ggcgaagtca gtcctgctca
105421 agtgtgagga agtgggacta gcaaaggccc agggccaccc aatgtcccat gggcccatgg
105481 gaccagtage cacccacage tgccaacctg agtetgcage cetgacactg tggcaacaac
105541 aggaggcgtc agtgccaagc cctccaatgc ctgcagggag caactgttgc tcccggagtg
105601 ageteetggg egaceggget teetaggeae tatgettatt etteettte aeggatattt 105661 aegeaecaae egtgtgeeag geatteetea aaatgetgea aatteeaetg taageaaaag
105721 attetecceg aagetaacgt getaagtgae etggagaeae atecteaete accetegetg
105781 ggccccagtt tctgcagccg ttaagtggag ttccaggcct tggtgcttgg aaggccctct
105841 gtccaacaaa cagatggggt cacaggctac cgggttttgc cagcccaggc tctgagcggg
105901 gacaggaggg cactgcactg ggtgtcagca gccctgggtt ctaagcctgc tcctcctcc 105961 tgatgcagga gtcaaaaggc ctggctcca ctgtttctac agcttactat ctgtgcaacc
106021 gtcggcacct cagtttcctc atctgtaacg tgggcacagc aaaagcacca acccaccgtg
106081 gggctcatta caagaatcct aggagatgat gtacctgcag cgtgctggca gacgcggtca
106141 acggtaagtg ctccaggaac gcgtcacgtt cttcttgctc cctgctgttc ccgctactgc
106201 ttggacagtg gtagccctgc accttagttt tctctctgct tccaggacta ccgtgcctat 106261 taaatgacac catgaagagt gcccaccttc gcgcaggccc tcggtgaatg ggcatgtcct
106321 tgaacgcaaa cttggctcca acggggcagg agaaggatca ttcagactca gctacagaaa
106381 aacagacttt tgtgcaacta acgctaacaa aactggaaag gaaagaggaa ctacggcctg
106441 gggaaaagct tgtatcgaac atgacagaaa gtcaatatct aaaaagagat aaagggctta
106501 tcccaatata taagaccca ggagataaac aggcaaagga cttaggaata ggagacatgc 106561 agagtaatca aacccaggga agatcactca tcctcgccag taaccaaaga agcgcaaatt
106621 agcgcaaaaa gcaacgccgc tttgctgccg gagcagcaaa atattaaaca ctaaagcccc
106681 cgtgctggtg aggatttgga gaaaccagga gctgctgtgg gagccagtct ggctctgccc
106741 cgagtggtga gtctgttaag cgctgggatt tcctaattca tttagtcact cagtaggtgc
106801 cccctgatgg ctgctcaggg ccagggctcg agcgcgtctg ggctggctca ggccgccatc 106861 tgccgggtca gcaacagata cctatttgca ggaacagaac ctgaggtcag ctcccaggat
106921 gtccccaccc ctgagtttca agagagtttg caccaggagc agggagcatt ccagctgtct
106981 cgggcagctt ttgtgtgggg aacagctggt agcgctgcct gcggcccctt ggggtggaca
107041 ggaaggetet geetgeaaag geetagagge ageeacacae eetgeeetge acaeteetaa
107101 gtacgtgcag gccacagttc ctgcatccat tcatcccggc cagtctgggg tccctcccca
107161 cagtggcagg caaggggaag ctggaccggt cctgctagac aaacaaggat gcacacacgt 107221 ccatgggacc ccaaacctca cactgtccct gacagcccgc cccacagagc acagcctctg
107281 cctcccggag caagaggagg tggcagtgca tcccagggcc tggctgcctg tggggctgca
107341 ttgggggctc ctgccccgc cccgtgagtc tgggaacaca tgggtcttgg ccttggcacc
107401 ttctttcctg ggaaaacacc tccctctggg ccagggcagt gcagagcagt ggaagcgggc
107461 agetgtggag teagagtgat gggtgeeaat tetgaeteet geaegtggee eagaceaect 107521 aacetgeeae eeceaecage acacetgeee ggeeaeceee aceageaeae etgeeeggee
107581 agectcagge caccagecag ceteccagee aegtgacete teaggggeag gatgtgteet
107641 tgattccttc cttcacacca cgtcccggaa gctccacctc aaactcatcc tgaacccact
107701 gcctccaccg ccatctgtca ccgggactcc teectgcttc cacgccgtcc accgaaaacc
107761 ctccaaaggc ctccaccgca cagggaatga attctcaccc cgtaccgtga ccgtcccttc
107821 aaagcgatga gtgccaccca tccctcccgg ccctgcacgc ctcccactcc cccattacgt
107881 cctcagttcc aggtactagc tcttccttct gccccttggt cacgctgcgg taactccagc
107941 ctcagggctc ctgcatgtgc tgttccctct gcctggaaca cccttcccag ggctgggctt
108001 teccateate accaacetgg ggegeeteec tecettacet geetteteac getgeeettt
108061 caccccgttt tactttgttc acaggattct ccactgtctg cgagcatctg ctcaccaggt
108121 ctcccctgcg gggctgtgag cccagagaac agggactcga tcgggttcct ccgctgctac
108181 agccccagca cccagtcctg tcagacacat ggtggacaca tagcaaqaac gtgacgagtg
108241 aatgcaggaa aatacacttg tggcagcagg caaggtgccc tctctgagcc tcagtctccc
108301 cctaagcagt agagctgcta atgctattat tcccccatga tttggggagc agtattattc
```

```
108361 ccccatgatt tggggagcag tattattccc ccatgatttg gggagcagca ttattcccc
108421 atgatttggg gagcagcatt attcccccat gatttgggga gcagcattat tccatgattt
108481 ggggagcagc attattcccc catgatttgg ggagcagcat tattccccca tgatttgggg
108541 agcagcatta ttcccccatg atttggggag cagcattatt cccccatgat ttggggagca
108601 gcattattcc cccatqattt qqqqaqcaqc attattcccc catqatttqq qqaqcaqcat
108661 tattccccca tgatttgggg agcagtatta ttcccccatg atttggggag cagcattatt
108721 ccatgatttg gggagcagca ttattccccc atgatttggg gagcagcatt attattgagc
108781 attaatgaac ccgcatggca ttcaggtgcc cggccttttc ccaaccagac cagcgcacca
108901 tctgggtgtg ccgacagttt gggatgggag gcgtgggagg cgtgagctgc gctcctggcc
108961 gggttctcta ccagctgtgc tcgtggcgca gcccacacct cacggcaagc cccagccaaa
109021 gggaccaagt caagagetet gagagacate ceageegaag aateeageee ttgteecaaa
109081 cgtgtgtatg cacaggcaca cgaaagaagg tgagacagaa ggagagaaaa atgaagccag 109141 agagcaggag agagagaaga cagacgccag cacgcccatc tgactgcgcg acctttcccc
109201 gctcagagct ccttcagggc ccagagcaca gcgctgccta ggattaattt caaagagaaa
109261 cgggtcaaag aaaattggaa atttttatag aaaatatttc aggcttggag ctggctgaag
109321 tgtctgccaa cctgcagaga attctgagag gagatggggc ctgtggtcag aggcctccgg
109381 ctggcacaaa ctggcagagt ttggacctcg gacccaaatg cagtttctga gccaggcctg
109441 tectegetge tgetggggaa gagetteetg teccetteag atgteeetae agetgeetet
109501 gcagccctga tgctggtacc caacgcctct cacctgtcgc cccacccctc tctatcccca
109561 agaggeetet gtetagggae ceaetatggg atgeagteee tttgteecea ttatgeaggg
109621 tgcccatgtc tctttcaccg tcatccatgg ggcagccagg gcatgaagga agcctcacct
109681 gggtcccaag caggtcccac tgctccttgc ccaaacttca ccccagccag caggctccta
109741 catccaagge acagatgtca cagacatgaa aagatgccct ggacacatgc ctctctccca
109801 gaagcctgcc tctgccatgc tggggacctg aaaagagggg gcatgcccag cccacagttg
109861 ctgatcaaac gccagatgcc cccgtgagca gatcacagct tcacccctga gccgtgtact
109921 gtctgcatgc cagggactgt taccttgtgc aaaacccgaa aagctctttg gaggacattc
109981 ccaacacaga tccaagggaa ggaaagaaag tatcaattca ctgtgtctgt ggaagatggc
110041 gaggcagagg agggaaaggg gacggagagc aagtgtcgca gtgagcactg ggcaggcgcc
110101 ctgtgccctg cgtaattcca gcagcccctg tgccactgca cccaggtaca gtggagatct
110161 cagcacccag gttctgagat cctgaggggc tgggtgagct gctctgggcc ccttagtgag
110221 ccagaacaac agcatgtcgg gtggagctga gcacactgac ccctgcacca acagcagcat
110281 gctgggcgga gctgagcgcg ctgacccctg caccagcgct gacccctgca ccaacagcag
110341
       catgccgggc ggggctgagc acactgaccc ctgcaccaac agcagcatgc cgggtggagc
110401 tgagcacact gacccctgca ccaacagcag catgccgggt ggggctgagc acactgaacc
110461 ctgcaccaaa ctgcccgctg cccaccccac tcacccacct agtgctggaa gcatctgtgg
110521 gagcagccct aatgcagctc ctcagaacca ctggccggtc ttccagaact gtcccctgca
110581 ctcgagttgg ggctgcagcc aagccagggc caaggccacc atcctccggg tcaggcttgt
110641 cacctgccca cggtgctcca ccaaagatcc aggcccttgc cagccacatt tacctggtcg
110701 gctccaccc tgaaccagaa accatgtcgg gaggggagag gtggcggggg aagggcaagc
110761 ctgagactca gggactaaat ttatgtcgga ggcacagggg agttgctgcg cacgtggggg
110821 ctgtcaggcg gagtgccagg cccagacgcc gtggaggggg agcacaccct ggcacgtctc
110881 cactgtggaa taaggggggc ccagccctcg ctggggctgc aagcctcgct tctgccttca
110941 cageceaggg ggtgggaage acceacaggg cagegetetg ageageagae tecagecaga
111001
       gagccagcca ggcccgggag ctggcccctc ctgctctccc cggctgaccc caggcaactc
111061 cagcetegga gaatgtgeag ceteggettt ceeagegeeg geeeeegee acceetteeg
111121 cgtgggccac atcaccgcgc tggcatctcc aacagccatc ccaagggccc ggtctgcacg
111181 aggacaggag cgccgcggcg tctgccaagg gtgcgctcag ccctgaagca cgcctcccgg
111241 agccgcctcg ggtttcacaa tcagtgcttc tccctgggtt tcccggggcc tgggctgcag
111301 gctcagctcc agggtggaaa gagaggatga gctgagagga ctccagggat ccagcgccga
111361 ggcgctgaac tcagtgagtc ggcaacagtg gcttggcagg gcccaggctg accagggtat
111421 gagagagagc acctatcacc acgccagagg ccctggcctc aggggtctgg ggagtcactt
111481 gggaagtgcc cggttggaga cacagagaca ggtctgggca caagacgctg gccaggtcca
111541 gggctcaccc tgcaaatcca gccaaagccc tctctccatt ctccttagg acccaaggtt
111601 caacacttag acatgtcagc tgaatcatga cccccggacg tccatgtcct aatcccccaa
111661 aactcgtgag cattacctta tatggcagaa gagactttgc aaatgtgttt aaatcagggg
111721 tcttgagatg gggaaagtaa cctggatggt cccagcgggc cctaaatgtt atcacaagtg
111781 tccttctaag agggagaget ggctatagaa gaggagaage cacgtgacca gggaggeaga
111841 gactgcagca atgttgccac aagccaagga acgccaacag cccccaggag ctgggagggg
111901 ccaggaatgg attctgccct ggggcctccc gaaggaacca gccctgccag caccttgatc
111961 ttagccccta aaatcctatt tcagagttct gagctcccga actgtgagga atgcaggtgt
112021 gctgttttaa gccattaagg tgtgggtaac ctggtacagc agccacagga agctgagatg
112081 gacgtcgaca gctacagggc agaaaggctc tctgacctgg cattcagcaa attggcaccc
112141 cccaacaaag cacacagece tectgeecca teetgggeec eccageecee acetgggeca
```

```
112201 agcctcacat ccgctgtgtc agtggggctg gctatctgct cgccactgaa tggatgagtc
         tegectgete eccagteetg tggtetgaca gaacagaget cetetete teetgtgeca
112321 ttgctccagc ctcccccacc agcctccctc acactgcaac cagtacgagc ttgctgaaac
112381 actcaactct ttgtgagact ggagggcgcc atccccacct tgggtcattc aaggctgctg
112441 cttccatgga qqctqcccca caqctctctq cctccagccc tgggctctqc acacccaggq
112501 ggaactgtca tgcctgaggt ccgccccac ccccgccgcc cactcttccc ccaggatccc
112561 ctgcggcctg gaaaactcct acccaactca aggcaaagtc acagggtgga gactgtgggt 112621 caggagggc tcttcctggc ctggtgggga agggctggct gtgggctgca ggtggcagcc
112681 acgctcagcc acatggagga gctgcccagt gccggcgctt gtcctctgtc tcctggaggg
112741 ccttccttgg tgcagcgagg ctgagaggct cccgtggtgg cgtgcctcgt ctgcccgtca
112801 gggaggatgc tgcagcctga cagcagcagg cagaggcttg gcaccggcgg tgtctggggt
112861 ggaggcagcc aaggtcactg gcacgttgct gtctgacttc tcttccttca gcccagcagg
112921 gtgtgtgcac agcagcetgg tagcagttcc ccaggatggg aagcacetgc cceteetetg
112981 teccaaggec aggeegggc gageeccagg agageageec acagaggagg gcagaagatg
113041 cttctacctc tgcatcacag aaagcatggg tagccaatgg gggaccgtgt tttgtttggt
113101 ctatatagtg agcacgggag gggaccccag gcatgacagc tcccactggg tgtgcagggc
113161 ccagggctgg aggcagagag ctgatgtgga ggcttctgtg gaaagagggc tttgtctgga
113221 tttgctggct gagccctgga cctggccagc gtccttgtgc caggacctgt ctctgtgtct 113281 ccaaccaggc acttcctgag tgactcccca gacccctgag gcctggtcct ttcgcatggt
113341 gataggggct gtctctcgta cccgggtcgg cctgggccct gccaagccag ctgttgccga
113401 ctcactgage teagegeegt ggetggatte etggageett eteagtteat ceteteatte
113461 cagaaatttt aagccacatt ttaacatcag gaaagttcac ataaaaagtc tgatgtctgg
113521 attttcttga taggatgttc agctgcacca gacccaactt ctaccaaatt gaggtcaagg
113581 gagttgagga gggtctgtcc ctccttgcag ggcctcccag acgccctgtg cccatggcaa
113641 ggccagggct ggacaccacg tgtggctgca ttcccactgc tgtttctttt tagtggagat
113701 gtattcttgg tctccacgtt tccatcaaaa ggagagaaat gaaagccagg ccaagggtgg
113761 gtgcaattat cttttttcc tccactgctg tccttgttgg cattgcctgc caggccctgc
113821 aggetetgag tttgcagete ttgtetttet geaaatggea etgtgtgtet gaaacagaga
113881 ecacatgete aacaegtgae teggggtett teteaetgtg tggcaacett cacagagtee
113941 caaggtcagt ctctgggaag ctaagacagg ccctcagtgt cagcacaggg ttggcttctc
114001 tgtgcacgtg gtcttggagt cagccgctcc aggtccctta acgcgggcgg tgggggagga
114061 ctgccaggct gagactggca cttagacatg cagggaagag ctcccacacg acagggtgga
114121 gggtccagtg agggaggcag caggaccagg gcctgcctgg gctgtgcctc tgggctatat
114181 gccctgggga ggcgtaagtg aagcctacag tgctgctcct ccgcgtgacc cagacgggcg
114241 cctcccgggt gtgctgtgca ctgcgtggcc agccttgtac gtgagggcca ttcacatcct
114301 gtagctggct gcgtggtgcc cccaaagatg ctggatcctg atccctgcaa cctgagacgg
114361 gtaccttcta tgggaagaaa gggctttgca gatgtgcttg cagtaaggct cttgagatga
114421 gaageetgte etggattaet egggtgagte etaaatgtaa teaaggeate ettgeaagag
114481 ggaagcacag ggacacgtca gaagaggagg gggcgacatg atccgggggc agagattggc 114541 atgatgcagc cacaagccaa gggaggctgg cagcccccag gagcggggat gggccagaaa
114601 cagattetee cetggageet etggagggag caeageeetg tecaecettg atettggete
114661 agtgagattc atttcagact tctggcccac agagctgtga gagaggcatt tgtattagtc
114721 cgttttcaca atgctgataa agacataccc gagactgggc aacttacaaa agaaagaggt
114781 ttattggact tacagttcca cgtggctggg gaggcctcac atcatggcag aagatgaaag 114841 gcacgtctca catggcagca gccgagagag agagagcttg tgcagggcaa ctcccgttt
114901 taaaaccctc agatctcgtg agacccactc accatcatga gaacagcatg ggaaagaccc
114961 acccccatga ttcaatcatc tctcactggg tccctcccat aacacatggg aattatggga
115021 gctacaagat gagattcagg tggagacaca gagacaaacc atatcaatgt tcctattgtt
115081 tcaagctccg tgaggactcc ctcctcaaca gtcccacaca ggatgagatg cacacacacc 115141 agagaggaca atgccacagg gtgccctgtc cctgtacccc agcacagtgt ccctggacac 115201 agagctggcc ttgggaaggg cagagaacag ggattggaga tgcctgtcag aatgcctggg
115261 gggacacctc aaccactgct ccccaaaagg ccacccagcc tcagagctcg gcctccggtc
115321 ctggccaggt tcccaggcca gcagcactga gcaggaccct tctgccaagg ccagcatggc
115381 cagggaggag agaaaaggac cctccccgct ccctcacccc ttgcccctcc taataacatc
115441 ctctcccggg tgttgcctaa gctgcccagt gcacacactc atccctggcc tgtctgtgaa
115501
         atgctttaaa accgtcattt tctatccgtt tcccccaggc aatctgcaat ccagcaactg
115561 atcttggatg acagagacta ttagtgaaaa tgattccctg aggctccatg agtccccgag
115621 atcaccctga gcagcccgtg ggcttctcgg ggaaaacagg acatcctgaa aaggaggcac
115681 ccctgacgct gcagggatat cctgccaccc agacagatgc ccaccccca ctgggacacc
115741 cagggcaggt gtgtcacctt ccccggcaga acataaatag cagggtgctt cacacccact
115801
        tccagacgtt gcttttgggg aggcaggaag aaactgccag ccagcacctc ctgccagctt .
115861 ctgccagggc cacactgata tatcagggtt ccctcagaat tcactggaag aaagggtccc
115921 ctatacacac acacacatac acacacacc gcacccaggt cctggagttg tgtgccaggc
115981 aggctgtgcc cctcactatg cctggccaca ggacacagct tttatgtatc tcccagttgc
```

```
116041 cactetggge cetgaaaagg eecaggeaga tggaaagetg gaegeetgag gteacegtgg
       gccctccacc cagctccggc actcactggg cctggtgccc ttccagtcag tgtgtcgatc
116161
       tcagcccagg gccacgtggg aacgattagg tgcatggcgt gggagctagc tcactgaagg
116221 cccgagcccc tcatgcaggg tctgctgaca ccagacagga acatcaagca aaggggactt
116281 ggccccagcc ccaagttctg ggatccagac ctatagcccc aggcccacgc tcacatccac
116341 agcctgggcc ccaggcctgg agctaaggct ggacaggctc acctcctccc cgacagccca
116401 ttaccaaacc cccaccttcc agcccagcct cacccctgac ctggcagctg gcctcaccca
116461
       gcgtcttcta aggccaatgg tttctgggct tattctgaga ttgaaattcc tttcctgtgt
116521 totgaattto aagttotoat taaagatatg tggattgggg gtgggggtgg agggaggatt
116581 cagcagaaga tgccaaacac cagcagaagc ccagaaaata aggcaaggcc ggccaggctg
116641 tgggggaagg gctgccatgt tcaggaagac aagcaccata tggaatctgg gatcagagac
116701 atggccaagg gcacgtggcc agctcacctc acctgagcag aggcccccag aaccaccctg
116761 aatottocag gagaggocag coagaagcac caagcocaca goacaagtga coagcocotg
116821 ageteteggg gacacagggg ttgetaatge caetgggett geeggacage agetagetag
116881 caaggagcaa agctggggcc ctgccccgg gtctggagca ctcgctcagc cccttccacg
116941 ctggccctcc tagattactc ctccttcctt ccctgcaaaa tagtccaagg gtggggataa
117001 gtcgaggctg agaccacagc tggaaaaggc tgggcaggca gtacccagtg gcccggctgt
117061 ctgcagcata gcagacgctg atttgtcacc aaggaacaag gggccaccgg ttgcactgat
117121 tggctccaga gtacattggg cttcctgatg gaacaattcc tttgcaaagg tatctgatgc
117181 cgtttcatga aattagaagt atgcctgcca ggctgtaccc aattttctg tcaagctagg
117241 aagtcagaca gacctacagt aaatgaggcg gggctgctat ggagtgacgg gagtacctta
117301 gtaaatcaca gcacggggc tggcccagcc caggcccctg gagcactcgc tgtgaacgtg
117361 caggtgtgcc cgatcctggg ccccagactc cagactctcc tcacccaggg gtcctgacca
117421 gaggetgagg getgageteg eagetteeea eteteceage aagageeaag cacaggeeag
117481 gagtccctga ccacacgggg gaccctgaga actatgggcc tgcagaacca catcagacac
117541 caaccetgge tteaceacaa teeaggacea gagactgggg gatgetggga ggtgtggget
117601 ggcacagtga ggccagatct gaggcgacag tcatggactg tcaccatggc cgcctggcag
117661 ctcctttcac gtttctgggc ccagggcaca cgtgggttct gagttgaaaa agacagacgc
117721 ccatgagtct gtgcagagac tgctgaggct gctgggagca cctccagagt ccttgtaggg
117781 cacatgcctc cagggatcca gaaagagcat gcagggcctt tctccctgag cagccaggtg
117841 agggttggga cctaccacag gcaccctccc agggaccatg gcagcacaga gcaggagagg
117901 cgctgtctgg ggctctggag gcctcttcac aggcacagac tcagagacgc aggcactgga
117961 ctcaggcctg gccgggggcc cccgccccgc tccacgacac ttgcttgcct ttaggcaaca
118021 gaagatgggc ccttggacag ccttcatagt ccaccatgga ggccccagac atgaaggcag
118081 aggtgtctgg gctgcttgtc acccacatgc acccagaaca gaggccccag ccccagcagc
118141 cctgctacgc cctgccgtca gccaggcagc tggcccattt ctgagccact gagaccgggg
118201 ctcagcctca gcagccaagc tggtctgtgg agagctgcct gagtctctgg gatgctcccc
118261 tggggaccag ggcctcagag ggctctccac acagcctgcc cacctgcagt agcctcacct
118321 gtgtccaggg cctgtggccc cccgagagga ggggacgtgg gtggccggcg atacaccaca
118381 tgcacacggc cttgctcagc ctcctgcgcc gccagccct tctccaaggg ttcgatgaag
118441 aactcctcct cctccatccg gatcagacca gcctgcggga caaagacaac aggatcagat
118501 ttccagcaca caaaagacca aggaagggga acagcgagga gaccccctca gggagtacct
118561 cccacctgaa gaccctgccc agcaccccag ctggtgctca gcttgaaccc tgggctggcc
118621 ggagggtatg aacatgtggt cccagaggcc gcccccgcc gcccaccctg tctaggaaag
118681 gggcctctgt ctgggtcatc tccaccccta tacaccaacc ctgtctgctt tcagaaaagt
118741 tactgtgttt ataaagtcaa aaccgtccag agaagcaggg agacattcaa gggcagctgt
118801 gggcctgtgc gtgtccccag gagggcatcc accaaagtgc atcaatatgg gccaagtgct
118861 gcccccactc ccaggagccc agagtccaag acaaaggtca aaacagccag ccggggattg
118921 aatctgccca cacacatgtt ccatctgggc caaacaatat ttttaaagct ctgaagctaa
118981 cactcagaat gatgagattt catgtcttga acatggaatc ccagctttcc ttggaaacgc
119041 aggccctgac cacagcgggt cttggatgga acacatgccc ctgcaactgg ctccagtccc
119101 tactgccccc caactgtctc tcctgctctc tgtgtcagcc accagcccag actctacagg
119161 cagctgaact getgeceetg acceectagg ceagecagea ceeteeetga etacaaacte
119221 ctcgctgggt cctcatttcc gttgggactc aggctgctct atatgctggc attcaggctc
119281 ttggcctgcc ccaccctccc agaccgcgc ttgcaccacc ccatgcttct cactgggctg
119341 ggtgcaccct gccgagccac ccagcccctg aaccccatgc tgccaactca ggaatcccca
119401 ttctcccacc ccaccaccc atccccagct cggccatctg gtaaacctgt gttccccctt
119461 cgaggeetga tteagaeeee eteacetete etgeeeteee etgeeateea geetgeeete
119521 ccctgccata ccctgccctc ccctgccata ccctgccatc cagcctgctg gcaccatcag
119581 gtccacccat cccatgacaa ctccagctcc tacactttta tcttctggtc cattatccat
119641
       aaaccaaggt ctcacactgg aagtgcacac tgtgtccaqc cttcagagtg tttccttcag
119701 atcacaagct tatgacccat gcaggggatt ttaaaagctt gaatttgttg ccaaacttaa
119761 qaaacaggag agttcacata aacgaccaga tttccagact ctcttgaaaa tcagaaaagc
119821 tggcatttcc agcacccatc gacactccag cttagctggc gctggccggg gtcccctgtc
```

```
119881 cagttaggag tgtgccctct ggtgggcagc ccccggcacc tgccatctgg atgtgcggaa
       accacaccc ccccaaagta acctcatgat ggcctctgcc atatcatcat cttggttgtg
120001
       ggggggcacg gtggcgcacg ggctgcccct ccttctccct gaccccaggt gctcggtgag
120061 ccccatcctg ttgctggctg ggagcctctg cagaccgaga tgcagtcagt gccccccagg
120121 gcctgctggg cggctgcccc tagcctcaag tgtagcgagg gaggctqqag atqcctcccq
120181 gcgcactcag cctgggccct cgggaagctg atgtgccagg caggggctgg tggaggtgca
120241 gggcctggag gaacacagag cccagcatca ggcctggctc cagaatgaag gatgcctccg
120301 gcaggaggtg acatetacce aaacceacce aatccetttg tgctggccag gcaaagagte
120361 agagagaga ccagtgctcc atatggggga aaccgcacat gccatggccg gggaggtgga
120421 cggagcacag ctggtgggaa gagctgacca ggtgggtgga caggagcatc aagggcacgg
120481 tgcccggtgg cccatcactc agggggctgg tgagggagat tgtaggcagc ccagggcttc
120541 tggggggagc cttgatctga ttccagttca gaagcatggt ggctgcggca gggggaatgg
120601
       gctgcggaac aaaaatgggt ctggggtcct ggggagaagg tgttacaggc acctgggaga
120661
       ggggtaatgg tccagacggg agcatgagag acaaggacga gtggcaggta tgaaggaggt
120721 gaggagcgaa atggacagga cgtggtaggg tagagccggc tgagatggga gggaggagga
120781 ageacctggt gggettecag gtetgtgget gaagaaccgg eecceaaagt tacceaggee
120841 cccatccctg gcagctgtga gggtagtgga catggtggaa agagactctg cgggtgtgat
120901 caggtcagct ctggggctgg ctgggccctg aatgcagtcc ttgcccactt ccttatgccg
120961
       gggagtggag ggggattagg cagatgcgca gaggacgagg ccatgggcag acagggagga
121021 tgccagatgc cagctttgga gattggagcg atgtggcctc aagccaagga atgctggcag
121081 cccccaggag ctggcagagg ccagaaagtg tcctcccca gagtctccag agggagcgca
121141 gccctgccga tgcctggatt tgggtcaggt tataccgact tcggacgtcc ggcctcagaa
121201 ctgtgagaga acgaattcct gctgttttaa gtggttcctt acagcagccg cagaaaagta
121261 attcagggtc ctggtgggtg gccggcaaag tgggtgccat tctccgaggg gcatgagaag
121321 aagggcaagg ggcgcaggac cctctgggct caggcatcct gggcttctgg ggaagaggcc
121381 taggaggcag tggtaaccag agttaccagg gcaagaccga ggtcggagaa ggaggtcagc
121441 agggctgtgg gaggagagc gaagaggggg tgggaaccct gcaggcccca cgcttctgac
121501 tcatccctgg gtctcagggc tcaaccaggc ctggcgaaga ctcagcagat gcctgtggaa
121561
       tgagcgaacc gatgacccca aagctgcagg ccacgtcccc caagggaggc accgagcagg
121621 caggcgggaa gaacacagcc aggcctgtcc actggcacag gggcagtgtg tttaccagtg
121681 caggagttgg gagggtccag cactgatggt cccggtgcgt ggtgtggaga aggctggtgc
121741 ctcaaatcca tettatgact gaaactcatt ggatgaagtg caggaattaa eeetgggggg
121801 cggcagcggg caagctgtcc tggagcgtga agttctgact tcctggcacc ctttctatct
121861
       ggccaggtga cctcaggcaa ggtgtcaagc tccccaagcg tccagtgact cgtctgtaca
121921 tgaggccggt catttcccgt gcacactcac acaggagcac atgcagcctg ggagacactg
121981 agaaccaggc cacgcctcca cccaagtgat ttcatccagc cagcttgctt tccaaatgag
122041 gaaaccgagg cctagatggg cagacaggct gctggggaca cacaggttct agggatcaga
122101 actcacacct acacggaaag ggcatctccc agacaggtcc ctgggccaga ctgggccgat
122161 tgagccaatt agggcaggac actggggcat gaggacccct tatggcagct ccatcttctg
122221
       ggggaacttg cagcccaggt cgggagccat cgatgccaca ggcctgaggc cctggggtta
122281 ttctggaggg acctagtgtg acaatgaggc caggctcagc ctggggaagg gcagtactct
122341 ctggccggag taacccgggg gacagtttgg ggtctccctg accagcaggg gtcaggctcc
122401 cctccctggc tgcctccctg aggacaatca ctgggctgag ccaacagcac tagctccatc
122461 tgatgctgcc ctgggccttg cctcctggaa gggcacccct gcaggcgact cctcggaggg
122521
       cacaggagca cactggggtc catctgaagc agggcctggg ctcaggcttc ctcacacagc
122581 cagaagcctc caagcggtgg cattctccaa cacagacgtt caacatgctc ctcacagccc
122641 cgcccgtctc tgttgaccac cgtgcgatgc gcacaacgca tgctggacga tgaacatggt
122701 ggcacctgcc ccgagaccaa aggctgaccc ccccgagacc aaaggctgac cccccccga
122761 gaccaaaggc tgacccccg cgagaccaaa ggctgaccgc ccccgagacc aaaggctgac
122821
       cccccccc gagaccaaag gctgacccc cacccgagac caaaggctga cacccccag
122881 agaccaaagg ctgaccccc cgagaccaaa ggctgacccc cccgcgagac caaaggctga
122941 ccccccaccc gagaccaaag gctgacaccc cccagagacc aaaggctgac cccccgaga
123001 ccaaaggctg acacccccca gagaccaaag gctgacaccc ccgagaccaa aggctgaccc
123061 ccccgcgaga ccaaaggctg aaccccccg agaccaaagg ctgacacccc ccgagaccaa
123121
       aggetgaceg ecceegagae caaaggetga ecceeegeg agaceaaagg etgaceeee
123181
       ccgagaccaa aggctgaccc cccgcgagac caaaggctga cccccccga gaccaaaggc
123241 tgacccccc ccccgagacc aaaggctgac cccccacccg agaccaaagg ctgacacccc
123301 ccagagacca aaggctgacc cccccgagac caaaggctga cccccccgag accaaaggct
123361 gaccgcccc gagacaaaag gctgaccacc cccgagacca aaggctgacc ccccgcgaga
123421
       ccaaaggetg acceccega gaccaaagge tgaccecce caagaccate agetgacgte
123481
       ctgccaagac cgctggccag aataatgctc ggggcggggg gcacttcacg gaagaagtgg
123541 agatcatttt attccctgat tttcaaacac ttcagtatat gcatcccagg aatgatctgt
123601 ctaaaacaca cagaagaaaa ttgacaggag agcaaagcac aaaatgtgag ctatgttttg
123661 ctgcattttt ttccgggact ttgattttcc tgctgctagt gtcaagtgta tctgttttta
```

```
123721 catgtaattt ttattaatta gaatcagttt cctctcccca ctcaataaat attaaagaaa
123781 ctccagaagc acactaggct gaaaagcact cagttgggag cctgctggtg gcctgtctgt
123841 ccaaccccac agetgtccag cetggggtet tacagaaagg ttggtacccc gacetggete
123901 taagtgtgag tcccgctctg ctcttgaagt ctgtggatgt ctggcaaacc cagccaggtt
123961 ctcccctggg ggacagagag aggatcatgg ggagggctct gtccctgacc ttcaggtgcc
124021 accgcagggg cccagagcct ggtagtaccc gggtcatcaa gtcaagttgc cggcattcag
124081 atcctggtga gttacacaac gcctgccctg cctcttcctt ctatagaacc tgctcctttg
124141 cagttggatt gatggtaaag tagttactag aaatggcaac tagatgttaa aaatttataa
124201 agatccaaag gcttaacagc tctcctctat tactctgaat ttttaagtat tcaaccacag
124261 acagcetgga agttaggggt teacaggaaa cacaagcatg cateetgttt cettetgeag
124321 agcaccagg ctggctggtt cccactgccc cttcccatgg aagccacagc tgcagccatc
124381 agcaqccccc cacctgtgta tgactgggac ctggtctgtc actcaacct gtcaacctcc 124441 agcataaaca ctgtcaggtg tgtgccaagg ttgcagtggc aacaatcaag catagaaggc 124501 acaaagcata ggaagcacac aggtccatgc acagagggac ccagactttg ccaagggaca
124561 aggctgcaag tccctgttgc cctcaaactc acctccctcc gaaatacaca cacagcacgc
124621 accttgccaa gagtccccca gatgctggca tctgctaaga ttcccattcc tgaaagtatt
124681 ctaactccaa gattetttet ecceatette ettttggtaa tgaacetggg agatetgetg
124741 gacaacgggg caatggccag gcagcctccc ctgctgtgac agctgcctgg tggaatgacg
124801 gtctcacagg gagagctgca cagtgcctgc agttcccagg gcgcctcctc tcagagcctg
124861 ctcgggcact ctcttgcctc tcccagctcc ccagggaggt ctctaacaac cttgggagct
124921 ttcagggaag ggggctggac ccctcactac tgaacagtcc caggagtggg aagtgtcatt
124981 gagtgggatt tgagccactc cgtcctcacc actggacagt cccaggagtg ggaagtatcg
125041 agtgggattt gagccactcg gtcctcacca ctgggggctc ctttacagtt cagcatccca
125101 gaggatttca cacactgact tttccacttt tccaaaaggg acgccagcgg gcaggagctg
125161 tccatggggt taggaaacag ctgtcctcac ccgcatctcc accagctcct cctctgtctc
125221 atgggatect egecaggtge cagecactee egteetteet ettggagage gaeceettgt
125281 ctagggctct gtcttggagc tatggctgga gctgggcctt ccagggttct gctgagcaca
125341 gtgaccacaa cagagttgcc tctgagctcc acagaacctg atgactttgc ttggccactc
125401 taacetteec tggacetggt tteaggeect acagacettt acteeagaaa gtetetttt
125461 tggeetaage tggeeggage caattteeaa caggaceaag gageeecgae agteacatge
125521 ccagcgaggc tctaaggaaa gctagactcc actttgaagg gcagggtggg gggcgaggca
125581 ggcaggaga gtaagcactg gacgctgagc caggggccct ggtttccaat gcggtcatgg
125641 ccagtcctgc ccccttgcag gcccccagtt ccctcatctg caaactgagg agctggacta
125701 cgtaacctat gaattactgc ttatcctgtt tattcatcac cccaaaaaga aaccccgcac
125761 acgttggcag gtaccgatca tccttctaaa actctactag gaccaaggag aaagaaccaa
125821 accaaaaacc agaaacccac tcctgtaaaa taaaggccaa ggccgtccca tggcacgcaa
125881 ggccttccat ggggtcccag cagccctctg tccctgggcg cacccccagt gtcttcctct
125941 ctctccgggc ttctatttgc acctcaaagc ctacaccact gcccttctct cttgttatag
126001 aggtcagtaa gtagcagaga gctggtaaag atctgtcagc accaaactga gactccctc
126061 gactcaacca gagagtttaa aatgcaactg aaaagggaat catttttcat tataaagttc
126121 aatgettttt ttettetttt tttgagacag agtetegete tgteacceag getggagtge
126181 agtggcacaa cctcagctca ctgcaaactc tgcctcccat ttttaagcga ttctcctgcc
126241 tcagcctccc aagtaactgg gattactggt acacaccacc acatccagct aatttttgta
126301 \quad {\tt tttctagtag} \ \ {\tt agatggggtt} \ \ {\tt tcaccatgtt} \ \ {\tt ggccaggctg} \ \ {\tt gtctcaaact} \ \ {\tt cctgacctca}
126361 ggtgatccac ctgcctcggc ctcacaaagt gctgggatta caggcataag ccatggcgcc
126421 cggccagttc aatgcttttt aatatataac agctttatgg tgctgtgatt accattccat
126481 acateteage catetaaact atatgetgaa agtgaacaat teaaceataa eeactattga
126541 ttttagaaca ttttcatcac cccaaaaaga aaccccgtac acattggcag tcactcccca
126601 tgttttcccc aacctctcct ccccaaccca gccctgggca accactaatc tacattctgt
126661 ctctatgaat tggcctattc tggacatttc atatacgtgg aatcacatgc tatgtggcct
126721 tttgtgactg gcttccttca tttagtatgt tttcaaggtt catccatggt gtagcatata
126781 gcagtatttc attcctcttt tattgtcaaa taatacccca tcacatgtat ataccacatt
126841 ttatttatcc atttgccggt tgatggacat gtgggttgtt ggtttttggc tcctatgcat
126901 aatgctgcta tgaacatctg tggacaagtt tttgtgtgga catgtgtttt cattcctctc
126961 aaagtggaat tactgggtca tacagtaact gtgccagact gtcctctaca ggggctggac
127021 cattctcagt gcccccagca gtgtgtgagg gttcaatttc ccctcatccc caccaatact
127081 cattattctt aggetetttg actetageta tecageaggt gtgaagtggt gteceateat
127141 gcttcggctt gcatttccct gacaactaat gatgctaagc atcttttcat gagcttatag
127201 gtcatttatt taactttgga gaaacatcca ttcagatact ttccctattt ttaataagac
127261 cattttcttt ttattgacct gtaagagctc tttatatatt ctagacacaa atcccttatt
127321 agatatacaa tttatgaata ttttctcttg ttctgtgggc tgtcttttca actttcttat
127381 tagtgtccac tgaagtcatg aaggactttc ttgaagtcca gttcacctat tttttcttt
127441 tgtccacttg tgcttctggt gtcatatcta agactttgcc taatccaaag taacaaagat
127501 ttactcctac attatttaag agttctatag ttttagctct tacatgtaga tctatgatcc
```

```
127561 atccatttac agttaatatt tgtgtatggt gtgaggaagg ggtccaactt catttttcca
127621 tatgtggata tccaggtgtg ccaacaccat ttgttgaaaa gaccattctt tcccccactg
127681 acttgtcttg gacctttgtc aagaatcaat atgaggatgt atttccaaac tctcagttct
127741 attctaccaa tctatatgtc tatccttctg ccaacaccac acagtcttga ttactacagc
127801 tttgtagtaa gtcttagaat tacaaagcat gagcccttcc tctgttcttc tcctcaatag
127861 cattttggtt agtctggatc ccttgtattt ctgtatgaat tttaggatca gcttgtcaat
127921 ttctgccaca aagctagctg ggatttgata gaattaaatg cattctggag tcatgtttgg 127981 tacccattag ttcacctcct aggccaatgt ttaggaaaca ttggcctaca aagaaactct
128041 gcattagaaa ccaagggctt ggtcaggcat ggtggctcac accetgtaat cccagcactt
128101 tgggaggctg aggcaggcgg atcacgaggt caggagattg agaccatcct ggctaacacg
128161 gtaaaaccat gtcatcttga gatgggagcc ctaagtctat caactaacca ggtgagccac
128221 tgtgagcaac tctgggccct gggagagggt gcacagaggg atggcttcaa ccctgctgct
128281 agagaatgcc ctcgagagcg tctgtctcag ttctgcttgg catccctccc cagcacccc
128341 cacctgccac tttacgcagc ctggacttga ctttaaaact gagacacctg gcaagtgggg
128401 aaatcacagg tcgaaatagc ggaattgccc tctgcatcta tgctacaggg ataatgaggg
128461 ttacaaatca gaagacattt agcatatatt ctggaaaaaa aaagctatgt aatatataaa
128521 ctattcataa tttaacttta ataaatgggg gcaggcaaaa aattgccaaa caagcccaca
128581 acaatcagac aaagagtaga ggaagaaaaa aggaattaca gtttaattgc actcgtttcc
128641 taatcttcag aatcttcagt tagcatcaac agttactggt aagtttctaa aatcagtaga
128701 tacaagctga agaattctac tcaaaattag aaaagtcaca actagtaaaa ctaatgtata
128761 ccttccaaat gactgaaggc agaccatata gaaaatatgg tagactagaa aaacagcaaa
128821 aaaaaaaaaa aaaaaaaaa tccagaaaaa cagaaaacat aaattagatg acagaagtaa
128881 gaacaaatat ataacaataa atgtaggctg ggcatgatgt gatcccagaa ctctgggagg
128941 ctgaggcagt taggaatttg agaccaggct ggccaacatg gtgaaacccc atctgtccta
129001 aaaatacaaa attagccaga cgtggtggtg cacacctgta atcccagcta ctcaggaggc
129061 tgaggcggga gaatcacttg aacccaggag gcagagttac agtgagccga gatcatgtca
129121 ctgcactcca gcctgggaga cagagacaga ccctgactca aaaaaaccaa aacctaaaac
129181 taaacaaaca aaacaaaaca ataaatggtc agattattat tattattatt attttggaga
129241 ctccagcctg ggagacagag agataccctg tctcaaaaaa acccaaaatc caaccgggcg
129301 cagtggctca cgtccataat cccagcactt tgggaggacg aggcgaatgg atcacaaggc
129361 caggagttca agaccagcct ggccaatatg gtgaaacccc gtctctacta aaaacccaaa
129421 aattageegg gettggtggt acgegeetgt ggteecaget gettgggagg etgaggeagg
129481 agaattgctt gaacccagga ggctgaggtt gcagtgagcc gagattgcat cactgcactc
129541 cattctgggc aacagagtga gactccatct caaaaacaaa caaacaaaca aaaacagaca
129601 acaaaaacaa taaatggtca gattattatt attattattt tggagacagt gtcttgttct
129661 gtcacccagg ctggagtgga gtacagtggc ctgagctcag ttcactgaga cctctgcctc
129721 ccaggttcaa gcaattctcc tgcctcagcc tcccaagtag ctgggattac aggtgcacaa
129781 caccatgcct ggctaatttt tgcattttta gtagagacgg ggtttcgcca tgttggccag
129841 gctggtctcg aactcctgac ctcaggtgat ccgcccacct cggcctccca aagtgctggg
129901 attacaggtg tgaaccaccg ttcccagcca gtcagattat ttcaataaca ctctatgccc
129961 tgcaaaataa ttttacaaaa tttacagatt tatgctaggc taaaagagtt tctcagattt
130021 tttgaccact taaggaacag acacaccat gacatattgg tgaccgaaga aggcggcaag
130081 cccagctgca gcatgacctc cttacgtaaa atcatgtata tctctgtgcc aaacgtcagc
130141 acagtotaat aattaagcat gtggcotoog agtoactotg cotogattoa aatgtttact
130201 tcacctctga ctgagtggcc tctctgtgga cagtgtctgc agggttgaat ggagataata
130261 acagggtttc catggctgat gtgagggcta agcgagatac cgcgtctcta gcactgggca
130321 cagcacgtga taaatcagcc gactggcagc accatcacca tcatgatgat catggcatga
130381 cagctgttag gaaacgcgta acaaagggtc agcagtgtta cgatcggggg tgagtttcac
130441 tttttattaa tattttctgt attttttttg ttttacattt ttacaaaggg catatagcaa
130501 aacagacaat tcatgtgaag acaggagaga cggaaagggg gagagcacag agagaaagat
130561 aagggggaaa atggaataaa caagatgccg acaagaatgc ctcacggggc cagcgcaggg
130621 gccagccagg cggccttctg ctaaatcaag caacgcttga gtggctccct cgggacctgg
130681 cctgtccaga atgtcccaca ctcagccctc tgcagccagc tcccccatct ccatggctcc
130741 tgcacacac aatgccgggg tagcctccag gaaacagagc tggccagcca gacccagcca
130801 ggacacagag gtcagtgggt cagacccaga ctctgggact gcaacaggcc tgcctatttg
130861 tgacgagaac tgacactcgt cccggccaga ttctctggct gacatttccc aggtctcgtt
130921 cagcatgaag cccacgtcgg ggaacgtccc cagtcacaaa ttaacattca cataaataac
130981 agggcgctct ctactaaaga agaaaaatga ctcqtqctqc aqqaacattt qccaaactat
131041 caaaaagcaa gatttttctt tctgagcttc catgtctcac cagctggacc acagcagatt
131101 gtggccttga gacgtgtggt ggaggagagc tcatggaata aggtccaact tccccattca
131161 agatectgee aacaggeegg geaeggtgge teaegeetat aatectagea etttgggagg
131221 ccgaggcagg cggatcacct gaggtcagga gtttgagacc atcctgggca acatggtgaa
131281 accetytete taccaaaata caacaaatta gegggacatg gtggtgggeg tetgtagtee
131341 cagctactcg ggaggctgag gcatgagaat cgcttgagcc cagaaggcgg aggttgcaat
```

```
131401 gagetaagat egeacegetg eacteeaget tgggetacag agtgagagae tettgtetea
       aaaaaaaaaa aaaaaaaaa agaccctgtc gacaggccct tccctgggct ggcacctgcc
131521 cacaccaget ggaacetaac acetttgcac agetgtteec tgecageete eetgeeteet
131581 tggaggtctg cacacaccgc ccctcccttc ctccaaccag cccgggagac cagcacgcct
131641 gagcaccage acteccagag acagageegg caeggtgggt etgtetgete agggggetgg
131701 ggtggcaggg gcacatgtct gggagttgcc aacatatgct teettaccag attececagg
131761 ggacccaccc tggagagcaa ccaaaccctg caaggctgca ctccaagaac tgagggcctg
131821 gggacccagg accgtcccc agcattcaca gcaggctcac ccacatccac caggagatgc
131881 tgcccaggta gactgccagc accccctcc acaaaaggtc ggggccggcg ccttccctag
131941 gttgctcggg caaccatcac agggcagcac aggccggggc ttgaatagca gaacctattc
132001 totcacagto otggaggeta gagetetaaa attaaggtgt gggeagagge ggtttetete
132061 gaggcctctc tccttggctt gtcgacagca tctttcccct gtcctcacat ggccgtcccc
132121 ctgtgtgtac ttctgtccta atcgcttctt cttaggacac cagtcattca tgttgaatca
132181 gtgacttcat tttcagttaa ttatctcttt aaagaccctg cctccaaata cagccaatat
132241 cctgatctac gggagtttag gacctcaaca aaggaactgg gggatctagg gagggcgtca
132301 ctcagcccat aacagcctcc aggcgccaag tccacacaga atcggagcag gctgctggca
132361 gggtccggtg gccagagctg ggcgggctgt tccttgggga gccactctgg acaggccgga
132421 aggtcaatgc caggatcact ccccaggggc cagaaatcca gcatggagga aagctgccac 132481 tccagggaag taggagccg cccagggctg gccacatggg atgcccatct caccettect
132541 tctaaactgg gcattctcac atggggacac ggggcagtga gtgcaggcgc agggagacga
132601 gaatgctgca cagccggtag gtggtggacg ggcctcagga cccctccgcc agcagcaggc
132661 cacteteta eggtecagea ggageeetge tecagageee aegaetggag eeagetgagg
132721 etggtgtete acatteetge agagaggetg getaaggete eegtgtgggg geacteecea
132781 tgeecactge accecagaat tttetgggeg atcecaagge tgagtetaeg eagetgttgg
132841 aagacggggt atgcaattct agatgtgtgg cgtgttttga acagcatcca ataccctttc
132901 tgtggcagct cagcccggag agcaggtccc cagtctcgag gacccaggag gcagggtctg
132961 ctccttccca cagcgggtgc tcctccagga ggggccaggt gctcagaggg aaaccagtgc
133021 ccaccaaggg cccagctgcc tggctggctc ccagcagtgt ggggaagaca cactacccga
133081 cggacgtccc ccttagaagc aggggcagac aggaactccc atggggagag cacaggctgg
133141 gacgcagccc gcccaacgcc agtcccccca ctccactgtg caacaaggat cagcctttcc
133201 tetetcaaag ceteggttee eccagagggg getgeagttg agagttgatg gtgagactea
133261 gtggggcatg tcctccatgt ctgcttgtgc aaagctgccc agatcaggca gttttcccag
133321 ccagaggacc ccccctttca ctttccatca caggctgtca tctccccggg tccctgggcc
133381 acaggeeect cteaggacee eteeggeete atgeacacae agageetgtg caetgeetea
133441 ctcctgcttc ctttgaattg ggcttctttt cctgctgtga tctctggggc ccactgtgct
133501 atccagggca cgctgaccgc cgaccgtcct ctgcccgcct gcccagctgc cactcccggg
133561 cgggcagccc tgccaggccc gaggctgtct gcttcccctt ctgtccagag ttcccaaaac
133621 aaaaatcagg ccataccatc tgacgaagga tcctgtctgg tttatttatg ggaagagcca
133681 gggctctgag ggccaggttg tctgggctgt ggccaggctg ctctgcaggc cttcagacac
133741 tgcccagccc gtgtccccac ccacccaggg tggctccggg ggaggggcgg gggcagggcc
133801 ccagcactgg tgagcccaca ctggtgactc tgggatgtgt atttattcta gagccaggac
133861 agcageegce agggeectag geeetetgt gggtggttgg eecactggag ageeggagea
133921 gcgaggccag caatgaccaa aggcgccgta tccagaatgc aggcaggctc aggcgcacct
133981 gccctccctg gatgccacta cagattcggg gagactgaac tcatgggatc aagtgcccca
134041 cagatectgg tecteacaag ggacaaggee accaggtgte acaetgggag acagtggeae
134101 cccagggtat gaaaggccac accaggetta tgtccagtaa ccctgcctgc acagcacagc
134161 acggcacggc atccataccg cagcacagcc ccgccctccg gcagtgccaa gcccgggatc
134221 tcagggcccc caccagaaac cagacaggtg agcaggtggc agctccaggc caggtgctga
134281 ccttgtgcat accaggcctt ccccgagage aggctgcage cccccagctg gttctgactg
134341 ccacaggact gegecectee tgeagggete tgeteacace cacactecet geteagagae
134401 ggcctgtccc accgccccgt gtgaaatcac acccaagcac agcggaacga tggaggaggc
134461 agctggaagg tgctttcggt ggtcaaatct ggggcaattt gaacacaata ataaatgata
134521 gtaataggtt agaacccatt gaataaaata aatatccaca gatcagtatt ggtagaaaca
134581 aataactgaa taataaataa gtgggagggg aagggcagct ctttctcaca gggtaattca
134641 actaaaaatg taaaagaaat gatgagatag aaaatcatgg tagtaaaccc catcggcaac
134701 agcacagtca ggactgcggc aggtacgact tatccgtgga ggctacaatt agtgagcaaa
134761 aggataacaa gaaacagaat gctcacatca cgtcacagca gctacccacg ggagatttaa
134821 tcatcgcaat gggaaaaaag agtgaaagag tggtttgctc atcaagccac tcatctgaga
134881 cctgaaaaaa cctcacagtc acageectag ageteeeggg geateeagtg gaateeeagt
134941 aggtaacacc ttagccaaat gaagaagggc atcactgaca ataggagaca actggacatc
135001
       ccaatgtgac agtcccagcg tggtgcccta cggagggcac agtgcttctg tgacagtcct
135061 gccagaaaca cgtaagctca agccagtaca aggcacacca gaaaaaccca tggggatgca
135121 ccgtctacaa aacagctgac cagtcctctt caaaaacatc caggtcatga aacctcagat
135181 gggaggaaac gggagagaca caacaactaa atgccacgtg ggatcctgag ggggagcctg
```

```
135241 aaccagacaa cggacatgag tcggaagact gacaaaattc agtgcagtct ggagtgctac
135301 ggttagaatg tgactggttt gttcccacca aaactcatct tgacatttgg tccccagtgt
135361 ggcagtgttg gaaggtgggg cctggggtga ggtatctgaa tcatggaggc cgatccctcg
135421 tgagtggctt gatactgttc tcaaggtagc aagggaattc ttgctctgga gaggcttgat
135481 tagttcccga gcctgggttg ttataaaagc aggacactcc ctgggtttcc cttctttgca
135541 cacatgggct ttccctttga ccctctccac cacgttatga cacagcacaa aaaggcctca
135601 ccagaaqcca gggccatgct cttgaacttc ccagcctgca gaaccatgag ctaaataaqc
135661 ttcttttctt tataaattac ccagtctcag gtattccatt atagcaacac aaaatagact
135721 aaaactaaga cactaagtac caacgcttag tatcaaccta caaagttcct ggtttcagtc
135781 cttgttctac gttgcataca gaggaagctg ggtgaagggc acagaggaaa tctatgctat
135841 ttttgcaact tttcttgcaa tttttccaag acagcataga tctaaagtta tttcaaaatt 135901 aaaactttaa acacataaaa ataaaactgg gccccagcct ccctcagtgc tctctggccg 135961 gtccattctt cacattggct gcctttccct ggagtggagg cgcccactgc atccccagtg
136021 tccagggagc aggtcctgta gaaggtggta ggttccaggg atcggggagc aagtacagag
136081 gccctqaqaa qqaaqcaaqc ctqqcqtqtt ccaqqaacac caqqqaqaac cqtqtaqccq
136141 gagcaatgct cttgtgcaga gggcctatgc ctgagccgcc ctgtgggccc tgccgttccc
136201 ttcagggcac tetecaacce tetgecetgt gcatggggce acggatgcce caggagetet 136261 agggetgttg actatgaggt tgetteaggt etcagtgagt ggettgatga gegagecace cteaetggce aggaggggac tteetteaca ggtgtgaatg ggaetgagee accageatga
136381 tgctgacacg tgggttttga ggattcccac tcacatcaga cagaatgagt gcggggctct
136441 gggatacage tgcccaagee teaageetga gtggcaettg tgggeteetg categgetgt
136501 ggggccacct ccgggctctg gtgttcaggg gtgggcagtg gcagcagaca tccttcactc
136561 tgtgcctctg tcactggtgc ccagggcggt ggcccacacc ctcaaaggtt ccgtgtcatt 136621 tccgggcagt cttccagggc tggctgcatc cacctgcttg gagtgctttc agagggaagc
136681 tgttgccctg caatgccacg accettcccg tgtcctctct tgcctccaag ccgtgctgga
136741 catcatgctc tcctcccagg ctggtctgca gagggatgga atgcctgtca caactgggat
136801 ccctcttctc ttgtcattct gcctgctggt ggcagagtgt ggaaggcggg agtgtgccca
136861 ccattaaacg aggttgaatt ctgggagtgc agaagtaaca gcctcaggac tgatggggaa
136921 gatgaggctg caagatgtgt ggttcttccc ttcgctataa aggtccaaac gatatttatt
136981 tatttattta tttatttaga gacaggatct tactgtgtca cccactgcag tacagtggct
137041 caaacacage teactgeage etggaceee tgggeteaag tgateeteee aacteageet
137101 cccaagtagc tgggaccaca gacgtgtgcc acaacagcta gctaattaaa agaaaaaaaa
137161 aaatttgtag aaatgaggte ttgetatgtt gecagggetg atgttgaact cetgggetea
137221 agtaateeta etgeettggt eteceaaaat getgggatta eagatgtgag eeaceacace
137281 tggcccaaac attaaattta acacgaccag atgaggacgt atggctcaca ttttcttgca
137341 cactotgggc aagatocaca ttggtggtca toattaatga agcacggtaa coacottcaa
137401 gggaacaacg gaagccggca ttcccggggg cagagagaag cggcggagtc aggagaaatg
137461 ccacaaccag cactaaatac atggggctgg ggaatgcggg gcaagaagat atacagcatc 137521 tccacacaaa caggttccaa agagccacac attgtgagcg gtaacagctt tgctattacc
137581 ccccagctgt gggagatata aatatgaaat tagctgggac agcacactcg accataaaga
137641 acaggaagag atagctcctg agcctgagca gtaacgaggg tctctgcaag cactgagcag
137701 acagtgagca aatgtgttcg tgcttctcct ccccgtcccc taaatcttcc ttgatacatc
137761 ttgctattcc ccatgtgggc tcatgaatct tgttataaat tttttaatca aattgtctat 137821 atagacagga gtcctgcagg aaatatatgc ccagggcccc atgtatccta gggacagcca
137881 gccatgcctt tgggaacagc ctagaaggac tgtcaggaag gggcctgggt gggtgggagt
137941 cagcttqccc aaggtqactc tctctccttq caaqatacat ctqaqaqaqa aqcccattqt
138001 aagcagggcc aatccaagct cccaccccac cctggagtgc agaccactgc ccagacggct
138061 tectgaggte etggetgggg eceteeaagg taccceattt ecaggeetee ageceeagee
138121 ccccaatage etgeettgaa ttgtettetg ettaagtgag ttgaggteag ttttgeeate
138181 caaagagaag ccctcctgtt ttcctagagg ttgtcaggag ctacgctggc cggtcccctg
138241 \quad {\tt ggcttgggac} \ \ {\tt atcctctgtt} \ \ {\tt gttgggggga} \ \ {\tt gagggtggga} \ \ {\tt agcatctttc} \ \ {\tt ctgcagccat}
138301 gacctcacct tggtgacagc cacagcttct cactcacagc actggtgtaa gtgctaacct
138361 gaagccgctc ctccttgtcc acggggaaga cagtctgacc ccactttcct ctgctccccg
138421 aaaataagga acgttattgg tgttgctttg tcctgacaga ctcacacgtc cttaaaaagt
138481 gctaatcttc acaaaagagg cagcggcctg tgccttcctt gaggaaagtc agattaatta
138541 gctgactccc acatgagcag cctctgattc ttgcaggctt tgtttatgga tcagaaatca
138601 ggcttgaagt gaaaactgac atctcaatgt gaagagtatt ttccctgcta actgcagtga
138661 gtcagagccg tgcgctgagc tagacagata gggaacatgg ccttcccatg tggactggag
138721 tgtgccaacg cctccgggcc acagcccagg acaagcgtgg gacatcagcc tcccattgct
138781 aggccagaac aggccagtgc cccatagatc ccagcccaag acaagcaccg gagttggcat
138841 tccagggtag ggttttgttt gtttgtttgt ttttctcaag atggaatctt gctctgtcgc
138901 ctaggctgga gtgcagtggc atgatctggg ctcaccacaa cctccacctc ctgggttcaa
138961 gtgattctcg tgtctcagcc tcccgagtag ctgtgattac aggcacacgc caccacacc
139021 agctaaattt ttttttttt tgtatttttt tagtagaatg gggtttcatc acattggcta
```

```
139081 ggtggtctcg aactcctgac cctgtgatcc gcctgccctg gcttcccaaa atgctgagat
139141 tacaggtgtg agccaccgca cctggccaag gtttttttgt tttttgttt ttttgtttta
139201 aggtatttgt gcatctcaaa cattccactt aatgactggg aactggggcc tgcaatccca
139261 gcacttttgg gaggccgagg caggaagact gcttgagccc aggagttcca gaccagcata
139321 gtgaggcctc atctctacaa ataatttaaa aattagctgg gtgtggtggt gcatgcctgt
139381 ggtcccagct acttgggagg ctgaggtggg agaatcacct aaaccctgaa ggtccaagct
139441 gcagtgagct aagatgctgc cactgcactc cagcctgggt aacagaaaaa gacactttca
139501 aaaagaaaa atatgactgg gaaccgggag aaagatgttg atgaaggcac gcagcctaca 139561 gtcagagctg acagcccaga aacacgtcca gccagccaat tattttaat gaatgccctt
139621 cctttggtga ctcaatccca tgaacaggga agatgggtgc atggctagaa gctctgtcca
139681 ggctccgagg gctgcccagc agacccaccc tagggggtgc caggatcaac ccgacccagg
139741 gatgctgagc acccatgcaa gtctgaccca cccacgtggc ccaaggaggc agcttgtgga
139801 ggtccggaat ggtggtctgg agattgggca cccacagact tggggagtgg aagggccacc
139861 ccaagecetg eeceegeee cactgeaget teecegeagg getgeaceca cateegeagg
139921 gtggcccctg ccccgtgtgc ccagcttcca aggtggcctg cccctgatgc cagagaaact
139981 tcctgctggc caagcggagg ggcttgcttt ctagggtcag caggaaatgt caacattttc
140041 cctgaaaaat ccttcaattc cctcattgag tctccagtag acttaggtca tgtatacact
140101 caacaggaca actetttee acceeaaatg etgacageet etgaggeagt etaaagaagg
140161 aaggaagagt cactgtgcag actcctggca tggaggccct cctgtcgctc tcaactactg
140221 cctctaggcg aacgggcctg tggggaactt ggcgggttcc cactggccgc atggatcatt
140281 gtttccactt caaaaccagg ccttgagcac cctactggag gctgctgggt ttgtctgtca
140341 tcctcagage ctgagageat ctggcaccag gcctggctga ataaatagat tctggattag
140401 aaaggaaacc tggctttgaa aagacacaga gaagaaccag gtccctgcgt cccttccttc
140461 caggetgatg ttetgggetg gegggtetet gttgggetee ceacceette acettetgee
140521 etgteetaca geceagtagg cagacetgat ggactggete eteetggete teeetgggtg
140581 aaggggggca ccgacaggaa gccagggctg gggagagaga cagaaggttt tatttctccc
140641 gctgtggtgg ccccaagect ccccgccctg caageteect egtectgeec geagetetgt
140701 gagttgtgcc tttgtcaact cctttctgtt gatcccttat gtgtcccagg cccctgactg
140761 atccgacatg ccctgtagcc cgaccaggca gccctcactc tcatagtcca ggtgctggtc
140821 ccatctctag ggtttgggat gggacttcca cactccagcc caatttccac cctgaagcac
140881 acgggtgagc cagttcctg caaccaccac agactcagga cacaaagtcc caggctggtc
140941 cagaacattc tqaqcaqqqc aqaqqaqccc cqtccatqqc qqctqqqqca qtcccqcaaq
141001 tgagagtcgg ggtgggagga gctggaggct ctggaaggga ttcaggagca gccaccaagg
141061 ccaccttcca cacacgtcct caaaagccct tccatattcc gctgaaacca ctagtggggc
141121 ctgtgctggg agcaagggag gcgtggagac aggtggggct gtggaaggag gctgccatga
141181 ggagggaagg ctcctccaac ccaggacgcc ccactgcagg aggaaatgcc tttctggctg
141241 tggtccagga gactgagggt cctgctcagc cacacagcac gtgccaaggt gcagagccca
141301 ggggaagage aaaccgagga getggeggtg ceteggaega tgeagtgatg gtgaageagg
141361 aggatggggg aggcctgagc cgtggggaca ggagaatgac cacaggatcc acacctctgt
141421 ggtccgtggg acctcagcag acgctttggg tgatgccaga gagccatgga ggaggtggcg
141481 gcaggggctg tgcttctgag aatgctgaca atgatgggac ccgggagcag ccggagctca
141541 agggacggc aggggcaatg ccggggcctg tctgtgctcg gaggagggg aggtgggtga
141601 gcaaggaggt gggtgagcag ggagcgggaa ggtcccaagg ggggatgctg cctgcagagg
141661 ccagcagtca ggaatgtcga agtagateet teagegagge tggggeeeet geteggagge
141721 aggaaagtaa gggaggaggg atggggctgg acccagcaat tcagcaagga aagcaggagg
141781 cgggagacag tggtacaggc agggagcaag tacagcaaag aggaccagtg gcatccgact
141841 cggataagga aggaccgcga ggcaggtgga gatgggctca gtgggtaagg tccccagggg
141901 cggcctgggc agagggcagg aggggagaggc ggcgggcaga gagaggctgc tgcgtgctgt
141961 gggtcaggag ggtggtgcct gggaagacca gctgcctgcc tgctcccagg gtggacaggg
142021 gacaagtcaa gcataaagat gcaaaggtgc aggccgaaaa aaggacgggc cactggtatc
142081 actaacacaa ccatcaatgg gtttaacatt gcagttagag atcaaccaga ctgagatgga
142141 acaaacaagg catgccgtct gtaacacatg cctgaaacat gctaaaagag agacagagaa
142201 aactgcaaac ccagaaagca gggtgtctgt agtatcatca aaatagaact cagagcaagt
142261 actaaatgac tggaaactcc tgttgtattg acaaggcttg gtgaaagcac acagtcacca
142321 agctttacaa accaagggcc gcagcatctg ccatggttag aaacacaagt ggctcaacag
142381 ccctgtcaaa gggaaatgcg aacggccact cccagtgggt gacaggtctc ctagaccaca
142441 gcagagggc acagactcat tgactcggga aatgggccgg attgatttct ggatggatct
142501 gacgacttac aaccgaaagc aaatgagtat tetttacaag catgggggag catttacaaa
142561 aattgateec ggceteecet geetgeetgg eetgaateec ecaageetgt eageegtage
142621 ctcccaccc acctgcctgg caatgcagaa acctgagatt gctgcttctc ggcaccaaga
142681 accaagaggt gaagttggta tggggacccc cttctgcccc actccctgct agtactgtcc
142741 agccagaagg ccctccccac agcctgcccc tttctcttga ctgttccctt ccccaatacg
142801 ctgaggcccc atgtctccca ggaccctccc tcaagacccc ggcttccctc tccagggtga
142861 cttgggccct tgcatcatgg ggcataatgc caactcccca cccctactga tgaagtcact
```

```
142921 ggcagagtgc ccccaacgcc ctccactata atcccagagg acggagagct cttgctctga
142981 gccqaqacaa cccactqccc accaccagct ccctcagggc tctccacaag tcccttctcg
143041 cctcccctgc tgcgtcttcg gcctcctcct ctctaaagtc ctctctcagc ccaacaacag
143101 aaccgggtct cttcaatcct gaacaagaag actctgcttc ccctccagcc acaggacctc
143161 ccttcctca cagcccttct cagcaggctg gcctctgctg ctccctcca cgcaccaatg
143221 cccatggcct ctgtccctcc tccccagggc cccggggacc tccacaccct cctgctcagc
143281 ctctctctgg ccgccccag ctgctccggt ttccacagca ccagaggcca gggtcccctc
143341 gtgccacagt gaccctgcaa cgcagattcc gtgctccctt cagaagccca cctgacattc
143401 atagaagctg agcaaacacc aggagacaga ggcaatttca gaaattcccc gaggctcggg
143461 gaacccagge tgtccccttc actcctaatc tgtggcagge ctggccctgc caagcctcca
143521 tggagatgag ctcttcctgt cccaaggtga tggtgtgaag cgggcctttg gaaggtgatg
143581 aggtcatgag ggtggggacc ccgttaatgg gattagtgcc cttatcagag aggcccaggg
143641 agcttgtgca ccctccactg tgtgcaaaca cagcaagaag gccccagcta tgagcgagga
143701 agcagecete accagacace aaacceaetg gegeeeegat eteacatgtg agaeteeaaa
143761 actgtgagaa ataaatttct gttgtttcta aacacccagt ctgtgatatt ttgttatggc
143821 agcctgaacg gagggacacc tgcagagcct gggatgctca gaatacacac gtggcaggag
143881 gggtgtggac gggctctacg gaactgggag atgcctagaa atgctagagg ggttgagggg
143941 gaggcattca caagcccttg taggaaactg agatctgcgc tggttagggg tggggtgtca
144001 ctggaatggc aagatgcaga tataaatgct gacaagaccc aatttaaacc cagagatgct
144061 aaggtetgaa aacatttgga ttatactagg aatcaaegea aagettaata aeetaaaate
144121 caaccactcg gaagtttttt caacattcct ctaaatagct cttaagttac tggaatcaaa
144181 atcataaatc tttttaaaat gatgacagtg agaattcagc acatcagaac ctgtggatga
144241 gaccaaagcc accaccagaa gcaagttcac aaccttctta attatagacc agagtgaaaa
144301
       taaatgaagc cagtgctcca gtcaagaggg cagaagagag agcaaccata aacctaaaga
144361 tgttgataca aatagcatga gtgacaagat ctcacttctg agtgtgacat atatgtaaca
144421 agatggaaaa acggttagtt tgtatagctg taacaaatta ctgcaaatgt agtggcttaa
144481 aaacacaaat ttgtccaggc gcggtggctc acgcctgtaa tcccagcact ttgggaggcc
144541 aaggtgggtg aatcacgagg tcaggagatc gagaccatcc tggctaacac ggtgaaaccc
144601 catctctact aaaaatacaa aaaattagcc aggcgtggtg gcgggcgcct gtagtcccag
144661 ctacttggga ggctgaggca ggagaatggt gtgaacccag gaggcggagc ttgcagtgag
144721 ccaagatcac accacagcac tccagcctgg gcaacagatc aagactccaa ctcaaacaca
144781 cacacacaca cacacacaca cacacacaca cacacacaca catttattat ctgacagttc
144841 \quad {\tt tagagatctg} \ {\tt aagtccacaa} \ {\tt tgggtctcac} \ {\tt tgggctaaaa} \ {\tt tcaaggtgtg} \ {\tt gggagggctg}
144901 catteettet ggaageteta aggagaatgt tteettgttt tttteeaget tttagagget
144961 acceacatte ettggettgt ggeeceetee tecatettea aagceageae eggageatet
145021 actgaccct ctctgactct qaacttctgc ctccatcttc tacttttatq aatccttgtc
145081 atggccagct cacacctgta atcccagcac tttgggaggc tgaggcgggc ggatcacaag
145141 gtcaggagat ggagaccatc ctggctaaca cagtgaaacc ccgtctctac taaaaataca
145201 aaaaattagc caggcgtggt ggcaggcgcc tgtagtccca gctactctgg aggctgaggc
145261 aggagaatca cttggaccca ggaggtggag cttgcagtga gcctgagatt atgccactgc
145321 actccagcct gggcgacaga gtgagactcc gtctcaaaaa aaaaaaaaa aaaaaaagaa
145381 gaateettge cattacactg tgccatccag gataatetee ttatettaaa agtcaactaa
145441 ttagcaacct gacttccatc tgtaaccttc actgcccctg ctatgtcacc tgatttattc
145501 ccaggttctc gggactggga catggacaac tttgggagaa ggattattct gtctctcaca
145561 gagactatct caaaagggta ggatttcatg gtttttgctt tctccttaat acttttctac
145621 attattcaat gataatgacc atatgttttg tatgttcaaa agtaattttt aattgtgaat
145681 aatgtaaatt attgtgaatc atgttttgtc agttgttgtg aataatgttt aattgtaaac
145741 aatggaaaac taaagaaaca aaagaatagc atcetettat agcacccatt gatgtetttg
145801 caacactttt tggctggtct tttgtccccg tccccctgac tttgagctgc ctgaggacaa
145861 gccagacccc ccttcacttc tgtggctcta gcagtaagca tgaggacttt ggcacagcag
145921 gctttagcag acatttctca aagtgaagat aaatccccta ataaaggagg ccctggttta
145981 agaagaatga tgtgcacact caaaagtgca ctttaaggcc aagctccgaa taaacacgat
146041 gatattattt tatttaagag tottoataca tacaacttaa ttoagtaaca gtotgagaaa
146101 cgcaagccag cagacagata aaccgttatg gctctggctc tggcaaaaac tcttcatcta
146161 cgcggagcca gaagaaagcc aattaaaagt cggagaggtc ccgcaggaca gaggccggag
146221 gatgtcccca cacactgagc acaagcccca aacacaggcc tccccagtct ggagccggcg
146281 gccagccccc tcctggcctc agtgaagcct ggactcctca ctctgtccaa gtgggaggaa
146341 ctggtcccag ctgcaaqaac cgcctactgt gatctgggca aaggttctgg aggctctgct
146401 cgctcctgtc ccccaggaaa aaaaaaaaaa aaaagacagc agagggcatt gctcaggggc
146461 ccagcctggc tgtcatccct gaacatcctg ggctgaagga aagaattgag cccagccgaa
146521 acttgagate tttagactta aatececact etgteaettg tggetatttg geetettteg
146581 acctctgctt ttccgtgtct aaaatggcac aatattacct actttacaga gttgtcaagg
146641 gattgaaaat aagataatga aggcaaagga agtgagctca gtatcattat gcccatttta
146701 cagattggga aacaggctcc aagagatgac atgactcttt caggattaga cagctaatga
```

```
146761 gtggtggatc cggatctgct cgcacagggc tgggctcctc cccagccccg cactgggaca
146821 ggggcatete ttgagggetg ceetgtggeg eecagatgee geagggagae aaggetgtgt
146881
       gcacagatet etetecaetg ggcageaeet gagtaaetgg gggagagaag tgggttteaa
146941 gcatctcctt tgtgaaccac tgggcttaag tatgctgaac ttcagttttg acgcagaact
147001 tggagacaac ccatcctctg ggaaaagaca caaatgaggg caggacccct gcaccatgtg
147061 ccctgctgcc ccagcagtgt cctctcatcc agcgtgtgaa gaaggagtgc agccggagag
147121 ccggtggcag cagggcgtgc gggatgcccc gctcacagtg tgctgtgcct gggagaggag
147181 cgagggcagg cccccagctg cttgggaaca gtcagcctgc acacctcccc cctgggtgcc
147241 cttccaaggc agccctcagg ccccaggctc cgggactccc tgcagaggaa ctgcaagcca
147301 gtcctggccc agcacagccc ttccgccagc ctctggccag cgtcaggaag gggagtgtag
147361 agtgagtagg aagccacaca ggagcagaag ccgggacttc tgcctctcac cccactgcat
147421 gtatgaaaat agacgggggt gatggccggg tgcggtggct catgcctgta atcccagcat
147481
       tttgggaggc tgaggtgggc ggatcatgag gtcaggagat ggagaccatc ctggctaaca
147541 cagtgaaacc ccgtctctac taaaaaaata taaaacatta gccgggcgtg gtggggggcg
147601 cctgtagtcc cagctgctct gggcgacaga gcaagaccgt ctcaaaaaaaa aaaaaaaaa
147661 aaaaaaaaaa aagcggggga gtgataaggc cccggacaac ccaaactgca gcaagattct
147721 ctgcggaggc agagctgcct cctcctgggg gtcctctgga ccaggaagga gccctgagga
147781 cttgtggccc agtgggtccg gcttcccaac ctccaccttg ccagcagcac cgatagatgt
147841 ggccacaaag gtgcattcac atttgcgacc tgtggctgaa tgcagaccct gggtgctatc
147901 tcccgggggg gcaaatggca gtaagcaagc aaagaggaag tcgacagaga gtgacgcagc
147961 cgtgaggaca acagcacaga gtattgttga ggggggggg ggacttcctg gaagagatga
148021 cactggagct gaggcctaaa tgattggaaa gaggcagcga tggagagatc tggggaagtg
148081 ggctccagca cagagaacag cacatgcaga ggacccgagg tcagaacaga cctgccatgt
148141
       ttgaggaaag ggaagaaggc caatgtgagt ggagtgtgga gagcaaaggg tgggcggggg
148201 cgagggacag gagggcagag tggtgggcct gggtggggta caggaggtca gagtggtggg
148261 cgggggcaga ctgcacagag cttcctctgc tggggggagg agattggatt ttctcctctg
148321 tgcagtgggc agcccctgga gggtggaaga gacctgattc ccctgtcagt tgctctgggc
148381 atgttgtgag aattgctggg ggcaggatct ccctccctct ctctatgaaa ttcctgttca
148441 gcagggatct gcctatggct gtatttctgc tggtagaagt ccctccctga ttataaaccg
148501 ctcaacacat agagaggtcc ctaggagaag gttcaggttc cagtaggatg gtgtgagcac
148561 gcctcacctg catccccac tgcctgcagc cacccaaatg cactggattc atgagcagct
148621 agctgaggac cctgcaaaat aaataacagc atgcagattg gggaagaaga ctagaatgtg
148681 aggttcagca aaccegcaga gtttactett cattetetgg tatteetcag cetagataca
148741 aggcaggtca aactccagaa gcgggcactg ggtacagaca gacagagctc gagacaagcc
148801 ctgttgttgt agctcaagga tagaaaaagc atttccgaat gctcagagcc aagccaacac
148861 ctcatttttc tttcctattt cctttttctt ttcttcgtgt tctcacacgc cagctcatgg
148921 cagcccacag gcacctaaaa ctctaagagg ggagcctggc tgtgtagctg gaagtgctgt
148981 ggtcctagaa aggtggagtg aaaccccatt gctctttcct cttttggtcc tcccaggagt
149041 gtagttgcag gaagtgtgca agacagcagg gtcaataaag ccccagcttt ctggccagag
149101 agatttaaca aggagccgca ggaaactgga cagggctagg aagatggcag agacagcaga
149161 gcttggggaa ctggcatcag aaagttggtt agaaactcct gggctcgtgc ttgagccgtg
149221 cacgagtggg tctgacccta aacaacacgc cataggttct ggggactgac ttaggaggtg
149281 gaccaatgcc caggtcccag acgtgccact gggttgtgtt tacatgggat tgatcagaat
149341 aggactgcac aggctttgaa aatggacctg acattgaacc gcaatccaca ggcacattgg
149401 aacttgcagc cggaacccaa ttaacccaag ggttaattac ctgatcaaac aaaaataatg
149461 accttctcca tagcatttaa acaagatcca aagtctcata gggtaatatc aaagtgtcca
149521 ggatacagtc caaaattact tggcatacca agaaccagga aaatctcaac tcctccaggc
149581 aaatacaacc aacagataac aagactgaga tagcacatat gttggaatta actgacaatg
149641 atcttaaagc agctattata aaaatactcc ataaagtaag ggcaaaaact ctggcaacta
149701 atggaaagat agtctcagca agaaacggaa gacatattt taaaaaggac caaacggaaa
149761 ttttagaact gaaaaataca ataacagaaa ctttaagaac tcactggata ggctcaagag
149821 cagaatggat atgacagagg aatgagtcag tgaacttgag gatagagcaa tagaagttac
149881 ccaattcaaa ctgcagcgag taaaaatatt ttataatgcc aagagcctta gagactgtgg
149941 gaaaataccg aaagatctaa ctaacagtca tgtcccagaa ggagaagaga aagaatgtat
150001
       tactaaacaa atatttggat aaataatggc tgaaaacttc tcaaattctg tgaaatgcat
150061 aaacctacca attcaacaga tcggcaaacc tcaaatgaga gaaatccaag gaaacacaat
150121 cccacacgtt ataaacacac tctgaaaact atagacaaaa aaaagtcttg aaagcagtca
150181 aagaaaaaca gtgcattact tataggggaa aaatggttca gataactgca gatttcttat
150241 caaaactgtg aagtccaaag gaagtgcaaa acattgttaa aatgctgaaa aaaaaaaaa
150301 agaactgtca acccagaatt ctatctccag caaaaataca cttcaagaat taaggagaaa
150361 taaagacatt ctcagatgaa gcaaaactta tagaatgtgt ggccagcaga tctaccctaa
150421 gatggttgct gaaggaagtt cttcagacag ggggaaaatg atgctagaaa gaaattttga
150481 acatcaggaa taaaggaaga gcaacagaaa tacctgaaaa aatataacag attaggctct
150541 tgcgtatttt aaagaggaat gataatgctg tctgatgtag ttttccatgt atgtaggtgt
```

```
150601 ataaaagaca acaacattca ggggaggaca gagggaccta tatgatggca gggtctcaac
150661 attcaacttg aagtggtaaa atattgattt gaaaaagact ctgaagagtt acataggttt
150721 attataatcc ctggagcaac cagtaaacac tatacaaaga tatacaacca aacacaatag
150781 gtaaattaaa attgaatacc aaaacatgct caaatagaaa aagcaaaata agcccaaagc
150841 aagtagaagg gaggaaatga taagagtaaa aatcaatgaa actgaaaata tgaaaataat
150901 agagaagatc aatgaaacca aatttggttc tttgtaaaga tcagtcaact gataaatctc
150961 tagtgagact gaagaagaga aacagaaaaa aatatgaatt accagtatca gaatatttt
151021 aaaaaggata tcactaatga catcacagcc ataaaaaaga taatggaata gtataaacaa
151081 ttctatgcat ataaatccat cagtgttgaa gaaatgcatg atttcctcaa aaactataag
151141 ctaccaaaac ttacccaaga caaagtagat agcataaaaa gttctgtaac tattaaagaa
151201 aaagaattca tagtttaaaa tootgoaaaa aagaaattto caggtotaga cggttttact
151261 ggaaaattct actaacctct caggaaaaaa tggcaccaat tctcccattc attttatgag
151321 gtcaacatta ccctgatatt aaaaccagac aaagacagtt caataaaaaa aaaaacccta
151381 caaaccaata tccctcatga acctataaac caatatccct caatgaacat agacacaaaa
151441 atcctcagca aaacactggc aagtctagtc cagccatgta taaacagcag agtgcacaac
151501 agacaagtca tgtttgtcct ggatttgcag agtctggcac aatatccaaa agtcagtgta
151561 acccagcata ttaacagact gaagaaggaa aaaaaatatg cttatatcaa gtgatagaga
151621 aaaccatatg atatgattca ttcatgacta aaaattaaaa actctcaact aacagagaaa
151681 gaaacgtgct caacctggta agaatatcta caaaaaaact aaagctaaca caataccgca
151741 tcctgagaaa ctgttttccc ctaaaataag gagcattttc acgactccta ctcaaccttg
151801 ggttgagtcc tagacagcac ctctgtacac acccagcacc cagcacagac cctcaggcca
151861 gggcaggaaa gggccccaga gagcttcccc aaaacccgtg ttcctqqqqa aqqtqqatqt
151921 ccaggaaggg tgactggccc ctaaagccta ggggaagcgg gggccctcct gctccagcct
151981 catgaagctt tgatctccag tgccaagccc ggtgccagca gagagccagg cagatgaact
152041 caaccaggga aaggacaccc aggaaggaag caactccatg agatcgagtc tcatagcacc
152101 aagtgctccc acaggctctg aggacatggc tcttattcca ggaccaggcc tgacaggagc
152161 acagcctgag ggatgagagg gcagggcagt cttctgctgg gtggggaatt ggccaccagg
152221 gccagtccca catctgttgt ggccctggca ggatcaaccc tgggcctgag tccttggagg
152281 tgaggccagc acgtagtaga ggggcagccg agtaagaaga atctctcggg gaagtcagtg
152341 gccagccagc ctaagcccgg cccagacct cgcctgcta gcatgagaca gacacagggg
152401 gcccgcactg cagagetgcc ccggcccacg cgcccctgcc ctgctgtgct ccgccatctg
152461 ccccagcagt gctgtgagag catcgcaccc tgcaagcctc agccttcagg gacggcaaga
152521 cetggggecc acaggaggte caccggccet ctcagggcte gagcacccgg ccaaccetgg
152581 gtggccactg ctcagcactc caggacagct ccatgacaca gaagcagctc tgcccatgag
152641 cattcaacag cccggtccgg ggggcaccac cacgcagggg cttcccgggt catgctgcac
152701 catccactaa tagcaccatc acgtatgcca ggctgggagc ccgggcgtcc caagcctgtg
152761 accteattet etatgeteet caeggetgee ceacagaate tetgaaacae gaeteagaee
152821 tgtcactgcc tgcccaaagc cctccagcgg cttcccacca catgactgcc ccggtccccg
152881 ctgatttctc cttcactcaa gtgccagccg tggagatctc ctctgtgtcc ttggcacact
152941 tcaactcagc acctgcctca gggcctttgc acctgctgct gcctccacct ggaatggcct
153001 tettecagaa gtecaggtee tageteegat geeteeteac aaggaeettg gtgaagggtg
153061 tecettetee ateacactee acactgeeat cetgteetat ttttttgtaa caccatttee
153121 caatcatcga cacgtgggtt ctttattggg tcactctctg ccccctgacc agggatctta
153181 cgagagcaaa gttgtccttg ctgggtccac gtcaccagac cagtgcctgg catctcacag
153241 gcatggagtt gagtacggga ggtcgccggc cctcccgagg ctcccttccc ctacttcggg
153301 atggtgtaag gtttccttgc caaggtccct gtggtgcaga gtgggccaag tttgccgcct
153361 tetggagega caacaaggag aaaacagggg tttaagtgga ggateeggtg etetgattte
153421 tececagita giaaageatt caggetgete ggtggaggtg ggaagaeagg egetgagagt
153481 tgtctgacac aattgtctta gcagcaggag acgctgatgg gatgtcggga gtcaccagga
153541 ccatctgaca aatgaccgcc ttggggatcc gtggagctca gcggtgccca gagagagcac
153601 tcgaaatgcc agctggaaag gtcacgcacg ccagctggaa ggggagccgc gcagccctg
153661 ggcaggctga ggacaggaac gggcagccgc cactgttcac gagcaagggt gcaggggcac
153721 cagageceae aggageteet geaatgegat gaceatgeet geaggeeece ataatagaea
153781 gcctcatttt ttttttctag gcaaaacttt gggaggatcc tttttaattg tatttgcaaa
153841 acagtttctc ccaacatgat gcccatgtgt atgtggattg ggggaaattc ccaaggcctc
153901
       tcagagaagt gcctccttcc taaggtggtg tcccagcaga tgaatctggc tggcgtcctg
153961 agtggaagca gggcgcgggc tgccatggaa ccccaccctc ctgcaggttc ctggcccctc
154021 tgcctcctct tccttcccac cccaggggcc ctgggatgca gctaggccag ctgggagcca
154081 gacagocact gaagoootog gggtactgtt coctqoottt aqcatococc toaqotqooc
154141 atteatteag ceattettet aggaggacag geeaggeeat ggtgaggeee tgggteeagg
154201 gaaagatacg aagagggctg aggcgggcgt teetgeeett gggtetette egetgeeetg
154261 gcagcccgt gcctcctgac tgtggactgg agttctgcag ctgcgccatc cacaggaagc
154321 tacatggaga gatgggccag ctcagcagag aggcgcaaac accaattcag ttgaaaactc
154381 tgtgttcccc gggtagaggc cagttaggag ccagcatgcc tcccaagggt tgtgcaggga
```

```
154441 gacttcagcc aggcacccac tggggcagac ccagtcccac tgcttctgcc ttcagtggcc
        acaggcctgg ggccattggt ggatagagct ggagaaaggc cacctcttcg ggacccaggt
154561 cacaggatgt ccccccaaag ccatcccagt cagatgtctg cagacacctg ctcccctggc
154621 aacagtgacc cagacctgac cttcaactct aactgtgcac agcttcctag cccggccccc
154681 aagcctgaag cctggtccct ccagacactg cagaaagctg gggctgactg taatcccagc
154741 actttgggag gccaaggtgg ggcgggtcac gaggtcagga aatagagacc atcgtggcta
154801 acatggtgaa accetgtetg tactaaaaat acaaaaaaaa tagccaegca tggtggcaeg
154861 caccggtaac cccagctact caggaggcta aggcaggaga atcgcttgaa cctgggaggc
154921 ggagttgcag tgagccgaga tcatgccatt gtactccagc ctgggcaaca cagcaagact
154981 cagtetecaa aaaaaaaaaa aaaaaaaaaa aaaaaggete tggccetgce acttgacegg
155041 gtgggtcacc tctccgtgcc tcagtttctt ctatttaaaa tgcatagggg aggagctctg
155101 agggcaaaac accetgggtt tgcctcaggg cagggcagga ccctggaccc agcaggcccc
155161 cactgcatgt ccctcctgtc ctccctgcc cacccctgcc ctctggcttc tggggttcaa 155221 gtcagggagg ccttgggagt agcctgcggc cctggggaca gacaagggtg cccctgaatg
155281 tcctgtggat ctgcccaggt tgatgccttg actgctcctt cctgtcaccc aggaccctcc
155341 aggagagace accompact acquetque agggetecet gracqtecca tqtccccaca
155401 gcgctcaggc gctgagatgc tctgctgtct gctgtggggg cctgtggacg gccctcctcc
155461 cccaccagge tgcagetece agegggeagg gatetaggea tgcettgete ataccacaag
155521 gcagaaacac agtgaagaaa gacagagaac tggtcttgtt gtctttgggg gctcagcccc
155581 ccagctccaa gctggaggat caggaggcat ctacaagcct ttccgaagcc cccccatagg
155641 ctgccttgca gggtacagta tggcctagag agccccagag ggctcccctg gtcattaaat
155701 atctcaggat ttccaggaac aaggagaggt tcaagtccac agaagaatct gattggcgtc
155761 tctgggccac ccaccggtgc tagaatcccg gctggggtga gggatggtgg tgcagagcct
155821 ggctatgcaa aatgtggcct ggagcagcct gggggccccc gggagcttgt tagagatgct
155881 gaatccaggc cccatccaga ccagctgaac taaaacctgc attttggcaa gttcccaggt
155941 ggtctgatga cattgaagtc tgggacacac tgctctagac cctcccaggg tccctcaaag
156001 gtgggtgtag aggccctact gccctgccct ggggacgcag aggcatcagg gccttagtcc
156061 tcctggggac agtgaaaggg ccaccaccc agaccatggc caaactgcag gggtcaggga
156121 ggcatggccc aggacagcag ctcagcaggg tgcccaaccc cacctgcccc tgcctgcccc 156181 aacccacttg ccggctgggt cctctggacc tccgcccctt tccaccccag gttggagcca
156241 aagaccaccc tetecactec ceageceece accecceaac ceaecgagtg cagggeeegt
156301 tgactcctat ctcaacaaca acaggaaacc atttttccag acagcattat ataaggggag
156361 gatgcgtatg ttcagcagat gttcactctg aggccgagcc tccccgccc tctgaacagg
156421 aaggccacgt ccccatecet ctcccccagg gcctggcgct cctggcccag gtggagctgg
156481 cctctggctg gccacttctc tggaagggcc tcgtccaget ctgtcctgtg cagggtcatg
156541 cccctccact ctgctctctc tagcccatgg gcaggcgccg cctggctcag aggcacagca
156601 atgggccagg gtcagacagt ggtgagcagc atgccaagaa tcacagggac atccacctgc
156661 cagcaaagcc tcaatgacaa caaaggacct gaacagtgga cactgacagg gactctcctg
156721 cttgaccaaa ctttagtcca gctcctgaac cttctccttc gcccacttcc ttgtaagatc
156781 cagtttatca agaactctgc taagtcacga atgccccatc tctccatatc tgatcaccct
156841 tgatatctgg tcaggctcgt cctccccatc acccctctgg tgatgtctgg tcaccccagc
156901 ctgtcttcag ctagaatcat gttaggtgag tttagctaga atccccgacc cctgatgttg
156961 ctcttagtaa ttccccatcc cctggcccct accctgctcc ttggctatca ccccccactc
157021 gcccgtgctg tattcggagt tgagcccagt ctctctcccc gactgcaaga gcccactcta
157081 gcggttcctg tgtctatctc catggtcctg aataaagtcc gccttaccgc gctttaataa
157141 gtatcattga atcatttttc atttaacaac actctgcctt gctgaaggga aggtagaaat
157201 gacagcagtg gggaggaggg agaaggggca tgggaaccct gtgccgctaa gggcatactc
157261 tagaccctct gccccaggct aatgttagaa gctgcagagg tgcaaatata acagtcagac
157321 gaccatggca gtggtcagct gaaaaatggc ccccgaagac acgtccgggt cccaatccct
157381 ggaacccata aatgttacct tccatggcaa aaaagaactt tgtagatgcg gtgagtccaa
157441 ggatcctgag atggagtgac tgctggattt tccgggtggg cccagggata gacagaatgt
157501 ttatattccc cccaaattcc gatgttgaaa gctactcccc caaggtgata tattaggaag
157561 tggggccttt gggaggtgat tatgtcacca gattccatcc acacgaatgg gatttgtgcc
157621 ccgatcagag ggaccccaga gagctccctc accctttcag catgtgagga tgcaacaaga
157681 tgccttcttg aaccagggag cagaccttca ccacaaccat atgcacagct tccagaaccg
157741 tgagaaataa getteegatg ettttaagee geteegttta tggtatttgg etatageage
157801 ctgcatggac taagacaggc cctaaatgca atcacacttc tctttatcag aggaaggcag
157861 agcaagatga gccaggcaga ggagaaggcc acgtacaggc agagcagagg gagatggagg
157921 atgtcggccc tgaagcccag agcgaagagg ccacaagcca agcactgctg gctgccacga
157981 ggacctggaa gagcccagga cgcatcctcc cctagaggct ccggagggag cgcggccctg
158041 ccgccacctg cgttttgccc tgttgaaact gatttcagcc tccagaaccg tgagaggata caattctaat gtttcaaacc agcaagcttg tagtaatttg caggcagcct cagaaaccaa
158161 tacaatgggg aactctgata tggactaaaa gtggtgagag aattatggta gaagaatggg
158221 gctgggaggg gcagcagtgt tgtcagtgag ctaaaccctc ctcttccagg gcaggaagtc
```

```
158281 aatggacaac atcgaaaccc gatacatcaa gaaacagcaa tagaatagca tttcaggact
158341 teatggcaac eccagaacea gecageagee taaageetta eeggggetee eteeteagga
158401 gtggcctgtg aagaggggac gcacacgcat tcacactcat gcacacacac acaccgagac
158461 agaggagggc ctggccagag caggggtgtc agcagagggg acgcacacgc attcacactc
158521 atgcacacac tcacaccgag acagaggagg gcctggccag agcaggggtg tcagcagagg
158581 ggacgcacac gcattcacac tcatgcacac acacactcac atcgagacag aggagggcct
158641 ggccagagca ggggtgtcag cagaggggac gcacacgcat tcacactcat gcacacacac
158701 actcacaccg agacagagga gggcctggcc ggagcagggg tgtccgcaga ggggacgcac
158761 acgcattcac actcgtgcac acacacactc acaccgagac agaggaggc ctggccggag
158821 caggggtgtc agcagagggg acgcacacgc attcacactc atgcacacac acactcacac
158881 cgagacagag gagggcctgg ccggagcagg ggtgtcagca gaggggacgc acacgcattc
158941 acactegige acacacaca teacacegag acagaggagg geetggeegg ageaggggtg
159001 tcagcagagg ggacgcacac gcattcacac tcgtgcacac acacactcac accgagacag 159061 aggagggcct ggccggagca ggggtgtcag ctccaggacc aggagttccc aggcagaacc
159121 tgatggtggg gcgggggtt cctcacacac cccacaccc tgcctatgcc cagacctcca
159181 gcttcgggct ctgcatccac acggaggctt cggattgggc gcagcctggg agcacacaga
159241 ccggccaggg ccagggccag gactggcatt tcccgggctc ctggtcccat cctgcccctc
159301 ccaccgggtc ggccctgtcc ttgtcttgct cagctcgggg gaagcacctc tcgccagcca
159361 tctggggctt ggctgggcct cagcctcctg gctgccacgt ctcactggga gctgggcggc
159421 cgccagctct gagctaagtg agcgcagagg agagtgcagg gagcggcaag gccaggctcc
159481 tccccaccc gtggcgtggc gtggcgtggc cggaatactc agttttccct gctttttgag
159541 acaagagtag taaatgcacc gtgctgtact cagagcccag gaagcagccc tcccacccac
159601 agegetectg cetetgeage ecceegggee gtgtetetet eteaegggee cacatectea
159661 ctggactgtc tcccttttac agatgaggtg agacagcatg cagaggccca tgtgcttgtc
159721 ccacagggtg acgggccaga attacaagcc cctgattctg ggggcttcca cgctcttcca
159781 ccaagccctt gtagccttcc tgcacccagg tggggctcct gtcccccgcc agtgccccca
159841 acctetacte cageagacet ceaectacag acaggagtet tgggcacaca ettttttgtg
160081 tggaagtggt actggattcc tacacccacc cccccacaa tccccaaggc cccacccgg
160141 cctcctcctc cccctgcccc tgcatggagc aggcctcact cactctctct cttctgttcc
160201 teetgggtee etgeeteaga eceteceace taacacagee tetgeeceac eceagaggge
160261 tcctcccaag acacgcgtcc acgtcgccat ggacaagatt aaataccctg gcttctggaa
160321 agcactgagg ccacagttgg cttctggaaa gcactgaggc cacagttggc ttctggaaag
160381 cactgaggcc acagttggct tctggaaagc actgaggcca cagtgctttg ggaaggtcat
160441 gtcgggatcc cagggctgac tgcactcctg ccagtgaagt gggggtgtcc ccaaaggggg
160501 tttgtttccc accattggga gccaggatcc caggtcagga aacagagctt gggtgggagg
160561 gaagccatct ctggggactt tcctcccatc tcccttgtcc cgctcacgag gagaagccag
160621 agctagaagc tggcatgagc cctcctagca ccaccagcca cagtctccac ctccggggac
160681 acgagetggg atetgagtgg cgcaggtact atgttetaga gaggeegtac ecaggacege
160741 ccatggcacg cagaggaaaa ctgaaacaac gatccttcca gagacaaagc acagcccag
160801 atggccacag gaactggccg cccccaggag ctgctgagca caaacgccac tggagagagg
160861 gcttggtggc tgcaccgaag agcagaacag aggaactgaa cagccacagc caccgcagaa
160921 ctgggggatc tggacagagc tctcgctgtg tgctaagaaa ggagcaagag acagagggca
160981 gggagaaaag ctgcgagacg tgggcaagtc ccagaagaga gtcggggagg tgagagaagg
161041 aatatttcaa aaaacaaaat tacatgaaag attccagcat ggatgggttc ctagaggcct
161101 tatcaataca tatataagaa aaagctccat agctagaccc acgataatga aacctaagaa
161161 catcaaagac aaagagaaag ttcaaaagct cccagaggga aagagcagat cagatcagtg
161221 taaacaggga ggcagcaggc agacatccaa gtcccagact ggggcgtggg caccgggcag
161281 cagacgggag acaagagccc aggaagtcct gctggcaaag aattcaaagg ctcttgcctg
161341 gagggaagag gctgccccat tccgaggcca gagccaccgc agcagaggac agctgtgtcc
161401 ctcagagggg tcggcaggga cagagqccac accagagcag cagagatcta gcaacccaga
161461 agggtgacac cctgggagat gctgagagca gcagggccct caggagcagg gctggggagt
161521 eggecacage teagggggte attgeatgtg ggeateceag geteetgeet aggeceeta
161581 gggctcccca gccccacaga acaccctccc cactcccagg gatggcattt gagaccttcc
161641 tgctgtgtcc ctccaggaac ctgtgagctc caagagaaca gaaggctgcc tcttcaaccc
161701 cagtccagca aggcccaggg cagagcaggc acggagaact gctgtcgaac atgaagtggg
161761 gacgggacgc agtggtgtac acctataatt ccagcacttt qqqaqqccaa gaaccgctta
161821 agtccagaag ttcaagatca gcctgggcaa catagtgaga ccccatctct acaaaaaata
161881 aatttaaaaa attagccagg catggtggtg cacacctgta ctttcagcta ctttggaggc
161941 tgaggcagga ggatcccatg aaccaggagg tcaaggttgc agggagctac gattgcacca
162001 ctgccttcta gcccgggaga gagcaagacc ctgtctcaaa aaaaggaaat atatttaatt
```

```
162121 gatagggaaa gaacaaaaga aggaaagaaa gaaattccag ctaattctca gcaacagaca
       attacaggaa cacaaggaca aagcccagag ccccaacccc acgtggcctg ggtccccaca
162241 gcctccagcc ctcctgtcac tctgccagct ggcagcaggg ccacctctga gcatcctttt
162301 cctcagcact ttqqcqtctt tcctcccaqt ggtttcttgg tagttcctca taaatccatg
162361 cgtaggtctg gctacagcta tccttgtccc tgaagatgga ctcagctagc agagtcgctg
162421 atatggtaac acaatatcac acatctcatc caagectgct cggacgctgc ccttctgacc
162481 ccgattcctg tcaccaacac aacaggaaag gagettgaag acccaggagg ccacagcaca
162541 qttcctcqtq qaqqqaqaqa qatqcqaqca ggtgggcgga gggtgcactc atgagacttc
162601 tataagcacg gacccagagg ccatcccagc gacactgtgt ggggactcct gcacctcttc
162661 ctgctgccca gaccatgggt ggccagcagc actgcagtgt tggtgtaatc tatgtccccc
162721 ggatggccag cgggcacaga gcatatgtgt gctgagggac acatgcccca cacaaacgcc
162781 cccacatgtg catcgcatac atcacccaca cacacagtg tacatttcag cacgcgtcta
162841 ggggaggtta gcgtgccagc accagctgag actccctggc cagactcatc gccagttggg
162901 gagagtggag cagacgtaca ggatggaggg tagaggtggg gctggtccac agtgagggag
162961 ggaggcaggt gtagactggg ccagggaaag gttctggaaa cccagactga aggttccctg
163021 gggtccctgg ggctcatcca gggctggggt ggagccagga catgaggaac gggcagtgat
163081 gaatetgaag eeetgetggt eageagagee teeacetgea egteeteece aaaggteagg
163141 caggetteae eetggeeaeg tetetaeeet ggeeattage aaagaggeee eeettggaee
163201 aggaggaaca cageaggeea geeeteetge eetteeeate caaggeteea geeaetetea
163261 tggagactet gagetgagae acteccagea gaaagggtea tttateteag agettaaeta
163381 gagtattaat taaatgcgct geegetgage etcageacae aggaggetga geeetcatta
163441 aaaaggcatg agactaaagc aagacaggga ggagaggcgg ggccagctag acaggggatg 163501 gggagagaag gagatgccgg gcggggcggg gacagccagg gacggccaca gctgccctgc
163561 caggaggac agggccact gcaaagtggg acagctgctt ctagccctct cacaagaagg
163621 ctggtgggga agaagccaag cacacgcaga gggtgctccc gcacacccct cgcctccgtc
163681 tttttggaat cttgacagtt agaagacgac aagggccact gtccagtggc tggcatttgt
163741 ccccatgaga ccacagagag gcagaggaca gctccttctc agaccagggc aggtggggca
163801 atgccaaggc cccctcggct caggatgag ctgagcctcc ccaggatgac tcccctgggg
163861 gaaacactga tgtcgctgtt tgagcgttga gacgttgggg cctggcctct gagaggcggg
163921 gccccgaagg gtcttccagg aaggtcagac cccagcccaa aagcagcagg cctgggccac
163981 aaagagaget ggteeetggg eeagaaagee etetteeace atgeaetetg ggeaagggge
164041 gtgtgtgcca ttaggaacac agctgcacgc tatttctctc ctgtcttcct ccagctgaag
164101 atttcacaca gccctgttat gactgagggt tcccaacagc tattccctca acacacaggc
164161 ccccacacac atgcatgtgc actcatgcac tcccacatgc agcatgcatg cacccacata
164221 caaatgtcca tacgcatcac atgcaccacg tgtgcactca cacgcaggcg tcacacaggc
164281 accatgcaga cgcatgcaca cacacatcac tcatatgtgc atctcctgtg acacatgcat
164341 cacatacaca tgtccacaca tgtgcactac acacaagtac acacatgcac cagaaaaatg
164401 ccccatgcat gtgcatggca gacattaccc acacatacac atgtgcatcg gtcatacatg
164461 tgtatcatat gcaggtatca tatgtacagg catgcagtgc acacatgcat gcatcaagca
164521 catgcattat acatgcacac gcccgcacat gtgcacacat gcatgacact catgcactca
164581 cacatgcctc acatttgcac acatgcatca ctgacgtgct cacacatcag ccacacacat
164641 gcactcactc acaccetect getgeteeca gcetcactge etgettgett aettteecag
164701 tteetgeeae tacetgagaa ggtgtttatt tggeettttg ettattgtat gtetetaeea
164761 eetcateeta eeeeteeeag eeeteeeat eeacaeteaa eeagtagaat agaageetet
164821 cccctctgtt gaggcaaaaa gctgtgaccc tcttttcacc cagaaaccac aggaagcatg
164881 eqtqcaqact ggactcaqce ttcaccaqce eccqcaqtca ttacqcetqq etceccaqca
164941 cccaaaccca ggtccccact ggtcagcacg ttcacaccca gcctgccaca tctccggcct
165001 ggcccacaga atgcctggtc ccagactcct aatgtaggaa gactgccctg cctgatctca
165061 aggcttgctt ctctgcattc aggccactcc tgctgcccag cctgacggct cccggagcag
165121 ccggtgatca gtcaacctcc ccagccttct gtttgccttg cagagccagc cgactcccag
165181 gagagetqta gaggetggte ageageetea etgteeetge eetgeetggt gagggaaggg
165241 aggccacgga ggaaattccc tcccgctcca tgtctgcctc gtgtccttct ctctcctgct
165301 gtgctcctgg gcagcagctc cctcctccag ccttccaggt ctcccaatcc tggccccagc
165361 cactteettg ggaaccetaa geetgeetgg agteeaccet cetecatttt tttgggtttt
165421 ttttgagacg gagteteget etgteactea ggetggagtg eagtggeacg atettgacte
165481 actgcgagct ccacctcctg ggttcacacc attttcctgc ctcagcctcc tgagtagctg
165541 agactacagg tgtccaccac tacgcctggc taattttttt ttttttttt tgtattttta
165601 gtagagacga ggtttcacca ttttagccag gatggtctca atctcctgac cttgtgatcc
165661 gtccacctca gcctcccaaa gtgctgggat tacaggcatg agccactgtt tctggcccac
165721
       ccttctcctt ctgatagcac agcccctgtg tcactcagga accagctctc atccctgcgt
165781 caccagtggg caaggagggc acatgaccca gcctaggcca ggtagaatac gttgtcatct
165841 gactacatga acatagetea gggatgagga ettgecacaa ggtattecat gaagttaaat
165901 ccaggaacta ttgctggaat tgttggaaag gaaaagctgt ttcccccggg ttgttgccct
```

```
165961 gtgaggaggt aatgcagcag ctgcctgcat ccatttttct gcctcagaga agagcaggcc
166021 tgagagtgaa atcgacatag aggagagcaa agccaagggt tggggatgtg ggaaaaaaaa
166081 caactgaaaa tttatttggg cacctggatc cagccacacc tgaagctaga tagttctaga
166201 acttggattt ccaacacttg aggaataaca cctgactaat acactctctc ttctatagct
166261 tcaaactctc catctcccgg atcctcatcc tcggtccctg agcaaactca agccacctaa
166321 aatcctctgt gctcgaggca gggccacaca cacatctaca caagcgcaca cgtaaacact
166381 gcactcacat ctaagactgc acaccctccg cagctgatgt ctgccccacc acagcatgtg
166441 tgccatgcgc accagettcc etccaetece ttgcetetea etggeceete acetggteag
166501 totagettee accaacteee cagegaceet geaaageeee etettggetg etgggeetga
166561 tgcccctgc catcccaatt ccctgaaccc cctcctcttg aacctctctc atcctttagc
166621 aggtgggcag ccccgetect aagaccccae tgccteetee aettgtetge acatggtggg
166681 gggccaagga gcactteett eceettetge eteetette etttggtgee egeeeacea
166741 ccccaggatg tggaatccac agccctccat acagagcgct cccaacccga attctaccca
166801 gaccttgccc ctgcacctag gacctgcatt tccagctgcc agactccttc caagagacag
166861 ccccagtgac aaaccctctc tccaagctac ccttcctctc taccacccat ctgtgcaagt
166921 caaaagctgg ggagtgcttt teeteageet eteeeteage eeceaggeee acagaeecaa
166981 gtgcctggag atcccggcct ctccatgttt cctgagtaga ttatgctgcc tctattgaaa
167041 gatgttccgg cagaacactg gatgatccag aaatatttcc attatgtgtg gcatgggcag
167101 aggcagatca caaagggaag gtacaatacg accettttgt cattaagtat gtttacacat
167161 atgtgcatgg acgtgggaga cacacaaaaa tgttgaaagc taatggcact gcagggattt
167221 ccattttctc cttttggctt atttctgcat tctgttttat atgaaggcac atacgacagt
167281 ttttaactta aagacaggac aaaaagttgc cagccatcgt gagtcacccc aggactgccg
167341 gtgctgggaa tgccaaaatc tgatgggacc cagcgcaggt ggggagagga gcagaggatg
167401 cacccacggc ccgtgccttc tttgaatcag tcctcacggg gccatctcaa ggtggagact
167461 ctgaaagtgc agagaagtga aataacccgc ccatggtcac acaggaggga gtgcagggtc
167521 cagttctccc tcccccaccc aggtccgcac tacaggctct gatccacgcc ctcccttgag
167581 gacaaaccct gagccacgct gggtcctccc gcaggccctg aaatagagct tcattgccac
167641 atcagacacc gggagacgcg aggaggccgt gagccaattc cagatgactt gtcaaggctg
167701 cgccagccac agagtcaggg aagcctctgg ctgcctctgt aatataagaa ccaggactga
167761 aggecetet gggagggeac tagacgaggg ceteggeage teegeaggea ggtggggeec
167821 aggccaggcg ggacagaaac ccaaatgtgg cgatgcaaac tggacagaaa gaggcctctc
167881 tgggctgcgg ctccctcact cggggcctga cggtaccagg gggagttaat ctctcacaca
167941 caagetggeg ceagaceet aactgeaggt gteetaagg agaggtgeet ggeaagteet
168001 ctcctgggag tggacgctct cctcctgagc acggtgtgga agcagggccg tgcccagcat
168061 gggtgcgtga ggactggatc ctgcctgcag acaggactgg cgggaggcag aacttgagct
168121 gcctaggact gaggccactc cagagccaag actgacagtc tccacaaaac caaggagccc
168181 tcacctgtct catggctggc aggggctgca caggaagtga cagaggcctg gtgccctcga
168241 gaggcaggca ccgagccagc cagtgtcagg gagcaggtct gcacatctga tggaaaatcc
168301 atccgtggtc ccccttctga caggcctttg gctgccttcc cttctaaata gctgcgaagg
168361 gaaatggcct ggcagaagga aagacaatgg ggccccaggg gcagcagtcc aggagggcct
168421 gggccccca ccctccagct gtaggactcc caagctaagg acagagagaa tactttgggg
168481 aggagaaaga agcagacacc aggcttcgtg gcaggtgtca gcatggctga gggcaggcag
168541 aacagccgcc agcttgatct ggacacctgg tcctgccaca ggccacagca cttgccaggg
168601 gccgttggga cctgtcactg ccctgtggga gctccctgga gagttcttaa cctgggctcc
168661 ataaactggg aaaagagaac acttcaactt catctttact aactgggaac tgaaagctgc
168721 catteeette aactetggag agaggeagea acceeagaet taacageace tgegeeegte
168781 agggcagaaa tcacaggctt cggcaactgt cagcaccgct gctgcagacc agaccaaatg
168841 gtgtttacac tcagcacaac ttaaattata gaggctgtaa gatgcactcc taggtcttat
168901 tatttaatgc atcaattaaa agcacacaaa aaagttttac atgaatgttc ctggcagcat
168961 tattcacaag agctaaaggg tggaaacaac ccaatccatc aacccatgag tggatttaaa
169021 aaactgtggt acatccatgc aatggaatca tatctttcca tccaaagtaa tgaagctctg
169081 atgcatgctg caacctagat gaaccttgaa aacattatgc tgagtgaaag aagccagaca
169141 caaagggcaa atattgtgtg attcatttat actaatgaaa tgcccagaac aggcaaatct
169201 atacaggcag aaggtaggtc agtggttgcc taggcctggg aggacggggt aattgggggt
169261 tactaaaggg tctggggttt cttttcagag tcttgaacat gatctaaaat tgtggtgatg
169321 gttgcaccat tctgtgaaca tactaaagcc attcattgaa ttttacgtta taagttggta
169381 aaatacatag tatgtgaatt atgtctcaat aacattatta tcaaaaatgt gtaaggtata
169441 ataatgatta aaaattttaa aagcatgtgt atgttgatag ctttattttt ctctttttt
169501 tttttttga gacagagtet cactetatag ceceaactgg agtgeagtgg tgegatetea
169561 gctcactgca acctccacct ccagggttca aacaattctc gtgcctcagc ctcctgaata
169621 gttggaacta cagatgcccg ccaccacgcc cggctagttc cttgtatttt agtagaggca
169681 gggtttcacc atgttgccca gggtggtctc aaactcctga gctcaggcca tcctcctgcc
169741 ttggcctccc aaagtgctgg gattataggc gtgaggcacc atgcctggcc gatagcttta
```

```
169801 tttcaatcag atttatttcc tttgtatttt gtagtgtaca ctaaacacat tattttgatc
       aggggtccat gggcctcacc aggctggcag gagggttcac gacatggaac agctgtgcta
169921 actaccagga cagaagacag gaaggtttgc tggaagaggg gtgatgagaa gttggccagg
169981 cctatggggt tcccagcatt caggcaaaag cccagaggtc ctcagggacc ccccactgt
170041 ctgctctgct aatgcaaagc ccatgaggcc caaggagtct cagcttcttc agccacccga
170101 tcacaccccg acacacacta ggccctggtt ccttcaagtc cttaggtcat tttcagattc
170161 aacttcagcc aagacaaatg gtcccctcct gcacctgcca caggcactgt ttccaacgtg
170221 ggcagagttg acagttgatg ggtgtgtgt atctttcgga gctcctgtcc caggcccaca
170281 ggatgaacgg gaaggtggac atggtgggta gagcaagcag gaaatgatga tggtcaggag
170341 gggccttgaa tgctggttct gggggcctgt gctttaccct caaagtggag gagccatggg
170401 gagcatttcg ggtggggcac ggaagggaga ccgcgtgctt atcatgggca gctggaaggg
170461 agtgggagaa acgggggcag ggagaagaca gggcagatgt cctggagaca gaaggcaatg
170521 gggacccata gctcctcctg acacatcagc ctggctttcc tctggggccc atcctctcc
170581 cgacccactc ccagagggtc agaggacaga cgccagccct ggagccacag cagtcctgtg
170641 acgaggeetg gecageegaa gteetgetee getgteetgg ceatagtgat ttgeetgaag
170701 catgtgaccc aacctgagcc agtgagaact caccactggg ctctcccaga aaccctcggg
170761 gaacctgggc ctctctctgc cgggcggctg gtgcactgcc caggcaggac ccacggggag
170821 ggcggctgag ctgaaaccgt gcgggaggcc tgggctgccg ccctgagccc cgcattcccc
170881 ctttggcccc agccgcttct gccccggttt tctgtcactt gcagtcacag gagtgtggac
170941 ctggggatgg cctgtgggag ggacaggggc acaggcacca gctgcacagg tgtggatggg
171001 aggacaggag cgaggccagc cgcctctggg ccacaccctc cggattcact cccaaaggag
171061 aacggccagg cggccaagtc ctcccagctg aggggtgcgg aggaagggat cagagcgctc
171121 ccccaacaaa ggctgcctct ccgtcctgca catcccctcg ccacactgac ctccatttcc
171181 cttcttgggg cctgcccgcc acgagactct tctcccattc cagactggaa atcttttccg
171241 caccttgact aattgttttc aggtgggaag gatttggtgg agaaatggcg tttgtgtgtg
171301 cgtgtgtgtg tgtgtgtgt tgtgtgtgtc caccccagc cgggcagctg ccccaggaat
171361 gctgtattgg cgggaagagc tagaggaccc ttggcctcag ccatgtcctg aggggctctc
171421 ggtgatgtca gcggctcctg gcctcttcca gtaaacatct gttcttattc tgacccagga
171481 attocatttc agaacagtaa cggcctccac tggcaacaca tcccaggccg gtgatgcctg
171541 gggcagggag agcatectae eeeggeetgt geeeegeee eggeeeegee eeeeacteee
171601 atgcccgcc aagccccgcc cacagagctc tcaaaaggga caaaatctgc acctggctcc
171661 gtgtgtccaa gcgctttcac actgtggtcc ctcctagcag cgccatcagg aaaatatgat
171721 cttgtagtaa caggcccttc gctgctcagt gctggccctc gcttcattta atcctcatca
171781 taacccacca gagtagttac cgtcatcagc ttttaccttt cacagatgag aaacaggagg
171841 ctcgctcgcc cagggaggga gggagcagaa aaccaagccc acgtgttgga gcgagatcgc
171901 gtctgactcc agcgcacggg accttgcagg ggctgatggc caaaaactga agtcatggga
172021 gcagcactca totcaaaata agagaaactc tcaggtgcct acacagggag tgaatgcgcg
172081 tgaagcccgc cagggtaatg atagggagca gcagagactc ccaaggcacc tggaactgtg
172141 ggaccettet agagggttee atcettgete agetetagee etecageaca taggeeegge
172201 agatttcctg gttctcaaga gaaactggaa atcttgagct ttgtgagaaa ttttcaaaca
172261 ctggaaaagc caaacaaaac tcatctgtgg gtggacatgg cccgtggccc accagtgtgc
172321 aaactccgcc ctgcacaatg ggaaccctga agtgcagaaa attatctcat tgtgaagggt
172381 aaggcaggga ctcaaaacag ggctcctcag tccacattca tagagtctcc aggttgtacc
172441 accgaatcta ctcgccagcc ttctcctgaa agtgtctcac tgaaccacat cccccgtaga
172501 aactcagggc atctttcaaa gaccgcagtt ttcctgccag cctgcaaaca accctgtgca
172561 tgcccggtgc actgctcccc aaccacaggg gacacctaac agaccacgag ggactgagag
172621 agcctccttg actgaaaggg aaggtcaacc gccgccactc atccccataa aaccacaaca
172681 tgggcacatc ctgcgttcga agctctactt gatgcaagag agcagggaaa ggaaagccgt
172741 gccaccgtgg ggaaatgggc ctgggagatc cattcaggcc aaggtttgtc cactttgggt
172801 ctaccaccac cagcattcac agaagaagca gcacctggtt ctcaattccc ttagaagcgg
172861 ggctagatgc tctgaaggca tggttgtagc tcccacacaa aattactaaa gacataaaac
172921 gaaaacatgt tgaaaaagaa gagacaatat tatgaactgc agaaagtaac tgcacacgta
172981 gagaatcctc acccccaaaa acatccaaaa aaaggaacca aataataaca aggaagttca
173161 ctgtcgccca ggctggagtg cagtggtgca agcgatctga gctcactgca ggctccgcct
173221 cccgggttca cgccattctc ctgcctcagc ctcccgagta gctgggacta caggcgcgca
173281 ccaccacgcc cggctaattt tttgtatttt tagtagagac ggggtttcac cgtgttagcc
173341 aggatggtct cgatttcctg acctcgtgat ccacccgcct cggcctccca aagtgctggg
173401
       attgcaggcg tgagccaccg cacccggcaa gagatttatt tcagaaggac tttttgtgat
173461 tatctgtggt tcatatttgt gccattctag taacagagag actgctttgc taagacatgg
173521 gaagatgcag gtcattggga gcaaaggatc tgaagcaggg gctgttgcca ggaagggcgc
173581 gccttgagga cagcaatgct ggggcttggg cttgccaggt caaccatggg tatcaagtgg
```

```
173641 ttcqtqqcaq ctctqcacat qcatqtatqa tttqcactaa tqtqtcattt ttaactctqt
173701 tttctccctg ggaataaaga tgtctaaatt ctgagaatat cattagtctg aaagaagcag
173761 gtcccaggta ttctgagtaa ataatcacct actgtattat aaattaaaag tgttcccaga
173821 taacaatctg gtgtaaaata taatggaaaa gaccctattg acaatggcaa taacattcta
173881 agtetettag taataaacet aetgggetat gtttttaaac atetgaatea atettettat
173941 ttccgtgaga aaattaaaca tcatgaagat gtcgttcatt tgttcagcaa agatttgctg
174001 agggcettet geaaagggga cactaettta ggeattttt taaaacetea egatggtgat 174061 acttgeeeta teagatgtea gaacatattg teaaceaaca geaattaaag acceetggae
174121 tggtgcaaaa gaaaaacaga aaaggccagg cacagtggct catgcctgca atcccagcac
174181 tttgggaggc caaggaggc ggatcacgag gtcaggagat ggagaccatc ctggctaaca
174241 cggtgaaacc ccgtctctac taaaaataca aaaaattagc cgggtgtggt ggcgggcgcc
174301 tgtagtccca gctactcttg aggctgaagc aggagaatcg cttgaaccca ggaggcagag
174361 cttgcagtga gccgagatag tgccactgcg ctccagcctg ggcaacagag tgagactccg
174421 tctcaaaaaa aaaaaaaaa acaaaacaaa acccagaaag gccagaaata aaccccatat
174481 cctccatgaa cttcacagat gatggaatat acattccaaa gtcaagaaga aagagtgaat
174541 tagcaaacga atggtgttga gacaacagca tggcaattta gaaaaaaatg aacacttaaa
174601 accaacact tatacagtat aagaaacaca tttcacttga attaaaggag ttacatattt
174661 aaaaatcaag tcaggaaaaa agcaaaacat ataatggagt atttctttga aaggctgata 174721 ctttctaca ggctgagtaa ccagaagaaa gcaactagag aggctgacag agctgaccga
174781 agaaacaaaa caccagcccg gcagaataaa aaaggaagct ctgcaaatat aaacccaccc
174841 aagctagcag agggttaatg actagcccca gggagaacca atcagcttca gaggaggaaa
174901 gttgggggcc gtaaccacca gccattaaag aaacaagttt caggccgggc gtggtggctc
174961 acgcctgtaa tcccagcact ttgggaggcc gaggcgggtg gatcatgagg tcaggagatc
175021 gagaccatcc tggctaacaa ggtgaaaccc cgtctctact aaaaatacaa aaaattagcc
175081 gggcgcggtg gcgggcgcct gtagtcccag ctactcggga ggctgaggca ggagaatggc
175141 gtgaaccegg gaagcggage ttgcagtgag ccgagattgc gccactgcag tccgcagtcc
175261 tttcaacaat aacacgattg cctgactccc accaagggtc ccaggccagc ccagccccag
175321 eggacteetg eaggeettgg ggagecaggt gggeacetge aggeaggttg ggggaagget
175381 gtgaggactc tgagccccca gagtctatca ggacaggctg acaccaagac agagacggcc
175441 tacatetace caceccatae catgeccagt cetggaccag ceatecetgg ceccaaagge
175501 cacagegtag teaceacage tgagaetgee ceaateaggg ecaeetgeaa tgteeageag
175561 cctcctgca actgcccgg ctttggtttt taatgtccct agtcccgaga atgcagaagc
175621 tctgcaaaga gaagaacgca gcaactctgg caacctgact gtggaggcag acacctggca
175681 cacatttccc ctccccagt gcccgtgatc tccacccagc gctgggcacc ctccaacctc
175741 cactccattc actcccagac ggagcaaagg ctggcctcat tggccacctt gcccagcaca
175801 ccacctgcac aaccttccca gcagccctgc tcatcgggcc accctcccca gtgaggacac
175861 agcccgtgac agcctgggca ccccaacagg aaagacagcc caaaggccaa gccgccctat
175921 ctgaggtgga ggatgctctg gcagggcagg gactcagcct tgaccttgtt tgctagaaaa
175981 tgcaccaaga actcagtagc aggccaagga gaggagacat gaattcccct tttcagcaat
176041 tcaccctgct tgtacaggtg gggagttatc tgtacctctg aggaggtaca gatttcatct
176101 ggtgctccag ctgcagtgaa aggagctggc tctgggctct gtgggacctg gggtgggtca
176161 \quad {\tt tccccatcgc} \quad {\tt tgtgccctga} \quad {\tt tttcctccca} \quad {\tt gcacattggg} \quad {\tt atggctcgtt} \quad {\tt gttggttccc}
176221 agaatgtacc aggaaggtac aggtgcagag tgcagctgac gacgaagggc ccccagccag
176281 gaagggtccc caggagtcct ggctgatgaa agactctggg aaagaaaggt gggaacaggg
176341 agaggacaga aggggcaggg aggggagagg acataaaggg agaatggaga gaaaagggaa
176401 aaaggggaga tgaggagaa gagaaggga gggagtggga aaaagaggaa tgagaaaaga
176461 agggggaaga gagaggaggg aaggggagga gaagctggag ggagaggagg gggaagggag
176521 ggagaggagg gggaagggag gggaagggag gggaagggag gggaagggag
176581 ggagaggagg gggaagggag gggaagggag gggaagggag gggaagggag
176641 ggagaggagg gggaagggag gggaagggag gggaagggag gggaagggag
176701 ggagaggagg gggaagggag gggagggggg gggaggggctc ccagcaccag
176761 gacccagcac aaccgtccta tgacagttgt ctctgcagct gcatttaggg ctgttctgga
176821 aactcaggcc ttctccctgt cggcagggct gagccctggt ctgggacctc cccttgttct
176881 atcagagece ecaggetggg tgaggtecae tgggatetgt ttteacteae aatgettetg
176941 acaccaaaca tgtggtttee etcacaccaa ecagttetee aacetecaga egetagetgg
177001 gtgccccaca gttgagtgca atgctcacgc caactacctg gggtcagctt agccctcagg
177061 ttaaggeete agteeeacae ageageecea ettgeggtgg caagtteeag ettteeacet
177121 gtgcctctga ccaggcggct ataaattggg cgggtcccac aactccctcc tcaggttctg
177181 taatttgcta ttaggttggt gcaaaagtaa ctgtgacctt ggaatcagac agacatgtgt
177241 tcattaatag aacagatcac agaactcagg gaggcatttt acttactatt tccagttgat
177361 aagggetgea gageeteeae geeetetetg ggeaeteaee eteccaqaae etecacetgt
177421 tcaccaaccc aaagctctcc aaaccttgtc atttaggggt tttcatggaa gttccatgac
```

```
tcccatcccc agaggttggg gaagtgaggc tgaattctca acccaacaat ccagaaactc
177541
       ttatatcagg aacaagggga ctcagaccaa atctgataat aaaaggtgtt tctatcaccc
177601 ttaacactca ggaaattaca aaggttttag gagctctgag gcaggaacca gagatgaaga
177661 acaaacatac atttataatt teccaetate acagggtete agacagtace teagtetgtg
177721 acccaacctg cattgcccca gaagcccaga cctcagctca gggccagtgt gctgggatca
177781 gtggccagtg gccagccatc gtgcagagag gggagggcag aggggaggga gggaggggat
177841 gggagaggaa gggagggagg agtgcagaga ggaagggagg ggaaggaagg gaaggagagg
177901 agaccaggag cctcccaggg cctgggcacc tgcctgggag ggcactgagg agcaccaagg
177961 aggatgccta ccactgccc caccttgccc tgatcaggtc tgcaggatca gtgctcaacq
178021 cccatggagc tccaggtggc cgccaagtgt ggacagccct gcagcaaagg ccagctactg
178081 ccctgggagc cctcacccc ttatcctgcc cgcttgcctg tgaggacccc tccctactgt
178141 gtggccttgg ggatagccat gcgacggcgg ctgccttcct tctgccgggg ctctgaattt
178201 ccaggtgaga gacccgagag cagagggcca ggagccgaca ccgctgtggc agcttcccgc
178261 atcccaagcc gggccatgcc cactggccat cgcttccttc cacctcaagc cccccatgga
178321 attecettig actgaggeca gecagectea tecceettig eteceteact gacacacac
178381 ttgtgaggca ggtggtgtct taactgggaa aatggagggt cacaggccag caagagaaga
178441 gccaggcccc aagtctggtc tgtgagcccc cactccccac agccctcgct agtgagcacc
178501 cgtcatgctg tacaaaagac tctcctgtgt agcttttgaa aagtacagac cccagggctc
178561 acgcaggtct gataaagcag aatctctcag gatggggcct atgtacagat gctgtgcaaa
178621 gctcctcaaa tcccatgccc atcagtgggc aggcagagag atcacacaat ggaaatgctc
178741 gacagagtct cactctgctg cttggctgga gtgcagtggc gcaatttcag ctcactgcaa
178801 gctccgcctc ctgggttcaa gagattctcc tgcctcagcc tcccaagtag ctgggactac
178861 aggcgtgtgc caccatgccc agctaatttt tgtattttta atggagatgg ggtttcacca
178921 tattggccag gctggtctca aacacctgac ctcaagtgat ctgcccgcct cagcctcctc
178981 aagttacaca ggcgtgagcc actgtgcccc gcctacagat ttcttctaag gagggaaatg
179041 tctttgcttg gaaaaacacc ttctagaagc acgtgggata acagataaca gtgggactgg
179101 aagagcagga gactetgeag acagtgeeac caceteagag eagegggeaa agteegetgt
179161 taagacacag gaggagaatg gagggattge tecagagaaa etggacagag ggagggagae
179221 gccactggga gggaagaaag aacccacaga tgaaagtgga aatgccccca cacatggccc
179281 aaagggcttt ccaagaacag gqtcctqttc ttccagaaqt cacccqcqtq qccqqqaqqt
179341 gctggctccc ccaccttctg caggaaggct gcccctccct acgagggctt cccatggtgc
179401 gtaaatgggg actgggtttc attcctggcc cagcaaagtg gacagctgag gccgaggctg
179461 agaacacaaa cacccggaa tcgcaacacc tctggctttt ggaggtgaga gaagggagcg
179521 ttaagagtta agacacattt tatcttgatt tcagctcctt tactgataaa aatgggatct
179581 tagaaaacga gaattcagag gatattgcct tcacatgaaa tccatcttaa tccacagcaa
179641 gcgctgtatt aagcagagaa ataccggggg cgttgccgtt aaagccaggc acagatgagg
179701 atgcgtgtag ccacggctgt gacttaacat cgctctgaag gttccagacg gtgcagattg
179761 gagatgagga tccaaaatta tcagtgttta cagagtgcaa ctgtatacct agaaaaccca
179821 agggactcca caaagatata ttagaattaa tgagttcaat caagctgctt gataaaagat
179881 agttctataa aaatcagtag ccttcctgtg taccaataga tggaaagtat tcaatgagca
179941 atggcaaaaa gaaaaaaaat ccttgaaata atcctgattt ttaaaaatgg atgacctgta
180001 taaaaatatg tatatataat acttcatggt acaacatcaa agcagaatga aataagctga
180061 aaaaatatac tatgttcctg atgaatactg taaattatgt caattcctcc tttaattagt
180121 ttctaagttt aatttactat caatcaaatt cacgagggat ttttctaccc gacaaaacaa
180181 ttataaaatt catttgaaag aataaacata tgtgaccagc caagaaaatt ttgtaagaga
180241 ataccagcaa agggggacgt atccagccag atgttccaaa gccacacagt ccaacagaaa
180301 tagaactcga gctttatatg tagccatgtt tttaaaaaaa aaagacacag gtgaaattaa
180361 tttcagaaat atatttatt taacccagta tgcccaaaat attaccattt caacctgtaa 180421 tcaatacttt aaaatgatct attaaacatt ccacattctt tttggggggt acgaagtctc
180481 tgaaatccaa tgtatatttt atactcaggg tacctctcaa ttcagaccag acacatttta
180541 agtetteaat ageettgtgt ggettatage taetgtattg gacageaaag etteaaagta
180601 cttaatactt tgactattag agccttacag ttctaataat aaacacagct taatattggt
180661 acaagaacag aaagatggaa aagtagaatg tatctgcggt actgcttaac ctgaggtttc
180721 atttgcaact gactggcgat ggtgtactat aacccataaa atagacagat gtaaatacat
180781 accaatatge teacagetet caageeeett tteateatat gtecagaage tetgteeeaa
180841 tcagaatggc cactagcaag ccttagacaa gccttgcatg aaacgtgaag acaccctact
180901 ttccatgtgc tcccaatccc tgctttcaaa caqccqcqtq qqaqqqatqq qcaqqqcaaq
180961 gtaacgggaa gggctgcaga gcctccacgc cctctctggg cactcaccct cccagcacct
181021 cacctgttca ccaacccaaa gctctccaaa ccttgtcgtt taggggtttt caaaggaaaa
181081 atacccgggt gtaaagatga caggetttaa caettggaaa taettttaat acattgaaat
181141 ttcagattag ggctttcaaa ggaaaaatac ccaggtttaa agatgaatcc cggacattct
181201 gcacagaget ggtgaggget ggteeeteea acacqeatet ttecatttee caacceetga
181261 actgaggatg caatcggcgg gtctcaggcc ccggccctgg cccccgcctc ctgggccacg
```

```
181321 acacttccaa cgcagtccct cactgtcaac accctggaca ctcaaaatgt ctttgaagag
       tcacqctqtq agqtcaaaaa qttagggtqc acqcaqaaaq gcqcatqtaq ctttqcattq
181441 gtgaggcaaa tacctatccc tggaggaagg accgctactt cgtaattcac aagaggaaga
181501 cccccggagg cggacgaagc caaccgaact cagttcccgg gagccgtgac aagcgacggc
181561 caggcagcag aaatggccca cccattaggc tgcagacagc atcagagaaa ccaagcactg
181621 tggcagtggg gcccgcgcct ccagggaacc acaaggcaca gagttgcagt ttaaatggga
181681 gtgtctcctc tttcttggtg gcgtataaag taatggtgtg tcctgtaacc gatggcacct
181741 tagagetaat gatatgeaga caeggeeace gettteteae eeeeggeet ggggtaggeg
181801 cttgctgcac acceacctt tcactgccac tgaagtgcgt gcggacagaa cccatctttt
181861 gctattggag gaactaaggt tctcaggatc gtggtgcttg tccgccctgc cggtcacgag
181921 gagcacagcg gaccatgtga cccgcaacag cctccagccc acaataggcc cctgccttcc
181981 ctgggttaac ccgtgaaatg cacaaggcag ggtggggatg gcgtagagcc tgcctggctt
182041 cagcagcacc caggeettgg teetggacae tagggtteee tgtgeetetg ageggaaget
182101 gtgcacccca ctctgcagcc ctggagtcgt cgtgcagtgt aattgaaatt catggacaag
182161 cccgaggagc cagctccggg ctcggtaata acttctccat attaatggca gcaccgcaga
182221 ccctgtggac agctgatatt taatatgaaa catacgcagc agagtgtgca gctcctacct
182281 ggatcctccc attccggggt aaccaccagt aggggatggg ggtgtctaac gtggcgccaa
182341 gattgagggg getggggtee teeteteee tgagtaeete aaceeeaett aaggeeeete
182401 ttctacagag tgcaggaaac ccctcccgag aaatacataa acacatgctg gcccatgctc
182461 actcaaatgc acaccctccc atgcagacac actcatgtgc acacacgtgt acacactcat
182521 tcagacgtgc acaaacatat gcacccccac acgcacactg catgcacgta ctcctacatg
182581 caagacatgc agaggcaaca cgtacatgca cacactcccg ccatgcacag gcccaggaca
182641 cgcacacgtc cacatgcage caccagcctg ctgtgccggc agcaacacag ggacccccag
182701 ggctgcccaa gccagagagg caggtggggt aaaqaaggac atgtctgcct gccagcacag
182761 acccagggtc ccaggaggc tgccatgcac acttgcctct ttgggtcttc agataccaca
182821 gtgggcaggc ccagaccata gctcaggcag ccacgaggca aagccagcct cgctgctgag
182881 eggatgtece tggetgatte cettacteae ceaggtgtgg eccetgtgag ecteaeagea
182941 ggcctgggtg aggacctggc cttcacctcc cagctgactc tgcacgaggg cctgaattca
183001 ctcactcacc caggtgagge ccctgtgagc ctcacagcag gcctgggtga ggacctggcc
183061 ttcacctccc agctgactct gcaggagggc ctgcattcac tcaggcatga ctcgctaagc
183121 actggagaca tgggggacag ggaagccacg gcgagccatt gggcaggaga agcctgccac
183181 acctgaatga gcacatggcc gcgcacattt accagtgcca gaaacatacc cagccacaca
183241 atggagtgca gctctcccag ggagagctgg ccttggtggg ctccggctga gaccagtgct
183301 gactatgccg gccttcatga ggggctggga gccggctcca ctctgcccct ccctaaagga
183361 ttccaggaga gacgccagcc cacacagaga acctgcatat gtaactccta gagcctcggt
183421 ttcctacctg tgaaatgggg ccacggtggc tggctcacag gaaaaccgca gggactgggt
183481 tcaaagcccc aagcagaggt agatggtgtg gatgctgctc ccccgacccc ctcctgaggc
183541 tggccgccgc ctccagaggg actgcgctgc actgctggat ccctcaggca tctctgtagg
183601 ggccctcagc tcacgtaagg cagcagggga gggagtcatt gccccaccct cccaggggca
183661 cctgagggga acgctggagt tctgcctcct gcagcccttt ctcccggagt ctcattccag
183721 accagcagag caggcgactc aggccggagc tggagggccc tgaccaggtc acgggggcct
183781 tgaatgccag gccagtgggt ttggatgttt ttaagagcag taagaaccac tgagaggtct
183841 taagtgaagg cgtgacatga gttgctgcat ggtttctaaa aatccctctg gctgcagagt
183901 ggagaagggt tgtcggggag agaccatggg gcagtggggg gtacaagagc agaaagcagg
183961 ggttggcacc aggcgtggag ggaagccggg ccctgagaga gctctagaat tggagctggc
184021 taggggaggg cgatcctgga agggtggggt ctggaggaga gtggggagag ccacgtgact
184081 tgagtatggg gtcatccagg gaagggggtt ccagaggcag ccgagcaggc aagcctggag
184141 cccaggagga cttctaagcc caacatgggg tctggagtcc aggagaaggg tggccacaac
184201 cgtgttcacc accetgcaca attetectec ettettgtat gataggeece tetteattee
184261 agagtttggg agtctgtccc tccccctcag tcccaaaggt gggcaggaga cctgggctag
184321 gcccgcacca cagccatggg tttgaagatg ggcctccaat ccctccccca actctcacag
184381 gtgtcaccca gagaggaggg ctttccatct caaaggttgc ctccttggaa aacgagttgg
184441 gcctggagcc gctggtgggc cgggggttga ggggtggaga gcaattctga aatgaacact
184501 gagaggcagg gctgagaaat ggatagcatg ctctgagccc ctggattcag ccaggcctga
184561 agccaacact cctcaggacc cccagataat tggggccatg ctgtcccttg tttgtttcat
184621 ccaatatgag caggggtttc tgtcacttaa actgagcaag tcttaaggtg acaagtatgg
184681 cggaggctga gactggcctt agcagctgtg taggctgctt gcagctgggg cccacaggag
184741 cctctgctcc tacctgggga gccccgacac cctagggaac ccagaggttc ctgcagccc
184801 tctttagtct tcctgacaac ctctcattgc gatccaggca gtgccaaggt ggggtgggag
184861 gaaggaagac cctaccagcg gcagctgcaa atctcaggtg cccctcaccc cactgcacag
184921 teccaggace egeteacace tgeetgatet getetageae etgageetge tggageecag
184981 tgtgtggcct cgaaggcagc agccttgctg ggaaaaatga aactcatctc gatcccttag
185041 gccggcttct gacttctctc tgtggccttt atgactctta atgtccagca agacagagtg
185101 ggtgcctggc ccagacagca gccccgcagg ggagccccag cctgaaaggc agcagccctg
```

```
185161 gatttcttct tgccatgcaa ccttgggtct ctctgagcct cagccacgca gtggggcagc
185221 cctatctcac agggttgtgg ggttcgcatc aagcatccag ggaagggcat acacttcctc
185341 tggaggette atecaetget geceageetg geaggagagg ateceegtge tgeeetgagt
185401 ggggaggcag aggcgggcag ggttgcttcc atcccacgga agtcccagct gcagtccccc
185461 accagtgagg acttaggcca cccataggag ctgcagccca gcgcaggtca cgagccagtc
185521 aaggccactc agctcccagg cctgctcccg gctccactca cactgacgat ggtcaaaccc 185581 acaatgagaa cgtctccagg agtcaaataa gaaaggtggg aaatgttgta aagaaatgca
185641 tttttaaaat totttttgta ggcatgcagg aaaaggcaac aaaacatagt gagcatggcc
185701 ttggaatcag atttgtgttc aaatactggc ttcgaagctt gaagcaagct atctcgactt
185761 ttggagcctc agtttattca tctgtagaag ggggatgatg tcgggatatg ttccgtaggg
185821 tgctgtgagg attaaacaag gcgaggtggc acagggggct cagctgagag cctggcacac
185881 aatgttaata ggaacacagt caactgtcac ttaccatcat taccttttac gccaaaaggc
185941 ttctcactgg gtttttaatg ggcatgtaaa aaccacgtga aattagcacg cctaccacgc
186001 tgcccaggag atactggaaa actettccac agcaacgtga ggcacaacac cactetgtgc
186061 agcctgtttt gctcatgcct tgtgcaaagg gacattttgc tgtggatact atgaataacc
186121 cctcgctgtg gatattatta tgaataactt ccgtctagtc actcaacctc ccagagcctg
186181 agtgctccac ctgtaaccag ggatgagatg cctccccgac cagggctctg tgaggacaag 186241 aggtgccctg tgtaaagacc caggtcctta gcaaagaagc ctatcgtggt ggcagcagag
186301 ggggatttaa cagtaggaca gacacatacg cagcaacaaa gtcagaaaaag gaaagaagag
186361 gccgggcgcg gtggctgagg cctgtaatcc cagcacttta ggaggccaag atgggcagat
186421 cgcttgaggt tgggagtttg agaccagcct gatcaaaagg aaagaaagaa agaaaaaaag
186481 gaaggaagga aggaaggaaa gagaagaga gagaaagagg acaagcgaaa agaaaagagg
186541 ctgggcgcag tggctcatgc ctgtaatccc agcactttag gaggccgagg caggcagatc
186601 acaaggtcag gagattgaga ccatcctggc taacacggtg aaacaccgtc tctactaaaa
186661 attttaaaaa aaataaaaa aaattagctg cacgtggtgg cgggcgcctg tagtccctgc
186721 tacttgggag gctgaggcag gagaatggcg tgaacccgga aggcagagcg cttgcagtga
186781 gctgagatcg cgccactgca ctccagcctg ggtaatagag tgagactccg tctcaaaaaa
186841 aaaaaaaaa aagaaagaaa acagaaccaa tggtgctgtc ccactgtcca aggccattat
186901 tcagtgacag cattcaatgc cgctcaggca ggtcccagct cctcttccaa ccccaatatt
186961 cttcccagct ctgtctggta catgggacac ttcagcaggc ctgtcctgcc caggccaatc
187021 cacacetggt acctetgeac acgetectec etetgeeegg gttgeeaace tgegtetttt
187081 ccagetggcc acteattett ccagececca tteaaacage cececaggag caeactetee 187141 aagteetgge cagagtgtee gteagecace etgacgacag gagecetggg tgggtaccag 187201 acetgeetea ttgetgacea gtacagggga taaacatatg agaaggtget ggetgaaaaa
187261 tgaatcacca aatgaactgc tgaatgaatg aaacagtgac aagtcctccc caaaatgctc
187321 tccatcagga atgcatagta cacaggtgtt ggcccaccaa cagactgcaa ccccatgtca
187381 actoccacca cottacetca ecctaagtee geageaaaca teteetttea titaggaaat
187441 taacctccag cgtaaaatgg gacacacctc tgaggcccag gatgtcctca gagacagtgg 187501 gcgatgtcaa gggctcacca ttttaaccca gctcctccag ggatatttac agttgtttgc
187561 aatatggcca agttctaact aaatccagcc aaaggcagtg attttccaaa gcaacaagtg
187621 atattttctg tgtctccata gaaagaatga cagtggttgc agagccctgg tgtaattgcc
187681 ggctctgcag actgtaggat gagcctcagc tgcccgagta cgggcgtgct caggggccac
187741 gggggctggg agagtggcca ctcactcggg gcaggagttc cctgagtagc aattagagcg
187801 gaacccatgg tgggcggctt cagatgtctg gccagcacag ccagcctgac caccacaca
187861 ccaatccaaa atagaaaact gcagtggcct ctgctgtgtg ccaggccccg ggcagccgga
187921 cagageaccg ccaatgteag cetecteect cageategat ecaggettee tetgaggeec
187981 ccttgtgctg agccacggtc cctcctgccc tctccaggaa gcagagcttc ccagagctcc
188041 agtcacagga ctagagaggc gcaggcagtc tcaaaaggga tcccctagcc tctctcttgt
188101 ccttcaggcg ctgccccaa aagatcgagc agctcatggg cactagagcc ttcatttcca
188161 aatgcacccc tcagctcaaa atagagaaaa ccaacttttc aaagaaccag ctggagttca
188221 acaggaaacc acagcagaaa aaccaatgat tcccggtcag ccaaggggca gagggctaac
188281 tgggcatttc agcatcactg ccagctccct gggctggtat tacccgcacg caaggaaaca
188341 ggaagactga ctgccagccc ataagtccac cacacata tcacgccagt atgcacaagg
188401 acggacacaa actcaacaga tgctcaacac actgatgtgc agaaacccag acacatacgt
188461 gcacaagaga cactggcaca cgcacatgtt cacacaggtg cacgggcacc cagatgcagg
188521 tacacaccaa cgttccacaa cacatgtgca cacactcaca aaggtacaca cacatacacg
188581 gacccaccc cggatgcaag ccagagacct gttcaggcag gcaaaagaga gaggcgcacg
188641 ctcctgcctg ctgagccttt tggagacccg ggcgctcccc atgcataaat ggccccctgc
188701 tcagaccagt caaaacaacc tgctttccag ccaagccctt cagttggagc acgaggctca
188761 ctaaagcacg ggaagggcgc ggaaagtcct cagcgcaggc cttgccctcc caagggactc
188821 ccaggtaacc cttttccaaa acccaggcga gagcagcgga gagaaaggag ctagagaagt
188881 gcgtactcac caqcccatcg caqttqctqa qcqccacaqa qqaqqcttcq qctaqqccqq
188941 ccacgtetee gacgtagaga cageteeega geaggggete caegegggtg gtgeeettet
```

```
189001 egecetgeca etecatagtg geceeggeg ceaegaggeg ggegttggge egeageegea 189061 ggtgeaggte teggeeaaag acegtgacat tgtagaagag gtgRetgeca ggeteeteet 189121 egttgeetee gggRaagete ggggteegga eeggggegge eetgeggget egtaceeetg 189181 etetggaegt agetgeegae aceaYgtggg acaceaageg geeetgggeg teagtgegea 189241 egggeacege eaggatgege teegeteegt geeeeagggg eeegeetggea acgggaaggg 189301 gegttagate ggeggagaee aeggageee agtgeeteag agaceegeeg geaageeaeg 189361 eeeeeeaga eeegeeea etgegaaggg aaggggeatt eegeeaggeg aceeeagaag 189421 eeageetgea eeteeeegge ttteetgeaa
```

[0254] Following are human cDNA sequences for transcript variant 1 (long form) and transcript variant 2 (short form) of *ADAMTS2* (cDNA sequences 1 and 2, respectively). Alternative splicing of the *ADAMTS2* gene generates two transcript variants, therefore, *ADAMTS2* exists in two forms: a "long" form comprising a molecule approximately 130 kDa in length, and a "short" form comprising a molecule approximately 70 kDa in length.

#### ADAMTS2 cDNA Sequence 1 (SEQ ID NO. 2)

NM\_014244 Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 2 (ADAMTS2), transcript variant 1, mRNA

```
1 atggateege eggegggage egetegeege etgetetgee eegegetget getgetg
  61 ctgctgctgc cgccgccgct cctgccqccg ccgccqccgc ccgcgaacgc caggctcgcc
 121 geogeogeeg acceeccagg egggeeeetg gggeaeggag eggagegeat eetggeggtg
 181 cccqtqcqca ctqacqccca qgqccqcttq qtqtcccacq tqqtqtcqqc aqctacqtcc
 241 agagcagggg tacgagcccg cagggccgcc ccggtccgga ccccgagctt ccccggaggc
 301 aacgaggagg agcctggcag tcacctcttc tacaatgtca cggtctttgg ccgagacctg
 361 cacctgegge tgeggeecaa egeeegeete gtggegeeeg gggeeactat ggagtggeag
 421 ggcgagaagg gcaccacccg cgtggagccc ctgctcggga gctgtctcta cgtcggagac
 481 gtggccggcc tagccgaagc ctcctctgtg gcgctcagca actgcgatgg gctggctggt
 541 ctgatccgga tggaggagga ggagttcttc atcgaaccct tggagaaggg gctggcggcg
 601 caggaggetg agcaaggeeg tgtgcatgtg gtgtategee ggccaeceae gteceeteet
 661 ctcggggggc cacaggccct ggacacaggg gcctccctgg acagcctgga cagcctcagc
 721 cgcgccctgg gcgtcctaga ggagcacgcc aacagctcga ggcggagggc acgcaggcat
 781 gctgcagacg atgactacaa catcgaggtc ctgctgggcg tggatgactc tgtggtgcag
 841 ttccacggga aggagcacgt acagaagtac ctgctgacac tcatgaacat tgtcaatgaa
 901 atctaccatg acgagtectt gggtgeecac atcaacgtgg teetggtgeg gateatecte
 961 ctgagctatg gaaagtccat gagcctcatc gagatcggga acccctctca gagcctggag
1021 aatgtctgcc gctgggccta cctccagcag aagccagaca cgggccacga tgaataccac
1081 gatcacgcca tcttcctcac acggcaggac tttgggcctt ccggcatgca aggctatgct
1141 cetyteaccy geatytycea teegyteege agetyeacce tyaaccatya gyacygette
1201 tecteagegt ttgtggtgge ceatgagaet ggeeaegtge tgggeatgga geaegaeggg
1261 cagggcaacc gctgtggcga cgaggtgcgg ctgggcagca tcatggcgcc cctggtgcag
1321 geogeettee accgetteea etggteeege tgeageeage aggagetgag eegetacetg
1381 cactectatg actgectget ggatgacece ttegeceaeg actggeegge getgeeceag
1441 ctcccgggac tgcactactc catgaacgag caatgccgct ttgacttcgg cctgggctac
1501 atgatgtgca cggcgttccg gacctttgac ccctgcaagc agctgtggtg cagccatcct
1561 gacaacccct acttttgcaa gaccaagaag gggcccccct tggacgggac tatgtgtgca
1621 cctggcaage attgttttaa aggacactge atctggctga cacctgacat cctcaaacgg
1681 gacggcagct ggggcgcttg gagtccgttt ggctcctgct cacgtacctg tggcacgggc
1741 gtgaagttca ggacccgcca gtgtgacaac ccacacccgg ccaacggggg ccgcacctgc
1801 tegggeettg cetaegaett ceagetetge ageegeeagg aetgeeeega etecetgget
1861 gacttccgcg aggagcagtg ccgccagtgg gacctgtact tcgagcacgg cgacgcccag
1921 caccactggc tgccccacga gcaccgggat gccaaggaga gatgccacct gtactgcgag
1981 tccagggaga ccggggaggt ggtgtccatg aagcgcatgg tgcatgatgg gacgcgctgc
2041 tectacaagg aegeetteag eetetgtgtg egeggggaet geaggaaggt gggetgtgae
2101 ggtgtgatcg gctccagcaa gcaggaagac aagtgtggcg tgtgcggagg ggacaacagc
```

```
2161 cactgcaaag tggtcaaggg cacgttcaca cggtcaccca agaagcatgg ttacatcaag
2221 atqtttqaqa tccctqcagg agccaqacac ctqctcattc agqaggtaga cqccaccaqc
2281 caccatctgg ccgtcaagaa cctggagaca ggcaagttca tcttaaatga agagaatgac
2341 qtqqatqcca qttccaaaac cttcattqcc atqqqcqtqq aqtqqqaqta caqaqacqaq
2401 gacggccggg agacgctgca gaccatgggc cccctccacg gcaccatcac cgttctggtc
2461 atcccggtgg gagacacccg ggtctcactg acgtacaaat acatgatcca tgaggactca
2521 ctgaatgtcg atgacaacaa cgtcctggaa gaggactctg tggtctacga gtgggccctg
2581 aagaagtggt ctccgtgctc caagccctgt ggcggagggt cccagttcac caagtatggc
2641 tgccgccgga ggctggacca caagatggta caccgtggct tctgtgccgc cctctcgaag
2701 cccaaagcca tccgcagagc gtgcaaccca caggaatgct cccagccagt gtgggtcaca
2761 ggcgaatggg agccatgtag ccagacctgt gggcggacag gcatgcaggt gcgctccgtg
2821 cgctgcattc agccgctaca cgacaacacc acccgctccg tgcacgccaa gcactgcaat
2881 gacgcccggc ccgagagccg ccgggcctgc agccgcgagc tctqccctgg tcgttgqcga
2941 gccgggcct ggtcccagtg ctcagtaacc tgtggcaacg gcacccagga gcggccagtg
3001 ccctgccgca ccgcggacga cagcttcggc atctgccagg aggagcgtcc tgagacagcg
3061 aggacctgca ggcttggccc ctgtccccga aacatctcag atccctccaa gaagagctac
3121 gtagttcagt ggctgtcccg cccggacccc gactcgccca tccggaagat ctcgtcaaag
3181 ggccactgcc aaggcgacaa gtcaatattc tgtaggatgg aagtcttgtc ccgctattgc
3241 tecateccag getacaacaa getgteetge aagteetgta acetgtacaa caaceteace
3301 aacgtggagg gcaggataga gccaccgcct gggaagcaca acgacattga cgtgttcatg
3361 cctacctcc caqtqcccac tgtagccatg gaggtgcggc catcaccaag caccccctg
3421 gaggtccctc tcaatgcctc cagcaccaat gccacagagg atcacccaga aaccaatgcc
3481 gtagatgaac cctacaaaat ccatggcctg gaagatgaag tccagccacc caacctaatc
3541 cctcgacgac cgagccccta tgaaaagacc agaaaccaaa gaatccaaga gctcattgat
3601 gagatgcgga agaaagagat gctcggaaag ttctaa
```

## ADAMTS2 cDNA Sequence 2 (SEQ ID NO. 3)

NM\_021599 Homo sapiens a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 2 (ADAMTS2), transcript variant 2, mRNA

```
1 atggatccgc cggcgggagc cgctcgccgc ctgctctgcc ccgcgctgct gctgctgctg
  61 ctgctgctgc cgccgccgct cctgccgccg ccgccgccgc ccgcgaacgc caggctcgcc
 121 gccgccgccg acccccagg cgggcccctg gggcacggag cggagcgcat cctggcggtg
 181 cccgtgcgca ctgacgccca gggccgcttg gtgtcccacg tggtgtcggc agctacgtcc
 241 agagcagggg tacgagcccg cagggccgcc ccggtccgga ccccgagctt ccccggaggc
 301 aacgaggagg agcctggcag tcacctcttc tacaatgtca cggtctttgg ccgagacctg
 361 cacctgcggc tgcggcccaa cgcccgcctc gtggcgcccg gggccactat ggagtggcag
 421 ggcgagaagg gcaccacccg cgtggagccc ctgctcggga gctgtctcta cgtcggagac
 481 gtggccggcc tagccgaagc ctcctctgtg gcgctcagca actgcgatgg gctggctggt
 541 ctgatccgga tggaggagga ggagttette atcgaaccet tggagaaggg getggeggeg
 601 caqqaggctg agcaaggccg tgtgcatgtg gtgtatcgcc ggccacccac gtcccctcct
 661 ctcggggggc cacaggccct ggacacaggg gcctccctgg acagcctgga cagcctcagc
 721 cgcgccctgg gcgtcctaga ggagcacgcc aacagctcga ggcggagggc acgcaggcat
 781 gctgcagacg atgactacaa catcgaggtc ctgctgggcg tggatgactc tgtggtqcag
 841 ttccacggga aggagcacgt acagaagtac ctgctgacac tcatgaacat tgtcaatgaa
 901 atctaccatg acgagtcctt gggtgcccac atcaacgtgg tcctggtgcg gatcatcctc
 961 ctgagctatg gaaagtccat gagcctcatc gagatcggga acccctctca gagcctggag
1021 aatgtetgee getgggeeta eeteeageag aageeagaea egggeeaega tgaataceae
1081 gatcacqcca tcttcctcac acqqcaqqac tttqqqcctt ccqqcatqca aqqctatqct
1141 cctgtcaccg gcatgtgcca tccggtccgc agctgcaccc tgaaccatga ggacggcttc
1201 tecteagegt ttgtggtgge ceatgagact ggceaegtge tgggeatgga geaegaeggg
1261 cagggcaacc gctgtggcga cqaggtgcgg ctgggcagca tcatggcqcc cctggtgcag
1321 gccgccttcc accgcttcca ctggtcccgc tgcagccagc aggagctgag ccgctacctg
1381 cactectatg actgcctgct ggatgacccc ttcgcccacg actggccggc gctgcccaag
1441 ctcccgggac tgcactactc catgaacgag caatgccgct ttgacttcgg cctgggctac
1501 atgatgtgca cggcgttccg gacctttgac ccctgcaagc agctgtggtg cagccatcct
1561 gacaacccct acttttgcaa gaccaagaag gggcccccct tggacgggac tatgtgtgca
1621 cctggcaagt tcaggccggg cgcggtggct catgcctgtt atcccagcac tttgggaggc
1681 caaggtaggt ggatcgcctg a
```

[0255] Following are human polypeptide sequences for isoform 1 (long form) and isoform 2 (short form) of *ADAMTS2* (amino acid sequences 1 and 2, respectively).

## ADAMTS2 Amino Acid Sequence 1 (SEQ ID NO. 4)

NP\_055059 a disintegrin and metalloprotease with thrombospondin motifs-2 isoform 1; procollagen I N-proteinase; Procollagen N-endopeptidase [Homo sapiens]

MDPPAGAARRLLCPALLLLLLLPPPLLPPPPPPANARLAAAADPPGGPLGHGAERILAV PVRTDAQGRLVSHVVSAATSRAGVRARRAAPVRTPSFPGGNEEEPGSHLFYNVTVFGR DLHLRLRPNARLVAPGATMEWQGEKGTTRVEPLLGSCLYVGDVAGLAEASSVALSNC DGLAGLIRMEEEFFIEPLEKGLAAQEAEQGRVHVVYRRPPTSPPLGGPQALDTGASLDS LDSLSRALGVLEEHANSSRRRARRHAADDDYNIEVLLGVDDSVVOFHGKEHVOKYLLT LMNIVNEIYHDESLGAHINVVLVRIILLSYGKSMSLIEIGNPSQSLENVCRWAYLQQKPD TGHDEYHDHAIFLTRQDFGPSGMQGYAPVTGMCHPVRSCTLNHEDGFSSAFVVAHETG HVLGMEHDGQGNRCGDEVRLGSIMAPLVQAAFHRFHWSRCSQQELSRYLHSYDCLLD DPFAHDWPALPQLPGLHYSMNEQCRFDFGLGYMMCTAFRTFDPCKQLWCSHPDNPYF CKTKKGPPLDGTMCAPGKHCFKGHCIWLTPDILKRDGSWGAWSPFGSCSRTCGTGVKF RTRQCDNPHPANGGRTCSGLAYDFQLCSRQDCPDSLADFREEQCRQWDLYFEHGDAQ HHWLPHEHRDAKERCHLYCESRETGEVVSMKRMVHDGTRCSYKDAFSLCVRGDCRK VGCDGVIGSSKOEDKCGVCGGDNSHCKVVKGTFTRSPKKHGYIKMFEIPAGARHLLIOE VDATSHHLAVKNLETGKFILNEENDVDASSKTFIAMGVEWEYRDEDGRETLOTMGPLH GTITVLVIPVGDTRVSLTYKYMIHEDSLNVDDNNVLEEDSVVYEWALKKWSPCSKPCG GGSQFTKYGCRRRLDHKMVHRGFCAALSKPKAIRRACNPOECSOPVWVTGEWEPCSO TCGRTGMQVRSVRCIQPLHDNTTRSVHAKHCNDARPESRRACSRELCPGRWRAGPWS QCSVTCGNGTQERPVPCRTADDSFGICQEERPETARTCRLGPCPRNISDPSKKSYVVQW LSRPDPDSPIRKISSKGHCQGDKSIFCRMEVLSRYCSIPGYNKLSCKSCNLYNNLTNVEG RIEPPPGKHNDIDVFMPTLPVPTVAMEVRPSPSTPLEVPLNASSTNATEDHPETNAVDEP YKIHGLEDEVOPPNLIPRRPSPYEKTRNORIOELIDEMRKKEMLGKF

## ADAMTS2 Amino Acid Sequence 2 (SEQ ID NO. 5)

NP\_067610 a disintegrin and metalloprotease with thrombospondin motifs-2 isoform 2; procollagen I N-proteinase; Procollagen N-endopeptidase [Homo sapiens]

MDPPAGAARRLCPALLLLLLLPPPLLPPPPPPPANARLAAAADPPGGPLGHGAERILAV PVRTDAQGRLVSHVVSAATSRAGVRARRAAPVRTPSFPGGNEEEPGSHLFYNVTVFGR DLHLRLRPNARLVAPGATMEWQGEKGTTRVEPLLGSCLYVGDVAGLAEASSVALSNC DGLAGLIRMEEEEFFIEPLEKGLAAQEAEQGRVHVVYRRPPTSPPLGGPQALDTGASLDS LDSLSRALGVLEEHANSSRRRARRHAADDDYNIEVLLGVDDSVVQFHGKEHVQKYLLT LMNIVNEIYHDESLGAHINVVLVRIILLSYGKSMSLIEIGNPSQSLENVCRWAYLQQKPD TGHDEYHDHAIFLTRQDFGPSGMQGYAPVTGMCHPVRSCTLNHEDGFSSAFVVAHETG HVLGMEHDGQGNRCGDEVRLGSIMAPLVQAAFHRFHWSRCSQQELSRYLHSYDCLLD

# DPFAHDWPALPQLPGLHYSMNEQCRFDFGLGYMMCTAFRTFDPCKQLWCSHPDNPYFCKTKKGPPLDGTMCAPGKFRPGAVAHACYPSTLGGQGRWIA

[0256] Modifications may be made to the foregoing without departing from the basic aspects of the invention. Although the invention has been described in substantial detail with reference to one or more specific embodiments, those of skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the invention, as set forth in the aspects which follow. All publications or patent documents cited in this specification are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference.

[0257] Citation of the above publications or documents is not intended as an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. U.S. patents and other publications referenced herein are hereby incorporated by reference.

#### What is claimed is:

- 1. A method for identifying a subject at risk of osteoarthritis, which comprises detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variations are detected in a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
  - (d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby the presence of the polymorphic variation is indicative of the subject being at risk of osteoarthritis.

- 2. The method of claim 1, which further comprises obtaining the nucleic acid sample from the subject.
- 3. The method of claim 1, wherein the one or more polymorphic variations are detected within a region spanning chromosome positions 178746000 to 178751000 in human genomic DNA.
- 4. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions selected from the group consisting of 210, 3608, 3609, 4318, 5593, 5629, 5639, 5640, 8943, 17968, 19887, 21034, 21085, , 21596, 23379, 23432, 24007, 26121, 26273, 26755, 27411, 27710, 27842, 28379, 29603, 31232, 31504, 32583, 32794, 32840, 33044, 33150, 33218, 33513, 33959, 34486, 36289, 36570, 38247, 38477, 38518, 38529, 38667, 39781, 39856, 39927, 40506, 41869, 42452, 44788, 46059, 46846, 47712, 48796, 49441, 49602, 49723, 50050, 50171, 50477, 50818, 50833, 50881, 50882, 51386, 51534, 52317, 52368, 52970, 53023, 53356, 53882, 54553, 55475, 55530, 55691, 55848, 55879, 56316, 56911, 57320, 57391, 57437, 57478, 57500, 59111, 59333, 59715, 59804, 59851, 59929, 60052, 60240, 60359, 60381, 60456, 60724, 60875, 60968, 60978, 60998, 61557, 62091, 62645, 62943, 63131, 63145, 63406, 63427, 63554, 63661, 64093, 64153, 64409, 64544, 65257, 65626,65739, 66392, 66720, 69177, 69336, 69636, 69823, 69928, 70547, 70633, 71805, 72181, 72200, 72474, 72567, 72973, 73468, 73889, 75730, 75970, 76114, 76342, 76449, 76465, 76791, 78042, 80758, 80778, 81356, 81576, 81689, 81759, 81950, 82562, 83591, 83700, 83821, 83842, 83923, 83929, 84021, 84175, 84417, 84747, 85746, 86129, 86335, 87315, 87648, 87764, 87770, 88221, 90474, 91148, 91150, 91160, 91733, 91772, 91785,

93140, 93148, 96080, 96157, 96313, 96759, 97026, 97320, 97732, 98713, 99707, 99959, 100009, 100020, 100065, 100086, 101270, 101276, 101371, 101376, 101439, 101820, 102392, 102602, 102604, 102896, 189104, 189134 and 189205.

- 5. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in SEQ ID NO: 1 selected from the group consisting of 5640, 33150, 38247, 38529, 46846, 49723, 50050, 63427, 73889, 189104 and rs428901.
- 6. The method of claim 1, wherein the one or more polymorphic variations are detected at one or more positions in linkage disequilibrium with one or more positions in claim 3, 4 or 5.
- 7. The method of claim 1, wherein detecting the presence or absence of the one or more polymorphic variations comprises:

hybridizing an oligonucleotide to the nucleic acid sample, wherein the oligonucleotide is complementary to a nucleotide sequence in the nucleic acid and hybridizes to a region adjacent to the polymorphic variation;

extending the oligonucleotide in the presence of one or more nucleotides, yielding extension products; and

detecting the presence or absence of a polymorphic variation in the extension products.

- 8. The method of claim 1, wherein the subject is a human.
- 9. The method of claim 8, wherein the subject is a human female.
- 10. The method of claim 8, wherein the subject is a human male.
- 11. A method for identifying a polymorphic variation associated with osteoarthritis proximal to an incident polymorphic variation associated with osteoarthritis, which comprises:

identifying a polymorphic variation proximal to the incident polymorphic variation associated with osteoarthritis, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;

- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation;

determining the presence or absence of an association of the proximal polymorphic variant with osteoarthritis.

- 12. The method of claim 11, wherein the incident polymorphic variation is at one or more positions in claim 3, 4 or 5.
- 13. The method of claim 11, wherein the proximal polymorphic variation is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the incident polymorphic variation.
- 14. The method of claim 11, which further comprises determining whether the proximal polymorphic variation is in linkage disequilibrium with the incident polymorphic variation.
- 15. The method of claim 11, which further comprises identifying a second polymorphic variation proximal to the identified proximal polymorphic variation associated with osteoarthritis and determining if the second proximal polymorphic variation is associated with osteoarthritis.
- 16. The method of claim 15, wherein the second proximal polymorphic variant is within a region between about 5 kb 5' of the incident polymorphic variation and about 5 kb 3' of the proximal polymorphic variation associated with osteoarthritis.
- 17. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and
  - (e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d);

wherein the nucleotide sequence comprises a polymorphic variation associated with osteoarthritis selected from the group consisting of a cytosine at position 5640, a cytosine at position 33150, an adenine at position 38247, a thymine at position 38529, an adenine at position 46846, a cytosine at position 49723, a cytosine at position 50050, a cytosine a position 63427, a guanine at position 73889, a thymine at position 189104, and an adenine at position rs428901.

- 18. An oligonucleotide comprising a nucleotide sequence complementary to a portion of the nucleotide sequence of (a), (b), (c), or (d) in claim 17, wherein the 3' end of the oligonucleotide is adjacent to a polymorphic variation associated with osteoarthritis.
  - 19. A microarray comprising an isolated nucleic acid of claim 17 linked to a solid support.
  - 20. An isolated polypeptide encoded by the isolated nucleic acid sequence of claim 17.
  - 21. A method for identifying a candidate therapeutic for treating osteoarthritis, which comprises:
- (a) introducing a test molecule to a system which comprises a nucleic acid comprising a nucleotide sequence selected from the group consisting of:
  - (i) a nucleotide sequence in SEQ ID NO: 1-3;
- (ii) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (iii) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (iv) a fragment of a nucleotide sequence of (a), (b), or (c); or introducing a test molecule to a system which comprises a protein encoded by a nucleotide sequence of (i), (ii), (iii), or (iv); and
- (b) determining the presence or absence of an interaction between the test molecule and the nucleic acid or protein,

whereby the presence of an interaction between the test molecule and the nucleic acid or protein identifies the test molecule as a candidate therapeutic for treating osteoarthritis.

- 22. The method of claim 21, wherein the system is an animal.
- 23. The method of claim 21, wherein the system is a cell.

- 24. The method of claim 21, wherein the nucleotide sequence comprises one or more polymorphic variations associated with osteoarthritis.
- 25. The method of claim 24, wherein the one or more polymorphic variations associated with osteoarthritis are at one or more positions in claim 3, 4 or 5.
- 26. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a nucleic acid, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
  - (d) a fragment of a nucleotide sequence of (a), (b), or (c); and
- (e) a nucleotide sequence complementary to the nucleotide sequences of (a), (b), (c), or (d); whereby contacting the one or more cells of the subject with the nucleic acid treats the osteoarthritis in the subject.
  - 27. The method of claim 26, wherein the nucleic acid is RNA or PNA.
  - 28. The method of claim 27, wherein the nucleic acid is duplex RNA.
- 29. A method for treating osteoarthritis in a subject, which comprises contacting one or more cells of a subject in need thereof with a protein, wherein the protein is encoded by a nucleotide sequence which comprises a polynucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
  - (d) a fragment of a nucleotide sequence of (a), (b), or (c);

whereby contacting the one or more cells of the subject with the protein treats the osteoarthritis in the subject.

- 30. The method of claim 29, wherein the treatment comprises administration of an effective amount of a composition comprising an active *ADAMTS2* polypeptide or fragment thereof, wherein the polypeptide fragment is selected from the group consisting of: 252-1211, 253-1211, 254-1211, 255-1211, 256-1211, 257-1211, 258-1211, 259-1211 or 260-1211 of SEQ ID NO: 4.
  - 31. The method of claim 30, wherein the polypeptide or fragment has biological activity.
  - 32. A method for treating osteoarthritis in a subject, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the one or more polymorphic variation are detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis treatment to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

- 33. The method of claim 30, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.
- 34. The method of claim 30, wherein the treatment is selected from the group consisting of administering a corticosteroid, a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.
- 35. A method for detecting or preventing osteoarthritis in a subject, which comprises:

  detecting the presence or absence of one or more polymorphic variations associated with
  osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a
  nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence in SEQ ID NO: 1-3;

- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

administering an osteoarthritis prevention or detection procedure to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

- 36. The method of claim 35, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.
- 37. The method of claim 35, wherein the osteoarthritis prevention is selected from the group consisting of administering a corticosteroid, a nonsteroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) inhibitor, an antibody, a glucocorticoid, hyaluronic acid, chondrotin sulfate, glucosamine or acetaminophen; prescribing a heat/cold regimen or a joint protection regimen; performing joint surgery; prescribing a weight control regimen; and combinations of the foregoing.
- 38. A method of targeting information for preventing or treating osteoarthritis to a subject in need thereof, which comprises:

detecting the presence or absence of one or more polymorphic variations associated with osteoarthritis in a nucleic acid sample from a subject, wherein the polymorphic variation is detected in a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence in SEQ ID NO: 1-3;
- (b) a nucleotide sequence which encodes a polypeptide encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (c) a nucleotide sequence which encodes a polypeptide that is 90% or more identical to the amino acid sequence encoded by a nucleotide sequence in SEQ ID NO: 1-3;
- (d) a fragment of a nucleotide sequence of (a), (b), or (c) comprising a polymorphic variation; and

directing information for preventing or treating osteoarthritis to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

39. The method of claim 38, wherein the one or more polymorphic variations are detected at one or more positions in claim 3, 4 or 5.

- 40. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and an antibody that specifically binds to a protein, polypeptide or peptide encoded by a nucleotide sequence identical to or 90% or more identical to a nucleotide sequence in SEQ ID NO: 1-3.
- 41. A composition comprising a cell from a subject having osteoarthritis or at risk of osteoarthritis and a RNA, DNA, PNA or ribozyme molecule comprising a nucleotide sequence identical to or 90% or more identical to a portion of a nucleotide sequence in SEQ ID NO: 1-3.
- 42. The composition of claim 41, wherein the RNA molecule is a short inhibitory RNA molecule.

## Abstract of the Disclosure

Provided herein are methods for identifying a risk of osteoarthritis in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating osteoarthritis, and therapeutic and preventative methods applicable to osteoarthritis. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.

App No.: Not Yet Assigned

Docket No.: 524593008900


Inventor: Steven MAH, et al.


Title: METHODS FOR IDENTIFYING RISK OF

OSTEOARTHRITIS AND TREATMENTS THEREOF

FIGURE 1

ADAMTS2 - DISCOVERY P-VALUES (female only)





Chromosome position

### **Application Data Sheet**

## **Application Information**

Application Type:: Provisional

Subject Matter:: Utility

Suggested Group Art Unit:: Not Yet Assigned

CD-ROM or CD-R?:: None

Sequence submission?:: None

Computer Readable Form (CRF)?:: No

Title:: METHODS FOR IDENTIFYING RISK OF

**OSTEOARTHRITIS AND TREATMENTS** 

**THEREOF** 

Attorney Docket Number:: 524593008900

Request for Early Publication?:: No

Request for Non-Publication?:: No

Total Drawing Sheets?:: 1

Small Entity?:: Yes

Petition included?:: No

Secrecy Order in Parent Appl.?:: No

## **Applicant Information**

Applicant Authority Type:: Inventor

Primary Citizenship Country:: US

Status:: Full Capacity

Given Name:: Steven

Family Name:: MAH

City of Residence:: San Diego

State or Province of Residence:: CA

Country of Residence:: US

Street of mailing address:: 12820 Via Nieve #74

City of mailing address:: San Diego

State or Province of mailing address:: CA

Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Germany

Status:: Full Capacity

Given Name:: Andreas

Family Name:: BRAUN

City of Residence:: San Diego

State or Province of Residence:: CA

Country of Residence:: US

Street of mailing address:: 3935 Lago Di Grata Circle

City of mailing address:: San Diego

State or Province of mailing address:: CA

Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Germany

Status:: Full Capacity

Given Name:: Stefan

Middle Name:: M.

Family Name:: KAMMERER

City of Residence:: San Diego

State or Province of Residence:: CA

Country of Residence:: US

Street of mailing address:: 3825 Elijah Court, Unit 334

City of mailing address:: San Diego

State or Province of mailing address:: CA

Postal or Zip Code of mailing address:: 92130

Applicant Authority Type:: Inventor

Primary Citizenship Country:: US

Status:: Full Capacity

Given Name:: Matthew

Middle Name:: Roberts

Family Name:: NELSON

City of Residence:: San Marcos

State or Province of Residence:: CA

Country of Residence:: US

Street of mailing address:: 1250 Calle Prospero

City of mailing address:: San Marcos

State or Province of mailing address:: CA

Postal or Zip Code of mailing address:: 92069

Applicant Authority Type:: Inventor

Primary Citizenship Country:: Sweden

Status:: Full Capacity

Given Name:: Rikard

Middle Name:: Henry

Family Name:: RENELAND

City of Residence:: San Diego

State or Province of Residence:: CA

Country of Residence:: US

Street of mailing address:: 7555 Charmant Drive, #1114

City of mailing address:: San Diego

State or Province of mailing address:: CA

Postal or Zip Code of mailing address:: 92122

Applicant Authority Type:: Inventor

Primary Citizenship Country:: United Kingdom

Status:: Full Capacity

Given Name:: Maria

Middle Name:: L.

Family Name:: LANGDOWN

City of Residence:: San Diego

State or Province of Residence:: CA

Country of Residence:: US

Street of mailing address:: 3701 Yosemite Street

City of mailing address:: San Diego

State or Province of mailing address:: CA

Postal or Zip Code of mailing address:: 92109

**Correspondence Information** 

Correspondence Customer Number:: 25225

**Representative Information** 

Representative Customer Number:: 25225